

Scientific Programme

Friday, 05. July 2019

Registration
15:00 - 19:00

Main Foyer

Registration

Scientific Programme

Saturday, 06. July 2019

Registration
06:30 - 19:00

Main Foyer

Registration

Special Session
08:00 - 10:30

Clarendon A/B

Trainee Session

The Trainee Session of the ISTH 2019 Congress in Melbourne welcomes all trainees and early career professionals interested in Thrombosis and Hemostasis. This 2.5-hour session developed by the ISTH Early Career Committee will provide career mentoring discussions along with round tables with experts on various career and methodology topics and educational tips. Come and start your ISTH Congress by networking and engaging with peers and experts in your field of interest!

Chair: Claire McLintock (New Zealand)
Chair: Marc Blondon (Switzerland)

Introduction and Lecture: Make the Best of Your ISTH Membership	08:00
Speaker: Claire McLintock (New Zealand)	
Career Mentoring Sessions: Learning from Each Other	08:15
Speaker: David Rabbolini (Australia)	
Speaker: Vincent Muczynski (United Kingdom)	
Speaker: Matthew Harper (United Kingdom)	
Speaker: Eileen Merriman (New Zealand)	
Speaker: Alisa S. Wolberg (United States)	
Speaker: Christopher M. Ward (Australia)	
Transition to Round Tables	09:00
Round Table Discussion 09:05 - 09:30	09:05
How to Become a Good Journal Reviewer	
Speaker: Mary Cushman (United States)	
How to Optimize Papers for Publication	
Speaker: James H. Morrissey (United States)	
How to Succeed in Getting Funding: Writing a Grant and the Review Process	
Speaker: Ross Ian Baker (Australia)	
How to Combine Research and a Laboratory Career	
Speaker: Emmanuel Favaloro (Australia)	
How to Combine Research and Clinical Work: Difficulties in Early Career Stage	
Speaker: Mandy N. Lauw (the Netherlands)	
Speaker: David Rabbolini (Australia)	

Scientific Programme

How to Transition from a Postdoc Position to a PI: Difficulties for Scientists at an Early Career Level

Speaker: Caterina Casari (France)
Speaker: Robert Campbell (United States)

How to Establish a Career in Thrombosis and Haemostasis in Reach-the-World Countries

Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil)
Speaker: Pantep Angchaisuksiri (Thailand)

Tips for a Good CV / Cover Letter / Recommendation

Speaker: Christopher M. Ward (Australia)

Tips for a Good Short Oral Presentation

Speaker: Peter Lenting (France)

How to Improve Your Poster Presentation

Speaker: Geoffrey Barnes (United States)

How to Be a Good Mentee

Speaker: Alisa S. Wolberg (United States)
Speaker: Deborah M. Siegal (Canada)

How to Maintain a Healthy Work-Life Balance

Speaker: Claire McLintock (New Zealand)
Speaker: Eileen Merriman (New Zealand)

Tips and Pitfalls for Systematic Reviews and Meta-Analyses

Speaker: Marc Carrier (Canada)

Minimizing Biases in Observational Studies

Speaker: Marc Blondon (Switzerland)

How to Be a Good Session Moderator

Speaker: Walter Ageno (Italy)

Break and Networking - 09:30 - 09:50

09:30

Round Table Discussion 09:50 - 10:15

09:50

How to Become a Good Journal Reviewer

Speaker: Mary Cushman (United States)

How to Optimize Papers for Publication

Speaker: James H. Morrissey (United States)

How to Succeed in Getting Funding: Writing a Grant and the Review Process

Speaker: Ross Ian Baker (Australia)

How to Combine Research and a Laboratory Career

Speaker: Emmanuel Favalaro (Australia)

How to Combine Research and Clinical Work: Difficulties in Early Career Stage

Speaker: Mandy N. Lauw (the Netherlands)
Speaker: David Rabbolini (Australia)

Scientific Programme

How to Transition from a Postdoc Position to a PI: Difficulties for Scientists at an EC Level

Speaker: Caterina Casari (France)
Speaker: Robert Campbell (United States)

How to Establish a Career in Thrombosis and Haemostasis in Reach-the-World Countries

Speaker: Pantep Angchaisuksiri (Thailand)
Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil)

Tips for a Good CV / Cover Letter / Recommendation

Speaker: Christopher M. Ward (Australia)

Tips for a Good Short Oral Presentation

Speaker: Peter Lenting (France)

How to Improve Your Poster Presentation

Speaker: Geoffrey Barnes (United States)

How to Be a Good Mentee

Speaker: Alisa S. Wolberg (United States)
Speaker: Deborah M. Siegal (Canada)

How to Maintain a Healthy Work-Life Balance

Speaker: Claire McLintock (New Zealand)
Speaker: Eileen Merriman (New Zealand)

Tips and Pitfalls for Systematic Reviews and Meta-Analyses

Speaker: Marc Carrier (Canada)

Minimizing Biases in Observational Studies

Speaker: Marc Blondon (Switzerland)

How to Be a Good Session Moderator

Speaker: Walter Ageno (Italy)

How to Become a Good Educator

Speaker: Renee Eslick (Australia)

10:15

Supported Symposia
11:30 - 12:45

Meeting Room 203/204

Supported Symposium

Title: Transforming Research Into Clinical Reality: Takeda's Gene Therapy Program in Hemophilia This session is supported by [Takeda Please view the program here](#)

Supported Symposia
11:30 - 12:45

Meeting Room 210/211

Supported Symposium

Title: The Role of the Protein C System in a Rare Disorder and its Impact in Critical Care This session is supported by [Takeda Please view the program here](#)

Scientific Programme

Supported Symposia
11:30 - 12:45

Meeting Room 212/213

Supported Symposium

Title: The Evolution of Turning Genes Into Medicine: Leveraging Innovation To Create a Path Forward This session is supported by [Spark Therapeutics, Inc. Please view the program here](#)

Supported Symposia
11:30 - 12:45

Meeting Room 219/220

Supported Symposium

Title: Understanding the Outcomes of Anticoagulation: Insights From the GARFIELD Registries This session is supported by [TRI Please visit here](#)

Supported Symposia
11:30 - 12:45

Meeting Room 105

Supported Symposium

Title: Navigating the New World: Haemophilia in the 21st Century This session is supported by [Sanofi Genzyme Please view the program here](#)

Supported Symposia
11:30 - 12:45

Meeting Room 106

Supported Symposium

Title: Defining a New Paradigm for the Management of Acquired Thrombotic Thrombocytopenic Purpura This session is supported by [Sanofi Genzyme Please view the program here](#)

Supported Symposia
11:30 - 12:45

Meeting Room 109

Supported Symposium

Title: Inhibitors: Prevention and Evolving Treatment Paradigms This session is supported by [GRIFOLS Please view the program here](#)

Supported Symposia
11:30 - 12:45

Meeting Room 110

Supported Symposium

Title: A Decade of Innovation: from DOACs to Reversal Agents This session is supported by [Boehringer Ingelheim Please view the program here](#)

Scientific Programme

Oral Communication Session
13:00 - 14:15

Melbourne Room 1

OC 02, New Antithrombotic Targets

Chair: Robert Flaumenhaft (United States)
Chair: Freda J. Passam (Australia)

Thymidine Phosphorylase Is a Novel Anti-atherothrombotic Target	13:00
Speaker: Wei Li (United States)	
The Cyclooxygenase-1/Microsomal Prostaglandin E Synthase-1/Endothelial EP4 Receptor Pathway Constrains Myocardial Ischemia-Reperfusion Injury: New Insight into Microcirculation	13:15
Speaker: Miao Wang (China)	
Recombinant Factor VII Activating Protease (FSAP) Decreases Infarct Volume and Improves Neurological Outcome in two Different Mouse Models of Ischemic Stroke	13:30
Speaker: Jeong Yeon Kim (Norway)	
Patients with Atrial Fibrillation Overexpress Fibrin-binding Platelet Receptor GPVI-dimer. A Future Anti-thrombotic Target?	13:45
Speaker: Isuru Induruwa (United Kingdom)	
New Peptide-agonist of PAR1 Demonstrates Neuroprotective Effect at the Photothrombosis-induced Damage of Mouse Brain	14:00
Speaker: Liubov Gorbacheva (Russian Federation)	

Oral Communication Session
13:00 - 14:15

Melbourne Room 2

OC 01, Gene Therapy Clinical

Chair: Guy Young (United States)
Chair: Julie Curtin (Australia)

AMT-061 (AAV5-Padua hFIX variant) an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Follow-up up to 9 Months in a Phase 2b Trial	13:00
Speaker: Adam Giermasz (United States)	
Initial Results of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Subjects with Severe Hemophilia A	13:15
Speaker: Barbara A. Konkle (United States)	
Health-related Quality of Life Improvements in Adult Haemophilia B Patients at One Year Follow-up after Receiving SPK-9001 Gene Transfer	13:30
Speaker: Sylvia von Mackensen (Germany)	
Stable Expression of FIX and Maintained Reductions in Bleeding and Factor IX Consumption Following AMT-060 Gene Therapy with up to 3.5 Years of Follow Up in Adults with Severe or Moderate-Severe Hemophilia B	13:45
Speaker: Frank Leebeek (the Netherlands)	

Scientific Programme

Oral Communication Session
13:00 - 14:15

Meeting Room 203/204

OC 04, APE Outcomes

Chair: Grégoire Le Gal (Canada)
Chair: Zhi-Cheng Jing (China)

- | | |
|--|--------------|
| Incidence of Residual Perfusion Defects by Lung Scintigraphy in Patients Treated with Rivaroxaban Compared with Warfarin for Acute Pulmonary Embolism | 13:00 |
| Speaker: Ming Sheng Lim (Australia) | |
| The Rule-out Criteria for Chronic Thromboembolic Pulmonary Hypertension can Identify Patients without Haemodynamic Abnormalities and Functional Limitation 3 and 12 Months after Acute PE | 13:15 |
| Speaker: Stefano Barco (Germany) | |
| Early Identification of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism (InShape II Study) | 13:30 |
| Speaker: Duliëtte Boon (the Netherlands) | |
| Long-term Clinical Prognosis of Massive and Non-massive Pulmonary Embolism: A Registry-based Cohort Study | 13:45 |
| Speaker: Marc Blondon (Switzerland) | |
| The Prognostic Value of Syncope on Mortality in Patients with Pulmonary Embolism: A Systematic Review and Meta-analysis | 14:00 |
| Speaker: Maria Adriana de Winter (the Netherlands) | |

Oral Communication Session
13:00 - 14:15

Meeting Room 210/211

OC 05, Hemophilia Basic 2

Chair: Johannes Oldenburg (Germany)
Chair: Huyen Tran (Australia)

- | | |
|---|--------------|
| Common and Rare Genetic Determinants of von Willebrand Factor Clearance and Factor VIII-binding Modify Factor VIII Pharmacokinetics in a Pediatric Hemophilia A Population | 13:00 |
| Speaker: David Lillicrap (Canada) | |
| Development and Characterization of an ELISA Combined Chromogenic Assay for Selective Measurement of Human FVIII Activity in Animal Plasma Matrix | 13:15 |
| Speaker: Gerald Schrenk (Austria) | |
| FXII Activation Leading to Kallikrein and Bradykinin Formation in Vitro Induced by Some Plasma Derived FVIII Concentrates, but Not by Recombinant FVIII | 13:30 |
| Speaker: Beate Kehrel (Germany) | |
| LPS-induced Release of Monocyte Microvesicle-Associated Tissue Factor Procoagulant Activity (MV TF PCA) Correlates with Markers of Systemic Inflammation in Patients with Hemophilia A and B | 13:45 |
| Speaker: Florian Langer (Germany) | |

Scientific Programme

- Identification of the Origin of de Novo Mutation in Hemophilia A without Prior Family History and Categorization of the Event how the de Novo Mutation Occurs** **14:00**
Speaker: Ming Ching Shen (Taiwan, Republic of China)

Oral Communication Session
13:00 - 14:15

Meeting Room 212/213

OC 06, Platelet Disorders and Anti-Platelet Therapies

Chair: Robert J. Bird (Australia)
Chair: Myung Ho Jeong (Korea, Republic of)

- Antithrombotic Therapy with an Anti-glycoprotein VI Humanized Fab Does Not Increase the Risk of Inflammation-associated Bleeding** **13:00**
Speaker: Martine Jandrot-Perrus (France)
- The Antiplatelet Drug Ticagrelor Kills Resistant Gram-positive Bacteria** **13:15**
Speaker: Cecile Oury (Belgium)
- Novel Assay Demonstrates Increased Procoagulant Platelet Response in Essential Thrombocythemia Segregating With JAK2V617F Mutation Status and Thrombosis** **13:30**
Speaker: Chuen Wen Tan (Singapore)
- Assessment of Platelet Thrombus Formation under Flow Condition in Patients with Acute Kawasaki Disease** **13:45**
Speaker: Nobuyuki Tsujii (Japan)

Oral Communication Session
13:00 - 14:15

Meeting Room 219/220

OC 03, Importance of Risk Prediction

Chair: Gabriela Cesarman-Maus (Mexico)
Chair: Cihan Ay (Austria)

- VTE-BLEED Score Predicts Major Bleeding in Patients with Atrial Fibrillation** **13:00**
Speaker: Gordon Chu (the Netherlands)
- Sex-Differences in Circulating Neutrophil Extracellular Traps (NETs) Levels and Stroke Risk: A Population-based Study** **13:15**
Speaker: Samantha Joyce Donkel (the Netherlands)
- Evaluation of the Clinical Utility of Biomarkers for Stroke Risk Scoring in Non-anticoagulated Patients with Atrial Fibrillation - An ACTIVE-A and AVERROES Sub-analysis** **13:30**
Speaker: Mandy N. Lauw (the Netherlands)
- Risk of Cardiac and Non-cardiac Adverse Events in Community-dwelling Older Patients with Atrial Fibrillation: A Prospective Cohort Study in the Netherlands** **13:45**
Speaker: Geert-Jan Geersing (the Netherlands)

Scientific Programme

Oral Communication Session
13:00 - 14:15

Meeting Room 105

OC 08, Megakaryocyte Maturation and Regulation

Chair: Benjamin Thomas Kile (Australia)
Chair: David Bark (United States)

GF11B Controls Vesicular Trafficking and Maintains Synchronism during Megakaryocyte Maturation	13:00
Speaker: Marie Levade (Australia)	
Megakaryocytes Form Podosome-Like Protrusions in situ Leading to the Formation of Transendothelial Pores	13:15
Speaker: Anita Eckly (France)	
Activation of Toll like Receptors 2 and 4 on CD34+ Cells Increases Human Megakaryo/thrombopoiesis Induced by Thrombopoietin	13:30
Speaker: Mirta Schattner (Argentina)	
Megakaryocyte Specific Deletion of NMDA Receptor Causes Abnormal Platelet Production and Function, But Normal Megakaryocyte Development	13:45
Speaker: James Hearn (New Zealand)	
Platelet-derived Microvesicles Reprogram Bone Marrow Megakaryocytes in the Setting of Inflammatory Disease	14:00
Speaker: Shauna French (United States)	

Oral Communication Session
13:00 - 14:15

Meeting Room 106

OC 09, Tissue Factor Pathway

Chair: Nigel Mackman (United States)
Chair: Jeffrey Zwicker (United States)

Identification of the Interacting Domains between the Extracellular Domains of Tissue Factor and β1-integrin and their Influence on Cell Proliferation	13:00
Speaker: Sophie Featherby (United Kingdom)	
Deletion of CD248, a Novel Cofactor for Tissue Factor (TF), Confers Protection against Thrombosis in a Mouse Model	13:15
Speaker: Edward M. Conway (Canada)	
Loss of Tissue Factor in Zebrafish Disrupts Hemostasis and Results in Synthetic Lethality, but Is Compatible with Embryonic Development	13:30
Speaker: Steven Grzegorski (United States)	
Heterozygous Tissue Factor Deficiency is Associated with a Human Bleeding Disorder	13:45
Speaker: Sol Schulman (United States)	
Expression of Tissue Factor and Production of Extracellular Vesicle by Human Macrophages Requires Alternative Polarization	14:00
Speaker: Philipp Hohensinner (Austria)	

Scientific Programme

Oral Communication Session
13:00 - 14:15

Meeting Room 109

OC 10, General, Blood Components and Cellular Therapies

Chair: Joanne E. Joseph (Australia)
Chair: Meera Chitlur (United States)

Plasma Levels of Activated Factor VII-Antithrombin Complex Predict Mortality in Subjects with Liver and Colon Cancer Undergoing Curative Surgical Intervention	13:00
Speaker: Nicola Martinelli (Italy)	
Platelet and Plasma Factor XIII Levels after Replacement Therapy in Severe Congenital Factor XIII Deficiency: Origin of Platelets Factor XIII	13:15
Speaker: Claudia Maria Radu (Italy)	
Apoptosis Inhibition: A Promising Approach for Cold Storage of Apheresis Platelet Concentrates	13:30
Speaker: Irene Marini (Germany)	
The Effect of a Viscoelastic-based Bleeding Algorithm Implementation on Blood Products Use in Adult Liver Transplant Patients: A Before-after Study	13:45
Speaker: Ecaterina Scarlatescu (Romania)	
Coagulation Function Changes after CD19 CAR T Cells Therapy for B-ALL	14:00
Speaker: Lan Dai (China)	

Oral Communication Session
13:00 - 14:15

Meeting Room 110

OC 07, Laboratory Diagnostics Bleeding

Chair: Emmanuel Favaloro (Australia)
Chair: Jovan P Antovic (Sweden)

Genotypical Classification of Patients with von Willebrand Disease	13:00
Speaker: Waander L van Heerde (the Netherlands)	
Quantitation of One-stage and Two-stage Discrepancies in Monitoring of Enhanced Half-life Factor IX Products	13:15
Speaker: Thomas Siegemund (Germany)	
Genotypic Abnormalities in Phenotypic Confirmed Patients with a Rare Bleeding Disorder	13:30
Speaker: Waander L van Heerde (the Netherlands)	
Analytical Performance Evaluation of a Dedicated Calibrator and Controls for Emicizumab Quantification	13:45
Speaker: Narayanan Ramamurthy (United States)	
Comparison between One-stage and Chromogenic Testing of FIX Extended Half-life Product Measurements in External Quality Control Assessment Programs	14:00
Speaker: Moniek P.M. de Maat (the Netherlands)	

Scientific Programme

SSC Session
14:30 - 16:30

Melbourne Room 1

SSC Joint Session: Genomics in Thrombosis and Hemostasis and Platelet Physiology

Moderators: Marina Camera Italy, Andrew Johnson United States

RNA Sequencing to Aid Clinical Diagnosis of Platelet Disorders	14:30
Speaker: Michele Lambert (United States)	
Statistical Integration of RNA-seq Data in Genetic Studies of Rare Platelet Disorders	14:45
Speaker: Ernest Turro (United Kingdom)	
Using Platelet Transcriptomics for Novel Gene Element Discovery	15:00
Speaker: Jesse Rowley (United States)	
Platelet Transcriptome and Cancer	15:15
Speaker: Thomas Würdinger (the Netherlands)	
De Novo Protein Synthesis Induced by Platelet Activation and Its Impact on the Platelet Transcriptome	15:30
Speaker: Loredana Bury (Italy)	
Impact of MiRNA on Antiplatelet Responsiveness	15:45
Speaker: Pierre Fontana (Switzerland)	
Standardizing Platelet Transcriptomics for Discovery, Diagnostics, and Therapeutics in the Thrombosis and Hemostasis Community	16:00
Speaker: Matthew Rondina (United States)	
Discussion on Platelet Transcriptomics Research Priorities	16:15

SSC Session
14:30 - 16:30

Melbourne Room 2

Hemostasis and Malignancy

SSC Hemostasis & Malignancy - Clinical Projects and Updates

Moderators: Cihan Ay, <i>Austria</i>, Casey O'Connell <i>United States</i>

Welcome and Introduction	14:30
Speaker: Marc Carrier (Canada)	
New Guidance: Anticoagulation of Cancer Patients With Non-valvular Atrial Fibrillation Receiving Chemotherapy	14:35
Speaker: Aurelien Delluc (Canada)	
Proposal for Guidance on the Role of Direct Oral Anticoagulants in the Primary Prevention of Venous Thromboembolism in Ambulatory Cancer Patients	14:50
Speaker: Tzu-Fei Wang (United States)	
Guidance on Prevention and Treatment of Venous Thromboembolism in Adults Receiving Asparaginase Therapy	15:05
Speaker: Jeffrey Zwicker (United States)	

Scientific Programme

Prospective Cohort Study on Management and Outcomes in Thrombocytopenic Patients Receiving Antithrombotic Therapy	15:20
Speaker: Avi Leader (the Netherlands)	
SSC Hemostasis & Malignancy - Basic Science Projects and Updates	
Moderators: Christophe Dubois <i>France</i>, Tzu-Fei Wang <i>United States</i>	
Proposal for Development of an Accurate Mouse Model of Cancer to Study Thrombosis	15:30
Speaker: Christophe Dubois (France)	
Plasminogen Activation in Pancreatic Cancer Progression and Associated Thrombosis	15:50
Speaker: Matthew James Flick (United States)	
New Project: Antiphospholipids and Lymphoma	16:10
Speaker: Johanna Gebhart (Austria)	
Q&A Session and Additional Proposals	16:20
Speaker: Marc Carrier (Canada)	

SSC Session
14:30 - 16:30

Meeting Room 203/204

Perioperative and Critical Care Thrombosis and Hemostasis

SSC Standing Session Moderators: James Douketis <i>Canada</i>, Jerrold Levy <i>United States</i>	
Introduction: Projects, Guidance Documents, PAUSE ER Study	14:30
Speaker: Jerrold Levy (United States)	
Factor Concentrates for Perioperative Bleeding	14:40
Speaker: Jerrold Levy (United States)	
Use of Viscoelastic Monitoring in Perioperative and Critical Care Hemostasis Management	14:50
Speaker: Andreas Greinacher (Germany)	
Timing and Management of Patients Needing Urgent and Emergent Procedures: PAUSE ER Study	15:00
Speaker: Deborah M. Siegal (Canada)	
Managing Bleeding in the Critical Care Patient	15:20
Speaker: Beverley J. Hunt (United Kingdom)	
Perioperative Bleeding and Thrombotic Risk Moderators: Jean Connors <i>United States</i>, Lisa Baumann Kreuziger <i>United States</i>	
Standardized Reporting of Patient-Related Thrombembolism Risk and Procedural-Related Bleed Risk in Periprocedural Antithrombotic and Bridging Therapy	15:50
Speaker: Alex C. Spyropoulos (United States)	
Discussion and Q&A Session	16:20

Scientific Programme

SSC Session
14:30 - 16:30

Meeting Room 210/211

Biorheology

SSC Projects

Hemodynamics: Wall Shear Rate/Blood Flow Values in Human and Mouse Vessels	14:30
Speaker: Mikhail Panteleev (Russian Federation)	
Multi-Center Study on Flow Assay Protocols and Designs	14:45
Speaker: Keith Neeves (United States)	
Visualizing and Characterizing Thrombosis and Hemostasis in Real Time	
Blood Flow and the Adhesion of Kinetics of Platelet Mimetic Nano-Carriers	15:00
Speaker: Netanel Korin (Israel)	
New Tools to Quantify Fluid Shear Stress on the Surface of a Forming Thrombus	15:20
Speaker: Josie Carberry (Australia)	
Numerical Models of Blood Flow and Thrombosis	15:40
Speaker: Dalton Harvie (Australia)	
New Optical Modalities to Image Thrombus Formation in Vitro and in Vivo	16:05
Speaker: Steve Lee (Australia)	

SSC Session
14:30 - 16:30

Meeting Room 212/213

Animal, Cellular and Molecular Models of Thrombosis

Pre-Clinical Models of Platelet Transfusion Related Adverse Events	14:30
Speaker: Laura Gutierrez (Spain)	
Q&A Session	14:45
Bleeding Time (Final Report)	14:50
Speaker: Jose A. Diaz (United States)	
Q&A Session	15:05
Cellular Models of Megakaryopoiesis and Platelet Production	15:10
Speaker: Laura Gutierrez (Spain)	
Q&A Session	15:25
The Cremaster Arteriole Laser-Injury Model of Thrombosis - Standardization	15:30
Speaker: Robert Flaumenhaft (United States)	
Q&A Session	15:45
Platelet Rich Plasma: Usage in Cell Culture	15:50
Speaker: Laura Gutierrez (Spain)	

Scientific Programme

Q&A Session	16:05
Pre-Clinical Models: The Need for Standardization	16:10
Speaker: Jose A. Diaz (United States)	
Q&A Session	16:25

SSC Session
14:30 - 16:30

Meeting Room 219/220

Lupus Anticoagulant/Antiphospholipid Antibodies

Moderator: Katrien Devreese Belgium

Introduction	14:30
Speaker: Katrien Devreese (Belgium)	
Multicenter Study on Solid Phase Assays: Role of IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome	14:31
Speaker: Walid Chayoua (the Netherlands)	
Role of Anti-Domain I β2-Glycoprotein I Antibodies Measured by Different Methods, in the Diagnosis and Risk Stratification of Antiphospholipid Syndrome	14:45
Speaker: Dongmei Yin (the Netherlands)	
Antiphospholipid Antibodies and Lymphoma and Follow up of Antiphospholipid Antibody Fluctuation in Patients with Clinical Sydney Criteria for Antiphospholipid Syndrome	15:00
Speaker: Johanna Gebhart (Austria)	
Unraveling Difficulties in Laboratory Diagnosis of Antiphospholipid Syndrome by Evaluation of 'Real Life' Sample Results in External Quality Control Program	15:15
Speaker: Piet Meijer (the Netherlands) Speaker: Katrien Devreese (Belgium)	
Update of the Guidelines For Lupus Anticoagulant Detection and Interpretation	15:30
Speaker: Hannah Cohen (United Kingdom)	
Standardization of Thrombine Generation Assays	15:45
Speaker: Marisa Ninivaggi (the Netherlands)	
An International, Multi-Centre Study to Validate the Taipan Snake Venom Time as a Lupus Anticoagulant Screening Test with Ecarin Time as Confirmatory Test	16:00
Speaker: Gary Moore (United Kingdom)	
Update on the New Antiphospholipid Antibody Syndrome Classification Criteria Development Efforts	16:15
Speaker: Stéphane Zuily (France)	

Scientific Programme

Plenary Session
17:00 - 18:30

Plenary Hall

PL 01, Opening Ceremony and Shosuke and Utako Okamoto Plenary Lecture

Chair: Claire McLintock (New Zealand)

Postpartum Hemorrhage

17:00

Speaker: Beverley J. Hunt (United Kingdom)

Plenary Session
18:30 - 19:30

Plenary Hall

Opening Networking Reception

Scientific Programme

Sunday, 07. July 2019

Registration
07:00 - 19:00

Main Foyer

Registration

Supported Symposia
07:00 - 07:45

Meeting Room 219/220

Supported Symposium

Title: aTypical HUS: Finding a Needle in a Haystack This session is supported by [Alexion Pharmaceuticals, Inc. Please view the program here](#)

State-of-the-Art Session
08:00 - 09:15

Plenary Hall

SOA 01, Cancer-Associated Thrombosis

Chair: Alok Khorana (United States)
Chair: Ingrid Pabinger (Austria)

Coagulome, Oncogenes, and Oncomirs in Cancer	08:00
Speaker: Janusz Rak (Canada)	
Risk Stratification of Cancer-Associated Thrombosis	08:25
Speaker: Nicole M. Kuderer (United States)	
Treatment of Cancer-Associated Thrombosis	08:50
Speaker: Agnes Y.Y. Lee (Canada)	

State-of-the-Art Session
08:00 - 09:15

Melbourne Room 1

SOA 02, Challenges in Anticoagulant Management I

Chair: Eileen Merriman (New Zealand)
Chair: Frederikus Klok (the Netherlands)

Management Bleeding in Patients Under AC Therapy	08:00
Speaker: Mark Crowther (Canada)	
Recurrent VTE on Anticoagulant Therapy: What Next?	08:25
Speaker: Marc Rodger (Canada)	
Which Patients Should Receive Long-Term Anticoagulation? What Dose?	08:50
Speaker: Peter Verhamme (Belgium)	

Scientific Programme

State-of-the-Art Session
08:00 - 09:15

Melbourne Room 2

SOA 03, von Willebrand Disease

Chair: Sandra Haberichter (United States)
Chair: Amanda Davis (Australia)

VWF Storage, Secretion and Function	08:00
Speaker: Daniel F. Cutler (United Kingdom)	
VWD Diagnostic Thresholds	08:25
Speaker: James O'Donnell (Ireland)	
VWD in Children and Young Women	08:50
Speaker: Sarah O'Brien (United States)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 203/204

SOA 04, The Intersection of NETs and PAMPs/DAMPs

Chair: Kim Martinod (Belgium)
Chair: Michael Hickey (Australia)

Neutrophil Extracellular Traps and Therapeutic Options	08:00
Speaker: Tobias A. Fuchs (Germany)	
Thrombin, NETs and Platelets In Vivo	08:25
Speaker: Craig Jenne (Canada)	
Inflammasomes in the Recognition of PAMPs and DAMPs	08:50
Speaker: Si Ming Man (Australia)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 210/211

SOA 05, Platelet Receptors and Novel Therapeutics

Chair: Martine Jandrot-Perrus (France)
Chair: Riitta Lassila (Finland)

PI3K Function in Platelet Production	08:00
Speaker: Sonia Severin (France)	
Platelet Protease-Activated Receptors (PARs): Function and Targeting	08:25
Speaker: Justin Hamilton (Australia)	
Platelet Adhesion Receptors in Hemostatic and Non-Hemostatic Function	08:50
Speaker: Pierre Mangin (France)	

Scientific Programme

State-of-the-Art Session
08:00 - 09:15

Meeting Room 212/213

SOA 06, New Technologies, New Approaches

Chair: Xiaowei Wang (Australia)
Chair: Murray Adams (Australia)

Innovative Molecular Imaging and Drug Delivery Techniques	08:00
Speaker: Karlheinz Peter (Australia)	
Genomic Discovery Approaches for Inherited Bleeding Disorders	08:25
Speaker: Jorge A. Di Paola (United States)	
Imaging of Transcription Factor Activity in Vascular Development	08:50
Speaker: Mathias Francois (Australia)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 219/220

SOA 07, Acute Stroke Management

Chair: Bruce Campbell (Australia)
Chair: Christopher Levi (Australia)

Novel Therapeutic Targets in Stroke	08:00
Speaker: Simon De Meyer (Belgium)	
Endovascular Therapy of Ischemic Stroke	08:25
Speaker: Bruce Campbell (Australia)	
Intravenous Thrombolysis for Ischemic Stroke	08:50
Speaker: Kennedy R. Lees (United Kingdom)	

Exhibition
09:30 - 17:30

Exhibition Hall

Exhibition

Plenary Session
09:30 - 10:15

Plenary Hall

PL 02, Peter Castaldi Plenary Lecture

Chair: Philip J. Hogg (Australia)

Molecular Drivers of Platelet Production	09:30
Speaker: Joseph Italiano Jr. (United States)	

Scientific Programme

Oral Communication Session
10:45 - 12:00

Plenary Hall

OC 11, Hemophilia Novel Therapies 1

Chair: Kathelijn Fischer (the Netherlands)
Chair: Julia Phillips (New Zealand)

- | | |
|--|--------------|
| BIVV001: The First Investigational Factor VIII (FVIII) Therapy to Break through the von Willebrand Factor (VWF) Ceiling, with Potential for More Optimal, Extended Protection in Hemophilia A | 10:45 |
| Speaker: Barbara A. Konkle (United States) | |
| A Phase 1b/2 Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PF-06741086, an anti-TFPI Monoclonal Antibody, in Patients with Severe Hemophilia A or B | 11:00 |
| Speaker: Johnny Mahlangu (South Africa) | |
| Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Hemophilia: Interim Analysis from the Open-label Extension Study | 11:15 |
| Speaker: K. John Pasi (United Kingdom) | |
| Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog alfa (activated) in Hemophilia A or B with Inhibitors: Pharmacokinetics, Efficacy and Safety | 11:30 |
| Speaker: Johnny Mahlangu (South Africa) | |
| Immunogenicity, Safety, Pharmacokinetics and Preliminary Efficacy Results from the First Human Subcutaneous Factor VIII Trial (Subcutaneous Turoctocog Alfa Pegol, SC N8-GP) in Previously Treated Patients with Hemophilia A (Alleviate 1) | 11:45 |
| Speaker: Robert Klamroth (Germany) | |

Oral Communication Session
10:45 - 12:00

Melbourne Room 1

OC 12, Thrombosis in MI and Stroke

Chair: Geoffrey Barnes (United States)
Chair: Hai Po Helena Liang (Australia)

- | | |
|---|--------------|
| Pathological Features of Ruptured Atherosclerotic Plaque and Thrombus Interface in Acute Myocardial Infarction | 10:45 |
| Speaker: Atsushi Yamashita (Japan) | |
| Modeling the Formation and Mechanics of Platelet Thrombi at Extreme Shear | 11:00 |
| Speaker: Aaron Fogelson (United States) | |
| Association of Glycoprotein Ia Gene Polymorphisms with Pediatric Ischemic Stroke | 11:15 |
| Speaker: Renata Zadro (Croatia) | |
| Role of Erythrocyte Gas Transport Function in the Destabilization of Atherosclerotic Plaque | 11:30 |
| Speaker: Ekaterina Iastrebova (Russian Federation) | |

Scientific Programme

Assessment of the Predictive Value of von Willebrand Factor Antigen and Activity Combined Detection in Patients with Acute Myocardial Infarction 11:45
Speaker: Bin Yan (China)

Oral Communication Session
10:45 - 12:00

Melbourne Room 2

OC 13, VWF Clinical

Chair: Sophie Susen (France)
Chair: Jane Mason (Australia)

Diagnosis of VWD Based on a Single Low VWF:RCo in the Zimmerman Program Comparative Effectiveness Study 10:45
Speaker: Pamela Christopherson (United States)

Evaluation of the von Willebrand Factor (VWF) Inhibitor in a Large Cohort of European and Iranian Patients Previously Diagnosed with Type 3 von Willebrand Disease (VWD3) Enrolled into the 3WINTER-IPS Project 11:00
Speaker: Luciano Baronciani (Italy)

Mixed Phenotype von Willebrand Disease Caused by a Novel Cysteine Variant that Results in Both Qualitative and Quantitative von Willebrand Factor Defects 11:15
Speaker: Orla Rawley (Canada)

Management of Patients with Severe VWD type 3 and Centrally Confirmed Anti-VWF Neutralizing Antibodies: Results of the 24-month Prospective Observation in 10 Cases Enrolled into the 3Winters-Ips 11:30
Speaker: Augusto B Federici (Italy)

Population Pharmacokinetic Modelling of Factor VIII Plasma Levels During Perioperative Dosing of a VWF/FVIII Concentrate in von Willebrand Disease Patients 11:45
Speaker: L.H. Bukkems (the Netherlands)

Oral Communication Session
10:45 - 12:00

Meeting Room 203/204

OC 14, VTE: Acute Therapy

Chair: Sam Schulman (Canada)
Chair: Helen Crowther (Australia)

Current Practice Patterns of Outpatient Management of Acute Pulmonary Embolism: A Post-hoc Analysis of the YEARS Study 10:45
Speaker: Stephan V. Hendriks (the Netherlands)

Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER Study): Interim Analysis of First 200 Patients 11:00
Speaker: Eileen Merriman (New Zealand)

Scientific Programme

Safety of Outpatient Management of Pulmonary Embolism: 2010 - 2018 in a Large Teaching Hospital	11:15
Speaker: Tim Nokes (United Kingdom)	
No Predictive Role for Right Ventricular Function Measurement in Patients with Pulmonary Embolism Treated at Home Based on Absence of Hestia Criteria	11:30
Speaker: Stephan V. Hendriks (the Netherlands)	
Prognostic Value of Respiratory Index (RI) in Haemodynamically Stable Patients with Acute Pulmonary Embolism: The RI-MODEL Study	11:45
Speaker: Cecilia Becattini (Italy)	

Oral Communication Session
10:45 - 12:00

Meeting Room 210/211

OC 15, Biomarkers of Thrombosis and Haemostasis: Venous Thromboembolism

Chair: Lai Heng Lee (Singapore)
Chair: Alexander S. Gallus (Australia)

Different Protein Spectrum in Patients with Venous Thrombosis after Lower Leg Plaster Cast Application or Knee Arthroscopy than in Controls	10:45
Speaker: Carolina Eveline Touw (the Netherlands)	
Evaluation of ADAMTS-13 Activity as Risk Factor for Deep Vein Thrombosis	11:00
Speaker: Maria Teresa Pagliari (Italy)	
Prognostic Value of Elevated D-Dimer Level after 1 Month of Anticoagulant Therapy in Patients with Venous Thromboembolism: Results of the 10-year Follow-up	11:15
Speaker: Natalya Vorobyeva (Russian Federation)	
DVT-on-Chip: In-vitro Model of Deep Vein Thrombosis Including Valves, Endothelium & Blood Flow	11:30
Speaker: Abhishek Jain (United States)	
A Clinical-Genetic Risk Score to Predict Cancer-Associated Venous Thromboembolism: a Development and Validation Study in Two Independent Prospective Cohorts	11:45
Speaker: Andres Muñoz (Spain)	

Oral Communication Session
10:45 - 12:00

Meeting Room 212/213

OC 16, Hereditary Platelet Disorders 1

Chair: Mo Yang (China)
Chair: Marie-Christine Morel-Kopp (Australia)

Premature Platelet Clearance via Clustering of the Hyposialylated GPIIb/IIIa Receptor in GNE-related Thrombocytopenia	10:45
Speaker: Rolf T. Urbanus (the Netherlands)	

Scientific Programme

Gray Platelet Syndrome: More than an Inherited Bleeding Disorder	11:00
Speaker: Louisa Mayer (United Kingdom)	
Whole-genome Sequencing of Rare Disease Patients in a National Healthcare System	11:15
Speaker: Ernest Turro (United Kingdom)	
Rare Variants in IKAROS Family Zinc Finger 5 (IKZF5) Are Responsible for Autosomal Dominant Thrombocytopenia	11:30
Speaker: Kathleen Freson (Belgium)	
A Novel F153S ITGB3 Mutation Found in a Glanzmann Thrombasthenia Patient Reveals a Structural Clasp that Modulates Integrin Activation	11:45
Speaker: David A Wilcox (United States)	

Oral Communication Session
10:45 - 12:00

Meeting Room 219/220

OC 17, Stroke and Thrombolysis

Chair: Manuel Yepes (United States)
Chair: Thomas Lillicrap (Australia)

The Use of in vitro Clot Lysis Assay for Predicting Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis	10:45
Speaker: Zsuzsa Bagoly (Hungary)	
Targeted Drug Therapy: Effective and Localised Anticoagulation without Bleeding Risks	11:00
Speaker: Xiaowei Wang (Australia)	
Inhibition of Complement C5a Rreceptor Ameliorates Tissue Plasminogen Activator (t-PA)-mediated Increase in Blood Brain Barrier (BBB) Permeability	11:15
Speaker: Charithani Keragala (Australia)	
Fibrin clot Resistance to Thrombolytic Therapy is Controlled by Bypassing Flow through Collateral Vessels, Clot Permeability and PAI-1 Level	11:30
Speaker: Alexey M. Shibeko (Russian Federation)	
Thrombus Composition in Acute Ischemic Stroke: FXIII Content Impairs Complete Revascularization	11:45
Speaker: Manuel Navarro-Oviedo (Spain)	

Oral Communication Session
10:45 - 12:00

Meeting Room 105

OC 18, Coagulation Beyond Hemostasis

Chair: Christophe Dubois (France)
Chair: Seán McCluskey (Ireland)

Mechanisms Coupling Fibrinogen to Colorectal Adenocarcinoma Growth	10:45
Speaker: Joseph S Palumbo (United States)	

Scientific Programme

Lysophosphatidylcholine: A Pro-inflammatory Lipid of Platelet Microvesicles Promoting Platelet Activation, Vascular Inflammation and Indicating Atherosclerotic Plaque Instability	11:00
Speaker: Philipp Diehl (Germany)	
EPCR Signaling Regulates Activity of Hematopoietic Progenitor and Stem Cells	11:15
Speaker: Thanh Son Nguyen (Germany)	
Effect of Combining Low Levels of Tissue Factor with Complete Deficiencies for Factor IX or Factor XI on Survival and Placental Development in Mice	11:30
Speaker: Nigel Mackman (United States)	
Distinct Spatiotemporal Thrombotic Mechanisms Promote Microvascular Obstruction during IR Injury	11:45
Speaker: Mike Wu (Australia)	

Oral Communication Session
10:45 - 12:00

Meeting Room 106

OC 19, Pregnancy in Inherited and Acquired Bleeding Disorders

Chair: Renee Eslick (Australia)
Chair: Jameela Sathar (Malaysia)

Comparison of Outcome Between Intrauterine Balloon Tamponade and Uterine Artery Embolisation in the Management of Persistent Postpartum Haemorrhage: A Propensity Score Matched Cohort Study	10:45
Speaker: Paul Ramler (the Netherlands)	
The Experiences of Hemophilia Carriers Surrounding Pregnancy: A Qualitative Systematic Review	11:00
Speaker: Tanja H. Aalders (the Netherlands)	
Prepartum Factor XIII Has Significant Impact on Postpartum Blood Loss	11:15
Speaker: Wolfgang Korte (Switzerland)	
Postpartum Hemorrhage in Women with von Willebrand Disease and Carriers of Hemophilia: A Retrospective Analysis	11:30
Speaker: Marieke C. Punt (the Netherlands)	
Maternal Death and Post-partum Hemorrhage in sub-Saharan Africa - A Pilot Study in Metropolitan Mozambique	11:45
Speaker: Annette von Drygalski (United States)	

Oral Communication Session
10:45 - 12:00

Meeting Room 109

OC 20, Platelet Production and Release

Chair: Susie Nilsson (Australia)
Chair: Owen McCarty (United States)

Scientific Programme

Novel Insights into Mouse Models of Ectopic Proplatelet Release	10:45
Speaker: Markus Spindler (Germany)	
Sustained Integrin αIIbβ3 Activation in Megakaryocytes Impairs Platelet Release in the Bone Marrow	11:00
Speaker: Dorsaf Ghalloussi (United States)	
Unexpected Redundant Function of Twinfilin1 and Cofilin Is Essential for Platelet Biogenesis	11:15
Speaker: Isabelle Becker (Germany)	
O-glycan Sialylation Regulates Thrombopoiesis through Interferon-secreting Plasmacytoid Dendritic Cells	11:30
Speaker: Melissa Lee-Sundlov (United States)	
M6PR-specific Targeting of Lysosomal Enzymes Regulates Platelet Production	11:45
Speaker: Hervé Falet (United States)	

Special Session
12:15 - 13:15

Meeting Room 106

ISTH Fellowship and RtW Program

Overview of ISTH Training and Improvement Programs	12:15
Speaker: Cary Clark (United States)	
Experience as a Reach the World Fellow	12:25
Speaker: Yee Yee Yap (Malaysia)	
Benefits from participation in the Regional Training Center Program	12:30
Speaker: Jameela Sathar (Malaysia)	
World Federation of Hemophilia IHTC program	12:35
Speaker: Assad Haffar (Canada)	
Invitation to participate in Early Career Activities	12:40
Speaker: Marc Blondon (Switzerland)	
Q&A	12:42
Reception	12:45

Product Theater Presentations
12:15 - 13:00

Theatre A

Product Theater

Title: Current Treatment Challenges in ITP This session is supported by Amgen [Please visit here](#)

Scientific Programme

Product Theater Presentations
12:15 - 13:00

Theatre B

Product Theater

Title: Prophylaxis in Hemophilia A at Modest Doses Impacts the Clinical Outcomes This session is supported by [GRIFOLS Please view the program here](#)

Product Theater Presentations
12:15 - 13:00

Theatre C

Product Theater

Title: Update on HIT - From Pathophysiology to Treatment This session is supported by [Aspen Pharma Please view the program here](#)

Special Session
12:15 - 13:00

Theatre D

Gene Therapy in Hemophilia: An ISTH Education Initiative

Chair: Flora Peyvandi (Italy)

Welcome and Introductions	12:15
Speaker: Flora Peyvandi (Italy)	
Gene Therapy in Hemophilia Roadmap - Process, Outcomes and What we Learned	12:20
Speaker: Flora Peyvandi (Italy)	
Introduction of the ISTH Education Initiative, Content, Formats, Timelines and How to Participate	12:35
Speaker: K. John Pasi (United Kingdom)	
Questions	12:50
Speaker: Flora Peyvandi (Italy)	

Supported Symposia
13:15 - 14:30

Melbourne Room 1

Supported Symposium

Title: Anticoagulation for the Management of VTE in the NOAC era This session is supported by [Bristol-Myers Squibb/Pfizer Please view the program here](#)

Scientific Programme

Supported Symposia
13:15 - 14:30

Melbourne Room 2

Supported Symposium

Title: Introducing Esperoct®* (turoctocog alfa pegol), a New Extended Half-Life rFVIII — a Continuing Commitment to Patients with Haemophilia A *This product is not approved in Australia This session is supported by [Novo Nordisk](#)
[Please view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 203/204

Supported Symposium

Title: The Future of Haemophilia A: Discussing SubQ-8, a New Subcutaneous FVIII Development Based on Simoctocog Alfa This session is supported by [Octapharma](#) [Please view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 210/211

Supported Symposium

Title: Taking Action in Hemophilia A: Transforming Patient Outcomes Through Innovation This session is supported by [Takeda](#) [Please view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 212/213

Supported Symposium

Title: Taking a Flexible Approach in Hemophilia B This session is supported by [CSL Behring](#) [Please view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 219/220

Supported Symposium

Title: Supporting Clinical Decision Making in Hemostasis by Innovative Diagnostic Solutions This session is supported by [Roche](#) [Please view the program here](#)

Scientific Programme

Master Class
13:15 - 14:15

Meeting Room 218

How I Treat: Anticoagulant-Refractory APS

Hannah Cohen is a professor of hematology at University College London and consultant hematologist at University College London Hospitals in the United Kingdom. She leads a large tertiary referral antiphospholipid syndrome service where she manages many complex thrombotic and obstetric APS patients, in a multidisciplinary setting. Her main specialist interest is the investigation, management and pathogenesis of APS. She led the first completed DOAC randomized controlled trial in thrombotic APS (RAPS; Rivaroxaban in APS), and, as chief investigator, is currently setting up RISAPS, to investigate the use of high intensity rivaroxaban vs warfarin for stroke patients with APS. She is a co-investigator in the HYPATIA trial, to assess the effect of hydroxychloroquine versus placebo supplementing usual medication, on pregnancy outcome in women with antiphospholipid antibodies.

Anticoagulant-Refractory APS

13:15

Speaker: Hannah Cohen (United Kingdom)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 1

Bleeding Disorders in Pregnancy

Master Class Focus: Clinical I am the Clinic Director of the Inherited Bleeding Disorder Clinic of Southeastern Ontario and its aligned Women and Bleeding Disorders Clinic. We provide care for ~340 patients overall, including 215 women with a variety of bleeding disorders including von Willebrand disease, hemophilia, platelet function disorders and other factor deficiencies. The management of bleeding disorders in pregnancy requires the interaction of a multidisciplinary team in order to optimize outcomes for both the woman and her baby. We provide care for approximately 3 - 4 pregnant women per month with a bleeding disorder. Our strategy for labor and delivery for women who have not normalized clotting factor levels in pregnancy typically involves a continuous infusion.

Bleeding Disorders in Pregnancy

13:15

Speaker: Paula James (Canada)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 2

Diagnosis Testing for Inherited Platelet Disorders

Master Class Focus: Clinical MC. Alessi, MD PhD, is associate professor in the laboratory of hematology at the Aix Marseille University. She heads the Cardiovascular and Nutrition (C2VN) research center in Marseille and coordinates the French National Reference Center on hereditary Platelet disorders (CRPP). CRPP consists in a medical network throughout the France territory with the purpose of improving patient care and developing the capacity to diagnose, to follow-up and manage patients with hereditary platelet disorders. Major publications aroused from her work notably the first report of a human CalDAG-GEFI mutation and the characterization of the thrombopathy associated with the deficiency in CalDAG-GEFI.

Diagnosis Testing for Inherited Platelet Disorders

13:15

Speaker: Marie Christine Alessi (France)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 3

Thrombosis in Myeloproliferative Neoplasms: Biology and Pathophysiology

Master Class Focus: Basic Professor Chloe James is a MD, PhD specialized in haematology and haemostasis. In 2005, she was a shared first author in the discovery of the JAK2V617F mutation in myeloproliferative neoplasms. These last 5 years, she focused her interest on the pathogenesis of thrombosis in myeloproliferative neoplasms, and recently demonstrated the prothrombotic properties of JAK2V617F endothelial cells. She is also particularly interested in the role of neutrophils in NMP related thrombosis, especially in terms of neutrophil extracellular traps formation.

Thrombosis in Myeloproliferative Neoplasms: Biology and Pathophysiology

13:15

Speaker: Chloé James (France)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 4

Thrombosis in Myeloproliferative Neoplasms: Risk Factors and Antithrombotic Prophylaxis

Master Class Focus: Clinical Early experience of Dr. Valerio De Stefano addressed the clinical management of inherited thrombophilia, focusing on primary antithrombotic prophylaxis and on the risk factors for recurrent thromboses. During the last decade, he applied his expertise in vascular medicine in the field of myeloproliferative neoplasms (MPN). He investigated in MPN either the patient-related and the disease-related risk factors for thrombosis, providing original data and contributing to the validation of thrombotic prognostic scores in this field. He coordinated some Italian and European multicenter studies estimating the rate of recurrent thrombosis in MPN patients with a first arterial or venous event; he investigated the different effects of cytoreductive drugs, antiplatelet agents, and vitamin K-antagonists in preventing novel thromboses by multivariable models adjusted for patient characteristics in single or pooled databases including over 1,500 MPN patients with thrombosis. Finally, he improved knowledge of clinical features of thromboses at rare sites (e.g. splanchnic vein or cerebral vein thrombosis) in patients with overt MPN or with the JAK2 V617F mutation without full WHO diagnostic criteria.

Thrombosis in Myeloproliferative Neoplasms: Risk Factors and Antithrombotic Prophylaxis

13:15

Speaker: Valerio De Stefano (Italy)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 5

Challenging Hemophilia Care with Limited Resources

Master Class Focus: Clinical •Hemophilia A and B can be diagnosed at bedside using mixing venous clotting time. •Replacement therapy at the early bleeding episode is cost-effective. •Low dose prophylaxis improves the quality of life among hemophiliacs and their families. •Genotypic analysis can be arranged with limited resources. •Accurate carrier detection and prenatal diagnosis are essential to prevent new cases of severe and moderate hemophilia.

Challenging Hemophilia Care with Limited Resources

13:15

Speaker: Ampaiwan Chuansumrit (Thailand)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 6

Platelets and NET Generation

Master Class Focus: Basic We study the interactions between platelets and neutrophils resulting in NET release. Additionally, we are interested in how NETs interact with platelets and trigger coagulation creating a positive feedback loop resulting in coagulopathy, vascular occlusion and tissue damage. Most of our studies utilize intravital microscopy to study platelet behavior and interactions within the vasculature of live animals in real-time. We have published numerous papers on this topic and continue to work to understand how infection-induced platelet activation is linked to NETs and tissue pathology.

Platelets and NET Generation

13:15

Speaker: Craig Jenne (Canada)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 7

PAI-1 and TAFI Assays

Master Class Focus: Basic Since 1986, I have been involved in the development and critical evaluation of assays designed to quantitate various molecular forms of Plasminogen Activator Inhibitor 1 (e.g. latent, active, complexed) and Thrombin Activatable Fibrinolysis Inhibitor (e.g. pro-enzyme, active TAFIa, inactivated TAFIa, activation peptide). Corresponding assays for identification and quantitation of these molecules in other species (relevant for animal models) have been developed. These assays have been applied in various studies, including in vitro cell cultures, epidemiological studies, clinical studies, and animal models.

PAI-1 and TAFI Assays

13:15

Speaker: Paul J. Declerck (Belgium)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 8

Stroke in Children

Master Class Focus: Clinical Associate Professor Mark Mackay is a pediatric neurologist and director of the stroke program at the Royal Children's Hospital, Melbourne, Australia. He leads the childhood stroke research Group at the Murdoch Children's Research Institute. His research focuses on understanding the causes of and consequences of childhood stroke, and improving accuracy and timeliness of stroke diagnosis. He is on the executive committee of the International Pediatric Stroke study and an invited stroke expert on the Global Burden of Diseases Study. He chaired the development of national best-practice guidelines for the investigation and acute management of childhood stroke. The Masterclass session will begin with an introduction discussing the challenges to treatment of childhood stroke, related to its uncommon occurrence, differences in risk factors and stroke mechanisms, and a lack of evidence for thrombolysis and antithrombotic treatments, when compared to adults.

Stroke in Children

13:15

Speaker: Mark Mackay (Australia)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 9

Non-Proteolytic Targeting of VWF in Microangiopathies

Master Class Focus: Clinical and Basic Dr. López has been working on thrombotic microangiopathies for the past decade. In that time, he has explored the possibility of using the thiol agent N-acetylcysteine (NAC) to disrupt VWF multimers as a way to treat thrombotic thrombocytopenic purpura (TTP). His laboratory has also defined the importance of VWF self-association on the intact endothelium in providing an adhesive surface for the formation of in situ platelet thrombi. In addition to containing platelets, these thrombi also contain erythrocytes and leukocytes, both of which contribute to vessel occlusion. Preventing platelet adhesion to VWF with anti-adhesive agents also prevents erythrocytes and leukocytes from attaching to the vessel wall surface. The basic mechanisms and their clinical implications will be discussed in the master class, as will clinical studies of NAC and anti-adhesive therapy in TTP.

Non-Proteolytic Targeting of VWF in Microangiopathies

13:15

Speaker: José López (United States)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 10

Polyphosphates and the Contact Pathway in Thrombosis and Inflammation

Master Class Focus: Basic In 2006, our lab discovered that polyphosphate secreted by activated platelets is a novel, potent modulator of blood clotting. We and others have delineated contributions of platelet polyphosphate to hemostasis, thrombosis, and inflammation. Platelet polyphosphate may finally explain the puzzling role of factor XI in normal hemostasis. Long-chain polyphosphate, which is present in some microbes and mammalian tissues, is especially active in triggering the contact pathway and may play roles in host response to pathogens/Immunothrombosis. Polyphosphate and extracellular nucleic acids represent a novel drug target for preventing and/or treating thrombosis, coagulopathies and inflammation.

Polyphosphates and the Contact Pathway in Thrombosis and Inflammation

13:15

Speaker: James H. Morrissey (United States)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 11

Looking at Sensitive Nursing Indicators for Thrombosis and Hemostasis Practice

Professor Newall is a clinical nurse with 20 years of experience in pediatric thrombosis. She has over 100 peer-reviewed publications and extensive experience mentoring nurses to disseminate their outcomes of research and clinical innovation. She is a member of the ISTH Nursing Committee and Co-Chair of the ISTH Pediatric and Neonatal Subcommittee.

Looking at Sensitive Nursing Indicators for Thrombosis and Hemostasis Practice

13:15

Speaker: Fiona Newall (Australia)

Scientific Programme

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 12

Effective Use of Social Media for Your Career

Social media is ever-present in our lives. It can be used effectively to great advantage in disseminating and discussing science, and as a networking tool to extend your science reach around the globe. In this session, the presenter will share experience to date with personal use, and use to disseminate science in the ISTH's open access journal, Research and Practice in Thrombosis and Haemostasis. She will also discuss the evidence behind the effectiveness of social media in science and medicine, and provide key tips to get started or enhance your social media presence.

Effective Use of Social Media for Your Career

13:15

Speaker: Mary Cushman (United States)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 13

Peer-Reviewing Journal Articles

Professor Lillicrap has served for seven years as an Associate Editor for the journal Blood. He was recently appointed Co-Editor-in-Chief of the Journal of Thrombosis and Haemostasis. He has served as a regular reviewer for several journals including Blood, NEJM, Nature Medicine, and for manuscripts deriving from his own research group. Professor Lillicrap is also an Editorial Board member of Br. J. Haem.

Peer-Reviewing Journal Articles

13:15

Speaker: David Lillicrap (Canada)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 14

Working with Industry to Advance Coagulation Science

Dr. van Ryn has worked in industry for over 20 years, in research and also in medicine (medical affairs) in the field of thrombosis and hemostasis. In addition, she has collaborated with many academic centers around the world, in basic sciences, in the field of coagulation. Therefore, she can discuss development of drugs within the pharmaceutical industry, but also possible pre-clinical interactions between industry and academic centers.

Working with Industry to Advance Coagulation Science

13:15

Speaker: Joanne van Ryn (Germany)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 15

Developing Skills in Clinical Trial Design and Execution

The path from a clinical research question to a clinical trial is paved with challenges. In this workshop, some important pitfalls in the conception, design, execution and analysis of clinical trials will be discussed. What are the keys to success?

Developing Skills in Clinical Trial Design and Execution

13:15

Speaker: Peter Verhamme (Belgium)

Scientific Programme

Oral Communication Session
14:45 - 16:00

Plenary Hall

OC 21, Choice of Anticoagulation in AF

Chair: Elaine M. Hylek (United States)
Chair: Ben Freedman (Australia)

Adherence to Direct Oral Anticoagulant Treatment for Atrial Fibrillation in the Netherlands: A Surveillance StudyD	14:45
Speaker: G. Denise Zielinski (the Netherlands)	
Rivaroxaban Versus Warfarin and Renal Outcomes in Non-valvular Atrial Fibrillation Patients with Diabetes	15:00
Speaker: Craig I Coleman (United States)	
Effectiveness and Safety of Rivaroxaban and Warfarin for Prevention of Major Adverse Cardiovascular or Limb Events in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes	15:15
Speaker: William L. Baker (United States)	
The Influence of the Total Number of Concomitant Drugs Used on Major Bleeding Risk of Direct Acting Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Atrial Fibrillation Treated in Primary Care	15:30
Speaker: Carline J. van den Dries (the Netherlands)	
Incidence and Risk of Major Bleeding in Patients with End-stage Renal Disease on Hemodialysis with and without Antithrombotic Therapy: Prospective Results of the Vienna InVestigation of Atrial Fibrillation and Thromboembolism in HemoDialysis Patients (VIVALDI)	15:45
Speaker: Oliver Koenigsbruegge (Austria)	

Oral Communication Session
14:45 - 16:00

Melbourne Room 1

OC 22, Gene Therapy Basic 1

Chair: Chris Barnes (Australia)
Chair: John Rasko (Australia)

Nonclinical Pharmacology of TAK-748/SHP648 a Novel Factor IX (FIX) Gene Therapy Vector in Mice and Rhesus Monkeys	14:45
Speaker: Werner Hoellriegl (Austria)	
Therapeutic Levels of Factor VIII Gene Expression were Achieved by Transcutaneous Ultrasound Mediated Gene Delivery into Canine Liver	15:00
Speaker: Megan Manson (United States)	
AAV5-mediated Gene Therapy for Hemophilia A with a Factor IX Variant that functions independently of FVIII	15:15
Speaker: Ying Poi Liu (the Netherlands)	
Oral Nanoparticles with FVIII and IL-10 DNA: Effect on the Immune Response to FVIII in Hemophilia A Mice	15:30
Speaker: Gonzalo Hortelano (Kazakhstan)	

Scientific Programme

Long Term Safety and Efficacy of Adeno-associated Viral Gene Therapy in a Canine Hemophilia A Model 15:45
Speaker: Paul Batty (Canada)

Oral Communication Session
14:45 - 16:00

Melbourne Room 2

OC 23, Antiphospholipid Syndrome

Chair: Mary-Carmen Amigo (Mexico)
Chair: Steve Krilis (Australia)

Increased Risk of Thrombosis in Antiphospholipid Syndrome Patients Treated with Direct Oral Anticoagulants. Results from an International Patient-level Data Meta-analysis 14:45
Speaker: Virginie Dufrost (France)

Detection of Anti-Domain I Antibodies Enables the Identification of High-Risk Antiphospholipid Syndrome Patients: Results of a Multicenter Study 15:00
Speaker: Dongmei Yin (the Netherlands)

IgM Antiphospholipid Antibodies: Long Term Follow-up and Thrombotic Risk 15:15
Speaker: Taiki Sato (Japan)

Predictive Value of Thrombocytopenia in Antiphospholipid Syndrome 15:30
Speaker: Stéphane Zuily (France)

The Prothrombin/MHC Class II Complexes on Procoagulant Cells as the Novel Immune Target for Pathogenic Antiphospholipid Antibodies 15:45
Speaker: Naoki Ohnishi (Japan)

Oral Communication Session
14:45 - 16:00

Meeting Room 203/204

OC 24, VTE Therapy: Anticoagulants and Bleeding

Chair: Laura Young (New Zealand)
Chair: Zhenguo Zhai (China)

The Influence of Renal Impairment on Clinical Outcomes in Venous Thromboembolism Patients Enrolled in GARFIELD-VTE 14:45
Speaker: Shinya Goto (Japan)

Clinical Utility of Measuring DOAC Levels in Patients with Major Haemorrhage or Requiring Urgent Anticoagulation Reversal - Results from the Anticoagulation Reversal and Events Study (ARES) Collaborative 15:00
Speaker: Ross Ian Baker (Australia)

Evaluation of the Predictive Value of the Bleeding Prediction Score "VTE-BLEED" for Recurrent Venous Thromboembolism 15:15
Speaker: Frederikus Klok (the Netherlands)

Scientific Programme

- Major Bleeding Rates are Similar in Patients who Use DOACs with Interacting Antiarrhythmics as Compared with DOAC Monotherapy** 15:30
Speaker: Nienke van Rein (Denmark)
- Major Bleeding Rates are High in Patients with a High INR Combined with a G1639A SNP in the VKORC1 gene** 15:45
Speaker: Nienke van Rein (Denmark)

Oral Communication Session
14:45 - 16:00

Meeting Room 210/211

OC 25, Novel Prothrombotic Mechanisms

Chair: Klaus T. Preissner (Germany)
Chair: Simone M. Schoenwaelder (Australia)

- von Willebrand Factor as a Determinant of Silent Cerebral Micro-bleeds during Trans Aortic Valve Replacement in a Prospective Cerebral Magnetic Resonance Imaging Cohort** 14:45
Speaker: Sophie Susen (France)
- Angiopoietin-like Protein 8 Overexpression Aggravates Lipid Metabolism and Promotes Atherogenesis in Mice** 15:00
Speaker: Xiaolu Jiao (China)
- Platelet Function in Non-severe Burn Injury** 15:15
Speaker: Matthew Linden (Australia)
- Dense Fibrin, von Willebrand Factor and Extracellular DNA Are Specific Structural Hallmarks of Platelet-rich Areas in Ischemic Stroke Thrombi** 15:30
Speaker: Senna Staessens (Belgium)
- Platelet Receptor Sensitivity is Associated with Acute Changes in Ambient Air Pollutant Concentrations in a Pilot Study of Patients Presenting with Acute Myocardial Infarction** 15:45
Speaker: Scott Cameron (United States)

Oral Communication Session
14:45 - 16:00

Meeting Room 212/213

OC 26, Primary Immune Thrombocytopenia

Chair: Yoshiaki Tomiyama (Japan)
Chair: Lucy Coupland (Australia)

- Familial Immune Thrombocytopenia (ITP) and Hereditary Persistence of Fetal Haemoglobin (HPFH) Associated with a Pathogenic Variant of MYB** 14:45
Speaker: Ian M Morison (New Zealand)
- Receptor Editing Deficiency Causes B-Cell Central Intolerance and Autoantibodies Accumulation in Primary Immune Thrombocytopenia** 15:00
Speaker: Shuwen Wang (China)

Scientific Programme

Interleukin-37 Reduces Inflammation and Impairs Phagocytosis of Platelets in Immune Thrombocytopenia	15:15
Speaker: Guosheng Li (China)	
Autoantibody Mediated Changes in Platelets' Glycan Pattern: Potential Impact on Platelet Function and Lifespan in Immune Thrombocytopenia	15:30
Speaker: Jan Zlamal (Germany)	
TNF-α Blockade Corrects the Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia (ITP)	15:45
Speaker: Yajing Zhao (China)	

Oral Communication Session
14:45 - 16:00

Meeting Room 219/220

OC 27, Platelet Function and Disease

Chair: Debra K. Newman (United States)
Chair: Andrew Murphy (Australia)

High Thymic Stromal Lymphopoietin (TSLP) Expression Promotes Platelet Activation and Thrombosis in Kawasaki Disease via Promoting Mitophagy	14:45
Speaker: Xiaoqiong Gu (China)	
Characterisation of Platelet Microvesicles Containing Mitochondria and Their Interaction with Neutrophils	15:00
Speaker: Harriet E. Allan (United Kingdom)	
Immune Complexes (ICs) Recruit Platelets in the Synovial Fluid (SF) of Rheumatoid Arthritis (RA) Patients	15:15
Speaker: Eleonora Petito (Italy)	
R5421 is Not a Selective Inhibitor of Platelet Phosphatidylserine Exposure	15:30
Speaker: Sarah L. Millington-Burgess (United Kingdom)	
Microthrombocytopenia Accompanied by Cytoskeletal Defects in Platelets Lacking the Small GTPase RhoB	15:45
Speaker: Katja Aurbach (Germany)	

Oral Communication Session
14:45 - 16:00

Meeting Room 105

OC 28, Common Pathway

Chair: Shogo Tamura (Japan)
Chair: Laurent Mosnier (United States)

The Pseudonaja textilis Factor V A2 Domain C-terminus Mediates Lipid-independent Cofactor Activity and Functional Activated Protein C Resistance	14:45
Speaker: Mark Schreuder (the Netherlands)	

Scientific Programme

A mathematical Model of Flow-mediated Coagulation Identifies Factor V as a Modifier of Thrombin Generation in Hemophilia A	15:00
Speaker: Kathryn G. Link (United States)	
Probing Interactions between the Tissue Factor Exosite and the Light Chain of Factor X	15:15
Speaker: Fabienne Birkle (United States)	
An Inducible Mouse Model of Factor X Deficiency to Test Novel FX Therapeutics	15:30
Speaker: Sebastien Verhenne (France)	
Whole Genome Sequencing in a Severe Thrombophilic Family Revealed a SERPINC1 Defect Impairing Antithrombin Activity that is Not Detected by Current Functional Methods	15:45
Speaker: Pierre Fautrad (France)	

Oral Communication Session
14:45 - 16:00

Meeting Room 106

OC 29, Inflammation and Sepsis

Chair: Craig Jenne (Canada)
Chair: Connie Wong (Australia)

Platelets Suppress Antigen Specific CD8+ T Cells in Sepsis Through MHC Class I	14:45
Speaker: Li Guo (United States)	
Blocking Activated Factor XII with a Monoclonal Antibody Prevents Organ Failure and Saves Baboons Challenged with Heat-inactivated S. aureus	15:00
Speaker: Florea Lupu (United States)	
Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis	15:15
Speaker: Zhenyu Li (United States)	
The Mammalian Target of Rapamycin in Megakaryocytes and Platelets Regulates Mortality and Disease Severity in Sepsis	15:30
Speaker: Robert Campbell (United States)	
Sepsis Can Modify mRNA Levels by Dicer-dependent microRNAs in Megakaryocytes and Platelets to Generate Adverse Platelet Reactivity	15:45
Speaker: Béla Nagy Jr. (Hungary)	

Oral Communication Session
14:45 - 16:00

Meeting Room 109

OC 30, Cancer-Associated Thrombosis: Biomarkers

Chair: Marc Carrier (Canada)
Chair: Soo Mee Bang (Korea, Republic of)

Scientific Programme

Haemostatic Biomarkers for Prediction of Therapy Response and Prognosis of Disease in Patients with Metastatic Colorectal Cancer	14:45
Speaker: Florian Moik (Austria)	
Hemostatic and Non-hemostatic Functions of Magnesium Transporter MAGT1 in Mice	15:00
Speaker: Elmina Mammadova-Bach (Germany)	
Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Patients with Gastrointestinal Metastatic Cancer: Results from the HYPERCAN Study	15:15
Speaker: Marina Marchetti (Italy)	
Role of Neutrophils and Neutrophil Extracellular Traps in Mice Bearing Human Pancreatic Tumors	15:30
Speaker: Yohei Hisada (United States)	
NETs as Thrombotic Risk Indicators in Biliopancreatic Cancer Patients at Diagnosis	15:45
Speaker: Julia Oto (Spain)	

Laboratory Workshop
14:45 - 16:00

Meeting Room 218

Diagnostic Updates for the Hemostasis Laboratory

Chair: Emmanuel Falaloro (Australia)
Chair: Robert Charles Gosselin (United States)

Heparin Induced Thrombocytopenia (HIT) Testing	14:45
Speaker: Moniek P.M. de Maat (the Netherlands)	
Direct Oral Anticoagulants: Testing and Interference	15:10
Speaker: Robert Charles Gosselin (United States)	
von Willebrand Factor (VWF) Testing for von Willebrand Disease (VWD): An Update	15:35
Speaker: Emmanuel Falaloro (Australia)	

SSC Session
16:30 - 18:30

Melbourne Room 1

SSC Joint Session: Hemostasis and Malignancy and Predictive and Diagnostic Variables in Thrombotic Disease

Prediction and Treatment of Cancer-Associated Thrombosis Moderators: Jeffrey Zwicker <i>United States</i>, Pierre Morange <i>France</i>	
Impact of Prothrombotic Genotypes on Venous Thromboembolism Risk in Cancer	16:30
Speaker: John-Bjarne Hansen (Norway)	
Prediction of Venous Thromboembolism Risk in Cancer	16:50
Speaker: Cihan Ay (Austria)	

Scientific Programme

How to Diagnose Deep Vein Thrombosis and Pulmonary Embolism in Cancer	17:15
Speaker: Grégoire Le Gal (Canada)	
Assessment of Bleeding Risk in Anticoagulant Treatment of Cancer-Associated Thrombosis	17:40
Speaker: Frederikus Klok (the Netherlands)	
Modern Treatment of Cancer-Associated Thrombosis	18:05
Speaker: Marc Carrier (Canada)	

SSC Session
16:30 - 18:30

Melbourne Room 2

von Willebrand Factor

Guidelines for the Diagnosis and Management of von Willebrand Disease	16:30
Speaker: Nathan T. Connell (United States)	
International Microangiopathic Thrombocytopenia ADAMTS13 Standardisation (IMATAS) Collaborative Study	16:35
Speaker: Ross Ian Baker (Australia)	
Examining Current Practices in the Care of Pregnant Women With Low von Willebrand Factor / von Willebrand Disease - Survey Results	16:55
Speaker: Michelle Lavin (Ireland)	
Von Willebrand Factor Calibration Studies: A Report on SSC/ISTH Lot #5 (GPIIb-Binding Methods); A Proposal to Replace the WHO 2nd International Standard for von Willebrand Factor Concentrate	17:15
Speaker: Craig Thelwell (United Kingdom)	
Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping	17:35
Speaker: Matthew Auton (United States)	
ADAMTS13 Conformation in Thrombotic Thrombocytopenic Purpura	17:50
Speaker: Elien Roose (Belgium)	
Project Update: 3Winters-Ips and Interactive Registry on Acquired von Willebrand Syndrome Projects	18:05
Speaker: Augusto B Federici (Italy)	
Discussion	18:25

SSC Session
16:30 - 18:30

Meeting Room 203/204

Control of Anticoagulation

Moderators: Jovan P. Antovic, Sweden, Jonathan Douxfils France

Scientific Programme

Bleeding and Thrombotic Events After Resumption of Oral Anticoagulants Following Gastrointestinal Bleeding	16:30
Speaker: Walter Ageno (Italy)	
International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism	16:42
Speaker: Walter Ageno (Italy)	
Management of Cancer-Associated Thrombosis in Patients with Thrombocytopenia: Guidance from the SSC of the ISTH	16:54
Speaker: Marc Carrier (Canada)	
An International Registry of the Outcomes of Stents in Patients with Venous Thrombosis	17:06
Speaker: James Douketis (Canada)	
Survey on Anticoagulated Patients - Register (Start Scientific and Standardization Committee - the International Society on Thrombosis and Hemostasis)	17:18
Speaker: Walter Ageno (Italy)	
Ad Hoc Working Party to Guide the Laboratory Measurement of the ODIs	17:30
Speaker: Ismail Elalamy (France)	
Post-Bleed Management of Antithrombotic Therapy (PANTHER): A Mixed-Methods Study of Healthcare Providers	17:42
Speaker: Deborah M. Siegal (Canada)	
Discussion of New Projects and Q&A Session	17:54

SSC Session
16:30 - 18:30

Meeting Room 210/211

Pediatric and Neonatal Thrombosis Hemostasis

Moderators: Fiona Newall Australia, Sarah O'Brien United States

Heavy Menstrual Bleeding - Project Report	16:30
Speaker: Ayesha Zia (United States)	
Guidelines for In-Hospital Thromboprophylaxis in Children - A Survey	16:45
Speaker: Julie Jaffray (United States)	
Pulmonary Embolism- Current Status and Future Projects	17:00
Speaker: Madhvi Rajpurkar (United States)	
Asymptomatic Venous Thromboembolism - Project Report	17:15
Moderators: Manuela Albisetti <i>Switzerland</i>, Leslie Raffini <i>United States</i>	
Prognostic Factors of Post-thrombotic Syndrome in Pediatric Patients: Systematic Review and Recommendations for Future Research	17:30
Speaker: Marisol Betensky (United States)	
International Pediatric Thrombosis Network, Clinical Trial Network	17:45
Speaker: Heleen Van Ommen (the Netherlands)	

Scientific Programme

Debate: Are Controlled Clinical Trials of Anticoagulation Necessary and Feasible in Children? - No	18:00
Speaker: Paul Monagle (Australia)	
Debate: Are Controlled Clinical Trials of Anticoagulation Necessary and Feasible in Children? - Yes	18:15
Speaker: Christoph Male (Austria)	

SSC Session
16:30 - 18:30

Meeting Room 212/213

Vascular Biology

Extracellular Vesicles	
Workshop Update on the Comparison of the Assays to Measure Procoagulant Extracellular Vesicles in Plasma Samples	16:30
Speaker: Romaric Lacroix (France)	
Standardization of Vesicle Concentration Measurements by Calibration of Flow Cytometers: METVES II	16:45
Speaker: Johannes Thaler (Austria)	
Q&A session	17:00
Neutrophil Extracellular Traps	
Can We Standardize Measurement of Neutrophil Extracellular Traps and Their Biomarkers?	17:05
Speaker: Kim Martinod (Belgium)	
Detection and Quantification of Citrullinated Histone H3 in Human Blood Samples	17:20
Speaker: Charlotte Thalin (Sweden)	
Q&A session	17:35
Endothelial Progenitor Cells	
The Combinatorial Impact of Endothelial Colony-Forming Cells and Mesenchymal Stem Cells on Treating Vascular Disease	17:40
Speaker: Jatin Patel (Australia)	
Distinct Expression of Neuregulin-1 in Human Endothelial Colony-Forming Cells	17:55
Speaker: Juan Melero-Martin (United States)	
Introduction to Platelets - and a New Collaboration Project	18:10
Speaker: Emma Josefsson (Australia)	
Q&A session	18:25

Scientific Programme

SSC Session
16:30 - 18:30

Meeting Room 219/220

Platelet Physiology

Moderators: Jose Rivera <i>Spain</i>, Matthew Rondina <i>United States</i>

Overview of Platelet Physiology SSC and Projects 16:30

Speaker: Marie Lordkipanidzé (Canada)

Evaluation of the ISTH Bleeding Assessment Tool for the Assessment of Inherited Platelet Disorders: Laboratory Findings and 2 Year Follow-Up 16:40

Speaker: Paolo Gresele (Italy)

Diagnosis of Inherited Platelet Disorders on a Blood Smear: An Update 17:00

Speaker: Andreas Greinacher (Germany)

International Survey on Practices Surrounding the Conservation and Shipment of Platelets for Platelet Studies 17:15

Speaker: Marie Lordkipanidzé (Canada)

A Multicentric Comparison of Platelet Aggregation Agonists Against NIBSC Standards 17:30

Speaker: Marie Christine Alessi (France)

Biomarkers of in Vivo Platelet Activation: A Systematic Review and Meta-Analysis 17:45

Speaker: Sofia Ramstrom (Sweden)

Speaker: Marina Camera (Italy)

Procoagulant Platelets: A Collaborative Project with the Vascular Biology SSC 18:00

Speaker: Sofia Ramstrom (Sweden)

Speaker: Emma Josefsson (Australia)

Speaker: Marina Camera (Italy)

Call for Collaboration with the Platelet Immunology SSC 18:15

Speaker: Paolo Gresele (Italy)

Speaker: Donald M. Arnold (Canada)

Speaker: Tamam Bakchoul (Germany)

Nurses Forum
16:30 - 18:30

Meeting Room 111

Nurses Forum Day 1: Bleeding Disorders

Chair: Regina Butler (United States)

Chair: Sulochana Badagabettu (India)

Transitioning from Clinical Research to Clinical Care with Novel Therapies in Bleeding Disorders 16:30

Speaker: Madeline Cantini (United States)

MSKUS - Professional Approach to New Therapies 17:00

Speaker: Mary Lesh (United States)

Scientific Programme

Nursing Role in Decision Making with Adult Patients and Families (Cost, Products, QOL, etc.)	17:30
Speaker: Anne-Louise Cruickshank (South Africa)	
Nursing Role in Decision Making with Pediatric Patients and Families (Cost, Products, QOL, etc.)	17:45
Speaker: Robyn Shoemark (Australia)	
Case Presentation - New Therapies	18:00
Speaker: James E. Munn (United States)	
Case Presentation - New Therapies	18:15
Speaker: BJ Ramsay (New Zealand)	

Nurses Forum
16:30 - 18:30

Meeting Room 112

Nurses Forum Day 1: Thrombosis & Anticoagulation

Chair: Bunis Packham (United Kingdom)
Chair: José Miguel Rivera Caravaca (Spain)

Future Direction for Caring for Adult Thrombosis Population	16:30
Speaker: Bunis Packham (United Kingdom)	
Future Direction for Caring for Pediatric Thrombosis Population	17:00
Speaker: Hollie Gilmore (Australia)	
AC Decision Making for Patient with Atrial Fibrillation and Families	17:30
Speaker: José Miguel Rivera Caravaca (Spain)	
Case Presentation: Pediatric Thrombosis	18:00
Speaker: Jennifer Meldau (United States)	
Case Presentation: Adult Thrombosis	18:15
Speaker: Laurie Sardo (Canada)	

Posters
18:30 - 19:30

Exhibition Hall

Poster Networking Session

Arterial Thromboembolism- Anticoagulant Therapy

Off-label Dose Reduction of Direct Oral Anticoagulants in Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analysis

Speaker: Linda Joosten (the Netherlands)

Effect of Switching from Well-controlled Vitamin K Antagonists to a Direct Oral Anticoagulant for Atrial Fibrillation on Quality of Life: Little to GAIN

Speaker: Jasper H.A. van Miert (the Netherlands)

Scientific Programme

Real-Life Anticoagulant Treatment with Edoxaban in Patients with Atrial Fibrillation and Venous Thromboembolism: A Subanalysis of Patients with Creatinine Clearance Greater than 95 ml/min. Experience of 26 Months in Our Centre

Speaker: Pablo Romero Garcia (Spain)

Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation

Speaker: Sandra Margetić (Croatia)

The Impact of an Educational Intervention in Patients with Atrial Fibrillation Treated with Warfarin: Protocol of a Clinical Trial

Speaker: Luci Dusse (Brazil)

Oral Anticoagulant Therapy in Patients with Atrial Fibrillation and Flutter in Macedonia

Speaker: Rada Grubovic Rastvorceva (Macedonia, the Former Yugoslav Republic of)

Arterial Thromboembolism - Atherosclerosis

Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients with Severe Coronary Artery Disease. The ROADMAP-CAD Study

Speaker: Patrick Van Dreden (France)

Efficacy of Immunomodulatory Therapy for Atherosclerosis-role of Tolerance and Protective Antibodies

Speaker: Xinjie Lu (United Kingdom)

Coronary High-signal-intensity Plaques on T1-weighted Magnetic Resonance Imaging Reflect Intraplaque Hemorrhage: A Novel Marker for Plaque Instability and Thrombogenic Potential

Speaker: Kuroiwa Yasuyoshi (Japan)

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Promote Melanoma Cell-induced Lung Cancer in B6;129s-Ldlrtm1herApobtm2sgy/J mice

Speaker: Xinjie Lu (United Kingdom)

The Prevalence and Genetic Basis of Sitosterolemia in a Group of Turkish Patients

Speaker: Zuhre Kaya (Turkey)

Biochemical and Hemostatic Predictors of Asymptomatic Carotid Atherosclerosis

Speaker: Kostiantyn Stepanchenko (Ukraine)

Large-scale Screening for Membrane Protein Interactions Involved in Platelet-monocyte Interactions

Speaker: Yi Sun (United Kingdom)

Developing of a New Hamster Carotid Artery Model of Atherothrombotic Occlusion: Monitored by Color Doppler Ultrasonography and Histopathology

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Lipid-based Encapsulated Methotrexate Nanoparticles - Mediated Photodynamic Therapy Decreases Inflammation and Restenosis after Laser Angioplasty of Carotid Artery Atherosclerotic Occlusion

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Docetaxel Administration Enhances Ultrasound-guided 5-aminolevulinic Acid-loaded Microbubbles Administration - Mediated Photodynamic Therapy of Intermediate Stage Atherosclerosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Scientific Programme

Encapsulated Methotrexate Nanoparticles Administration Enhances Verteporfin-mediated Sono-photodynamic Combination Therapy of Early Stage Atherosclerosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Focused-ultrasound Therapy Accompanied by High-dose Fluvastatin-loaded Microbubbles Administration for Improving of Endothelial Dysfunction

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Radiofrequency Thermal Balloon Angioplasty Accompanied by Verteporfin Administration Reduce Neointimal Hyperplasia

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Shock Wave-photomechanic Combination Therapy of Carotid Artery Atherothrombosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Intravenous Docetaxel Administration Enhance Ultrasound-guided Encapsulated Methotrexate Nanoparticles - Mediated Photodynamic Therapy of Intermediate Stage Atherosclerosis in the Hamster Carotid Artery

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Lipid-based Encapsulated Paclitaxel Nanoparticles Administration Enhances 5-aminolevulinic Acid- Loaded Microbubbles-mediated Sonodynamic Therapy of Early Stage Atherosclerosis in the Hamster Carotid Artery

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Ultrasound-guided Sonotherapy of Intimal Hyperplasia Accompanied by 5-aminolevulinic Acid-loaded Microbubbles Administration

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Arterial Thromboembolism - Myocardial Infarction

Joint Effect of Acute Myocardial Infarction on Markers of Haemostasis Lipoprotein(a) and C-Reactive Protein

Speaker: Syed Shahid Habib (Pakistan)

Current Status of Lipid-lowering Therapy and Low-density Lipoprotein Cholesterol Goal Achievement in Hospitalized Acute Coronary Syndrome Patients in Fuzhou, China: A Retrospective Real World Study

Speaker: Hongxin Zhao (China)

Free Ubiquitin Attenuates Myocardial Ischemia-reperfusion Injury by Inhibiting Cardiomyocyte Apoptosis and Inflammatory Response

Speaker: Jialu Yao (China)

Current Status of Korea Acute Myocardial Infarction Registry

Speaker: Myung Ho Jeong (Korea, Republic of)

Role of Phospholipase D in Processes of Myocardial Healing after Myocardial Ischemia and Reperfusion Injury in Mice

Speaker: Meike Klier (Germany)

High Prevalence of Inherited Thrombophilia and Antiphospholipid Syndrome in Myocardial Infarction with Non-obstructive Coronary Arteries: Comparison with Cryptogenic Stroke

Speaker: Anetta Undas (Poland)

Inhibition of Coagulation Factor XI Decreases Cardiac Inflammation and Impairs Survival in a Mouse Model of Myocardial Infarction

Speaker: Michael Molitor (Germany)

Scientific Programme

Lysozyme M+ Inflammatory Monocytes and their Activation Signaling by Angiotensin II Are Responsible for Vascular Endothelial Dysfunction in Heart Failure due to Myocardial Infarction

Speaker: Michael Molitor (Germany)

Coagulation and Anticoagulation - Microparticles

Microparticules Released by Myeloma Plasma Cells Enhance Thrombin Generation in the Microenvironment. A Modelization in vitro Study

Speaker: Patrick Van Dreden (France)

Microparticles: An Initiator of Thrombosis: The 18500 Feet Martse Mik la Experiment

Speaker: Prosenjit Ganguli (India)

Transmission of Tissue Factor Activity to Daughter Generations of Endothelial Cells upon Exposure to Cancer Cell-derived Microparticles

Speaker: Patrick Van Dreden (France)

New Generation Flow-Cytometry to Measure Circulating Microvesicles in Cancer

Speaker: Elena Campello (Italy)

Major Histocompatibility Complex Class I Related Chain A/B Positive Microparticles Associate with Severity of Acute Coronary Syndrome

Speaker: Songpol Haohan (Thailand)

Endothelial- and Monocyte-Derived Microparticles Associate with the Presence of Acute Coronary Syndrome

Speaker: Nantararat Komanasin (Thailand)

Phospholipid-dependent Procoagulant Activity and Risk of Venous Thrombosis in Patients with Lower-leg Injury or Knee Arthroscopy

Speaker: Carolina Eveline Touw (the Netherlands)

Platelet Microparticles Containing MicroRNA as a Marker of the Antiplatelet Therapy's Effectiveness

Speaker: Olga Sirotkina (Russian Federation)

Modulation of Microparticles Sub-populations and Thrombosis in Paroxysmal Nocturnal Hemoglobinuria Maybe Linked by Eculizumab Therapy

Speaker: Nour C. Bacha (France)

Coagulation and Anticoagulation - Thrombotics and Antithrombotics

The Therapeutic Potential of Heparin-binding Copolymer as an Inhibitor of Heparan Sulfate

Speaker: Andrzej Mogielnicki (Poland)

The Biologically Active Anticoagulant Substance from Pions

Speaker: Margarita Lyapina (Russian Federation)

Ir-CPI, a FXIa/FXIIa Inhibitor, Provides an Effective and Safe Thromboprotection During Extracorporeal Circulation Associated with Open-heart Surgery

Speaker: Valérie Pireaux (Belgium)

Evaluation of Hemostasia in the Search of New Anticoagulants of Natural Products: Mikania Laevigata

Speaker: Luci Dusse (Brazil)

Scientific Programme

Antithrombotic Effect of the Chimeric (Recombinant Form) of Bauhinia bauhinioides Kallikrein Inhibitor and its Structurally Related Peptide in the Experimental Arterial Thrombosis Model in Mice

Speaker: Maria Luiza Vilela Oliva (Brazil)

FVII: A Human Pluripotent Stem Cell Derived Hepatocyte Model with Potential Therapeutic Applications

Speaker: Maria Eugenia Chollet Dugarte (Norway)

Synthesis of Lactulose Octasulfate (LOS) its Anticoagulant Effect on Human Antithrombin and Evaluation of its Role in In Vitro Clot Formation

Speaker: Irshad Ahmad (India)

A Way to Make Rodent FXIa Accessible to Human FXIa Small Molecule Inhibitors

Speaker: Mayken Visser (Germany)

Coagulation and Anticoagulation - Tissue Factor Pathway

Thrombin Generation in Trauma Patient Plasma

Speaker: Saulius Butenas (United States)

TF-dependent Thrombin Generation of Circulating Cells: Redefining the Contribution of Platelets, Leukocytes and Microvesicles

Speaker: Marta Brambilla (Italy)

A Flexible Serine Loop in the Tissue Factor Ectodomain is a Potential Allosteric Linker between the Phospholipid Membrane and the Tissue Factor Exosite

Speaker: Fabienne Birkle (United States)

Simulations of Diffusion-mediated Factor Xa Generation by Surface Bound Tissue Factor

Speaker: Christian J. C. Biscombe (Australia)

Supraphysiological Intrahepatic Bile Acid Concentrations Induce Tissue Factor Activity in Hepatocytes

Speaker: Axel Schlagenhauf (Austria)

Mapping the Interaction between Phosphatidylserine and the Gla Domain of Coagulation Factor X

Speaker: Divyani Paul (United States)

TFPI Gene Polymorphisms (399C>T, 287T/C): Do They Predict High DVT Risk in Young Indians?

Speaker: Kamal Kishor (India)

Apixaban Suppresses the Release of TF-positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity

Speaker: Sophie Featherby (United Kingdom)

Excess Tissue Factor Is Preferentially Cleared from Endothelial Cells Through Microvesicle Release and Then, by Caveolae-mediated Internalisation, Through a Mechanism Requiring fVIIa

Speaker: Yahya Madkhali (United Kingdom)

The Ratio of Factor VIIa: Tissue Factor Content within Microvesicles Determines the Differential Influence on Endothelial Cells

Speaker: Yahya Madkhali (United Kingdom)

Scientific Programme

The Cellular Location of Tissue Factor is Constrained by MAGI-1 and Is Released by PAR2 Activation

Speaker: Mohammad Mohammad (United Kingdom)

Long Term Exposure to Tissue Factor Induce Cell Proliferation by Lowering PTEN Protein Levels

Speaker: Mohammad Mohammad (United Kingdom)

Coagulation and Anticoagulation - von Willebrand Factor Biology and Assays

Ex-vivo Trial of BT200 in Healthy Volunteers after Receiving Desmopressin or Endotoxin

Speaker: Katarina D. Kovacevic (Austria)

Evaluation of Platelet-dependent VWF Activity on a Heterogeneous Group of von Willebrand Disease Patients Using Four Different Methods: Two VWF:GPIbM and Two VWF:RCo Assays

Speaker: Luciano Baronciani (Italy)

Mechanisms for the Clearance and Recycling of Recombinant VWF D'D3 Albumin Fusion Protein

Speaker: Kim Lieu (Australia)

Identification of Murine Macrophage Galactose Lectin 2 as a Novel VWF Clearance Receptor Sheds Light on Differential Clearance Pathways for Hyposialylated VWF Variants

Speaker: Soracha Ward (Ireland)

VWF Production and Secretion, and Endothelial Cell Characteristics in Healthy ECFCs; Generating a Valid ex vivo Model for VWD

Speaker: Suzan de Boer (the Netherlands)

Mapping of von Willebrand Factor A1 Domain Binding Site on Collagen Toolkits II, III and XIII

Speaker: Samir Hamaia (United Kingdom)

Digestion of ADAMTS13 by Plasmin in Human Plasma Increase the Risk of Thrombotic Thrombocytopenic Purpura

Speaker: Yongchol Shin (Japan)

Cleavage of von Willebrand Factor Multimers and Fibrinogen in Human Plasma by Plasmin: Effects on Hemostasis Response

Speaker: Kenshi Togashi (Japan)

The Transcriptional Coactivators, YAP and TAZ Regulate Expression of the von Willebrand Factor Gene

Speaker: Elham Ghorbanpour (Canada)

Unshielding the A2 Domain of von Willebrand Factor (VWF): The Novel Function of the Core A2 Domain in Fibrin Clot Formation

Speaker: Christian Valladolid Brown (United States)

Diagnostics and OMICs - Blood Components and Management

Clinical Audit of Prescriptions for Platelet Therapy Using Computerized Physician Order Entry (CPOE)

Speaker: Bushra Moiz (Pakistan)

Diagnostics and OMICs - Cellular Therapy

Scientific Programme

Prolonged Chemotherapeutic Stress is Accompanied by Pro-invasive Signaling in Colorectal Cancer Models

Speaker: Patrick Van Dreden (France)

Circulating Intranuclear Proteins May Play a Role in Development of Coagulopathy Following Remission Induction Chemotherapy in Individuals with Acute Leukemia

Speaker: Kayo Harada (Japan)

Human Platelets Strongly Interact with Glioblastoma (GBM) Cells: Development of a RNAi-transfected Platelet Strategy for Treatment of Relapsing Glioblastoma

Speaker: Loredana Bury (Italy)

Diagnostics and OMICs - Epigenetics, OMICs and Bioinformatics

Global Distribution of CYP2C19 Genetic Polymorphisms Affecting Safety or Efficacy of Cardiovascular Medications

Speaker: Mohitosh Biswas (Bangladesh)

DIGEVAR, a Novel Software for User-Friendly Analysis of High-Throughput Sequencing Gene Variants in Inherited Platelet Disorders

Speaker: Jose Rivera (Spain)

Identification of a Shared Transcriptomic Signature between Sickle Cell Disease and Acute Myocardial Infarction Patients

Speaker: Erich Vinicius de Paula (Brazil)

A Single-cell Survey Reveals a Subpopulation of Mesenchymal Stem Cell Enriched with Coagulation Function

Speaker: Yuchen Gao (China)

Analysis of Antiproliferative Effect of Ankaferd Blood Stopper over caco-2 Cancer Cells Via Untargeted Proteomics Approach

Speaker: İbrahim Celalettin Haznedaroğlu (Turkey)

Transcriptomics Analysis of Melanoma Tumors Treated with Amblyomin-X, a Kunitz-type FXa Inhibitor, Searches for Pathways and Drug Targets

Speaker: Flavio Lichtenstein (Brazil)

Accurate Quantification of Nucleosome Citrullination for Next-generation Drug Discovery and Biomarker Development

Speaker: Andrea L. Johnstone (United States)

Diagnostics and OMICs - Laboratory Diagnostics: General and Other

Spatial Thrombin Generation in Platelet-rich Plasma: Sensitivity to the Alterations of Blood Coagulation and Platelet Function

Speaker: Anna Balandina (Russian Federation)

The Influence of FXII Deficiency on aPTT in Critically Ill Patients: A Common and Underestimated Problem

Speaker: Mirjam Bachler (Austria)

Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis

Speaker: Fakiha Siddiqui (United States)

Evaluation of Lupus Anticoagulant Interference in a Chromogenic Factor IX Kit for Determination of Factor IX Activity

Speaker: Pia Bryngelhed (Sweden)

Scientific Programme

Quantitative Determination of the Activity of Unfractionated Heparin and Low-molecular-weight Heparin in Plasma Using a Single Calibration Curve for Both Heparin Types: Performance Data Using a Chromogenic Assay Kit and Calibrator in Combination with Specific Applications for Four Different Coagulation Analyzers

Speaker: Matthias Wilkens (Germany)

Analytical Validation of Atellica COAG 360 System

Speaker: Renata Zadro (Croatia)

Study on the Effect of Sulodexide on Blood Coagulation Tests and Clot Formation. Comparison with UFH, LMW, Fondaparinux and DOACs

Speaker: Patrick Van Dreden (France)

Comparison of Antithrombin-dependent and Direct Inhibitors of Factor Xa or Thrombin on the Kinetics and Qualitative Characteristics of Blood Clots

Speaker: Patrick Van Dreden (France)

Bringing Thrombin Generation into the Diagnostic Setting: Standardisation and Establishment of Normal Reference Intervals for a Commercial Thrombin Generation System

Speaker: Sarah Just (Australia)

Comparison of Paired Placental and Venous Neonatal Blood Samples for Coagulation Assay

Speaker: Erica Scalabrino (Italy)

The Comparison of the Usefulness of the Four Diagnostic Criteria for DIC in Predicting Prognosis

Speaker: Yasumasa Kawano (Japan)

Analytical Performance of the Free Protein S Assay on the Cobas t 711 Analyser

Speaker: Steve Kitchen (United Kingdom)

Development of a Functional Assay to Measure Factor V-short in Plasma

Speaker: Elisabetta Castoldi (the Netherlands)

A Novel, Point-of-Care (POC), Hand-held Meter & Strip, Viscoelastic Coagulation Diagnostic Platform for Thromboelastography (TEG) Measurement

Speaker: Abhishek Ramkumar (United States)

Determining the Specificity of Commercially Available Thrombin Substrates

Speaker: Slavica Praporski (Australia)

Comparative Study between Thromboelastography and Conventional Coagulation Tests in Ischemic Cerebral Vascular Disease

Speaker: Bin Yan (China)

Performance Data of Four Assays for Determination of Coagulation Protein Antigen Levels on the Siemens Atellica COAG 360 System

Speaker: Silke Echternacht (Germany)

Interference of the Direct Factor Xa Inhibitors Rivaroxaban and Apixaban in the Determination of FVIII Using Dade Actin FS and Dade Actin FSL Reagents

Speaker: Matthias Wilkens (Germany)

Comparison of Thrombin Generation Measured with Calibrated Automated Thrombography versus ST Genesis in Patients with Chronic Liver Disease

Speaker: Lara Roberts (United Kingdom)

Scientific Programme

Analytical Performance of the Lupus Screen and Lupus Confirm Assays on the Cobas t 711 Analyser

Speaker: Gergely Rozsnyai (Switzerland)

A Diagnostic Solution for Specialist Haemostasis Testing on DOACs

Speaker: Will Thomas (United Kingdom)

Analytical Performance of the Factor X Assay on the Cobas t 711 Analyser

Speaker: Steve Kitchen (United Kingdom)

Multicenter Study of the Mid-volume Sysmex CS-2500 System Compared to the Sysmex CA-1500 System Using Reagents from Siemens Healthineers (Product Availability Varies by Country)

Speaker: Roland Barten (Germany)

Multicenter Study of the High-volume Sysmex CS-5100 System Compared to the Sysmex CA-1500 System Using Reagents from Siemens Healthineers (Product Availability Varies by Country)

Speaker: Roland Barten (Germany)

Integration of Routine Coagulation Tests on a Total Laboratory Automation (TLA) Platform in an Academic Laboratory in South Africa

Speaker: Susan Louw (South Africa)

Evaluation of the Performance Characteristics of a Commercial Lyophilized Normal Pool Plasma for Utilization in the Routine Coagulation Laboratory

Speaker: Susan Louw (South Africa)

Performance Evaluation of Automated C1 Esterase Inhibitor Measurement on the New Coagulation Analyzer Ceveron c100

Speaker: Lieselotte Wagner (Austria)

Assessment of in vitro Effects of Bivalent Direct Thrombin Inhibitors, Hirudin and Bivalirudin, through Clot Waveform Analysis of the Activated Partial Thromboplastin Time Measurement and Enzyme Kinetics in the Clauss Fibrinogen Measurement

Speaker: Yuta Fujimori (Japan)

Effect of Dabigatran in the very Elderly on Thrombinography and Fibrinography Parameters as Assessed with the Thrombodynamics® System

Speaker: Virginie Siguret (France)

A Method to Quantify Alpha- and Beta-Antithrombin in Plasma

Speaker: Helen Atkinson (Canada)

Analytical Measuring Range of Exogenous Coagulation Factors Assays with a New Extraction Thromboplastin

Speaker: Audrey Carlo (France)

Comparison of Two Thromboplastin Reagents for Exogenous Coagulation Factor Quantitative Determination

Speaker: Audrey Carlo (France)

Reference Range of Platelet Function Analyzer-100 Closure Time (CT) in Thai Adolescent

Speaker: Narin Khongjaroensakun (Thailand)

Exclusion of Heparin-induced Thrombocytopenia by a Rapid Lateral-Flow Immunoassay. Comparison to an Immunoturbidimetric Assay: Preliminary Results

Speaker: Marina Sol Lopez (Argentina)

Scientific Programme

Evaluation of Coagulation Profile in Patients with Adrenal Incidentaloma: A Two-center Observational Study

Speaker: Elena Campello (Italy)

Establishment of a Healthy Donor Reference Range for the T-TAS 01 PL Chip

Speaker: Jeffrey Dahlen (United States)

Analytical Performance Characteristics of the T-TAS 01 PL Chip Assay

Speaker: Jeffrey Dahlen (United States)

Estimation of the Influence of Hbb Mutation Site for the Screening Ability of Calculated Rbc Indices in β -thalassemia Minor

Speaker: Soyoung Shin (Korea, Republic of)

Identifying Reasons of Excessive Coagulation Testing in Medically Ill Patients - a Sneak Peek

Speaker: Sidra Asad Ali (Pakistan)

Thromboelastography Parameters in Normal Pregnancies

Speaker: Elvira Grandone (Italy)

Converting the Distinct Heparins Sourced from Bovine or Porcine Mucosa into a Single Anticoagulant Drug

Speaker: Stephan-Nicollas M. C. G. de Oliveira (Brazil)

Ongoing Improvements in Laboratory Performance of Coagulation Factors VIII and IX: Recent Experience from the RCPAQAP

Speaker: Emmanuel Favaloro (Australia)

Are Global Coagulation Assays Better Measures of the Intensity of Anticoagulation in Patients with Antiphospholipid Syndrome?

Speaker: Wan Hui Wong (Singapore)

A Rapid, Practical and Ergonomic Device to Prepare Plasma Sample Free of Platelets and Direct Oral Anticoagulant for Routine Hemostasis Tests

Speaker: Damien Gheldof (Belgium)

Pronounced Alterations of Thrombin Generation Profiles are Found in Whole Blood Compared to Plasma of Liver Disease Patients

Speaker: Jun Wan (the Netherlands)

Performance Evaluation of a Homogeneous PAI-1 Immunoassay on an Automated Coagulation Analyzer

Speaker: Silke Echternacht (Germany)

High Speed Centrifugation in Resolving Lipaemic Interference on an Automated Coagulation Analyser

Speaker: Vishnu Prasad (Singapore)

Effects of Hemolysis on Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) Clot Waveform Analysis (CWA)

Speaker: Yu Ling Clarice Lee (Singapore)

Antithrombin - Prothrombin Balance in Cirrhosis-associated Hypercoagulability

Speaker: Aurelien Lebreton (France)

Evaluation of a New High-throughput Haemostasis Analyser Using Coagulation, Amidolytic, Immuno-turbidometric and Light Transmission Aggregometry Assays

Speaker: Ian Mackie (United Kingdom)

Scientific Programme

Thromboelastography Assessment of Whole Blood Fibrinogen Concentration: An Ex-vivo Supplementation Model

Speaker: Joao. D Dias (Switzerland)

The New QXpert Analyser Is Suitable for Routine Use in High Volume Haemostasis Laboratories

Speaker: Anita Woolley (United Kingdom)

Assessment of the Efficacy and the Impact of the Rapid, Practical and Ergonomic DOAC & Platelets Filter Device on Thrombin Generation Assay

Speaker: Damien Gheldof (Belgium)

Thromboelastography Cartridge-based System Measurements Reflect Both Platelet Count and Function Contribution to Clot Formation: An Ex-vivo Evaluation

Speaker: Joao. D Dias (Switzerland)

Inter-reagents Agreement of D-dimer Test Results in the Low Range of Concentrations

Speaker: Pierre Toulon (France)

A Practical Method for Reducing the Interference due to Lipaemia in Coagulation Tests

Speaker: Ian Mackie (United Kingdom)

External Quality Assessment Scheme for Haemostasis Laboratories in India - Challenges and Opportunities

Speaker: Alok Srivastava (India)

Thrombin Generation Measurement Using the Automated ST Genesia Thrombin Generation System in Healthy Adults and Some Adult Patients

Speaker: Sara Calzavarini (Switzerland)

An SFMC and D-d Level According to Each Japanese Generation (Above 50 Years Old)

Speaker: Kazuo Kawasugi (Japan)

Coagulation Factors, Antithrombin, Protein C, Protein S Activity and vWF Antigen Levels of Tibetan Adults in China

Speaker: Weiling Shou (China)

Diagnostics and OMICs - Laboratory Diagnostics: Thrombosis

Responsiveness of the Activated Partial Thromboplastin Time (APTT) and Dilute Thrombin Time (dTT) to Argatroban: Results of a in vitro Study

Speaker: Erica Scalabrino (Italy)

Mechanisms of Paradoxical Prolongation of Clot Lysis Time by a Direct Thrombin Inhibitor Melagatran: Comparison with a Direct Factor Xa Inhibitor Edoxaban

Speaker: Yoshiyuki Morishima (Japan)

Heterogeneous Effect of Direct Oral Anticoagulants on Lupus Anticoagulant Assays

Speaker: Tomas L. Lindahl (Sweden)

Performance Evaluation of the INNOVANCE Free PS Ag Assay on the Sysmex CS-5100, Sysmex CS-2500 and the BCS XP Systems

Speaker: Angela Doimo (Germany)

High Variability in Rivaroxaban and Apixaban Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessed with Thrombin Generation in Patients over 80 Years

Speaker: Virginie Siguret (France)

Scientific Programme

A Novel, Point-of-Care (POC), Hand-held Meter & Strip, Viscoelastic Coagulation Diagnostic Platform for Anticoagulation Therapy Monitoring

Speaker: Abhishek Ramkumar (United States)

Neutralising Rivaroxaban Induced Interference in Laboratory Testing for Lupus Anticoagulant (LA): A Comparative Study Using DOAC Stop and Andexanet Alfa

Speaker: Emmanuel Favalaro (Australia)

Coagulation Function Tests to Measure Direct Oral Anticoagulant (DOAC) Levels: Comparison of Routine and DOAC-specific Tests in the PAUSE Study

Speaker: James Douketis (Canada)

Measuring the Anticoagulant Effect of Direct Oral Anticoagulants Targeted to Factor Xa Using the Ratio of Inhibited Thrombin Generation based on Dilute Prothrombin Time: Results from Multicenter Study

Speaker: Kazumasa Ohmura (Japan)

Analytical and Clinical Performance of 5 Recently Introduced Point-of-Care D-dimer Assays to Rule-out Venous Thrombo-embolism in Primary Care

Speaker: Geert-Jan Geersing (the Netherlands)

Correlation of TEG6S with Rivaroxaban level: An Advancement in Point-of-Care Testing

Speaker: Matthew Neal (United States)

Retrospective Review of the Impact of Performing Triage on Hypercoagulability Tests

Speaker: Kathryn Hogan (United States)

Evaluation of Anti-factor Xa Assays for Monitoring Indirect Xa Inhibitors Using External Quality Data

Speaker: Piet Meijer (the Netherlands)

Evaluation of Single-site and Multisite Precision of Apixaban Assay

Speaker: Audrey Carlo (France)

A Fluorescence Resonance Energy Transfer (FRET)-Based Protein Substrate for Measuring Thrombin Activity

Speaker: Ying Dai (Canada)

DOAC Filter Efficacy and Interest in Patients Undergoing LA Testing

Speaker: Audrey Carlo (France)

Accuracy of DOASENSE Dipstick for Assessing Patients Treated Peri-operatively with DOACs - Pilot Study

Speaker: Job Harenberg (Germany)

Characterization by 5 Different Methods of 16 Structural Variants in SERPINC1 Causing Antithrombin Deficiency

Speaker: Javier Corral (Spain)

Activated Charcoal Is an Effective in vitro Removal Agent of Dabigatran and Rivaroxaban in Plasma of Patients Who Need Lupus Anticoagulant Testing

Speaker: Ivana Celap (Croatia)

Activated Charcoal for Lupus Anticoagulant Diagnosis in Patients Treated with Direct Oral AntiCoagulants: Results of a Multicenter Study

Speaker: Virginie Siguret (France)

Scientific Programme

Hypertriglyceridemia Is Associated with Increased Thrombin Generation in Plasma

Speaker: Gian Luca Salvagno (Italy)

Use of a Novel Assay to Measure Anti-factor Xa Direct Oral Anticoagulant Levels in the Plasma Samples from the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Speaker: Luca Di Giuseppantonio (Canada)

Evaluation of DOAC-Stop® to Eliminate the Interference of Direct Oral Anticoagulants on Thrombophilia Assays

Speaker: Joseph Rigano (Australia)

Assessment of an Adsorbent Product to Neutralise the Effect of DOACs on Coagulation Testing

Speaker: Joanne Clifford (Australia)

Comparison of the Effects of Doacs on Clot Waveform and Thrombin Generation

Speaker: Jonathan Evrard (Belgium)

Mixing Study to Establish the Diagnosis of Type II Antithrombin Deficiency: A Case Report

Speaker: Mihir Bhatt (Canada)

Improved Correlation between DOAC Concentrations and Clotting Test Results using the Correction Ratio (before/after DOAC Stop)

Speaker: Thomas Exner (Australia)

Lack of Agreement between Different Anti-Xa Assays to Measure Low Molecular Weight Heparin (LMWH); Results of a UK NEQAS Blood Coagulation Study

Speaker: Ian Jennings (United Kingdom)

Dark-coloured Urine Impacts Test Results of the Novel DOAC Dipstick Point-of-Care Strip Test

Speaker: Bernd Jilma (Austria)

Chronometric vs Structural Hypercoagulability

Speaker: Carmen Delianu (Romania)

A Factor Xa Inhibitor Antidote (Andexanet Alfa) Is Capable of Neutralizing the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin in a Comparable Manner as Protamine Sulfate

Speaker: Fakiha Siddiqui (United States)

The (Fab)ulous Destiny of Idarucizumab: Highlighting the Interference with Urine Protein Immunofixation

Speaker: Nicolas Gendron (France)

Measurement of Anti-FIIa Activity of Bivalirudin in Plasma with Clotting and Chromogenic Assays

Speaker: Claire Dunois (France)

Neutralization of Heparin Interferences in DOACs' Measurement with Anti-Xa Chromogenic Assays

Speaker: Claire Dunois (France)

Bio-assay for the Measurement of Anti-FXa Activity of Edoxaban and its Metabolites in Plasma

Speaker: Claire Dunois (France)

Scientific Programme

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect their Biologic Spectrum

Speaker: Fakiha Siddiqui (United States)

Monitoring of Direct Oral Anticoagulants with STG-Drugscreen on Automated Analyzer ST Genesis

Speaker: Thomas Siegemund (Germany)

Prothrombinase Induced Clotting Time Is More Sensitive than aPTT and PT and Can Be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Speaker: Fakiha Siddiqui (United States)

Simple Anti-Xa-Activity Measurements Allow for an Easy Scaling of DOAC Levels

Speaker: Florian Prüller (Austria)

Hemophilia and Bleeding - Hemophilia: Basic

Study of the Serum Immunoglobulin and Cell-mediated Immunity in Patients with Congenital Severe Hemophilia

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Biochemical Evidence and Functional Effects of Molecular Aggregation of Marketed Recombinant FVIII Products

Speaker: Raimondo De Cristofaro (Italy)

Quality Control in Hemophilia: Performance Evaluation of Eighteen Laboratories in Argentina

Speaker: Pablo Martinez (Argentina)

How Patients with Bleeding Disorders from an Outpatient Haemophilia Treatment Centre in Germany Perceive their Health-related Quality of Life, Physical Functioning and How Satisfied they Are with their Treatment

Speaker: Sylvia von Mackensen (Germany)

FVIII Knock out Mice Treated with aPCC Reveal Thrombogenic Activity when Coadministered with Bispecific-FIX/FX Antibody

Speaker: Werner Hoellriegl (Austria)

High Prevalence of Recurrent F8 Genotypes in the First Series of Argentine Patients with Mild Hemophilia A

Speaker: Liliana Rossetti (Argentina)

A Survey of Physicians' Treatment Switching Practice in Long-term Prophylaxis for People with Haemophilia B in five European Countries

Speaker: Sally Tawil (Sweden)

Pharmacokinetic and Pharmacodynamic Profiles of Polysialylated and Pegylated rFVIII Indicate Consistent Extended Half-life Potential in Rodents and Monkey

Speaker: Werner Hoellriegl (Austria)

Physical Activity and Treatment Adherence in Persons with Hemophilia Receiving Standard Half-Life (SHL) vs. Extended Half-Life (EHL) Replacement Factor VIII (FVIII): Findings from the HemACTIVE Patient Survey

Speaker: Mark Skinner (United States)

Factor VIII Pharmacokinetics Associate with VWF Clearance, VWF-FVIII Binding Activity, and Variants in the CLEC4M Gene in an Adult Hemophilia A Population

Speaker: Kenichi Ogiwara (Japan)

Scientific Programme

A Complex F8 Rearrangement Associated with Template Switching and int1h-related Homologous Recombination in a Patient with Severe Hemophilia A

Speaker: Mahiru Tokoro (Japan)

Favourable Recombinant Factor IX Pharmacokinetics Outcomes in Severe Hemophilia B Patients with FIX Activation Site Mutations

Speaker: Alessio Branchini (Italy)

Evaluation of Single-site and Multisite Precision of Factor IX Measurement

Speaker: Claire Martin (France)

Evaluation of Single-site and Multisite Precision of Factor VIII Measurement

Speaker: Claire Martin (France)

High Concentrations of Polyethylene Glycol (PEG) Mediate Vacuolation of Human Monocyte-derived Macrophages in vitro without Impairing their Functionality

Speaker: Birgit Maria Reipert (Austria)

F9 c.87A>G is a Double-faced Deleterious Mutation which Causes a Synonymous and Inframed-mutant FIX due to an Aberrant mRNA Splicing

Speaker: Koya Odaira (Japan)

An Inv22-like F8 Inverted Disruption in Severe Hemophilia a Brothers Possibly Occurring from Template Switching between Sister Chromatids

Speaker: Shogo Tamura (Japan)

Dosage of Factor IX in Persons with Hemophilia B Treated with Recombinant FIX Linked to an IgG Fc Domain: Comparison of 3 Methods in a French Hospital

Speaker: Valérie Proulle (France)

Qualitative Evaluation of Fibrin Clot Structure Formed in the Presence of Emicizumab Using Scanning Electron Microscope

Speaker: Naruto Shimonishi (Japan)

Relationship between F8 Gene Mutations and Inhibitor Developments in Hemophilia A Patients as a Result of Japan Hemophilia Inhibitor Study (J-HIS)

Speaker: Keiko Shinozawa (Japan)

Bone Disease in Hemophilia: The Role of Different Bone Cells

Speaker: Stefano Lancellotti (Italy)

Co-administration of FVIII with IVIG: Effect on Immune Response to FVIII in Hemophilia A Mice

Speaker: Gonzalo Hortelano (Kazakhstan)

Synergistic Effect of the Bypassing Agents and Sequence Identical Analogue of Emicizumab on Secondary Hemostasis in in vitro Model of Hemophilia A

Speaker: Jovan P Antovic (Sweden)

Severe Haemophilia A Caused by an Unbalanced Chromosomal Rearrangement Identified Using Nanopore Sequencing

Speaker: Claude Négrier (France)

Rotem Analysis Shows Variable Clot Formation in Subjects with Intron 22 Inversion- a Possible Explanation for the Variable Phenotype

Speaker: Colleen Hamid (United Kingdom)

Scientific Programme

Low Plasma Level of OPG in Hemophilia A Boys

Speaker: Zhenping Chen (China)

FVIII and Variant Chromogenic Assays for Measuring Emicizumab and FVIII Inhibitor Antibodies in Human Plasma

Speaker: Jean Amiral (France)

Accuracy of BAY 94-9027 Potency Measurements Using FVIII Assays Available in Japan

Speaker: Sho Shinohara (Japan)

Improvement the APTT-based Mixing Test for Anti Factor VIII

Speaker: Mirta Arias (Argentina)

Validation of an Automate Chromogenic Assay Factor VIII:C

Speaker: Mirta Arias (Argentina)

Thrombin Generation in Subjects with Hemophilia A According to the ABO Blood Group

Speaker: Daniel Gonçalves Chaves (Brazil)

Improved Hemostasis and Joint Health over Time in a Subset of Patients who Did Not Reach Optimal Hemostatic Control in the First Year of Recombinant Factor VIII Fc Fusion Protein (rFVIII-Fc) Therapy

Speaker: K. John Pasi (United Kingdom)

Conventional and Contrast-enhanced Ultrasound in Evaluating Hemophilia Joint Structure and Predicting Recurrent Joint Bleeding

Speaker: Yingjia Li (China)

Immune Tolerance Induction Using Low-dose Fc Fusion Recombinant Factor VIII on Emicizumab in Hemophilia A Patients with Inhibitors, Tokyo Protocol

Speaker: Azusa Nagao (Japan)

Comparison of Pharmacokinetic Parameters of Two Different Extended Half-life factor VIII Concentrates in Hemophilia A (HA) Patients

Speaker: Jerome Teitel (Canada)

Successful Haemostatic Response during the Treatment of Bleeding Episodes and Effective Prophylaxis with Turoctocog Alfa in Previously Treated Patients from China with Severe Haemophilia A (Guardian 7)

Speaker: Renchi Yang (China)

N8-GP Treatment Sustains Low Bleeding Rates in Patients with Haemophilia A

Speaker: Meera Chitlur (United States)

Quality of Life of Hemophilia Patients with Inhibitors - Opportunities for Improvement

Speaker: Howard Levy (United States)

Daratumumab in Combination with Rituximab and Immune Tolerance Induction Can Rapidly Eradicate High-titer Factor VIII Inhibitor in a Patient with Hemophilia A

Speaker: Chatphatai Moonla (Thailand)

Long-term Safety and Efficacy of Nonacog Beta Pegol in Previously Treated Children with Haemophilia B, Treated for at Least 5 Years

Speaker: Manuel Carcao (Canada)

Scientific Programme

Extended Half-life Factor VIII Management of Hemophilia A Undergoing Surgery is Not Only Efficient but Also Contributes to Saving the Factor Consumption Compared to Standard Half-life Products

Speaker: Teruhisa Fujii (Japan)

Early Patient Experiences with Emicizumab in the United States: A Qualitative Study

Speaker: Anisha M. Patel (United States)

Evaluating Patient and Caregiver Treatment Preferences in Hemophilia A Using a Discrete Choice Experiment

Speaker: Melody Benton (United States)

Safety, Tolerability, and Pharmacokinetics of Repeat Dosing with BIVV001 in Patients with Severe Hemophilia A: Results of an Interim Analysis from a Phase 1 Study

Speaker: Karin Knobe (Sweden)

Public Health Policy Analysis of Clotting Factor Concentrate Procurement Policy in Canada

Speaker: Zachary Liederman (Canada)

D-dimer Levels in Haemophilic Patients

Speaker: Brigitte Tardy-Poncet (France)

Relationship between Serum Cartilage Turnover Biomarkers and Hemophilic Arthropathy Severity in Adult Patients with Severe Hemophilia A in China

Speaker: Xueyan Sun (China)

Health-related Quality of Life in Paediatric Patients with Haemophilia A

Speaker: Kate Khair (United Kingdom)

Perioperative Management of Eight Patients with Congenital Hemophilia A who Underwent Spinal Surgery in a Single Facility

Speaker: Yushi Chikasawa (Japan)

Real-world Clinical Management of Patients with Hemophilia and Inhibitors with aPCC: Effectiveness and Safety Data from Patients Reporting >6 Months in the "FEIBA Global Outcome Study (FEIBA GO)"

Speaker: Jerzy Windyga (Poland)

Safety of Activated Prothrombin Complex Concentrate (aPCC) Monotherapy in Patients with Hemophilia and Inhibitors (PwHI): A Systematic Review

Speaker: Robert Klamroth (Germany)

The WFH World Bleeding Disorders Registry - One Year Later

Speaker: Barbara A. Konkle (United States)

Pharmacokinetic Analysis in Hemophilia Patients Using WAPPS-Hemo: The Experience of a Single Center

Speaker: Alessandra Nunes Loureiro Prezotti (Brazil)

Hereditary Protein S Deficiency in a Family with Hemophilia B: A Case Report

Speaker: Alessandra Nunes Prezotti (Brazil)

Interferon- γ -inducible Protein 10 Levels are Altered in Patients with Haemophilia with Advanced Haemophilic Arthropathy

Speaker: Ciara Byrne (Ireland)

The Gene Mutation and Factor Activity of Hemophilia Carriers in China

Speaker: Qun Hu (China)

Scientific Programme

Expected Timing of Initial Exposure to Factor VIII Treatment in Non-replacement Therapies in Hemophilia A

Speaker: Fabienne Roelfien Kloosterman (the Netherlands)

Cross-Sectional Comparative Study of Pharmacokinetics and Efficacy after the Switch between Kogenate and Kovaltry Guided by WAPPS-Hemo

Speaker: Santiago Bonanad (Spain)

Correlating Clinical and Radiological Assessment of Joints in Hemophilia: Results of Hemophilia Study Group of Taiwan Society of Thrombosis and Hemostasis

Speaker: Te-Fu Weng (Taiwan, Republic of China)

Comorbidities in Haemophilia Patients, Data of Hemophilia Center in Algiers

Speaker: Meriem Bensadok (Algeria)

Web-based Application for the Population Pharmacokinetic Service (WAPPS)´s Impact on Dosage Selection: A Single Pediatric Centre Experience, Retrospective Review

Speaker: Celia Kwan (Canada)

Unexpected Diagnostic of Aggressive Stage IV Non Hodgkin Lymphoma in a Severe Hemophilia A Patient

Speaker: Melen Brinza (Romania)

General Situation of Hemophilia Patients in Taiwan: A Multicenter Registry

Speaker: Ching-Yeh Lin (Taiwan, Republic of China)

Effects of Preventive Physiotherapy on Joint Function and Health-related Quality of Life in Pediatric Patients with Severe Bleeding Disorders

Speaker: Ralf Knoefler (Germany)

Extended Half-life Recombinant Factor IXFc Is Effective in Preventing Bleeding after Major and Minor Surgery in Severe Factor IX Deficiency

Speaker: Kate Johnston (Ireland)

Rotational Thromboelastometry (ROTEM) in Patients with Severe Haemophilia A and Inhibitors Undergoing Surgery

Speaker: Aby Abraham (India)

Circumcision and Complications in Patients with Hemophilia and the Other Bleeding Disorders in Southern Part of Turkey: Cukurova Experience

Speaker: Ali Bulent Antmen (Turkey)

Intracranial Hemorrhage and Management in Hereditary Bleeding Disorders: The Experience of Cukurova

Speaker: Hatice Ilgen Sasmaz (Turkey)

Old Hemophilia Patients Have Problems Other than Bleeding: Like Cancer

Speaker: Fahri Şahin (Turkey)

Safety and Immunogenicity Results from a Phase 3b, Open-label, Multicenter, CONTINUATION Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A

Speaker: Eric Mullins (United States)

"Real Life" Results of Prophylaxis in Severe Hemophilia A (sHA) Polish Boys with Respect to Pharmacokinetics (PK) of Octocog Alpha o-α; A Preliminary Nationwide Study

Speaker: Andrzej Koltan (Poland)

Scientific Programme

Aerobic Exercise and Desmopressin Additively Increase Factor VIII in Mild Hemophilia A - Interim Results from a Randomized Study

Speaker: Riten Kumar (United States)

Population Pharmacokinetics of Recombinant Factor VIII in Korean Hemophilia Patients

Speaker: Jung Woo Han (Korea, Republic of)

Real-world Data of Immune Tolerance Induction Using Recombinant Factor VIII Fc Fusion Protein for in Hemophilia A Patients with Inhibitors in Japan: Observational Fc Adolescent and Children Treatment Study (FACTs) First Interim Reports

Speaker: Azusa Nagao (Japan)

Inherited Severe Type Combine Deficiency of Hemophilia A and B Reported in a Girl: Case Report

Speaker: Madiha Abid (Pakistan)

Distinct Antibody Signatures in Patients with FVIII Inhibitors Undergoing Immune Tolerance Induction (ITI) Therapy

Speaker: Birgit Maria Reipert (Austria)

Describing the Characteristics of New Zealand People with Severe Haemophilia with Inhibitors: Differences Between European and Polynesian New Zealanders

Speaker: Peter Bradbeer (New Zealand)

Real-World Use of Recombinant Factor IX Albumin Fusion Protein (rIX-FP) in Patients with Hemophilia B: A Multinational Prospective, Non-Interventional, Post-Marketing Surveillance Study

Speaker: Johannes Oldenburg (Germany)

Comparison of FVIII Prophylaxis Treatment Regimen and Associated Clinical Outcomes between rVIII-SingleChain and Other rFVIII Products Commonly Used in German Hemophilia A Patients

Speaker: Songkai Yan (United States)

Cause of Death and Effective Management of Hemophilia Patient to Improve Quality of Life and Save the Life

Speaker: Shin Young Hyun (Korea, Republic of)

Treatment Patterns and Clinical Outcomes after Switching from rFIX to rFIXFc: From the UK National Haemophilia Database

Speaker: Charles Hay (United Kingdom)

Catheter Ablation for Atrial Fibrillation in Patients with Hemophilia or von Willebrand Disease

Speaker: Roger Schutgens (the Netherlands)

Performance of a Clinical Risk Prediction Model for Inhibitor Formation in Severe Hemophilia A

Speaker: Shermarke Hassan (the Netherlands)

Adherence to Prophylaxis Is Related to the Prescribed Dose and to the Age of the Patient

Speaker: Ricardo Camelo (Brazil)

The Real-world Experience of Product-switching, Pharmacokinetics, and Adherence of rFVIII-Fc in Patients with Hemophilia A: The Preliminary Report in Taiwan

Speaker: Chia-Yau Chang (Taiwan, Republic of China)

Scientific Programme

Prevention of Bleeding in Haemophilia A by Prophylactic Treatment with Simoctocog Alfa and 2 Plasma-derived Factor VIII Concentrates: A Snapshot Analysis of a Prospective, Non-interventional Study to Evaluate Real-life Prophylactic Treatment Schedules - NIS-Previq

Speaker: Carmen Escuriola-Ettingshausen (Germany)

New Inhibitors in the Ageing Hemophilia Population (NIAP) Study: An International, Retrospective, Observational, Cohort Study of New Inhibitors in People with Hemophilia Aged 40 Years and Older

Speaker: Jan Astermark (Sweden)

Prophylaxis with Emicizumab in Children and Adults with Hemophilia A and Inhibitors: Preliminary Data on 7 Patients of a Portuguese Hemophilia Center

Speaker: Cristina Catarino (Portugal)

Circumcision in Haemophilia in the Setting of Low Factor Availability: Experience from Gombe, Nigeria

Speaker: Saleh Yuguda (Nigeria)

Impact of the SIPPET Study on Management of Australian PUPs

Speaker: Jane Mason (Australia)

Hemophilia and Bleeding - Hemophilia: Gene Therapy

Comparative Integration Site Analysis of Two Factor IX (FIX) Gene Therapy Vectors with Different Vector Design in Mice

Speaker: Werner Hoellriegl (Austria)

Evaluation of Gene Therapy Mediated Factor IX Activity in Selected in vivo Test Systems

Speaker: Werner Hoellriegl (Austria)

Influence of Obesity on Gene Therapy Mediated Factor IX (FIX) Expression in Mice

Speaker: Werner Hoellriegl (Austria)

Biological Relevance of Low-titer Anti-AAV8 Neutralizing Antibodies

Speaker: Maurus de la Rosa (Austria)

Platelet-Targeted FVIII Expression Rescues the Severe Spontaneous Bleeding Phenotype in a Novel Hemophilia A Rat Model with an Inversion Mutation

Speaker: Qizhen Shi (United States)

Increased Immunogenicity of CpG Containing Adeno-associated Virus Serotype 8 (AAV8) Constructs Might Contribute to the Drop of Transgene Expression

Speaker: Maurus de la Rosa (Austria)

Low Predicted Immunogenicity Risk Associated with FIX Variants that Can Promote Coagulation in the Absence of FVIII: in vitro and in silico Assessments

Speaker: Ying Poi Liu (the Netherlands)

Factor VIII Clotting and Chromogenic Activities for TAK-754 / SHP654, a Clinical Hemophilia A Gene Therapy Candidate, Using in vitro and in vivo Assays

Speaker: Hanspeter Rottensteiner (Austria)

No Evidence of Germline Transmission of Vector DNA Following Intravenous Administration of AAV5-hFIX to Male Mice

Speaker: Eileen Sawyer (the Netherlands)

Scientific Programme

Prevalence of Preexisting Immunity to Adeno-associated Virus (AAV) in Adults with Hemophilia: Interim Results from an International Epidemiology Study

Speaker: Mila Ayash-Rashkovsky (United States)

Immunogenicity Assessment of FVIII Variants for 2nd Generation Gene Therapy

Speaker: Maurus de la Rosa (Austria)

Systemically Administered LV-FVIII and LV-FIX Confers Normal Level of Clotting Factor Expression with No Evidence of Oncogenesis in Non-human Primates

Speaker: Robert Peters (United States)

FVIII Expression by its Native Promoter Sustains Long-term Correction Avoiding Immune Response in Hemophilic Mice

Speaker: Antonia Follenzi (Italy)

Nonclinical Efficacy and Toxicology Evaluation of a Human FVIII Gene Therapy Vector (TAK-754/SHP654) in Mice

Speaker: Werner Hoellriegl (Austria)

FLT180a: Next Generation AAV Vector for Haemophilia B - Long Term, Follow-up and In-depth Analysis of Transgenic FIX Using One-stage, Chromogenic and Global Assays

Speaker: Jonathan Foley (United Kingdom)

Correction of Canine Hemophilia A via Intraosseous Delivery of a Platelet-specific Factor VIII-lentiviral Vector

Speaker: Chong Li (United States)

Using Non-genotoxic, Antibody-drug-Conjugate Conditioning Enables Safe and Effective Platelet-specific FVIII Gene Therapy of Hemophilia A

Speaker: Qizhen Shi (United States)

Gene Therapy Knowledge and Perceptions: Results of an International ISTH Survey

Speaker: K. John Pasi (United Kingdom)

Hemophilia and Bleeding - Novel Biotherapeutics in Hemophilia

Phase 2b Trial of Subcutaneous Engineered FIX Dalcinonacog alfa: Pharmacokinetics and Safety

Speaker: Johnny Mahlangu (South Africa)

Brazilian Registry of Persons with Hemophilia A Receiving Emicizumab (Emicizumab Cases, EMCASE Project)

Speaker: Ricardo Camelo (Brazil)

Long-acting Multi-glycoPEGylated FVIII for Subcutaneous Administration

Speaker: K.-Y. Kang (Korea, Republic of)

A Comprehensive in silico and in vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared with Wild-type FIX

Speaker: Grant E. Blouse (United States)

Development of Single Domain Antibodies Targeting Protease Nexin-1 as a Strategy for Hemophilia Treatment

Speaker: Charlotte Kawecky (France)

A Comparison of Clot Waveform Analysis and Thrombin Generation Assay in the Laboratory Assessment of Haemostatic Function in a Patient on Emicizumab

Speaker: Joyce Ching Mei Lam (Singapore)

Scientific Programme

Treatment of Hemophilia A Using Factor VIII Messenger RNA Encapsulated in Lipid Nanoparticle

Speaker: Chun-Yu Chen (United States)

Management of Surgery in Hemophilia A Patients with Inhibitors during Emicizumab Prophylaxis

Speaker: Christine Biron-Andreani (France)

Next Generation Factor VIIa with Enhanced Half-Life

Speaker: Mattia Ferrarese (Italy)

Rescue of Multiple Haemophilia A-Causing Mutations by a Single ExSpeU1: The Importance of the Genomic Context

Speaker: Dario Balestra (Italy)

Bispecific Antibodies with Light Chain Specificity for Factor IXa and X Improve Thrombin Generation in Hemophilia A Plasma

Speaker: Michael Dockal (Austria)

Evaluation of a Chronometric Assay for Determination of Emicizumab Concentration in 3 French Laboratories

Speaker: Valérie Proulle (France)

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Hemophilia: Management of Acute Bleeding Events

Speaker: Steven W. Pipe (United States)

Exposure-response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients with and without Inhibitors against Factor VIII

Speaker: Fredrik Jonsson (United States)

Immunothrombosis and Vascular Biology - Blood Cells and Vessel Walls

The Role of Platelet Mitochondrial Function for Platelet Mediated A β 40 Aggregation

Speaker: Lili Donner (Germany)

Simulating Cross-stream Platelet Migration within a Rectangular Microchannel

Speaker: Nilanka I.K. Ekanayake (Australia)

Platelet-derived Calpain Mediates Protease-activated Receptor 1-dependent Vascular Inflammation in Diabetes

Speaker: Voahanginirina Randriamboavonjy (Germany)

Human Ectonucleoside Tri(di)phosphohydrolase 1 (CD39) Is an Exopolyphosphatase

Speaker: Stephanie A. Smith (United States)

Disturbed Blood Flow-induced Platelet Transmigration Modulates Vascular Inflammation

Speaker: Chaojun Tang (China)

Immunothrombosis and Vascular Biology - Endothelial Cell Signaling

Microvesicle-Mediated miR-30c Transfer from Platelets to Endothelial Cells Modulates Endothelial Cell Repair via PAI-1 in Type 2 Diabetic Mellitus

Speaker: Mao Luo (China)

Stimulation of GPR15 on Vascular Endothelial Cells Mediates Angiogenesis and Cytoprotective Function

Speaker: Masahiko Fukatsu (Japan)

Scientific Programme

Self-regulation of TNF-alpha Induces Dysfunction of Endothelial Colony Forming Cells from Patients with Deep Vein Thrombosis

Speaker: Jose Alvarado-Moreno (Mexico)

Statins Effects on Endothelium Dependent Relaxation of Rat Resistance Arteries Affected by Homocysteine Exposure

Speaker: Loredana Liliana Hurjui (Romania)

Immunothrombosis and Vascular Biology - Inflammation and Sepsis

Development of an Algorithm to Predict Mortality in Patients with Sepsis and Coagulopathy

Speaker: Matthew Rondina (United States)

The Anti-inflammatory effect of ϵ -viniferin by Specifically Targeting fMLP Receptor in Human Neutrophils

Speaker: Hsiang-Ruei Liao (Taiwan, Republic of China)

Aspirin Inhibits Intravascular Coagulation during Sepsis in Mice

Speaker: Agostina Carestia (Canada)

Standardisation of Protocols for the Diagnosis of Neonatal Sepsis by Molecular Methods

Speaker: Anjali Kelkar (India)

PECAM-1 Protects Sepsis-Induced DIC by Dampening Inflammatory Response and Restoring Vascular Barrier

Speaker: Heng Mei (China)

Lipopolysaccharide Induces IL6 and Upregulates IL8 Expression in Megakaryocytes

Speaker: Krystin Krauel (United States)

G-CSF Induces MyD88-independent Intravascular NETosis in Mice

Speaker: Chandini Rangaswamy (Germany)

Role of the Thrombotic Markers, NETs and Thrombin Generation Test, in the Diagnosis of Prosthetic Infection

Speaker: Julia Oto (Spain)

Design and Characterization of α 1-antitrypsin Mutants for the Treatment of Bradykinin-driven Inflammatory Reactions

Speaker: Steven de Maat (the Netherlands)

Plasma Thrombogenic Potential in Patients with Granulomatosis with Polyangiitis (GPA)

Speaker: Jacek Musiał (Poland)

CENTD-centre of Excellence in New Target Discovery: The Use of Animal Venoms to Identify Molecular Targets and Signaling Pathways Involved in Inflammatory Related Diseases

Speaker: Ana Marisa Chudzinski-Tavassi (Brazil)

Immunothrombosis and Vascular Biology - Innate & Adaptive Immunity

Neutrophil-to-Lymphocyte Ratio is Associated with Poor Prognosis after Endovascular Thrombectomy in Stroke Patients

Speaker: Manuel Navarro-Oviedo (Spain)

Natural IgM Antibodies Reduce Plasmatic Coagulation

Speaker: Christoph Binder (Austria)

Immunothrombosis and Vascular Biology - Non-Coding RNAs

Scientific Programme

Plasma Levels of microRNAs and Future Risk of Incident Venous Thromboembolism

Speaker: Vânia Maris Morelli (Norway)

Immunothrombosis and Vascular Biology - Protease Activated Receptors

A Genetic Variant in Human PAR4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics

Speaker: Michael Holinstat (United States)

Immunothrombosis and Vascular Biology - Stem Cells and Vascular Cell Growth

Coxsackievirus B3 Decreased Angiogenic Activity of Endothelial Colony Forming Cells through TLR3 Activation

Speaker: Paula Romina Zubiry (Argentina)

Platelet Disorders - Antiplatelet Therapy

Association of Platelet Response to Cilostazol with Clinical Outcome and CYP Genotype in Patients with Cerebral Infarction

Speaker: Yuichi Ikeda (Japan)

Investigation of the in vitro Effect of Aspirin and Tirofiban in Children Compared to adults

Speaker: Xavier Busuttill-Crellin (Australia)

Value of High Platelet Reactivity in Predicting Major Adverse Cardiovascular Events in Hypertension Patients with Coronary Atherosclerotic Heart Disease after PCI

Speaker: Qingkun Fan (China)

Effect of Cilostazol in Combination with Clopidogrel on Platelet Function in Patients with Ischemic Stroke at High Risk of Recurrence

Speaker: Masako Yamazaki (Japan)

Evaluation of the Newly-developed ADP Induced Platelet Aggregation Level (APAL) System in Aggregometer on Automated Coagulation Analyzer

Speaker: Tasuku Sakayori (Japan)

Aspirin Responsiveness in Essential Thrombocythemia

Speaker: Marco Cattaneo (Italy)

Clinical Predictiveness of Six Major Platelet Function Tests Used to Assess Aspirin Response in Patients with Stable Coronary Artery Disease - 10-year Follow-up

Speaker: Marie Lordkipanidzé (Canada)

Management of Antiplatelet Therapy in the Pacemaker Implant. Retrospective Study in our Intensive Care Unit

Speaker: Pablo Romero Garcia (Spain)

Efficacy and Adverse Reactions of Hydroxyurea and Interferon-alpha in a Cohort of Chinese Patients with Essential Thrombocythemia

Speaker: Xinyue Dai (China)

Development of Novel Drug-Eluting Stents for Acute Myocardial Infarction to Prevent Stent Thrombosis

Speaker: Myung Ho Jeong (Korea, Republic of)

Reversing Oral Antiplatelet Agents with Platelet Transfusion: A Review

Speaker: Paul Kruger (Canada)

Scientific Programme

Reversal of the Anti-aggregant Effect of Ticagrelor Using Untreated Platelets

Speaker: Paul Kruger (Canada)

Aspirin and Clopidogrel Resistance in Patients with Ischemic Vascular Disease in Indonesian Hospital

Speaker: Vivien Puspitasari (Indonesia)

Platelet Disorders - HIT

Prospective Evaluation of the HEP Score and 4Ts Score in Patients with Suspected Heparin-induced Thrombocytopenia from China

Speaker: Sen Li (China)

Performance Characteristics of Latex Immunoturbidimetric Assay and Particle Immunofiltration Assay for the Diagnosis of Immune Heparin-induced Thrombocytopenia

Speaker: Shu-Jie Wang (China)

Safety and Efficacy of Argatroban Therapy with Ethnicity-specific Doses in Japanese Patients with Suspected Heparin-induced Thrombocytopenia: Nationwide Post-marketing Surveillance Studies

Speaker: Shigeki Miyata (Japan)

HIT Diagnosis Workflow Experience at the Mayo Clinic in Arizona: PF4 ELISA Assay Optical Density Threshold for Clinical Guidance While Awaiting SRA Confirmatory Testing

Speaker: Ryan Robetorye (United States)

Serological Investigation of Suspected Heparin Induced Thrombocytopenia in China: 69 Hospitals

Speaker: Qingkun Fan (China)

Rivaroxaban for Heparin-Induced Thrombocytopenia - Safety and Efficacy Updates from a Case Series

Speaker: Yanchin Tan (Singapore)

Clinical Outcomes in Patients with Discordant Heparin-Induced Thrombocytopenia Laboratory Testing

Speaker: Zi Yun Ng (Australia)

Evaluation of the Automated HemosIL® AcuStar HIT IgG Chemiluminescent Immunoassay for the Diagnosis of Heparin-induced Thrombocytopenia

Speaker: Joseph Rigano (Australia)

Transition from Argatroban to Vitamin K Antagonists in the Real Life: Chromogenic Factor X Assay Alone Fails to Predict International Normalized Ratio

Speaker: Dorothée Faille (France)

Fondaparinux in Patients with Heparin-induced Thrombocytopenia and Dialysis; A Case Report, and Systematic Review of Available Literature

Speaker: Matthew Wanat (United States)

Fibrin Monomers to Monitor Anticoagulation with Argatroban in Patients with Acute Heparin Induced Thrombocytopenia

Speaker: Dorothée Faille (France)

Implementation of Electronic 4T Score Improves Platelet Factor 4 (PF4) ELISA Utilization

Speaker: Lisa Baumann Kreuziger (United States)

Scientific Programme

Autoimmune HIT - Successful Treatment with IvigG and DOAC and Laboratory Testing of ivlgG Therapy in HIPA-test

Speaker: Karina Althaus (Germany)

Natural History of Heparin-induced Thrombocytopenia (HIT) in Cancer: A Cohort Analysis of Thrombosis and Bleeding Outcomes

Speaker: Cristhiam Mauricio Rojas Hernandez (United States)

Platelet Disorders - ITP

Abnormal Expression of CD47 on Platelet Surface Participates in the Pathogenesis of ITP

Speaker: Zeping Zhou (China)

Abnormal Expression of APRIL may be Involved in the Pathogenesis of ITP

Speaker: Zeping Zhou (China)

Glycoprotein-Specific Direct Platelet Autoantibody Testing in Immune Thrombocytopenia: A Modern Reassessment

Speaker: David J. Kuter (United States)

Immature Platelet Fraction as a Predicting Factor for Hemorrhage in Immune Thrombocytopenic Purpura

Speaker: Huu Tuan Nguyen (Viet Nam)

High Dose Dexamethasone vs Prednisolone Therapy in Newly Diagnosed Myanmar Adult Patients with Primary Immune Thrombocytopenia

Speaker: HtunLwin Nyein (Myanmar)

Detection and Treatment of Helicobacter pylori in Patients with Immune Thrombocytopenia: An International Survey

Speaker: Prakash Vishnu (United States)

The let-7b-5p Contributes to B Cell Activation and Survival in the Pathogenesis of Immune Thrombocytopenia by Targeting ADAM10

Speaker: Yang He (China)

"Wait and Watch Approach" for ITP in Kabuki Syndrome

Speaker: Mona Faramawy (United Arab Emirates)

Platelet Function of Chronic Immune Thrombocytopenia: Impact of Platelet Size, Platelet-associated Anti- α IIb β 3 Antibodies and Thrombopoietin Receptor Agonists

Speaker: Hirokazu Kashiwagi (Japan)

Levels of Cytokines Secreted by T lymphocyte and the Relationship with Prognosis in Children Immune Thrombocytopenia

Speaker: Jingyao Ma (China)

Efficacy and Safety of Eltrombopag in the Treatment of Severe Chronic Immune Thrombocytopenia in Children: A Single-center Observational Study

Speaker: Hao Gu (China)

Fibrinogen Levels Are Associated with Bleeding in Patients with Immune Thrombocytopenia

Speaker: Heng Mei (China)

1623 Hospitalizations in Patients with Primary Immune Thrombocytopenia (ITP) - A Real World Study

Speaker: Xueqing Dou (China)

Scientific Programme

Evaluation of Therapeutic Response in Pediatric Immune Thrombocytopenic Purpura (ITP) Patients

Speaker: Kousar Perveen (Pakistan)

Baseline Endogenous Thrombopoietin Concentrations and Response to Avatrombopag in Immune Thrombocytopenia

Speaker: David J. Kuter (United States)

Reduced Antioxidant Capacity Induced Pyroptosis in Platelets in Primary Immune Thrombocytopenia

Speaker: Shuang Wang (China)

A Systematic Review and Meta-Analysis of the Use of Thrombopoietin Receptor Agonists in Patients with Primary Immune Thrombocytopenia

Speaker: Marco Cattaneo (Italy)

Response to Treatment of Paraneoplastic Immune Thrombocytopenia (ITP): A Systematic Review

Speaker: Marco Cattaneo (Italy)

Mutation Spectrum of ITP by NGS Sequencing

Speaker: Mankai Ju (China)

The Effect of Laparoscopic Splenectomy for Chronic ITP Patients

Speaker: Jun He (China)

Clinical Profile and Treatment Outcome of ITP In Malaysia: A Single Centre Experience

Speaker: Veena Selvaratnam (Malaysia)

Vindesine Efficacy and Safety in Treating Immune Thrombocytopenia: A Retrospective Study of 90 Patients in China

Speaker: Boyang Sun (China)

A Meta-Analysis of Thromboembolic Events in Patients with Immune Thrombocytopenia after Treatment

Speaker: Jingke Tu (China)

Clinical Patterns and Response to Treatment of a Cohort of Immune Thrombocytopenia Patients in Singapore

Speaker: Shin Yeu Ong (Singapore)

Immune Thrombocytopenic Purpura Management and Outcome: A Single Center Study

Speaker: Munira Borhany (Pakistan)

Efficacy of Thrombopoietin Receptor Agonists in Pediatric Immune Thrombocytopenia: Systematic Review

Speaker: Samuel Abegunde (Nigeria)

Increased Platelet Size and Pre-Activation are Associated with Bleeding in Children with Chronic But Not Persistent Immune Thrombocytopenia

Speaker: Anastasia A. Ignatova (Russian Federation)

Rotational Thromboelastometry Provides Greater Insight into Bleeding Risk in Thrombocytopenic Patients

Speaker: Lucy Coupland (Australia)

Scientific Programme

A 5 Year Retrospective Longitudinal Study of Assessment and Initial Treatment of Acute ITP in Adults

Speaker: John Hanley (United Kingdom)

The Role of Flow Cytometric Detection of Platelet Associated Immunoglobulins in Immune Thrombocytopenic Purpura Diagnosis

Speaker: Andra Grigore (Romania)

Comparable Avatrombopag (AVA) Efficacy in Patients with Chronic Immune Thrombocytopenia (c-ITP) Following Failure of Prior Thrombopoietin Receptor Agonist (TPO-RA) Treatment

Speaker: Michael Vredenburg (United States)

Avatrombopag (AVA) Dosing Regimen in Chronic Immune Thrombocytopenia (ITP) - A Dose Modeling Study

Speaker: Michael Vredenburg (United States)

Lack of Clinically Significant Hepatotoxicity in Patients with Chronic Immune Thrombocytopenia (c-ITP) Treated with the Novel, Oral Thrombopoietin Receptor Agonist Avatrombopag-pooled Safety Analysis of Four Clinical Trials

Speaker: Michael Vredenburg (United States)

The Effect of Thrombopoietin-receptor Agonists (TPO-RA) on Hemostasis in Immune Thrombocytopenia - A Systematic Review

Speaker: Wobke Else Marie van Dijk (the Netherlands)

The Landscape of Immune Thrombocytopenia (ITP) Treatment during the Patient Journey

Speaker: Wobke Else Marie van Dijk (the Netherlands)

In vitro Blockage of CD72 Dose Not Influence ITP Patients Lymphocyte Proliferation and Platelet Antibody Secretion

Speaker: Jianhui Xu (China)

Platelets and Megakaryocytes - Megakaryocytes and Thrombopoiesis

Measuring Preplatelet Division: An Imaging Cytometry Approach

Speaker: Paul Harrison (United Kingdom)

Role of PDGF and PDGFR Signaling in the Regulation of Thrombopoiesis

Speaker: Mo Yang (China)

Imaging Actin Dynamics throughout Megakaryocyte Ingression Membrane System Development

Speaker: Steven G. Thomas (United Kingdom)

Redundant and Non-redundant Roles of RhoA and Cdc42 in Platelet Biogenesis and Function

Speaker: Irina Pleines (Australia)

Platelets and Megakaryocytes - Platelet Antagonists & Novel Therapeutics

Differential Effects of Ticagrelor with or without Aspirin on Platelet Reactivity and Coagulation Activation

Speaker: Ludwig Traby (Austria)

Disagregin: A Possible New α IIb β 3 Integrin Inhibitor to Prevent Arterial Thrombosis

Speaker: Tilman M. Hackeng (the Netherlands)

Scientific Programme

Amplified Antithrombotic Effects of a Novel GPVI Inhibitor ACT017 when Used in Combination with Aspirin and Ticagrelor

Speaker: Fawaz Alenazy (United Kingdom)

APAC, a Dual Anticoagulant and Antiplatelet, Synergistically with Acetylsalicylic Acid Inhibits Collagen-Induced Platelet Aggregation

Speaker: Riitta Lassila (Finland)

Platelets and Megakaryocytes - Platelet Function and Interactions

Hypersensitive Platelet Subpopulations Determine Collective Behaviour: Results from a Study of Single Platelet Function Using Droplet Microfluidics

Speaker: Maaïke S A Jongen (United Kingdom)

The Platelet Surface Glycosylation Caused by Glycosidase has a Strong Impact on Platelet Function

Speaker: Chenxue Qu (China)

Insights into Defects in Ca²⁺-Mobilization in Platelets from Patients with von Willebrand Disease Type 2B (VWD2B)

Speaker: Margaret Rand (Canada)

The Active Recruitment of Red Blood Cells during Hemostasis and Thrombus Formation

Speaker: Meike Klier (Germany)

Evaluation of Platelet Function in Patients Receiving Lusutrombopag for the Treatment of Thrombocytopenia Due to Chronic Liver Disease: An Open-Label Phase I Study

Speaker: Kouji Joko (Japan)

MMP is Involved in Platelet Senescence on Platelet Concentrates

Speaker: Ippei Noboruo (Japan)

Artificial Cerebrospinal Fluid Can Recover Platelet Function Inhibited by Aspirin

Speaker: Yukinori Kozuma (Japan)

Analysis of Talin-1 Subdomain Structures in Determining Force Response under Tension

Speaker: Guy Butcher (United Kingdom)

Critical Role of Platelet-Derived VWF in Acute Occlusion of Stenosed Arteries

Speaker: Katrina J Ashworth (United States)

The Effect of Fibrinogen in Platelet Function Activity Using Viscoelastic Method among Neurological Disorder Patient

Speaker: Leni Lismayanti (Indonesia)

Propofol Has Suppressing Effects on Human Platelet Functions

Speaker: Kyo Inoue (Japan)

Flow Cytometry Mepacrine Uptake/Release Combined with CD63 Assay in Diagnosis of Patients with Platelet Disorders

Speaker: Mara Agazzoni (Argentina)

A Method for Determining the Density and Architecture of in vitro Thrombi Formed under Flow

Speaker: Joanne Mitchell (United Kingdom)

Scientific Programme

Agonist-induced Platelet Function in Hemato-oncologic Patients Is Correlated with Bleeding, an Interim Analysis of a Multi-center Study

Speaker: Rolf T. Urbanus (the Netherlands)

Platelets and Megakaryocytes - Platelet Proteomics and Genomics

Platelet Ageing Causes Changes in Key Metabolic and Structural Proteins

Speaker: Harriet E. Allan (United Kingdom)

Platelets and Megakaryocytes - Platelet Receptors

HLA I Cell Surface Expression is a Reliable Marker to Identify Young Platelets

Speaker: Arnaud Dupuis (France)

Soluble Platelet Glycoprotein V Strongly Inhibits Arterial Thrombosis and Thrombo-inflammatory Brain Infarction

Speaker: Sarah Beck (Germany)

The Effect of Thrombin Binding to GPIIb on its Binding with von Willebrand Factor

Speaker: Shinichi Goto (Japan)

Analysis of PAR4 Levels on the Platelet Surface Reveals Surprising Inter-individual Heterogeneity, Including Greater Levels in Individuals Expressing the Thr120 PAR4 Sequence Variant

Speaker: Volga Tarlac (Australia)

Platelet Glycoprotein (GP IIb/IIIa) Gene Polymorphism as a Potential Risk Factor in Ischemic Stroke (IS)

Speaker: Doha Abdel Hamid (Egypt)

Platelets and Megakaryocytes - Platelet Signaling

A Cross-species Preference for Platelet Protease-activated Receptor Signaling in Males but Not Females at the Time of Myocardial Infarction

Speaker: Scott Cameron (United States)

Cold-stored Platelets: Procoagulant or Apoptotic?

Speaker: Lacey Johnson (Australia)

Calcium Ion Chelation Preserves Platelet Dunction during Cold Storage

Speaker: Zhenyu Li (United States)

Characterization of Outside-in α IIb β 3 Signaling in Platelets by Protein Kinase C δ

Speaker: Preeti Kumari Chaudhary (Korea, Republic of)

Connexin 62 Hemichannels and Gap Junctions Regulate Platelet Function via Activation of PKA in a cAMP Independent Manner

Speaker: Khaled Sahli (United Kingdom)

Maintenance of Platelet Homeostasis by Bile Acid

Speaker: Zhipeng Cheng (China)

Bridging Integrator 2 Is a Key Regulator of Store-operated Calcium Entry in Platelets

Speaker: Julia Volz (Germany)

The Cell-cycle Control Pathway Gwl/MASTL-ENSA/ARPP19-PP2A is Present and Active in Human Platelets

Speaker: Elena Kumm (Germany)

Scientific Programme

Interaction of Platelet Signalling Pathways and Regulation of Functional Responses: Computational Modelling, Experimental Validation, and Online Simulation Tool

Speaker: Anastasia Sveshnikova (Russian Federation)

Phosphoinositide 3-kinase α (PI3K α) Triggers PI3K β Activation at Low Level of GPVI Stimulation and Controls Platelet Arrest on von Willebrand Factor at Arterial Shear

Speaker: Sonia Severin (France)

Platelets and Megakaryocytes - Platelets and Inflammation

Role of Platelet-Rich Plasma in Healing Diabetic and Leprosy Foot Ulcers in Resource Poor Setting

Speaker: Shambhu Joshi (Nepal)

Acute Phase Neutrophil Trafficking is Orchestrated by Platelet Serotonin

Speaker: Maximilian Mauler (Germany)

Mechanical Properties of Platelets Transitioning from a Prothrombotic to a Proinflammatory Phenotype

Speaker: David Bark (United States)

Extracellular Vesicles secreted by activated CD4+ T cells activate platelets

Speaker: Maria Albertina Romaniuk (Argentina)

Platelets and Megakaryocytes - Platelets Beyond Hemostasis

Ruxolitinib-associated Thrombocytopenia May Be a Major Problem in MF Patients

Speaker: İbrahim Celalettin Haznedaroğlu (Turkey)

Exploring Immunotherapy and the Role of Platelets in a Murine Model of Metastatic Small-cell Lung Cancer

Speaker: Stephanie R. Hyslop (Australia)

Platelet Glycoprotein VI Enhances Lung Metastasis by Coordinating Transendothelial Migration of Tumor Cells

Speaker: Elmina Mammadova-Bach (Germany)

Platelets and Osteointegration during Experimental Augmentation of Bone Defects

Speaker: Irina P. Antropova (Russian Federation)

Prothrombotic States - Antiphospholipid Syndrome

Direct Oral Anticoagulants in Patients with Antiphospholipid Syndrome: Results from a Retrospective Study

Speaker: Ulrich J. Sachs (Germany)

Triple Positivity Profile of Antiphospholipid Antibodies (aPL) is Associated with a Greater Amount of Non-criteria Manifestations on Obstetric Antiphospholipid Antibodies Syndrome (OAPS)

Speaker: Gabriela de Larrañaga (Argentina)

Standardization and Reliability of Lupus Anticoagulant Tests: Comparison of Real World and Core Laboratory Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Analysis

Speaker: Maria Efthymiou (United Kingdom)

Immunothrombosis and the Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Antiphospholipid Syndrome

Speaker: Nevine Kassim (Egypt)

Scientific Programme

Prevalence and Clinical Significance of Protein C Antibodies and Acquired Activated Protein C Resistance in Systemic Lupus Erythematosus

Speaker: Maria Efthymiou (United Kingdom)

Systematic Review and Case Series of Patients with Antiphospholipid Syndrome and Myeloproliferative Neoplasm

Speaker: Zara Sayar (United Kingdom)

Aspirin or Heparin or Both for Improving Pregnancy Outcomes in Women with Persistent Antiphospholipid Antibodies and Recurrent Pregnancy Loss

Speaker: Eva Nicole Hamulyák (the Netherlands)

High Antiphospholipid Antibody Positivity among Children and Adolescents with Non-Transfusion-Dependent Thalassemia

Speaker: Nongnuch Sirachainan (Thailand)

Citrullinated Histone H3, a Marker of Neutrophil Extracellular Trap Formation, is Increased in Patients with Persistent Lupus Anticoagulant and a History of Thrombosis

Speaker: Lena Hell (Austria)

Cut-off Values for the Dilution Method of dRVVT Test in Patients Treated with Vitamin K Antagonists

Speaker: Min Young Lee (Korea, Republic of)

Antiphospholipid Antibodies and Obstetric Complications as a Risk Factors for Thrombotic Complications in Women with Cancer

Speaker: Alexander Makatsaria (Russian Federation)

She Won't Stop Clotting Despite on Anticoagulants: A Challenging Case

Speaker: Bee Sun Lee (Malaysia)

Cut-off Generation for Percent Correction of Screen by Confirm in Lupus Anticoagulant Testing in Multiple Reagents with a Common Set of Normal Donor Plasmas

Speaker: Osamu Kumano (Japan)

The Usefulness of Paired APTTs by Low and High Lupus Anticoagulant Sensitivity for the Discrimination in Direct Oral Anticoagulant Drug Samples

Speaker: Osamu Kumano (Japan)

Intestinal Permeability: An Etiological Factor in Obstetric Antiphospholipid Syndrome?

Speaker: Valérie Louise Bernice Isabelle Jansen (the Netherlands)

Successful Treatment with Eculizumab in a Patient with Antiphospholipid Syndrome Presenting with a Thrombotic Storm

Speaker: Hana Iris Lim (United States)

The Prevalence of Criteria and Non-criteria Antiphospholipid Antibodies in Patients with Unprovoked Venous Thromboembolism

Speaker: Joseph Rigano (Australia)

A Well-Defined Subgroup of Chronic Thromboembolic Pulmonary Hypertension Patients Are Positive for Antiphospholipid Antibodies

Speaker: Zhi-Cheng Jing (China)

High Incidence of Antiphospholipid Antibody Positivity in Newly-Diagnosed Lymphoma Patients and A Proposed APLA Predictive Score

Speaker: Theera Ruchutrakool (Thailand)

Scientific Programme

Unfavorably Altered Plasma Fibrin Clot Properties are Associated with Increased Antiphosphatidylserine/Prothrombin Complex Antibodies in Patients with Antiphospholipid Syndrome

Speaker: Anetta Undas (Poland)

Thrombin Generation in Normal Plasma Spiked with Total IgG and Affinity Purified $\alpha\beta$ 2GPI from High Risk APS Patients

Speaker: Chun-Yan Cheng (Italy)

PFA-200 Short Closure Time Values Induced by Triple Positive APS Patients' Total IgG or Anti Beta 2 GPI Antibodies

Speaker: Chun-Yan Cheng (Italy)

MicroRNAs Identification in Primary Antiphospholipid Syndrome

Speaker: Camila de Oliveira Vaz (Brazil)

Plasmatic Oxidative Stress in Patients with Primary Antiphospholipid Syndrome: a Preliminary Study

Speaker: Camila de Oliveira Vaz (Brazil)

Anti-cardiolipin and Anti- β 2glycoprotein I IgA along with the Current Criteria Does Not Have an Added Value in Screening for Clinical Symptoms of the Antiphospholipid Syndrome

Speaker: Walid Chayoua (the Netherlands)

Gene Expression of Tissue Factor and the Risk of Thrombosis Associated with Antiphospholipid Syndrome

Speaker: Camila Vaz (Brazil)

Changes in Inflammation and Coagulation Markers in Patients with Thrombotic Primary Antiphospholipid Syndrome Treated with Hydroxychloroquine

Speaker: Camila Vaz (Brazil)

Prothrombotic States - Cancer-Associated Thrombosis: Basic Sciences

Platelet Hemi-ITAM Signaling Mediated Cancer-associated Venous Thrombosis Inhibited by a Monoclonal Antibody to Podoplanin, SZ-168

Speaker: Yiming Zhao (China)

Profile of Procoagulant and Proangiogenic Balance of Myeloma Plasma Cells

Speaker: Patrick Van Dreden (France)

Influence of P Selectin Glycoprotein Ligand 1 Polymorphisms on the Development of Thrombosis in Myeloproliferative Neoplasm Patients

Speaker: Rokas Gerbutavicius (Lithuania)

Procoagulant Platelets as a Diagnostic Predictor of Thrombosis in Lung Cancer Patients

Speaker: Emma E. Ramsay (Australia)

Impact of a Tumor-derived Exosome on General Coagulation Tests and Clot Waveform Analysis

Speaker: Naoki Tokunaga (Japan)

The Pro-inflammatory Heme Enzyme Myeloperoxidase (MPO) Partially Reverses the Anticoagulant Activity of Low-Molecular-Weight Heparin (LMWH), but Not Rivaroxaban in an in vitro Tumor Model

Speaker: Minna Voigtlaender (Germany)

Scientific Programme

Increase in Whole Blood Clot Stiffness in Patients with Peritoneal Carcinomatosis

Speaker: Shahsoltan Mirshahi (France)

The Role of DNA and Histone in the Rigidity and Viscoelasticity of Fibrin Clots

Speaker: Massoud Mirshahi (France)

Higher Plasma Clot Elasticity Decreases Clot Degradability

Speaker: Massoud Mirshahi (France)

Approach in the Study of Molecular Mechanism in Cancer Cell Implantation on the Fibrin Network

Speaker: Massoud Mirshahi (France)

Effect of Rivaroxaban on Growth of Human Pancreatic Tumors in Nude Mice

Speaker: Anam Maqsood (United States)

Pancreatic Cancer-derived Exosomes and their Differential Effects on Coagulation, Platelet and Endothelial Activation, and Extracellular Trap Generation

Speaker: Norbaini Abdol Razak (Australia)

Proteomic Investigation of In-Vitro Antineoplastic Effect of Ankaferd Hemostat with 2D Gel Electrophoresis and MALDI-TOF/TOF-MS in HepG2, Caco-2 and HT-29 Cancer Cells

Speaker: İbrahim Celalettin Haznedaroğlu (Turkey)

Expression of Von Willebrand Factor by Tumor Cells - Relevance to Cancer-associated Thrombosis and Animal Studies

Speaker: Nicolas Prévost (Japan)

Plasma Factor IXa Activity and HMWK Cleavage Are Elevated in Epithelial Ovarian Cancer: The Role of Intrinsic Coagulation Pathway in Cancer-associated Thrombosis

Speaker: Pansakorn Tanratana (Thailand)

Cancer-associated Thromboembolism: Antithrombotic Management of Patients Hospitalized at an Academic Medical Center

Speaker: Larry K. Golightly (United States)

The Role of the Androgen Receptor in Prostate Cancer-induced Platelet Aggregation and Invasion

Speaker: Gabriela Lesyk (Canada)

Preferential Aggregation of Platelets by Prostate Cancer Cells with Stem Cell Markers

Speaker: Gabriela Lesyk (Canada)

Interaction of Cancer Cells with Platelets Is Determinant for Clot Firmness. An in vitro Thromboelastometric Study

Speaker: Patrick Van Dreden (France)

Differential Gene Expression of Protease-activated Receptors in Solid Tumors Compared to Hematologic Neoplasias

Speaker: Prakash Vishnu (United States)

Venous Thromboembolism - Prevention VTE

A Real World Comparative Effectiveness Analysis of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin among Medically Ill and Abdominal Surgery Patients in a large US Hospital Database

Speaker: Zhimin Xiao (United States)

Scientific Programme

Effectiveness of an Admission Proforma in Improving Prescription of Thromboprophylaxis in Acutely Ill Medical Patients. Re-valuating Current Performance in University Hospital Limerick (Ireland) a Decade Later

Speaker: Michael Watts (Ireland)

Comprehensive VTE Prevention Strategy Including Root Cause Analysis of Hospital-associated Thrombosis Significantly Reduces Potentially Preventable Events: A Single Centre Experience

Speaker: Lara Roberts (United Kingdom)

Benefit-risk Assessment of 10mg Daily Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

Speaker: Gary Raskob (United States)

Extended-duration Thromboprophylaxis with Rivaroxaban Reduces the Risk of Major and Fatal Vascular Events in Hospitalized Medically Ill Patients

Speaker: Alex C. Spyropoulos (United States)

Thromboprophylaxis in a Brazilian Public Center - Data from Clinical Audit

Speaker: Pedro Henrique Fernandes Carmo Las Casas (Brazil)

Incidence of Venous Thromboembolic Disease in Hospitalized Patients at the "Hospital de Clínicas", Montevideo - Uruguay

Speaker: Cecilia Guillermo (Uruguay)

Adequacy of Hospital Thromboprophylaxis and Risk Assessment Models in the SWITCO65+ Cohort

Speaker: Marc Blondon (Switzerland)

Prophylaxis for Hospital Acquired Venous Thromboembolism: Why VTE Could Not Be Prevented

Speaker: Anoop Enjeti (Australia)

Improving VTE Prevention in the Hospital: Success of Online CME

Speaker: Jelena Spyropoulos (United States)

Risk Factors Associated with the Failure of Post-operative Rivaroxaban Thromboprophylaxis in Total Knee Arthroplasty Patients: A Retrospective Case-control Study

Speaker: Owais Mian (Canada)

Randomized, Double-blinded Phase II Trial of Weight Adjusted versus Standard Dose Enoxaparin Thromboprophylaxis in Hospitalized Cancer Patients at High Risk for VTE

Speaker: Jeffrey Zwicker (United States)

Venous Thromboembolism - VTE Novel Anticoagulants

Safety, Tolerability, and Pharmacodynamic Properties of AB002 (E-WE Thrombin), a Recombinant Protein C Activator Thrombin Analog, in Healthy Adult Volunteers

Speaker: Norah Verbout (United States)

Evaluation of Safety and in vivo Efficacy of Novel Hemostatic Powder Using Biocompatible Polymers

Speaker: Eunhye Lee (Korea, Republic of)

The Anti-factor XIa Antibody BAY 1213790 Shows Dose-dependent Antithrombotic Efficacy without an Increased Risk of Bleeding on Top of Antiplatelet Treatment in Rabbits

Speaker: Stefan Heitmeier (Germany)

Venous Thromboembolism - VTE Risk Factors

Scientific Programme

Additive Effect of Genes Polymorphism of Folate Cycle Proteins and Homocystein Level in Patients with Proliferative Diseases of the Breast as a Potential Factor of the Risk of Thromboses

Speaker: Alexandr Markovsky (Russian Federation)

Thrombophilia Caused by Methylene Tetrahydrofolate Reductase (MTHFR) Gene C677T Homozygous Mutation

Speaker: Tamar Saralidze (Georgia)

Racial Differences of Protein S Tokushima and Two Protein C Variants as Genetic Risk Factors for Venous Thromboembolism

Speaker: Hiroko Tsuda (Japan)

Role of Gender and ABO-blood Group in White Adolescents and Young Adult Patients with First VTE Onset

Speaker: Ulrike Nowak-Göttl (Germany)

Burden of Hospital Readmissions for Venous Thromboembolism among Patients Hospitalized for Non-cancer Acute Medical Illness in the US

Speaker: Alpesh Amin (United States)

Variation of Homocysteinemia during Venous Thrombosis: about 1045 Cases of Thrombosis

Speaker: Mohamed Habib Houman (Tunisia)

Epidemiological Characteristics of Thromboembolism Related to Oral Contraceptives in Japan: Results of a National Survey

Speaker: Kazuko Sugiura (Japan)

Genetic and Phenotypic Analyses of Protein S Tokushima and Two Protein C Variants on Healthy Japanese Young Women

Speaker: Kenta Noguchi (Japan)

Real-life Safety and Efficiency of Ruling Out venous Thromboembolism in Primary Care Using Clinical Prediction Rules

Speaker: Rosanne van Maanen (the Netherlands)

The Risk of Venous Thromboembolism Attributed to Recognized Prothrombotic Genotypes

Speaker: Line H. Evensen (Norway)

Beta Thalassaemia Trait is a Likely Reason for the Association Between Red Cell Distribution Width and Venous Thromboembolism- a preliminary report

Speaker: Taiwo Kotila (Nigeria)

Predictors of in-Hospital Mortality in Acute Pulmonary Embolism

Speaker: Jose Bonorino (Argentina)

The Risk of Venous Thrombosis Associated with Elevated Coagulation Factor Levels in the Elderly

Speaker: Huijie Wang (the Netherlands)

ABO Blood Type is a Predictor of Venous Thromboembolic Events in Patients with Cancer

Speaker: Simon Mantha (United States)

Demographic and Clinical Characteristics of Patients with Different Categories of Acute Pulmonary Embolism

Speaker: Julia C. Cambron (United States)

Scientific Programme

Incidence and Risk factors of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in African Americans Compared to Whites in Durham County, North Carolina

Speaker: Thomas Ortel (United States)

Outcomes of Patients with Different Categories of Acute Pulmonary Embolism

Speaker: Elias S. Saba (United States)

Genetic Variants of miRNA Machinery Gene Associated Venous Thromboembolism (VTE) Risk in Korean Population

Speaker: Eun Ju Ko (Korea, Republic of)

Gender-related Differences in Venous Thromboembolism Patients: GARFIELD-VTE

Speaker: Alexander G G Turpie (Canada)

Genetic Variants Related to Venous Thromboembolism. Preliminary Results of the First Study in an Argentinian Cohort

Speaker: Federico Aranda (Argentina)

Risk of Venous Thromboembolism In Orthopedic Surgical Patients: Results from a Population-based Case-control Study

Speaker: Suely Rezende (Brazil)

Prothrombotic Genotypes and Mortality Risk in Individuals with and without Venous Thromboembolism Recruited from the General Population

Speaker: Line H. Evensen (Norway)

Outcomes of Anticoagulation Therapy in Patients by Gender - A Single Center Prospective Data

Speaker: Ana I Casanegra (United States)

Role of a-fibrinogen Thr312Ala and PAI-1 -675 4G/5G Polymorphisms in Recurrence of Venous Thromboembolism among Young Patients from the North-western Region of Russia

Speaker: Anna Chechulova (Russian Federation)

Protein S Deficiency: Prevalence in Latin-America

Speaker: Cecilia Guillermo (Uruguay)

The Incidence Rate and Distribution of Venous Thromboembolism by Provoking Status in a Racially Diverse Population

Speaker: Aaron Mark Wendelboe (United States)

Underlying Co-Morbidity Explains High Levels of Protein S in Patients with Venous Thrombosis: Results of the MEGA Case-Control Study

Speaker: Deeksha Khialani (the Netherlands)

Thrombophilia as an Underlying Cause for Budd Chiari Syndrome

Speaker: Bushra Moiz (Pakistan)

Congenital Thrombophilia in East-Asian Venous Thromboembolism Population, a Meta-Analysis and Systematic review

Speaker: Ziyi Liu (China)

Genetic Profiling of Hemostasis Associated Genes in Chinese Patients with Venous Thromboembolism (VTE)

Speaker: Xuefeng Wang (China)

Scientific Programme

Incidence and Risk Factors of Recurrent Venous Thromboembolism After Pulmonary Embolism

Speaker: Wonil Choi (Korea, Republic of)

Venous Thromboembolism Mortality Trends in the Elderly Population: A Retrospective Analysis from the National Inpatient Sample Database

Speaker: Guillermo H Tafur (Ecuador)

A Systematic Review and Meta-Analysis of the Prevalence of Venous Thromboembolism in Patients with Sickle Cell Disease

Speaker: Mosaad Almegren (Saudi Arabia)

Congenital Thrombophilia in Chinese Population with Pulmonary Embolism

Speaker: TianYu Lian (China)

Is Plasma Elevated Lipoprotein(a) Level truly a Causal Risk Factor for Venous Thromboembolism?

Speaker: Junji Kanda (Japan)

Comparison of the Incidence of Venous Thromboembolism (VTE), Risk Factors and Bleeding Complications in Laparoscopic Versus Open Colorectal Surgery for Suspected or Confirmed Malignancy

Speaker: Kerry Hitos (Australia)

Homocysteine Screening at the Belfast Trust VTE Outpatient Clinic, Northern Ireland

Speaker: Gary Benson (United Kingdom)

Twenty-two New Mutations Identified in Czech Patients with Antithrombin Deficiency

Speaker: Ingrid Hrachovinová (Czech Republic)

New Thrombophilic Variants in the 3' End of the Prothrombin Gene - One Gene and Different Prothrombotic Mechanisms

Speaker: Predrag Miljic (Serbia)

Novel Copy Number Variant (CNV) Is Associated with Venous Thromboembolism in African Americans

Speaker: Minoli Perera (United States)

Risk Factors Associated with Massive PE

Speaker: Praveen Hariharan (United States)

Deep Venous Thrombosis in Two Chinese Families with Novel LYST Mutations

Speaker: Miao Jiang (China)

D-dimer, Antithrombin and Thrombin-antithrombin Complex in Deep Vein Thrombosis

Speaker: Usi Sukorini (Indonesia)

Scientific Programme

Monday, 08. July 2019

Registration
07:00 - 19:00

Main Foyer

Registration

Supported Symposia
07:00 - 07:45

Meeting Room 219/220

Supported Symposium

Title: VTE Prophylaxis and Improved Patient Outcomes in Orthopedic Surgery: How to Engage the Surgeon This session is supported by [Cardinal Health](#) [Please view the program here](#)

State-of-the-Art Session
08:00 - 09:15

Plenary Hall

SOA 08, ISTH-WFH Joint Session: Hemophilia Management

Chair: Glenn F. Pierce (Canada)
Chair: Johnny Mahlangu (South Africa)

Gene Therapy	08:00
Speaker: Amit Nathwani (United Kingdom)	
Bispecific Antibodies and Advances in Non-Genetic Therapy Options in Hemophilia	08:25
Speaker: Midori Shima (Japan)	
Huge Impact of a Tiny Difference	08:50
Speaker: Karin Fijnvandraat (the Netherlands)	

State-of-the-Art Session
08:00 - 09:15

Melbourne Room 1

SOA 09, Assessing VTE Risk and Prevention

Chair: Kerry Hitos (Australia)
Chair: Mandy N. Lauw (the Netherlands)

What's New in VTE Risk and Prevention in Orthopedic Surgery	08:00
Speaker: Susan R. Kahn (Canada)	
Venous Thromboembolic Risk Assessment in Hospitalized Medical Patients	08:25
Speaker: Alex C. Spyropoulos (United States)	
Risk Assessment in Pregnancy	08:50
Speaker: Fionnuala Ní Áinle (Ireland)	

Scientific Programme

State-of-the-Art Session
08:00 - 09:15

Melbourne Room 2

SOA 10, Congenital and Acquired Thrombocytopenia

Chair: Jorge A. Di Paola (United States)
Chair: Vivien M. Chen (Australia)

Inherited Thrombocytopenic Syndromes	08:00
Speaker: Patrizia Noris (Italy)	
Platelet Apoptosis and Clearance	08:25
Speaker: Benjamin Thomas Kile (Australia)	
Immune Thrombocytopenia in Children	08:50
Speaker: Jenny M. Despotovic (United States)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 203/204

SOA 11, Non-Hemostatic Functions of Platelets

Chair: Kellie R. Machlus (United States)
Chair: Pierre Mangin (France)

Platelets in Cancer and Beyond	08:00
Speaker: Thomas Würdinger (the Netherlands)	
Platelet CLEC-2 and Lung Development	08:25
Speaker: Katsue Suzuki-Inoue (Japan)	
Influence of Platelets on Other Cells: Mechanisms and Consequences	08:50
Speaker: Matthew Rondina (United States)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 210/211

SOA 12, ECMO and Artificial Circuits

Chair: Joyce Ching Mei Lam (Singapore)
Chair: John Roy (Australia)

Recent Advances in ECMO	08:00
Speaker: Graeme MacLaren (Singapore)	
Artificial Circuits and Coagulation	08:25
Speaker: Sebastiano Maria Colombo (Australia)	
Mechanical Circulatory Support Coagulopathy: Monitoring and Management	08:50
Speaker: Jose Mauricio Del Rio (United States)	

Scientific Programme

State-of-the-Art Session
08:00 - 09:15

Meeting Room 212/213

SOA 13, New Therapeutic Targets for Clotting and Bleeding

Chair: Olivier Christophe (France)
Chair: Paul Kim (Canada)

Factor X Variants: From Outback to Bedside	08:00
Speaker: Mettine Bos (the Netherlands)	
TFPI: Structure, Function and Therapeutic Potential	08:25
Speaker: Alan E. Mast (United States)	
Thiol Isomerases: Novel Regulation of Thrombosis	08:50
Speaker: Robert Flaumenhaft (United States)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 219/220

SOA 14, Fibrinolysis in Healing and Repair

Chair: Marie Ranson (Australia)
Chair: Tor Ny (Sweden)

Plasminogen Activation in Inflammatory Joint and Bone Disease	08:00
Speaker: Matthew James Flick (United States)	
Plasminogen in Wound Healing	08:25
Speaker: Tor Ny (Sweden)	
uPA and Its Receptor in Neurorepair	08:50
Speaker: Manuel Yepes (United States)	

Exhibition
09:30 - 17:30

Exhibition Hall

Exhibition

Plenary Session
09:30 - 10:15

Plenary Hall

PL 03, Barry Firkin Plenary Lecture

Chair: Christopher M. Ward (Australia)

Thrombotic Microangiopathies	09:30
Speaker: Marie Scully (United Kingdom)	

Scientific Programme

Oral Communication Session
10:45 - 12:00

Plenary Hall

LB 01, Late Breaking Abstract Session

Chair: Christopher M. Ward (Australia)
Chair: Flora Peyvandi (Italy)

- | | |
|---|--------------|
| Subcutaneous Prophylaxis with the Anti-TFPI Monoclonal Antibody Concizumab in Hemophilia A and Hemophilia A/B with Inhibitors: Phase 2 Trial Results | 10:45 |
| Speaker: Jan Astermark (Sweden) | |
| First-in-human Evidence of Durable Therapeutic Efficacy and Safety of AAV Gene Therapy Over Three-years with Valoctocogene Roxaparvec for Severe Haemophilia A (BMN 270-201 Study) | 11:00 |
| Speaker: K. John Pasi (United Kingdom) | |
| A Multicenter Trial of Vena Cava Filters in Severely-Injured Patients | 11:15 |
| Speaker: Kwok-Ming Ho (Australia) | |
| Magnetic Resonance Direct Thrombus Imaging Can Safely Rule Out Recurrent Ipsilateral Deep Vein Thrombosis of the Leg - The Theia study | 11:30 |
| Speaker: Lisette F. van Dam (the Netherlands) | |
| Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Children | 11:45 |
| Speaker: Christoph Male (Austria) | |

Oral Communication Session
10:45 - 12:00

Melbourne Room 1

OC 31, Gene Therapy Basic 2

Chair: Ross Ian Baker (Australia)
Chair: Maria Elisa Mancuso (Italy)

- | | |
|--|--------------|
| Whole Exome Sequencing of Patients Treated with Adeno-associated Virus Serotype 8-factor IX (AAV8-FIX) Gene Therapy Reveals Potential Determinants of Persistent Transgene Expression | 10:45 |
| Speaker: Birgit Maria Reipert (Austria) | |
| CTLA-4 IgGs - A Powerful Tool to Enable Re-administration in AAV8 Gene Therapy and to Suppress anti-AAV8 T Cell Responses | 11:00 |
| Speaker: Maurus de la Rosa (Austria) | |
| Neddylation and SUMOylation Site Modified Adeno-Associated Virus Vectors Demonstrate Enhanced Hepatic Factor IX Gene Delivery In Vivo | 11:15 |
| Speaker: Shubham Maurya (India) | |
| Preexisting Immunity against AAV8 and other AAV Serotypes in Healthy Individuals and Patients with Hemophilia B | 11:30 |
| Speaker: Maurus de la Rosa (Austria) | |
| Global Seroprevalence of Pre-existing Immunity against Various AAV Serotypes in the Hemophilia A Population | 11:45 |
| Speaker: Gregory M. Hayes (United States) | |

Scientific Programme

Oral Communication Session
10:45 - 12:00

Melbourne Room 2

OC 32, Hemophilia Clinical 1

Chair: Elena Santagostino (Italy)
Chair: Daniel Hart (United Kingdom)

rFVIIIFc for First-time Immune Tolerance Induction (ITI) Therapy: Interim Results from the Global, Prospective verITI-8 Study	10:45
Speaker: Manuel Carcao (Canada)	
Risk Factors for Inhibitor Development after 50 Exposure Days in Non-severe Hemophilia A - Preliminary Data of a Case-control Study	11:00
Speaker: A Abdi (the Netherlands)	
People with Haemophilia and Female Carriers in Sweden have a Higher Risk of Developing Anxiety, Depression and Pain Based on Treatment Patterns as Compared to Matched Controls: Data from a Registry Study over a Period of 11 Years	11:15
Speaker: Stefan Lethagen (Sweden)	
Health Status of People Living with Non-severe Hemophilia - Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study	11:30
Speaker: Chatree Chai-Adisaksopha (Canada)	
Elective Surgery in Patients with Inherited Bleeding Disorders: A Retrospective Analysis of Outcomes and Adherence to Guidelines	11:45
Speaker: Lisa Clarke (Australia)	

Oral Communication Session
10:45 - 12:00

Meeting Room 203/204

OC 33, VTE Outcomes

Chair: Harry Gibbs (Australia)
Chair: Heng Joo Ng (Singapore)

Negative D-dimer Not Sufficient to Stop Anticoagulation in Men	10:45
Speaker: Jean M. Connors (United States)	
Recurrence Risk after First Symptomatic Distal versus Proximal Deep Vein Thrombosis According to Baseline Risk Factors: A Cohort Study	11:00
Speaker: Luca Valerio (Germany)	
Validation of a Tool for Patients' Assessment of Villalta Scale	11:15
Speaker: Fredrik Bremtun (Norway)	
Tailoring of Anticoagulant Therapy by a Recurrence Risk Prediction Model in Patients with Venous Thrombo-embolism as Compared to Care-as-usual; the Vista Randomized Controlled Trial	11:30
Speaker: Geert-Jan Geersing (the Netherlands)	
Definition of Major Bleeding: Prognostic Re-classification	11:45
Speaker: Laura Franco (Italy)	

Scientific Programme

Oral Communication Session
10:45 - 12:00

Meeting Room 210/211

OC 34, Platelet Transcription, Immunity and Inflammation

Chair: Ian Stuart Hitchcock (United Kingdom)
Chair: Gabrielle Pennings (Australia)

- | | |
|--|--------------|
| Platelet Transcription and Translation Is Altered in Sepsis and Associated with Mortality | 10:45 |
| Speaker: Elizabeth Middleton (United States) | |
| Single-cell RNA-seq Transcriptome Analysis of Native Bone Marrow Megakaryocytes Identifies Significant Inflammatory, Metabolic and Mitochondrial Signatures Associated with Platelet Hyperreactivity in Aging and MPN | 11:00 |
| Speaker: Pavel Davizon-Castillo (United States) | |
| Platelets Regulate CD4+ T effector Memory Cell Responses via Platelet Factor 4-dependent Mitochondrial Biogenesis | 11:15 |
| Speaker: Nailin Li (Sweden) | |
| GPIIb-vWF Interactions Promote Neutrophil Recruitment Resulting in Aggravated Liver Damage in the Acute Phase of Hepatic Ischemia-Reperfusion Injury | 11:30 |
| Speaker: Carina Gross (Germany) | |
| Novel Platelet-neutrophil Interaction between Activated αIIbβ3 and SLC44A2 Mediates NETosis under Flow | 11:45 |
| Speaker: Adela Constantinescu-Bercu (United Kingdom) | |

Oral Communication Session
10:45 - 12:00

Meeting Room 212/213

OC 35, Thrombotics and Antithrombotics

Chair: Jeffrey I. Weitz (Canada)
Chair: Sol Schulman (United States)

- | | |
|--|--------------|
| A Safe and Potent Antithrombotic Agent: Salvianolic Acid B Inhibits Platelet Aggregation and Blood Coagulation | 10:45 |
| Speaker: Miguel Neves (Canada) | |
| Comparative Study of CM352 versus Prothrombin Concentrate Complex in Experimental Models of Haemorrhage Associated with Oral Anticoagulants | 11:00 |
| Speaker: Manuel Navarro-Oviedo (Spain) | |
| The Intestinal Microbiome Affects Thrombin Generation in Human Subjects Through Effects on Coagulation Related Plasma Protein Levels | 11:15 |
| Speaker: Harry R. Büller (the Netherlands) | |
| Enhanced Potency of Recombinant Factor VIIa upon Increasing Affinity to Activated Platelets | 11:30 |
| Speaker: Marianne Kjalke (Denmark) | |

Scientific Programme

A Single Domain Antibody that Inhibits Factor VIIa in the Absence but Not Presence of Tissue Factor 11:45
Speaker: Stephen Ferrière (France)

Oral Communication Session
10:45 - 12:00

Meeting Room 219/220

OC 36, Heparin-Induced Thrombocytopenia

Chair: Tamam Bakchoul (Germany)
Chair: Donald M. Arnold (Canada)

Prospective Validation of a Rapid and Accurate Diagnostic Algorithm for Heparin-Induced Thrombocytopenia 10:45
Speaker: Maxime G. Zermatten (Switzerland)

Thrombosis in Heparin-Induced Thrombocytopenia is Mediated by Neutrophils 11:00
Speaker: Jose Perdomo (Australia)

Dissecting the Mechanisms of Thrombocytopenia and Thrombosis in HIT 11:15
Speaker: Halina Leung (Australia)

Low-dose Argatroban Use in Child-Pugh B and C Chronic Liver Disease with Suspected Heparin-induced Thrombocytopenia at King's College Hospital 11:30
Speaker: Julia Czaprynska (United Kingdom)

5B9, a Useful Tool for Evaluating the Performances of Platelet Function Tests for the Diagnosis of Heparin-induced Thrombocytopenia 11:45
Speaker: Caroline Vayne (France)

Oral Communication Session
10:45 - 12:00

Meeting Room 105

OC 37, Fibrinogen and Immunopathology

Chair: Helen McPherson (United Kingdom)
Chair: Helen Philippou (United Kingdom)

Both Carboxypeptidase B2 and Carboxypeptidase N are Responsible for Inactivation of Bradykinin 11:00
Speaker: John Morser (United States)

Fibrin(ogen) Protects Neutrophils from Membrane Damage by Extracellular Histones and Ionomycin 11:15
Speaker: Matthew Locke (United Kingdom)

Molecular Mechanisms Underlying the Fibrin-VLDL Receptor-dependent Pathway of Transendothelial Migration of Leukocytes and the Inhibitory Function of Fibrin-derived β 15-42 Fragment 11:30
Speaker: Leonid Medved (United States)

Scientific Programme

Fibrin is a Critical Regulator of Immunopathology at the Oral Mucosal Barrier **11:45**
Speaker: Lakmali Munasinghage Silva (United States)

Oral Communication Session
10:45 - 12:00

Meeting Room 106

OC 38, Bleeding and Clotting Complications in Pediatrics

Chair: Christina Yip (Singapore)
Chair: Vera Ignjatovic (Australia)

Single-center Clinical Data Analysis of Hereditary Thrombocytopenia in Children with Chronic Thrombocytopenia **10:45**
Speaker: Jingyao Ma (China)

Oxidized Hemoglobin Is Associated with Increased Level of Cell-free microRNAs in Cerebrospinal Fluid of Premature Infants with Intraventricular Hemorrhage: A Pilot Study **11:00**
Speaker: Zsolt Fejes (Hungary)

Platelet Physiology and Function in Neonates and Children from Different Pathways onto Extracorporeal Membrane Oxygenation (ECMO) **11:15**
Speaker: Hui Ping Yaw (Australia)

Predictors of Recurrence and Post Thrombotic Syndrome (PTS) Following Lower Extremity Deep Vein Thrombosis in Children and Adolescents: PTS Risk Reduction Using Thrombolysis As Initial Therapy **11:30**
Speaker: Marilyn Manco-Johnson (United States)

Inherited Antithrombin Deficiency and Thrombosis in Childhood: Data from a Large Multicentric Cohort **11:45**
Speaker: Christelle Orlando (Belgium)

Oral Communication Session
10:45 - 12:00

Meeting Room 109

OC 39, Acquired Coagulopathy

Chair: Simon McRae (Australia)
Chair: Sarah O'Brien (United States)

An Engineered Activated Factor V (SuperFVa) for Prevention and Treatment of Acute Traumatic Coagulopathy and Bleeding **10:45**
Speaker: Bilgimol Chumappumkal Jospeh (United States)

A New State-of-the-Art Human Fibrinogen Concentrate versus Cryoprecipitate in Pseudomyxoma Peritonei Surgery: Efficacy and Safety Results from a Prospective, Randomized, Controlled Phase 2 Study **11:00**
Speaker: Cristina Solomon (Switzerland)

Shear-dependent Shedding of Platelet Receptor GPIIb/IIIa: A Role for Thrombocytopenia during ECMO **11:15**
Speaker: Antoine Rauch (France)

Scientific Programme

Effect of a Recombinant Human Soluble Thrombomodulin (ART-123) on Mortality and Levels of Coagulation Biomarkers in Patients with Sepsis Associated Coagulopathy (SAC)	11:30
Speaker: David Fineberg (United States)	
Inhibition of ADAMTS13 Prevents the Loss of High Molecular Weight von Willebrand Factor Multimers in an in vitro Left Ventricular Assist Device	11:45
Speaker: Shannen Deconinck (Belgium)	

Special Session
12:15 - 13:15

Meeting Room 106

World Thrombosis Day: Building Awareness to Improve Global Health

Introduction	12:15
Speaker: Beverley J. Hunt (United Kingdom)	
What Is World Thrombosis Day?	12:20
Speaker: Tetsumei Urano (Japan)	
The Value of Implementing VTE Risk Assessments	12:35
Speaker: Beverley J. Hunt (United Kingdom)	
Q&A with WTD 2018 Thrombosis Ambassador of the Year Christine Ashimwe	12:55
Speaker: Christine Ashimwe (Rwanda) Speaker: Claire McLintock (New Zealand)	
5 Simple Ways to Get Involved in WTD	13:10
Speaker: Fionnuala Ní Áinle (Ireland)	

Product Theater Presentations
12:15 - 13:00

Theatre A

Product Theater

Title: Quantra, a Novel Viscoelastic Device for the Management of Acute Bleeding This session is supported by [Stago](#)
[Please view the program here](#)

Product Theater Presentations
12:15 - 13:00

Theatre B

Product Theater

Title: Ceprotin®: a Critical Treatment in the Management of SCPCD This session is supported by [Takeda](#) [Please visit here](#)

Scientific Programme

Product Theater Presentations
12:15 - 13:00

Theatre C

Product Theater

Title: The Chronic Risk of Arterial and Venous Thrombosis: Managing Prevention with NOACs This session is supported by [Bayer AG](#) Please view the program here

Product Theater Presentations
12:15 - 13:00

Theatre D

Product Theater

Title: Think Again About VWD: Deliver Control To The Patient This session is supported by [CSL Behring](#) Please view the program here

Supported Symposia
13:15 - 14:30

Melbourne Room 1

Supported Symposium

Title: Gene Transfer Gene Therapy: From Bench to Bedside This session is supported by [BioMarin Pharmaceutical Inc.](#) Please view the program here

Supported Symposia
13:15 - 14:30

Melbourne Room 2

Supported Symposium

Title: Conveniently Protecting What Matters: Nuwiq® (Simoctocog Alfa) in PUPs and Personalised Prophylaxis This session is supported by [Octapharma](#) Please view the program here

Supported Symposia
13:15 - 14:30

Meeting Room 203/204

Supported Symposium

Title: What Everyone Should Know About Elevating Standards of Care in Haemophilia This session is supported by [Sanofi Genzyme and Sobi](#) Please view the program here

Supported Symposia
13:15 - 14:30

Meeting Room 210/211

Supported Symposium

Title: Reversal of Specific Direct Novel Oral Anticoagulants in Patients Experiencing Life-Threatening Bleeds This session is supported by [Portola Pharmaceuticals](#) Please visit here

Scientific Programme

Supported Symposia
13:15 - 14:30

Meeting Room 212/213

Supported Symposium

Title: Transformative Science in an Era of Comprehensive Care: From Lab to Life This session is supported by [Pfizer](#)
[Please view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 219/220

Supported Symposium

Title: The Power of Design: Evolving the Standard of Care With Jivi® This is supported by [Bayer](#) [Please view the program here](#)

Master Class
13:15 - 14:15

Meeting Room 218

How I Treat: Autoimmune and Atypical HIT

The learning points in this session will include: 1) What is the difference between “normal” HIT antibodies and autoimmune HIT antibodies; 2) Typical clinical presentations of autoimmune HIT; 3) Which laboratory tests to be performed if autoimmune HIT is suspected; 4) Anticoagulation regimen in autoimmune HIT; 5) Additional treatments including IVIG. Andreas Greinacher has more than 30 years experience in diagnosis and management of heparin-induced thrombocytopenia. He has identified the binding characteristics of autoimmune HIT antibodies and the key steps in the pathogenesis of autoimmune HIT.

Autoimmune and Atypical HIT

13:15

Speaker: Andreas Greinacher (Germany)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 1

Anticoagulation in Children

Master Class Focus: Clinical I have nearly 20 years' clinical and research experience in the area of paediatric anticoagulant management. My Masters and PhD theses both explored issues related to the clinical use and management of anticoagulant therapies in children. In my clinical role, I support the care of over 200 children requiring anticoagulant therapy at any time. I have expertise in clinical management, development of clinical guidelines, design and conduct of clinical trials as well as the development and implementation of novel approaches to support optimal patient management.

Anticoagulation in Children

13:15

Speaker: Fiona Newall (Australia)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 2

Advances in the Molecular Understanding and Treatment of ITP

Master Class Focus: Basic and Clinical Dr. Grainger is the lead investigator for the pediatric Eltrombopag and romiplostim clinical trials and is a co-author on the international ITP consensus guidelines.

Advances in the Molecular Understanding and Treatment of ITP

13:15

Speaker: John D. Grainger (United Kingdom)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 3

Perioperative Management of Heart Valves

Master Class Focus: Clinical Dr. James Douketis is Staff Physician in Vascular Medicine and General Internal Medicine at St. Joseph's Healthcare Hamilton, and Professor of Medicine at McMaster University. He received his M.D. and did his residency in internal medicine at the University of Toronto followed by a thrombosis fellowship at McMaster University. Dr. Douketis' research interests include: perioperative antithrombotic therapy and guideline development (2008, 2012, and 2018 ACCP Guidelines); prevention, treatment and prognosis of patients with venous thromboembolism. Dr. Douketis is President of Thrombosis Canada (www.thrombosiscanada.ca), Associate Editor of Journal of Thrombosis and Haemostasis, Deputy Editor of Annals of Internal Medicine Journal Club, and Editor of Canadian Journal of General Internal Medicine, and has over 300 peer-reviewed publications. Jim lives in Hamilton with his wife, Dr. Margaret Nowaczyk, a clinical geneticist, and two sons, Jack and Luke, and is a cellist with Symphony-on-the Bay.

Perioperative Management of Heart Valves

13:15

Speaker: James Douketis (Canada)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 4

VTE Management Dilemmas

Master Class Focus: Clinical Dr Timothy Brighton is a Senior Consultant Haematologist at Prince of Wales Hospital in Sydney. He has been involved in clinical management of patients with vein thrombosis for 20+ years. He has been actively involved in clinical research in the prevention and treatment of vein thrombosis over his career. Personal highlights include being principal investigator for the ASPIRE Trial (NEJM 2013) and the recent EINSTEIN-CHOICE study (NEJM 2017). He is the current secretary of the INVENT VTE Collaborative and represents Australian investigators in this international collaboration of several VTE research groups.

VTE Management Dilemmas

13:15

Speaker: Timothy A. Brighton (Australia)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 5

Laboratory Impact of New Hemophilia Therapies

Master Class Focus: Basic Geoffrey Kershaw has been the senior scientist in charge of the hemostasis laboratory at Royal Prince Alfred Hospital for the past 20 years. His interests include assays factor assays, factor inhibitor testing, clot waveform analysis and thrombin generation. Recent work includes conducting local field studies aimed at giving laboratories feedback on suitability of their current one-stage and chromogenic factor assays methods of for measuring the extended half-life factor therapies. Other work includes hands-on training of scientists and hematology trainees in all areas of hemostasis testing. Geoffrey also assists the local External Quality Assurance testing program in sourcing materials and designing the format of quality control exercises.

Laboratory Impact of New Hemophilia Therapies

13:15

Speaker: Geoff Kershaw (Australia)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 6

NETs in Vascular Biology

Master Class Focus: Basic Tobias Fuchs is an Immunologist by training. He did his PhD work on "The formation of Neutrophil Extracellular Traps (NETs)" at the Max Planck Institute for Infection Biology in Berlin under the guidance of Arturo Zychlinsky. As a postdoctoral fellow, he worked in the laboratory of Denisa Wagner at the Harvard Medical University on the role of "NETs on thrombosis". He is currently a Principal Investigator at the University Medical Center Hamburg-Eppendorf. He received several awards including the Eberhard F. Mammen Young Investigator Award (2015) of Thieme Medical Publishers, the Young Talent Award for Excellent Scientists (2015) and the Alexander Schmidt Award (2018) of the German Society of Thrombosis and Hemostasis.

NETs in Vascular Biology

13:15

Speaker: Tobias A. Fuchs (Germany)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 7

Risk Scores for Thrombosis and Bleeding in Atrial Fibrillation

Master Class Focus: Clinical •Validation of CHA2DS2-VASc and HAS-BLED scores in Asian AF patients. •Propose the concept of "delta-CHA2DS2-VASc score" showing the stroke risk of AF patients is dynamic. •Propose the concept of "delta-HAS-BLED score". •Propose a different age threshold for the initiations of NOACs for Asian AF patients. •Propose the concept of "modified CHA2DS2-VASc score" by lowering the age definition of the CHA2DS2-VASc scheme.

Risk Scores for Thrombosis and Bleeding in Atrial Fibrillation

13:15

Speaker: Tze-Fan Chao (Taiwan, Republic of China)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 8

Coagulation Testing in the DOAC Era

Master Class Focus: Clinical I am trained as a laboratory scientist and I am responsible for a service laboratory in a large UK teaching hospital in Sheffield. We offer DOAC assays regionally on a 24/7 basis. I am the scientific Director of UK NEQAS Blood Coagulation - a large international proficiency testing programme where we run surveys for Apixaban, Dabigatran, Edoxaban and Rivaroxaban. I am the Vice Chair (Hemostasis) for International Council for Standardisation in Haematology (ICSH) who have recently re-joined the hemostasis arena after some years focussing more on general hematology. Our first haemostasis guidance document addresses laboratory issues round use of DOACs.

Coagulation Testing in the DOAC Era
Speaker: Steve Kitchen (United Kingdom)

13:15

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 9

Tissue Factor

Master Class Focus: Basic Cloned the human tissue factor gene. Participated in the generation of knock-out rule. Made low tissue rule. Analyzed the roles of tissue factor in hemostasis. Analyzed the roles of tissue factor in thrombosis.

Tissue Factor
Speaker: Nigel Mackman (United States)

13:15

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 10

Antiphospholipid Antibody Syndrome

Session Focus: Clinical Tatsuya Atsumi, MD, PhD, Professor of Medicine in the Faculty of Medicine, Hokkaido University in Japan, is the head of the department of Rheumatology, Endocrinology and Nephrology. After graduating at Hokkaido University in 1988, he has spent most of his carrier as a researcher in Sapporo, except 3 years in the Lupus Unit, St. Thomas' hospital in London (1994-1997). His research interest includes clinical and basic aspect of systemic autoimmune diseases such as antiphospholipid syndrome, systemic lupus erythematosus and other rheumatic diseases. He has over 400 research publications dealing with several aspects of rheumatology, in particular, with the pathogenesis, diagnosis and treatment of antiphospholipid syndrome.

Antiphospholipid Antibody Syndrome
Speaker: Tatsuya Atsumi (Japan)

13:15

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 11

Building a Professional Network in Thrombosis and Hemostasis

Dr. Lauw is a member of the ISTH Early Career Committee and its former Chair (2015 - 2018). She is active in various (inter)national societies and early career programs. Key elements in building and extending her professional network in the field of Thrombosis and Hemostasis have been: 1) using the opportunities the ISTH committee and other positions have provided, 2) doing research fellowships abroad, 3) collaborating with (international) fellow early career and senior colleagues, 4) staying curious, open, enthusiastic, and willing to share, and 5) having great mentorship.

Scientific Programme

Building a Professional Network in Thrombosis and Hemostasis

13:15

Speaker: Mandy N. Lauw (the Netherlands)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 12

Clinical Trials Coordination: Getting Started and Going Strong

Allison Lamb was appointed to the Clinical Trials Manager position at the Royal Children's Hospital's Children's Cancer Centre in 2012 and became a member of the Royal Children's Hospital Human Research Ethics Committee in 2013. Previously, she has supported over 160 clinical trials at Peter MacCallum Cancer Centre in roles as Research Nurse, Clinical Trials Unit Educator, Clinical Research Nurse Consultant and Acting Unit Manager. She has coordinated and supported clinical trials from phase one through to four, while ensuring patient safety and capturing quality data. She has conducted and led in-services and training around clinical research to hospital staff including Good Clinical Practice training to doctors. She has also participated as a lecturer for the Good Clinical Practice component of the Specialist Certificate in Clinical Research Oncology at the University of Melbourne.

Clinical Trials Coordination: Getting Started and Going Strong

13:15

Speaker: Allison Lamb (Australia)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 13

Writing and Submitting Scientific Articles

Professor Reitsma is the Editor-in-Chief of JTH until the end of 2018. He has authored some 300 PubMed papers as (co)-author. Several publications have been published in high ranking journals. He is also experienced as an associate editor at Haematologica and PLOSOne.

Writing and Submitting Scientific Articles

13:15

Speaker: Pieter Reitsma (the Netherlands)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 14

Having a Career and a Life: My Experience with Work-Life Balance

Professor Middeldorp has mentored numerous MD and PhD students and residents (both male and female) on this topic. She has given talks on this topic at various stages of her career. Professor Middeldorp has made mistakes like many of us have. She has followed some coaching programs in order to help answer her own questions on improving work-life balance and is willing to share with mentees and colleagues these experiences.

Having a Career and a Life: My Experience with Work-Life Balance

13:15

Speaker: Saskia Middeldorp (the Netherlands)

Scientific Programme

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 15

Performing Systematic Review and Meta-Analyses

Dr. Siegal has published 10 systematic reviews/meta-analysis in peer reviewed journals. Her primary research interests include anticoagulant reversal and improving outcomes after anticoagulant-related bleeding complications. She has published over 45 articles in peer-reviewed journals including The New England Journal of Medicine, Annals of Internal Medicine, Circulation, Blood and Journal of Thrombosis and Haemostasis on the topic of anticoagulant associated bleeding and reversal. Dr. Siegal holds Master of Science degrees in Pharmacology and Health Research Methodology.

Performing Systematic Review and Meta-Analyses **13:15**

Speaker: Deborah M. Siegal (Canada)

Oral Communication Session
14:45 - 16:00

Plenary Hall

OC 40, Gene Therapy

Chair: Mark P. Smith (New Zealand)
Chair: Charles Hay (United Kingdom)

Targeted Exon Skipping As a Potential Gene Correction Therapy for Haemophilia A **14:45**

Speaker: Jim Y Tiao (Australia)

Therapeutic Levels of FVIII Generated by CRISPR/Cas9-mediated in vivo Genome Editing in Hemophilia A Mice **15:00**

Speaker: Alan Brooks (United States)

Exon-Specific U1snRNA-Mediated Rescue of Splicing and Missense Changes in Hemophilia A **15:15**

Speaker: Silvia Lombardi (Italy)

CRISPR Activation on Coagulation F7 or F8 Promoters Potentiate Transcriptional Activity in the Normal and Mutated Gene Context **15:30**

Speaker: Silvia Pignani (Italy)

Adeno-associated Virus Vector Based on Serotype 3 Represents an Alternative Serotype for Hemophilia Gene Therapy **15:45**

Speaker: Tsukasa Ohmori (Japan)

Oral Communication Session
14:45 - 16:00

Melbourne Room 1

OC 41, Cancer-Associated Thrombosis: Clinical

Chair: Kate Burbury (Australia)
Chair: Walter Ageno (Italy)

A Validated Profile of 6 miRNAs as Predictor of Early Incidental Post-surgical Pulmonary Embolism in Glioma Patients **14:45**

Speaker: Julia Oto (Spain)

Scientific Programme

Utility of the Thrombin Generation Test in Various Clinical Phenotypes to Predict Thrombotic Recurrences in Cancer Patients without Anticoagulant Treatment	15:00
Speaker: Julia Oto (Spain)	
A Validation, with New Clinical Applicability, of a Clinical-Genetic Risk Model that Predicts Thrombosis with High Sensitivity in Patients with Lymphoma	15:15
Speaker: Cristina Pascual (Spain)	
Subsequent Venous Thromboembolism after Upper Extremity Deep Venous Thrombosis in Patients with Cancer	15:30
Speaker: Ted Wun (United States)	
Prevalence and Relative Risk of Atrial Fibrillation in Patients with Cancer - a Nationwide Cohort Study	15:45
Speaker: Cihan Ay (Austria)	

Oral Communication Session
14:45 - 16:00

Melbourne Room 2

OC 42, Hemophilia Optimizing Prophylaxis

Chair: Shannon C. Jackson (Canada)
Chair: Sally Campbell (Australia)

PK-Guided Rurioctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A Targeting Two FVIII Trough Levels: Safety and Efficacy Results From the Phase 3 PROPEL Study	14:45
Speaker: Robert Klamroth (Germany)	
The Comparative Pharmacokinetic (PK) Profiles of Two Extended Half-life (EHL) Factor VIII Concentrates [rFVIII-Fc (Eloctate) and rAHF-FL-PEG (Adynovate)] in Adolescent Boys with Hemophilia A: Is there a Difference?	15:00
Speaker: Manuel Carcao (Canada)	
Exploring Methods to Predict an Individual's Pharmacokinetic Profile when Switching between Factor Concentrates in Hemophilia A	15:15
Speaker: Alfonso Iorio (Canada)	
Patient Reported Outcome Data on Switch from Standard to Extended Half Life in Irish Adults with Haemophilia	15:30
Speaker: Brian O'Mahony (Belgium)	
First Report of an Extended Half-life FIX in Previously Untreated Patients with Haemophilia B	15:45
Speaker: Chris Barnes (Australia)	

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 203/204

OC 43, Platelet Receptor Regulation and Function

Chair: Shauna French (United States)
Chair: Paul F. Bray (United States)

Fibrin Exposure Increases Platelet ADAM10 Activity in a Calcium-dependent Manner	14:45
Speaker: Samantha J. Montague (Australia)	
GPVI Sustains Platelet Activation to Maintain the Integrity and Stability of a Growing Thrombus	15:00
Speaker: Muhammad Usman Ahmed (France)	
The Interaction of Monomeric and Dimeric GPVI with Variants of Fibrin and Fibrinogen	15:15
Speaker: Julia S Gauer (United Kingdom)	
Dimeric form of Platelet Glycoprotein VI Binds to Fibrin Fibers in Fibrin Clots	15:30
Speaker: Stephanie M Jung (United Kingdom)	
Cancer Cell-derived Immunoglobulin G Activates Platelet via Binding Platelet FcγRIIa.	15:45
Speaker: Zhang-Yin Ming (China)	

Oral Communication Session
14:45 - 16:00

Meeting Room 210/211

OC 44, Laboratory Diagnostics Thrombosis

Chair: Gian Luca Salvagno (Italy)
Chair: Leonardo Pasalic (Australia)

Hemolysis Induces a Prothrombotic State in Human Plasma	14:45
Speaker: Gian Luca Salvagno (Italy)	
A Hemodynamically Controlled Micropump/mixer Applied to Anti-platelet Drug Screening	15:00
Speaker: Rose J. Brazilek (Australia)	
Effects of Edoxaban on Routine Tests of Haemostasis as Determined with a Full Range of Reagents: Results of a UK NEQAS Exercise	15:15
Speaker: Ian Jennings (United Kingdom)	
A Novel Whole Blood Thrombin Generation Model to Study the Involvement of Blood Cells in Coagulation	15:30
Speaker: Jun Wan (the Netherlands)	
Determination of Sensitivity and Specificity of Mixing Studies to Aid in Lupus Anticoagulant Confirmation in a High Volume Reference Lab Setting	15:45
Speaker: John Mitsios (United States)	

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 212/213

OC 45, Cancer and Coagulation Mechanisms

Chair: Janusz Rak (Canada)
Chair: Caroline Reddel (Australia)

Tumor-derived Factor VII Associates with Survival and Regulates Tumor Progression in Breast Cancer	14:45
Speaker: Chantal Kroone (the Netherlands)	
Tissue Factor Pathway Inhibitor (TFPI) Enhances Trans-Endothelial Migration of Chronic Lymphocytic Leukemia Cells through CXCL12/CXCR7	15:00
Speaker: Xue Yan Cui (Norway)	
Low Molecular Weight Heparin Reduces Tumour Formation, Invasion and Vascularisation	15:15
Speaker: Sophie Featherby (United Kingdom)	
Tissue Factor and Tissue Factor in Combination with Alpha-1 Antitrypsin or Reg4 Associate with Venous Thromboembolism in Patients with Colorectal Cancer	15:30
Speaker: Jeroen T Buijs (the Netherlands)	

Oral Communication Session
14:45 - 16:00

Meeting Room 219/220

OC 46, ADAMTS13 and TTP

Chair: Doyeun Oh (Korea, Republic of)
Chair: Simon De Meyer (Belgium)

Crosstalks between ADAMTS13 and Complement in Murine Models of Thrombotic Microangiopathy	14:45
Speaker: Liang Zheng (United States)	
Anti-ADAMTS-13 Autoantibody-specific Anti-idiotypic Antibodies Restore ADAMTS-13 Activity in Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Patients	15:00
Speaker: Silvan Rolf Heeb (Switzerland)	
Thrombotic Thrombocytopenic Purpura: 10 Year Analysis of the United Kingdom TTP Registry	15:15
Speaker: Jin-Sup Shin (United Kingdom)	
Patient Anti-ADAMTS13 Autoantibodies Induce an Open ADAMTS13 Conformation in Immune-mediated Thrombotic Thrombocytopenic Purpura	15:30
Speaker: Elien Roose (Belgium)	
HLA Variant rs6903608 is Associated with Disease Onset and Relapse in Immune-mediated Thrombotic Thrombocytopenic Purpura	15:45
Speaker: Ilaria Mancini (Italy)	

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 105

OC 47, Regulation of Coagulation

Chair: Hartmut Weiler (United States)
Chair: Annika de Jong (the Netherlands)

- | | |
|--|--------------|
| Using Site-directed PEGylation and the Insertion of Targeted Novel N-linked Glycans to Further Elucidate the Role Played by the A-Domains in Regulating VWF Clearance | 14:45 |
| Speaker: Jamie O'Sullivan (Ireland) | |
| Sec22b-Dependent Trafficking Is Essential for VWF Multimerization and Formation of Elongated WPBs | 15:00 |
| Speaker: Ellie Karampini (the Netherlands) | |
| A New Transgenic Mouse Model Tolerant to Human Recombinant Von Willebrand Factor | 15:15 |
| Speaker: Maurus de la Rosa (Austria) | |
| Skeletal Muscle Myosin Enhances the Anticoagulant Activity of Activated Protein C and Protein S But Not Protein C Activation by Thrombin: Thrombomodulin | 15:30 |
| Speaker: Mary J. Heeb (United States) | |
| APC Receptor Expression Analysis in Myeloid Cells Reveals Agonist-inducible EPCR Expression Leading to Increased APC Binding | 15:45 |
| Speaker: Seán McCluskey (Ireland) | |

Oral Communication Session
14:45 - 16:00

Meeting Room 106

OC 48, Pregnancy Associated Thrombosis

Chair: Briony Cutts (Australia)
Chair: Beatriz Grand (Argentina)

- | | |
|---|--------------|
| Thrombosis Risk after Switching Oral Contraceptive Type | 14:45 |
| Speaker: Deeksha Khialani (the Netherlands) | |
| Preventing Postpartum Venous Thromboembolism; Impact of Systematic VTE Risk Assessment | 15:00 |
| Speaker: Fergal O'Shaughnessy (Ireland) | |
| Performance of Standard Dose Enoxaparin in Preventing Pregnancy-Associated Venous Thromboembolism | 15:15 |
| Speaker: Ashwini Bennett (Australia) | |
| Enoxaparin Prescription during Pregnancy. Are We Using it According to International Guidelines | 15:30 |
| Speaker: Daniela Mezzarobba (Argentina) | |
| Promising Maternal and Fetal Therapeutic Outcomes from Sildenafil and Dalteparin Treatments in a Murine Pregnancy Loss Model | 15:45 |
| Speaker: Maha Othman (Canada) | |

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 109

OC 49, Thrombophilia and VTE

Chair: Timothy A. Brighton (Australia)
Chair: Suely Rezende (Brazil)

- | | |
|--|--------------|
| Molecular and Biological Characterization of Transitory Antithrombin Deficiency: A New Concept in Congenital Thrombophilia | 14:45 |
| Speaker: Carlos Bravo-Perez (Spain) | |
| Genomic and Transcriptomic Association Studies Identify 17 Novel Susceptibility Loci for Venous Thromboembolism: The INVENT Consortium | 15:00 |
| Speaker: Nicholas Smith (United States) | |
| A Novel Gain of Function Variant of Prothrombin (p.R541W) Causes Dominant Heritable Thrombosis and Is Associated with Antithrombin Resistance | 15:30 |
| Speaker: Vincent Muczynski (United Kingdom) | |
| Type of Combined Contraceptives and the Risk of Venous Thromboembolism in Antithrombin, Protein C and Protein S Deficient Women. A Prospective Cohort Study | 15:45 |
| Speaker: Daniela Tormene (Italy) | |

Laboratory Workshop
14:45 - 16:00

Meeting Room 218

Laboratory Monitoring of New Hemophilia Therapies

Chair: Geoff Kershaw (Australia)
Chair: Steve Kitchen (United Kingdom)

- | | |
|---|--------------|
| Measurement of FVIII Extended Half-Life Products | 14:45 |
| Speaker: Stefan Tiefenbacher (United States) | |
| Measurement of FIX Extended Half-Life Products | 15:10 |
| Speaker: Geoff Kershaw (Australia) | |
| Effect of Emicuzimab on Laboratory Assays | 15:35 |
| Speaker: Steve Kitchen (United Kingdom) | |

SSC Session
16:30 - 18:30

Melbourne Room 1

SSC Joint Session: Biorheology, Perioperative and Critical Care of Thrombosis and Hemostasis, and von Willebrand Factor

Extracorporeal Circulation: Extracorporeal Membrane Oxygenation (ECMO) and Ventricular Assist Devices (VADs) Moderators: Sandra Haberichter United States, Jerrold Levy United States, Pierre Mangin France

Scientific Programme

Introduction and Goals	16:30
Speaker: Jerrold Levy (United States)	
Mechanical Support Essentials: What the Coagulation Expert Needs to Know	16:35
Speaker: Jean M. Connors (United States)	
Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support	16:55
Speaker: Sophie Susen (France)	
Hemostatic Management in Ventricular Assist Device Patients: Too Thick or Too Thin, How Do We Get It Right?	17:15
Speaker: Lisa Baumann Kreuziger (United States)	
Biorheological Aspects of Thrombosis in Extracorporeal Membrane Oxygenation and Mechanical Support	17:35
Speaker: David Ku (United States)	
Implications of Hemostatic Differences Between Adults and Pediatrics for Extracorporeal Circulation	17:55
Speaker: Jun Teruya (United States)	
Discussion and Q&A	18:15

SSC Session
16:30 - 18:30

Melbourne Room 2

Factor VIII, Factor IX and Rare Coagulation Disorders

SSC Project Updates Moderators: Alfonso Iorio, <i>Canada</i>, Johnny Mahlangu, <i>South Africa</i>	
Hemophilia Carrier Nomenclature	16:30
Speaker: Robert Sidonio (United States)	
Gene Therapy Working Group	16:40
Speaker: Alok Srivastava (India)	
Definitions in Acquired Hemophilia	16:50
Speaker: Andreas Tiede (Germany)	
Definition of Immune Tolerance Induction Response with Extended Half-Life FVIII Products Working Group	17:00
Speaker: Maria Elisa Mancuso (Italy)	
SSC New Projects Moderators: Maria Elisa Mancuso, <i>Italy</i>, Guy Young, <i>United States</i>	
Novel Non Replacement Therapies for Hemostasis in Patients with Rare Bleeding Disorders, an Ex Vivo Thrombin Generation Guided Study	17:10
Speaker: Maria Elisa Mancuso (Italy)	
International Multicenter Validation Study of a Standardization Mathematical Tool to Improve the Reproducibility of Factor IX Results in Patients with Hemophilia B Treated	17:20
Speaker: Felipe Guerrero (France)	

Scientific Programme

Standardization Issues in Novel Hemophilia Therapies - Guidance from Experts	
Moderators: Maria Elisa Mancuso, <i>Italy</i>, Savita Rangarajan, <i>England</i>	
Key Considerations in Choosing Outcome for Assessing Gene Therapy	17:30
Speaker: K. John Pasi (United Kingdom)	
Key Considerations in Choosing Outcome for Assessing Non-Replacement Therapies	17:45
Speaker: Johannes Oldenburg (Germany)	
Achievable Goals in Standardizing Factor Activity Level Measurement for Extended Half Life Products	18:00
Speaker: Steve Kitchen (United Kingdom)	
Q&A Session	18:15

SSC Session
16:30 - 18:30

Meeting Room 203/204

SSC Joint Session: Lupus Anticoagulant/Antiphospholipid Antibodies, Women's Health Issues in Thrombosis and Hemostasis, and Disseminated Intravascular Coagulation

Moderators: Katrien Devreese <i>Belgium</i>, Toshiaki Iba <i>Japan</i>, Maha Othman <i>Canada</i>	
Classical International Consensus Clinical Criteria with Low Positive Anticardiolipin Antibodies or Anti-β2-glycoprotein I Antibodies Present Between the 95th and 99th Centiles or Intermittent Antiphospholipid Antibodies	16:30
Speaker: Hannah Cohen (United Kingdom)	
What is the Association Between Antiphospholipid Antibodies and Disseminated Intravascular Coagulation During Pregnancy or Postpartum Period?	16:50
Speaker: Stéphane Zuily (France)	
Does the Role of Isotypes and Antibody Profile of Antiphospholipid Antibodies Differ for Thrombosis and Pregnancy Morbidity?	17:10
Speaker: Walid Chayoua (the Netherlands)	
Treatment of Obstetric Antiphospholipid Syndrome	17:30
Speaker: Beverley J. Hunt (United Kingdom)	
Disseminated Intravascular Coagulation: Diagnosis and Management	17:50
Speaker: Satoshi Gando (Japan)	
Disseminated Intravascular Coagulation in Obstetrics and an International Registry	18:10
Speaker: Offer Erez (Israel)	
Diagnosis of DIC in Obstetrics: The Japanese Scoring	18:20
Speaker: Takao Kobayashi (Japan)	

Scientific Programme

SSC Session
16:30 - 18:30

Meeting Room 210/211

Platelet Immunology

Welcome and Introduction	16:30
Speaker: Donald M. Arnold (Canada)	
New Antigens and Mechanisms in Idiopathic Thrombocytopenic Purpura	16:40
Speaker: Ulrich J. Sachs (Germany)	
Immunotherapy-Induced Idiopathic Thrombocytopenic Purpura: Cohort Study	16:55
Speaker: Philip Choi (Australia)	
Standardization of Clinical Outcomes in Adult and Pediatric Idiopathic Thrombocytopenic Purpura: Proposal	17:10
Speaker: Donald M. Arnold (Canada)	
TORADI-HIT: Report	17:25
Speaker: Tamam Bakchoul (Germany)	
Treatment Strategy for Patients Suspected of Having Heparin-Induced Thrombocytopenia in Japan	17:40
Speaker: Shigeki Miyata (Japan)	
Call for Collaboration with the Platelet Physiology Scientific Standardization Committee	17:55
Speaker: Paolo Gresele (Italy)	
Speaker: Tamam Bakchoul (Germany)	
Speaker: Marie Lordkipanidzé (Canada)	
Discussion and Closing Remarks	18:10
Speaker: Donald M. Arnold (Canada)	

SSC Session
16:30 - 18:30

Meeting Room 212/213

Factor XI and the Contact System

Moderator: Joost Meijers, the Netherlands

Do We Need Reversal Agents for Anti-Factor XI Targeting?	16:30
Speaker: Jeffrey I. Weitz (Canada)	
Measurement of Procoagulant Activity in Immunoglobulins	16:45
Speaker: Helen Wilmot (United Kingdom)	
Performance of Factor XI and XII Assays: External Quality Control of Diagnostic Assays and Tests Experience	17:00
Speaker: Piet Meijer (the Netherlands)	
Performance of Factor XI and XII Assays: National External Quality Assessment Scheme Experience	17:15
Speaker: Steve Kitchen (United Kingdom)	

Scientific Programme

Contact System Network (COSYNE): Harmonization and Validation of Contact Factor Assays	17:30
Speaker: Coen Maas (the Netherlands)	
How to Handle Polyphosphates and Nucleic Acids	17:45
Speaker: Stephanie A. Smith (United States)	
Purification of DNA Without Silica	18:00
Speaker: Paul Kim (Canada)	
Polyphosphates: What We Know and What We Think	18:10
Speaker: Thomas Renné (Germany)	
SSC Subcommittee Business and Wrap Up	18:25
Speaker: Joost C.M. Meijers (the Netherlands)	

SSC Session
16:30 - 18:30

Meeting Room 219/220

Factor XIII and Fibrinogen

Standardization Topics

Update on the Collaborative Study to Additionally Assign Value for Total Factor XIII-B Subunit to the WHO 1st International Standard for FXIII Plasma (02/206)	16:30
Speaker: Verena Schroeder (Switzerland)	
The WHO 3rd International Standard for Thrombin	16:45
Speaker: Matthew Locke (United Kingdom)	

Scientific Topics

Fibrin Films and Their Future Implications	16:50
Speaker: Fraser Macrae (United Kingdom)	
Factor XIII and Platelet Microparticles	17:10
Speaker: László Muszbek (Hungary)	
Factor XIII-A in Lung Squamous Cancer	17:30
Speaker: Alessandro Porrello (United States)	
Factor XIII Structure: Organization of B Subunits and Changes with Activation Studied with Single-Molecule Atomic Force Microscopy	17:50
Speaker: John W. Weisel (United States)	
Congenital Factor XIII Deficiency in Pakistan - Challenges and Chances	18:10
Speaker: Munira Borhany (Pakistan)	

Scientific Programme

Nurses Forum
16:30 - 18:30

Meeting Room 111/112

Nurses Forum Day 2: Abstract Presentation - Clotting and Bleeding Disorders

Chair: Maura Malone (United States)
Chair: Jennifer Meldau (United States)

- | | |
|--|--------------|
| Physical Activity during First Year after Pulmonary Embolism and its Association with Respiratory Symptoms, Lung Function and Functional Capacity. A Longitudinal Observation Study | 16:30 |
| Speaker: Jenny Sofia Danielsbacka (Sweden) | |
| Psycho-social Status and Coping Strategies among Women Carrier for Hemophilia - A Descriptive Study from India | 16:48 |
| Speaker: Sulochana Badagabettu (India) | |
| The Management of Isolated Distal Deep Vein Thrombosis in Pediatrics: A Survey of CPTHN and ISTH SSC Members | 17:06 |
| Speaker: Rebecca Goldsmith (Canada) | |
| Scapular Site Injection of Low Molecular Weight Heparin in Neonates: Study Update | 17:24 |
| Speaker: Rebecca Goldsmith (Canada) | |
| Trends of Anticoagulation Usage and Patient Characteristics in a Tertiary Hospital Anticoagulation Service in Western Australia 2008 - 2018 Gurugram | 17:42 |
| Speaker: Michaela Walters (Australia) | |
| A Nurse Led Thromboprophylaxis Re-assessment Tool to Improve the Safety of Patients at Risk of Developing a Hospital Acquired Thrombosis | 18:00 |
| Speaker: Andrea Croft (United Kingdom) | |

Posters
18:30 - 19:30

Exhibition Hall

Poster Networking Session

Coagulation and Anticoagulation - Animal Models in Thrombosis and Hemostasis

Molecular Suitability of the Chacma Baboon Model of Acquired Thrombotic Thrombocytopenic Purpura when Evaluating Anti-VWF Agents

Speaker: Walter Janse Van Rensburg (South Africa)

Impact of von Willebrand Factor Deficiency on Placental Development and Angiogenesis

Speaker: Mario von Depka (Germany)

Acquired ADAMTS-13 Deficiency in a Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)

Speaker: Trung Nguyen (United States)

Unsupervised Classification of Multiparametric MRI Correlates with Red Blood Cell, Fibrin and Collagen Content in Murine Model of Venous Thrombosis

Speaker: Olivia R. Palmer (United States)

Scientific Programme

Significance of Combined Detection of D-Dimer and Fibrinogen in Rat Nephrotic Syndrome Induced by Adriamycin

Speaker: Bin Du (China)

The Mode of Anaesthesia Influences Outcome in Mouse Models of Arterial Thrombosis

Speaker: Maithili Sashindranath (Australia)

Anticoagulant Activity and Cholesterol Levels after PGP Application on the Model of Hypercholesterolemia in Rats

Speaker: Tamara Obergan (Russian Federation)

Characterisation of a New Mouse Model of Haemophilia A Developed Using CRISPR/Cas9 Technology

Speaker: Ciara Byrne (Ireland)

Linking the Anti-inflammatory and Anticoagulant Properties, the Natural Inhibitor EcTI Impairs the Physiopathological Aspects of Thrombosis

Speaker: Bruno Salu (Brazil)

ADAMTS13 Levels Correlate with Renal and Inflammatory Markers in Mice with Type 1 Diabetes Mellitus and Nephropathy

Speaker: Michelle Teodoro Alves (Brazil)

Evaluation of Oral Anticoagulation-associated Intracerebral Hemorrhage Induced by Collagenase VII-S in Rats

Speaker: Roberto Fonseca (Brazil)

Evaluation of Two Experimental Models of Deep Venous Thrombosis in Rats

Speaker: Neiva Pereira Paim (Brazil)

Development of a Laser-induced Thrombosis Model with Improved Reproducibility Allows Detailed Analysis of Dose-Response Effects of Antithrombotic Drugs

Speaker: Pia Larsson (Sweden)

Development of a Novel Acute Model to Evaluate the Effect of Pro-Fibrinolytic Compounds in Rabbits

Speaker: Stefan Heitmeier (Germany)

Sickle Cell Trait Accelerates Fibrin Formation and Resistance to Fibrinolysis in Mice and Humans

Speaker: Anton Ilich (United States)

Correlation of Tissue Factor- and Phospholipid-Activated Thrombin Generation Assays with Tail Bleeding in Hemophilia A Mice Treated with Coagulation Factor ViiA

Speaker: Mikhail Ovanesov (United States)

Generation of Transgenic Zebrafish with RFP-labeled Young and GFP-labeled Mature Thrombocytes: Analysis of their Lipids

Speaker: Pudur Jagadeeswaran (United States)

Coagulation and Anticoagulation - Coagulation Factors and Inhibitors

The Effect of Antithrombin Budapest3 Mutation for the Heparin Binding Affinity of Antithrombin

Speaker: Krisztina Péntes-Daku (Hungary)

Scientific Programme

Molecular Sequencing of Factor VII Variants through Collaborative Advocacy for Families in the United States: 223 Individuals using Multi-gene Next Generation Panel

Speaker: Diane Nugent (United States)

Coagulation and Anticoagulation - Coagulation Proteins Beyond Hemostasis

Protease-activated Receptor-1 Expressed by Hepatic Stellate Cells Drives Experimental Hepatic Fibrosis

Speaker: Lauren G. Poole (United States)

Von Willebrand Factor is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma

Speaker: Morayma Reyes Gil (United States)

Quantification and Analysis of the Interaction Between TLT-1 and Fibrinogen

Speaker: Angelia D. Gibson (United States)

ADAMTS-13: Its Increase in Plasma Would Have Some Role in Cognitive Decline?

Speaker: Luci Dusse (Brazil)

Factor XIII Deficiency Is Protective from Paralysis and Demyelination in a Murine Model of Multiple Sclerosis

Speaker: Eric Mullins (United States)

Coagulation and Anticoagulation - Common Pathway

Clinical Implications of Antivenom Failures to Neutralise Coagulotoxicity of African Snake Venoms

Speaker: Bryan Fry (Australia)

The Clinical Implications of the Differential Coagulopathic Effects of Asian Pit Viper Snake Venoms

Speaker: Jordan Debono (Australia)

An Overview of Coagulation Disturbances Caused by Australian Elapid Snake Venoms

Speaker: Christina N. Zdenek (Australia)

Coagulotoxic Activity in Venoms from Coral Snakes of the Americas (genus: *Micrurus*)

Speaker: Daniel Dashevsky (Australia)

Pathophysiological Implications of Differential Coagulotoxic Effects of Bitis Viper Snake Venoms

Speaker: Nicholas Youngman (Australia)

PLXDC2, a Novel Player of the Coagulation Cascade: Results from a Genome Wide Association Study on Plasma FV Levels

Speaker: Florian Thibord (France)

Monitor Lizard (genus: *Varanus*) Venoms Disrupt the Clotting Ability of Human Fibrinogen

Speaker: James Dobson (Australia)

Effect of Brazilian Snake Venoms on Hemostasis Evaluated by Thrombin Generation Assay

Speaker: Luci Dusse (Brazil)

The Shortened Activation Peptide of *Pseudonaja textilis* Venom FX Confers Zymogenicity and Resistance to Factor VIIIa-IXa Activation

Speaker: Mark Schreuder (the Netherlands)

Scientific Programme

Variability in Venom Coagulotoxins in Russell's Vipers (genus: Daboia) Compromise Antivenom Effectiveness

Speaker: Bianca op den Brouw (Australia)

Pseudonaja Textilis Factor Va Retains Structural Integrity and Cofactor Function Following Proteolysis by Activated Protein C

Speaker: Mark Schreuder (the Netherlands)

Coagulation and Anticoagulation - Contact Pathway

The Glycan Structure on Factor XIII B Subunit

Speaker: László Muszbek (Hungary)

Polyphosphate-induced Thrombosis is Enhanced in Mice Deficient in Histidine-rich Glycoprotein

Speaker: Rida Malik (Canada)

Hydrogen-deuterium Exchange (HDX) Mass Spectrometry Highlights Conformational Changes Induced by FXI Activation and Binding of FIX to FXIa

Speaker: Awital Bar Barroeta (the Netherlands)

FRET-based Assays for the Quantitation of (pro)Thrombin Binding to Factor XI

Speaker: Awital Bar Barroeta (the Netherlands)

Identification of the Histidine-rich Glycoprotein Domain Responsible for its Inhibition of Factor XIIa

Speaker: Tammy Truong (Canada)

Polyphosphate, Zn²⁺ and High-molecular-Weight Kininogen Modulate Individual Reactions of the Contact Pathway of Blood Clotting

Speaker: Yuqi Wang (United States)

Binding of Activated Factor XI to the Platelet Surface Facilitates the Activation of Factor IX

Speaker: Stephanie Elena Reitsma (United States)

Role of N-glycosylation on the Secretion, Plasma Levels and Function of Factor XII: Results from Patients with Congenital Disorders of Glycosylation and a Recombinant Model

Speaker: Maria Eugenia de la Morena-Barrio (Spain)

A Novel Antithrombotic Coating for Blood-contacting Medical Devices

Speaker: Lucia Musumeci (Belgium)

Mechanism of Activation Of The Intrinsic Pathway of Coagulation By Microvesicles Isolated from Red Cell Concentrates

Speaker: Anton Ilich (United States)

The N-Terminal Fibronectin Type II Domain of Factor XII Ensures Zymogen Quiescence

Speaker: C C Clark (the Netherlands)

Polyphosphate Does Not Affect Inhibition of Factor XIIa by C1 Inhibitor

Speaker: Stephanie A. Smith (United States)

Plasma Kallikrein Contributes to Coagulation by Activating Factor IX

Speaker: Mayken Visser (Germany)

Potential Contribution of Kallikrein to the Coagulation System Independent of Factor XII Activation

Speaker: Juliet Butler (United Kingdom)

Scientific Programme

Misfolded Proteins Can Differentially Modulate the Contact System

Speaker: Lewis Hardy (United Kingdom)

Fibrinolysis and Proteolysis - Fibrinogen and Factor XIII

Impact of Disulfide Linkage Alterations on Folding, Structure, and Activity in FXIIIa Inhibitor Tridegin

Speaker: Charlotte Anneke Bäuml (Germany)

Biorelevant Polyanions Modulate the Structure and Stability of Fibrin in a Size-, and Charge-dependent Manner

Speaker: Krasimir Kolev (Hungary)

Structure, Assembly and Dissociation of Plasma Coagulation Factor XIII Complex

Speaker: Arijit Biswas (Germany)

Impact of Fibrinogen Post-translational Modifications on its Structure and Function

Speaker: Žofie Sovová (Czech Republic)

Defining the Functional Role and Regulatory Mechanism of Fibrinogen Phosphorylation in Inflammation and Thrombosis

Speaker: Kingsley R Simpson (United Kingdom)

Feasibility of a New Automated FXIII Activity Assay

Speaker: Martina Leitner (Austria)

Interpretation of Maximum Absorbance Data Obtained from Turbidimetry in Plasma Samples

Speaker: Marlien Pieters (South Africa)

The Comparability Evaluation and Improvement Study of Fibrinogen Measurement

Speaker: Mingting Peng (China)

Fibrin γ -chain Cross-linking Increases Clot Elastic Modulus and Protects against Embolization as Demonstrated in a New Genetically Modified Murine Model

Speaker: Robert A.S. Ariëns (United Kingdom)

Genetic Abnormalities of Japanese Patient with Symptomatic- and Asymptomatic-dysfibrinogenemia

Speaker: Shogo Tamura (Japan)

Intra-assay Reproducibility of a Precalibrated Liquid Clauss Fibrinogen Assay

Speaker: Audrey Carlo (France)

Fibrin-derived (β 40-66)₂ Fragment Promotes Endothelial Permeability via the VLDL Receptor Dependent Pathway

Speaker: Sergiy Yakovlev (United States)

Acquired Factor XIII Deficiency in Patients under Treatment with Plasmapheresis: A Poorly Explored Etiology

Speaker: Fernando Chuliber (Argentina)

Phenotype and Genotype of FXIII Deficiency in Two Unrelated Proband: Identification of a Novel F13A1 Large Deletion Mediated by Complex Rearrangement

Speaker: Qiulan Ding (China)

Genetic Characterization of two new Families with Congenital Factor XIII Deficiency. A new Missense Mutation of gene F13

Speaker: Santiago Bonanad (Spain)

Scientific Programme

Clinical and Molecular Characterization by NGS of Spanish Patients affected by Congenital Deficiency of Fibrinogen

Speaker: Santiago Bonanad (Spain)

Thromboelastometric Detection and Laboratory Determination of Clotting Factor XIII and Fibrinogen Deficiency in Patients Undergoing Liver Transplantation

Speaker: Christina Yip (Singapore)

Analysis of fibrinolysis process in plasma with two D-dimer quantitative kit

Speaker: Yasuo Magari (Japan)

A Chemical Screen Identifies Small Molecule Modulators of Fibrinogen Production and Experimental Venous Thrombosis

Speaker: Rui Vilar (Switzerland)

Both Hemorrhagic and Thrombotic Complications in a Patient with Anti-Factor XIII Autoantibody; Characterization of the Antibody

Speaker: Julien Bovet (France)

Evidence for a Mutation in the Zebrafish fga Gene Affecting Embryonic Hemostasis: A Possible Functional Role for the Fibrinogen A α -E Isoform

Speaker: Cristina Freire Sanz (Switzerland)

Improved Specificity and Performances of a Novel Photometric Automated Assay for Factor XIII Activity

Speaker: Claire Dunois (France)

Fibrinolysis and Proteolysis - Plasminogen Activation in the CNS and Immunity

Conditions Associated with Low tPA Activity Are Prevalent among Patients with Schizophrenia or Schizoaffective Disorder

Speaker: Silvia Hoirisch-Clapauch (Brazil)

Temporal Distribution Pattern of Tissue-type Plasminogen Activator (tPA) Activity in the Central Nervous System (CNS) Delivered via the Intranasal Route: Implications for Targeted Delivery of tPA to the CNS

Speaker: Fiona McCutcheon (Australia)

Plasma PAI-1 and tPA Contents under Ischemic Stroke with Diabetes Mellitus Combination

Speaker: Olha Kravchenko (Ukraine)

Influence of Protein Modifications Leading to Bona-fide Misfolded Protein Oligomers on the Plasminogen Activation System

Speaker: Beate Kehrel (Germany)

Fibrinolysis and Proteolysis - Proteases & Cancer

Thrombin-cleaved Osteopontin Enhances B16 Melanoma Growth

Speaker: John Morser (United States)

New Functions of Prelatent Antithrombin

Speaker: Vicente Vicente García (Spain)

The Role of ECM Proteases in Cutaneous Squamous Cell Carcinoma

Speaker: Elahe Minaei (Australia)

Evolving Amiloride into uPA-targeting Candidates for the Treatment of Metastatic Cancer and Rheumatoid Arthritis

Speaker: Benjamin Buckley (Australia)

Scientific Programme

Heparanase: A Potential New Factor Concerned to Epithelial Mesenchymal Transition in Gastric Signet-Ring Cell Adenocarcinoma

Speaker: Massoud Mirshahi (France)

Fibrin Deposit on the Peritoneal Surface Serve as a Niche for Cancer Expansion in Carcinomatosis Patients

Speaker: Massoud Mirshahi (France)

Hemophilia and Bleeding - Hemophilia: Clinical

The Evaluation of the Joint Status of Hemophiliac Adults: Single Center Adult Hematology Clinic Experience

Speaker: Salih Aksu (Turkey)

Response to Recombinant FVIII Therapy in a Young Haemophilia A Patient with Spiral Fracture of the Left Femur

Speaker: Wuraola A. Shokunbi (Nigeria)

A Phase 3b, Open-label, Multicenter, CONTINUATION Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A: Clinical Course and Outcomes in Patients with Target Joints

Speaker: Srilatha Tangada (United States)

Interim Analysis of Effectiveness of Intraarticular Injection of Mononuclear Stem Cells in Hemophilia Patients with Joint Arthropathy: Two Case Reports

Speaker: Mehran Karimi (Iran, Islamic Republic of)

A Comparison of Haemostatic Response to Recombinant and Plasma-derived Factor VIII Concentrates in Patients with Hemophilia A

Speaker: Natalya Silina (Russian Federation)

Higher trough Levels, Improved Quality of Life and Reduced Costs when Switching to rIX-FP in a Severe Hemophilia B Patient with Considerable Neurological Disability

Speaker: Rosario Maggiore (Italy)

Pharmacokinetic Study of FVIII in Chinese Boys with Hemophilia

Speaker: Huang Kun (China)

Quality of Electronic Treatment Records in Patients with Hemophilia and von Willebrand Disease

Speaker: Andreas Tiede (Germany)

Efficacy of Short-term Individualized Prophylaxis Guided by PK and Joint Evaluation in Chinese Adult Patients with Severe Hemophilia A

Speaker: Xueyan Sun (China)

Use of Lower Dose of Extended Half-life rFVIIISE (Rurioctocog Alfa Pegol) Satisfies Prophylactic Purpose in Hemophilia A

Speaker: Hugh Kim (Korea, Republic of)

Chest Wall Haemophilic Pseudo Tumour in a Patient with Severe Haemophilia A with Inhibitor: A Case Report

Speaker: Melanie Jackson (Australia)

Immune Tolerance Induction in Patients with Hemophilia A and Inhibitors: Extended Results of the Brazilian Immune Tolerance (BrazIT) Study

Speaker: Ricardo Camelo (Brazil)

Scientific Programme

Real-world Utilization and Bleed Rates in Patients with Hemophilia B who Switched to Recombinant Factor IX Fusion Protein (rIX-FP) in Italy, Belgium and the United Kingdom

Speaker: Patrick Sommerer (Germany)

A Survey of Physicians' Treatment Switching Practice in Long-term Prophylaxis for People with Haemophilia A in Five European Countries

Speaker: Sally Tawil (Sweden)

Long-term Outcomes after Switch from On-demand Treatment to Prophylaxis with rFIXFc: Longitudinal Subgroup Analysis of the B-LONG and B-YOND Study Population

Speaker: Hervé Chambost (France)

Timing of Treated Spontaneous Bleeding in Persons with Haemophilia A (PwHA) in the HAVEN 3 Study

Speaker: Johnny Mahlangu (South Africa)

Clinical and Laboratory Evaluation of Female Carriers of Hemophilia

Speaker: Mariana S. Pastori (Brazil)

Genetic Landscape of Haemophilia A and B in Australia

Speaker: Sally Campbell (Australia)

A United States Multi-center Analysis of Characteristics Associated with Prescribed Factor Prophylaxis

Speaker: Duc Tran (United States)

Emicizumab Prophylaxis Improves Long-term Physical Health Scores in Persons with Haemophilia A (PwHA) with and without Inhibitors: Update from the HAVEN 3 and HAVEN 4 Studies

Speaker: Mark Skinner (United States)

Real-world Consumption rVIII-SingleChain: US Population Experience

Speaker: Michael Wang (United States)

Combining Data from Hemophilia Registries - A Proof of Concept Study

Speaker: Glenn F. Pierce (Canada)

Management of a Paediatric Patient with Mild Haemophilia A with High Count T-Cell Acute Lymphoblastic Leukaemia (ALL)

Speaker: Alice Wilkinson (United Kingdom)

A Retrospective, Observational Study using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States

Speaker: Maureen Watt (Switzerland)

Final Data from the Italian Registry on Intracranial Haemorrhage in Haemophilia Patients: EMO.REC Registry (2009-2018)

Speaker: Ezio Zanon (Italy)

Genetic Predictors for FVIII Inhibitors Formation in a Greek Population of Children with Severe Haemophilia A, Treated Exclusively with Recombinant Concentrates

Speaker: Helen Pergantou (Greece)

Ideal Body Weight Is Proven Most Reliable to Dose Factor VIII Concentrate in Overweight and Obese Hemophilia A Patients

Speaker: Iris van Moort (the Netherlands)

Scientific Programme

Development of a Population Pharmacokinetic Database for Coagulation Factor VIII Octocog Alfa (Advate®) in Taiwan, and Preliminary Assessment of Pharmacokinetic Parameters in Taiwanese Adults

Speaker: Yeu-Chin Chen (Taiwan, Republic of China)

High Risk of Intracranial Haemorrhage in Adult Mild Haemophiliac Patients: Data from the EMO.REC Registry

Speaker: Ezio Zanon (Italy)

Expert Opinion on the UK Standard of Care for Haemophilia Patients with Inhibitors: A Delphi Consensus Study

Speaker: Kate Khair (United Kingdom)

Population Pharmacokinetics of rVIII-SingleChain in Obese Previously Treated Patients with Severe Hemophilia A in Study CSL627_1001

Speaker: William McKeand (United States)

Emicizumab Improves Factor X Activation and Thrombin Generation Similar to Mild Hemophilia in Persons with Hemophilia A and Inhibitors

Speaker: Marilyn Manco-Johnson (United States)

The Difference of Bleeding Frequency and Hemophilic Arthropathy between Hemophilia A and Hemophilia B Patients

Speaker: Shixuan Wang (China)

Impact of Low Dose Prophylaxis vs. On Demand Treatment in Severe Hemophilia A Patients in Pakistan

Speaker: Munira Borhany (Pakistan)

The Relationship between Coagulant Activity (FVIII Levels and Thrombin Generation Assay) and Structural Evidence of Joint Disease in Patients with Mild to Moderate Hemophilia A

Speaker: Michael Laffan (United Kingdom)

Retrospective Analysis of 1533 Patients with Hemophilia B in 37 Medical Centres in China

Speaker: Xueqing Dou (China)

Clinical Validation of Population Pharmacokinetic Model for Plasma-Derived Factor VIII/VWF Using WAPPS-Hemo

Speaker: Santiago Bonanad (Spain)

Low Dose Prophylaxis Regimen in Children and Young Adults - Three Years Experience from Kerala, India

Speaker: Neeraj Sidharthan (India)

Marked Improvement of Analytical Resolution of Low-level Coagulation Factor VIII and IX Measurement by Applying Model Based Analysis of Clot Waveform

Speaker: Jaewoo Song (Korea, Republic of)

Real-world Study of Physician Practice Patterns, Efficacy and Safety of Human Cell Line-derived Recombinant Factor VIII in Adults with Hemophilia A

Speaker: Haowei Sun (Canada)

Haemostasis with Lower Doses of Bypass Agents for Major Surgery in Patients with Hemophilia and Inhibitors

Speaker: Aby Abraham (India)

Scientific Programme

The Rate of Factor VIII Inhibitors and Mutation Profile in Polish Previously Untreated Patients (PUPs) on Prophylaxis with Octocog-alfa

Speaker: Andrzej Koltan (Poland)

Real Life Experience in a Portuguese Haemophilia Center After Switching to rFVIII-Fc: the First Results

Speaker: Cristina Catarino (Portugal)

Clinical Review of 375 Patients with Hemophilia in Tianjin for 12 years

Speaker: Xuewen Song (China)

Hospitalization of Hemophilia a and B Patients in Brazil - Trends from 2004 to 2016

Speaker: Ana Guersoni (Brazil)

The Impact on Australian Haemophilia Nursing Roles after the Introduction of an Interim Agreement of Extended Half Life Products for the Treatment of Haemophilia

Speaker: Robyn Shoemark (Australia)

ADVANCE-AF: An International, Prospective, Longitudinal, Observational Registry Study of Hemophilia Patients with Atrial Fibrillation

Speaker: Robert Klamroth (Germany)

Switching To Extended Half-Life Product (rFVIII-Fc) In Children With Hemophilia A - Preliminary Findings From A Saudi Tertiary Care Centre

Speaker: Mahasen Saleh (Saudi Arabia)

Anti-Idiotypic Monoclonal Antibodies to Emicizumab Enable Measurements of aPTT-Based Coagulation/Anticoagulation Assays in the Presence of Emicizumab

Speaker: Kenichi Ogiwara (Japan)

Systematic Review of Efficacy and Factor Consumption of Long-Acting Recombinant Factor VIII Products for Prophylactic Treatment of Hemophilia A

Speaker: Songkai Yan (United States)

Case report: A Rare Case of Concomitant Sickle Cell Disease and Haemophilia A with Development of a High Titre Factor VIII Inhibitor

Speaker: Sharon Allen (Australia)

Thirteen Years of Clinical Experience with Immune Tolerance Induction (ITI) Using a Plasma-derived FVIII Containing von Willebrand Factor (pdFVIII/VWF) in Russia

Speaker: Nadezhda Zozulya (Russian Federation)

Prophylactic Factor VIII Use and Clinical Outcomes in German Hemophilia A Patients who Switched to Extended Dosing Intervals with Long-acting rFVIII-SingleChain

Speaker: Songkai Yan (United States)

Efficacy and Safety of rIX-FP in Surgery: An Update from a Phase 3b Extension Study

Speaker: Claude Négrier (France)

HaemoValue: Development of a Set of Outcomes for Measuring Value in Persons with Haemophilia

Speaker: Erna van Balen (the Netherlands)

Adding the Patient's Voice to a Hemophilia-specific Goal Menu to Facilitate Goal Attainment Scaling: A Qualitative Study

Speaker: Michael Denne (United States)

Scientific Programme

Exploring the Wider Value of Extended Half-life Products in Haemophilia: A Targeted Literature Review

Speaker: Jamie O'Hara (United Kingdom)

The First Chinese Hemophilia Individualized Prophylaxis Study (CHIPS): Improvement in Health-related Quality of Life (HRQoL) CHO-KLAT Scores in Boys with Severe Hemophilia A in China

Speaker: Runhui Wu (China)

Development and Validation of a Population Pharmacokinetic Model for rAHF-FL-PEG (Adynovate): A Report on behalf of the WAPPS-hemo Investigators ad hoc Subgroups

Speaker: Alfonso Iorio (Canada)

Real World Experience of Switching to FVIII-Fc (Extended Half-life): One of the Largest Case-series in a Haemophilia Center of a University Tertiary Center in Barcelona

Speaker: Amparo Santamaria (Spain)

Hemophilia and Bleeding - Rare Bleeding Disorders

Effect of Lower von Willebrand Factor and Factor XI Levels on Treatment Success of the Levonorgestrel Intrauterine System or Endometrial Ablation in Heavy Menstrual Bleeding - An Explorative Study

Speaker: Karina Meijer (the Netherlands)

Educational Guidance and Training Program for Patients in the Eminence of Home Therapy for Factor XIII Deficiency

Speaker: Ricardo Camelo (Brazil)

Combined Factor V and factor VIII Deficiency: A Clinico-haematological Spectrum

Speaker: Mostafa Paridar (Iran, Islamic Republic of)

Burden of Rare Bleeding Disorders on Blood Transfusion Services: A Developing Country Perspective

Speaker: Anila Rashid (Pakistan)

Combined FV and FVIII Deficiency: Perioperative Blood Management

Speaker: Nadezhda Zozulya (Russian Federation)

Prekallikrein and High Molecular Weight Kininogen Deficiency in Oman: A Challenging Diagnosis in Mucosal Bleeding

Speaker: Hanan Nazir (Oman)

Thrombin Generating Potential, Plasma Clot Formation and Clot Lysis Are Impaired in Patients with Bleeding of Unknown Cause

Speaker: Johanna Gebhart (Austria)

Demographic and Clinical Data of Afibrinogenemic Patients from the QalyAFIB Study

Speaker: Claudia Khayat (Lebanon)

Health-related Quality of Life in Patients with Rare Bleeding Disorders

Speaker: Joline L. Saes (the Netherlands)

Evaluation of GGCX Missense Mutations Effect on Vitamin K Dependent Proteins Identified in VKCFD1 Patients by a New Assay and in Silico Modeling

Speaker: Suvoshree Ghosh (Germany)

Scientific Programme

Archeogenetics of the p.Cys38Arg Variant Associated with FXI Deficiency: A 5,400 Years Old Mutation Identified in Different Southwestern European Countries

Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Congenital Factor VII Deficiency: Epidemiology, Clinical Characteristics and Management. Experience of the Northern Greece Hemophilia Center

Speaker: Vasileia Garypidou (Greece)

Efficacy and Safety of Fibrinogen Concentrate for Treatment of Bleeding, Surgery or Routine Prophylaxis in Subjects with Congenital Fibrinogen Deficiency

Speaker: Joseph Lasky (United States)

Congenital Factor XI Deficiency, Inhibitor and Clot Formation

Speaker: Erica Scalabrino (Italy)

Genetic Profile and Clinical Management of Rare Bleeding Disorders: Across the Province of Sindh, Pakistan

Speaker: Munira Borhany (Pakistan)

Genetic Characterization of Congenital Fibrinogen Disorders in Polish Patients - Clinical Phenotype and Follow-up

Speaker: Anetta Undas (Poland)

Detection and Analysis of Gene Mutations in Patients with Factor VII deficiency by Next Generation Sequencing

Speaker: Boyang Sun (China)

Coexisting Mild Hemophilia B and von Willebrand's Disease Type 1: A Rare Multiple Congenital Coagulopathy

Speaker: Michael Steiner (Germany)

A Nightmare in Congenital Factor XIII Deficiency: Inhibitor Development with Severe Bleeding

Speaker: Serap Karaman (Turkey)

Laboratory Phenotype and Molecular Characterization of Inherited Coagulation Factor VII (FVII) Deficiency Patients from India

Speaker: Amit Sharma (India)

A Rare Case of Bleeding in Early Postpartum Due to Factor XII Deficiency

Speaker: Melen Brinza (Romania)

A Heterozygous FGB Variant Causing Hypofibrinogenemia in a Swedish Family

Speaker: Marcus Fager Ferrari (Sweden)

Recombinant ADAMTS13 Reduces the Cell Adhesion of Blood from Sickle Cell Disease Mice under Shear Stress

Speaker: Gerald Schrenk (Austria)

Congenital Factor XIII Deficiency in Pediatric Patients in Kuwait: A retrospective chart review

Speaker: Hadeel Mohammad (Canada)

Associated Coagulation Factor Deficiencies & Bleeding History, 20 Years of Diagnosis in the Hemostasis Laboratory of Hematology Department of University Hospital of Beni Messous, Algiers, Algeria

Speaker: Karima Wafia Chennoukh (Algeria)

Scientific Programme

Improving Prevalence Data on Rare Bleeding Disorders Using A Bleeding Disorders Registry

Speaker: Nur Insyirah Abdul Kadir (Singapore)

Single Centre Experience on Pediatric Rare Inherited Clotting Factor Deficiencies (RICFD) From Kingdom of Saudi Arabia - an Impetus to Establish a National Registry

Speaker: Mahasen Saleh (Saudi Arabia)

Generation of Two HEK Reporter Cell Lines to Study Localization and Functional Interactions of VKORC1 and VKORC1L1 in a Native Cell Environment

Speaker: Francesco Forin (Germany)

Results from a Phase 3 Study of On-demand Treatment with Fibrinogen Concentrate for Acute Bleeding and Surgical Prophylaxis in Patients with Congenital Fibrinogen Deficiency

Speaker: Bruce Schwartz (United States)

DELPHI Expert Consensus Statements on Clinical Evaluation of Bleeds in Patients with Acquired Haemophilia

Speaker: Andreas Tiede (Germany)

Next-generation Sequencing for Diagnosis of Rare Inherited Bleeding Disorders

Speaker: Réka Gindele (Hungary)

Acquired Factor XI Deficiency: Diagnosis and Evolution. A Case Reports

Speaker: Marina Sol Lopez (Argentina)

Safety and Efficacy of Fibrinogen Concentrate in Congenital Fibrinogen Deficiency: A Post-marketing Observational Study

Speaker: Bruce Schwartz (United States)

Hypoprothrombinemia-lupus Anticoagulant Syndrome (HLAS) Case Report

Speaker: Daniela Brito (Portugal)

Rare Bleeding Disorder Manifestations in Women and Girls: Experience of One Center in Algiers

Speaker: Nawel Ferroudj (Algeria)

Rare Bleeding Disorders in Lebanon: Clinical and Molecular Data and Creation of a Registry

Speaker: Roula Farah (Lebanon)

Factor XIII Deficiency. A Case Report at Hospital Infantil de México Federico Gómez

Speaker: Aida Mashenka Moreno González (Mexico)

Hypodysfibrinogenemia in a Patient with Aortic Valve Thrombosis and Stroke: Diagnosis and Evolution. Identification of a Novel Heterozygous Fibrinogen Gamma Chain Mutation

Speaker: Veronica Privitera (Argentina)

Hemophilia and Bleeding - VWF & VWF Disorders: Clinical Conditions

vWF Activity is Associated with Bleeding Symptoms in Essential Thrombocythemia

Speaker: Jun Yamanouchi (Japan)

Low von Willebrand Levels Do Not Predict Bleeding in Children Undergoing Tonsillectomy

Speaker: Veronica Flood (United States)

Bleeding Symptoms and von Willebrand Factor Levels in Thai Patients: 30-year Experience in a Tertiary Care Center

Speaker: Chatphatai Moonla (Thailand)

Scientific Programme

von Willibrand Factor Levels in Sickle Cell Anaemia (SCA): Does it Have a Role in the Pathogenesis of Vaso-occlusive Crisis?

Speaker: Kingsley Akaba (Nigeria)

Investigation of the Epidemiology of VWD in Patients Attending the Royal Hospital, Muscat, Oman

Speaker: Rashid Al Ghaithi (Oman)

Desmopressin Plasma Concentration Does Not Correlate with VWF and FVIII Response in von Willebrand Disease

Speaker: Jessica Heijdra (the Netherlands)

The Management of Patients with von Willebrand Disease (VWD) Undergoing Surgery by Using a Pure Plasma Derived VWF is Easy, Efficient and Safe

Speaker: Jenny Goudemand (France)

Effect of Pathologic Flow on von Willebrand Factor Cleavage by ADAMTS13

Speaker: Maria Bortot (United States)

Acquired von Willebrand Syndrome during Mechanical Circulatory Support and Extracorporeal Membrane Oxygenation: Rapid Onset and the Demand for Point of Care Testing

Speaker: Andreas Straub (Germany)

Exploration and Treatment Strategies for Gastrointestinal Bleeding in VWD over a 3-year Period: A National Survey from the French Reference Center for VWD

Speaker: Antoine Rauch (France)

Genotype-phenotype and Pathophysiological Mechanisms Involved in Patients with von Willebrand Disease (VWD) Type 2A and 2M According to Domains Affected by Genetic Clinical-Grade Variants (CGV)

Speaker: Adriana Ines Woods (Argentina)

Gastrointestinal Angiodysplasia and von Willebrand Disease: Our Experience of Managing Challenging Bleeding

Speaker: Gary Benson (United Kingdom)

A Novel Mechanism in Severe Type 1 VWD: A Heterozygous Splicing Mutation Causes Exon 26 Skipping and Increases VWF Clearance

Speaker: Mattia Ferrarese (Italy)

Annual Bleeding Rates with Efficacy/Safety of the VWF Concentrates used on Demand or under Secondary Long-term Prophylaxis in a Large Cohort of Centrally Confirmed VWD3 Patients: Results of 24-month Prospective Observation in 169 Cases Enrolled into the 3Winters-Ips

Speaker: Augusto B Federici (Italy)

Successful Non-surgical Management and Use of Thrombopoietin Receptor Agonist in a Case of Spleen Injury in a Young Girl with von Willebrand Disease Type 2B

Speaker: Valérie Proulle (France)

Pathophysiology Underlying Genetic Clinical-grade Variants (CGV) Responsible for the Phenotypes Type 2A and 2M of von Willebrand Disease (VWD)

Speaker: Adriana Ines Woods (Argentina)

Platelet Transfusion in von Willebrand Disease type IIB in a Family with Normal Platelet Counts

Speaker: Kim Schafer (United States)

Scientific Programme

Variable Reproducibility of Type 2 VWD Diagnoses

Speaker: Stefanie DiGiandomenico (United States)

The Socio-economic Burden of VWD in Europe: the CCESS Study

Speaker: Jamie O'Hara (United Kingdom)

Type 1 VWD Caused by a Novel Dominant p.Thr274Pro Mutation Localized in VWF Propeptide

Speaker: Maria Teresa Pagliari (Italy)

Efficacy and Safety of hFVIII/VWF Concentrate in a Large Cohort of Patients with Von Willebrand Disease (VWD) Requiring Surgical Procedures: The French Experience

Speaker: Valérie Proulle (France)

BMI is an Important Determinant of VWF and FVIII Levels in Patients with Von Willebrand Disease

Speaker: Ferdows Atiq (the Netherlands)

Infusion Requirements in On Demand Treatment of Bleeding Events in von Willebrand Disease (VWD): an Indirect Treatment Comparison between Recombinant von Willebrand Factor (VWF) and Plasma Derived VWF Concentrates

Speaker: Björn Mellgård (United States)

Association of Easy Bruising with Female Gender: A Prospective Cohort Study

Speaker: Michael Nagler (Switzerland)

Behavior of von Willebrand Factor in Essential Thrombocythemia

Speaker: Yoshinobu Seki (Japan)

Acquired Type 3-like Von Willebrand Syndrome Complicated with Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia

Speaker: Jie Yin (China)

Management of Postpartum Haemorrhage in a Woman with Type 2B von Willebrand Disease

Speaker: Samuel Ackroyd (United Kingdom)

Safety and Efficacy of pdVWF/FVIII in Patients with von Willebrand Disease Undergoing Prophylaxis: Results from a Non-interventional Multicentre Study

Speaker: Joseph L. Lasky III (United States)

Determination of Large and Ultra-large Multimers in Recombinant Human VWF (rVWF) and Pharmacokinetic Analyses in Patients with Type 3 von Willebrand Disease (VWD)

Speaker: Peter L. Turecek (Austria)

Bleeding Patterns in Patients with von Willebrand Disease: An Analysis of a US Medical Claims Database

Speaker: Robert F. Sidonio Jr. (United States)

Quantification of VWF Propeptide Release before and after Desmopressin in von Willebrand Disease and Hemophilia A

Speaker: Jessica Heijdra (the Netherlands)

Poor DDAVP Response Does Not Explain Elevated Bleeding Score in Persons with Low von Willebrand Factor

Speaker: Megan C Brown (United States)

Scientific Programme

Sequencing of VWF Gene in Patients with von Willebrand Disease: Our First Experience in Slovakia

Speaker: Jana Zolkova (Slovakia)

Acquired von Willebrand Syndrome and Hematological Malignancies

Speaker: Yamina Ouarhjent (Algeria)

Detecting Structural Disorder in Multimeric von Willebrand Factor

Speaker: Matthew Auton (United States)

Von Willebrand Disease: An International Survey Assessing Important Topics for Decision-making

Speaker: Nathan T. Connell (United States)

DDAVP Challenge Test in Patients with von Willebrand Disease Type 1 (VWD1) and Low von Willebrand Factor (Low VWF): Analysis of 616 Patients

Speaker: Mara Agazzoni (Argentina)

Nurses & Allied Health

The Effect of Exercise-based Cardiac Rehabilitation on Heart Rates and Oxygen Consumption in Patients with Myocardial Infarction: A Meta-analysis

Speaker: Arif Nur Akhmad (Indonesia)

Some Haemostatic Parameters, Full Blood Count and Relative Plasma Viscosity of Blood Donors in Calabar Metropolis

Speaker: Dorathy Chioma Okpokam (Nigeria)

A Qualitative Analysis on Patient Understanding with Anticoagulation Use & Indication and the Effect of Nurse Practitioner Led Patient Education

Speaker: Laurie Sardo (Canada)

Comparison of Mindset between the Medical Doctors and the Staffs of Genetic Counseling about Support of Hemophilia Carriers in Japan

Speaker: Tomie Fujii (Japan)

It Takes a Village... The Implementation of a Multidisciplinary Clinic Review for Children and Adolescents with Bleeding Disorders

Speaker: Jaime Chase (Australia)

Current Nursing Workloads and Implications for the Future within Haemophilia Treatment Centres in Australia

Speaker: Susan Jane Webzell (Australia)

National Benchmarking of Paediatric Haemophilia Treatment Centres

Speaker: Stacey Hutchison (Australia)

The Nurse's Role in Training Others to Administer Missing Factor Concentrates to Patients with Haemophilia

Speaker: Pawel Laguna (Poland)

Risk Factors and Incidence of Venous Thromboembolism in Acutely-ill Clinical Hospitalized Patients: Results of a Prospective Cohort Study on Thromboprophylaxis

Speaker: Cassia Rodrigues Lima Ferreira (Brazil)

Pediatrics - Bleeding in Neonates and Children

Ichec: Refining the Pediatric Bleeding Assessment Tool

Speaker: Karin Fijnvandraat (the Netherlands)

Scientific Programme

MYH9 Related Disease Mimicking Immune Thrombocytopenia

Speaker: Bunchoo Pongtanakul (Thailand)

Genetic Confirmation and Differential Diagnosis of Inherited Platelet Disorders and von Willebrand Disease by Diagnostic Exome Sequencing: K-PHOG Study

Speaker: Ye Jee Shim (Korea, Republic of)

Does a Therapeutic Early Morning ACT and APTT Correlate with the Absence of Bleeding or Thrombotic Complications within the Next 24 Hours in Paediatric Patients on ECMO?

Speaker: Gabrielle Lee (Singapore)

Circumcision Experience in Children with Bleeding Disorder: Samsun Circumcision Protocol

Speaker: Canan Albayrak (Turkey)

A Development of Anaphylactoid Reaction in a Child with Congenital FVII Deficiency and Inhibitor: The First Reported Case

Speaker: Aysegul Unuvar (Turkey)

Hypofibrinogenemia: A Novel Long Deletion of the Fibrinogen Beta Chain Causing Mucocutaneous Bleeding

Speaker: Darintr Sosothikul (Thailand)

Kasabach-Merritt Phenomenon in an Infant: Tufted Angioma or Kaposiform Hemangioendothelioma

Speaker: Rumeysa Tuna (Turkey)

Impact of Hematology Involvement on Adolescents Admitted for Acute Heavy Menstrual Bleeding

Speaker: Viiia Anderson (United States)

Acquired von Willebrand Syndrome (aVWS) - A Complication in Pediatric Patients with Congenital Heart Diseases

Speaker: Ivonne Wieland (Germany)

Hemostasis Dysfunctions in Routine Otolaryngology Preoperative Laboratory Screening Tests - An One Year Retrospective Pediatric Study

Speaker: Rute Preto (Portugal)

Pediatrics - Thrombosis in Neonates and Children

Neonatal Venous Thromboembolism - A Regional Population-Based Study from Sweden

Speaker: Bader Allahyani (Canada)

Therapeutic Aspects, Determining the Outcome of Deep Veins Thrombosis (DVT) in Children with Hematological Diseases

Speaker: Daria Fedorova (Russian Federation)

Genetic and Clinical Determinants Influencing Warfarin Dosing in Thai Children and Adolescents

Speaker: Premmika Intapun (Thailand)

Septic Dural Sinus Thrombosis in Children

Speaker: Patcharee Komvilaisak (Thailand)

Central Venous Catheter-associated Thromboembolism: Still a Frequent Complication with No Reliable Predictive Indicators in Young Children with Diabetic Ketoacidosis

Speaker: Gary Woods (United States)

Scientific Programme

Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-analysis

Speaker: Leonardo Brandão (Canada)

Antithrombin III Replacement in a Premature Infant with an Occlusive Inferior Vena Cava Thromboembolism on Low Molecular Weight Heparin: Is There a Target Antithrombin III Activity?

Speaker: Chi Braunreiter (United States)

Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease after Hematopoietic Stem Cell Transplantation?

Speaker: Anne Demulder (Belgium)

Incidental Venous Thromboembolism (iVTE) in Children with Blood Disorders

Speaker: Daria Fedorova (Russian Federation)

Symptomatic Venous Thromboembolism (sVTE) in Children with Blood Disorders

Speaker: Daria Fedorova (Russian Federation)

Neonatal and Pediatrics Optimal Anticoagulant Therapy and Role of Clinical Pharmacist - A Medication Safety Model in Developing Country

Speaker: Gul Ambreen (Pakistan)

Predictive Value of D-dimers in the Diagnosis of Suspected Acute Limb Deep Vein Thrombosis in Children: A Prospective Study

Speaker: Maria Laura Avila (Canada)

Incidence of VTE in Children with Hematologic Disorders: A Monocentric Study in Russian Federation

Speaker: Daria S Morozova (Russian Federation)

Thromboembolism and Bleeding in Congenital Diaphragmatic Hernia

Speaker: Leonardo Brandão (Canada)

Highly Discordant Laboratory-based Aspirin Resistance Rates after Pediatric Organ Transplantation May Reflect Significant Cyclooxygenase 1-independent Thromboxane Production Postoperatively

Speaker: Lori Luchtman-Jones (United States)

Bleeding and Clotting in Children on ECMO at the Royal Children's Hospital: A Two Year Summary

Speaker: Suelyn Van Den Helm (Australia)

Comparison of Alpha-1-antitrypsin Glycoform Content in Newborns and Adults

Speaker: Helen Atkinson (Canada)

Platelet Phenotype and Function in Paediatric Extracorporeal Membrane Oxygenation (ECMO) Circuits

Speaker: Hui Ping Yaw (Australia)

Endothelial and Platelet Activations in α -thalassemia Diseases

Speaker: Pankamol Sirivadhanakul (Thailand)

Characteristics of Young Patients with Retinal Occlusion

Speaker: Dorit Blickstein (Israel)

Scientific Programme

Transition of Care for Adult and Pediatric Patients with Venous Thromboembolism - An American Thrombosis Hemostasis Network (ATHN) Project

Speaker: Maria T. DeSancho (United States)

Baseline and Inducible Fibrinolytic Capacity in Healthy Children

Speaker: Charithani Keragala (Australia)

Single Nucleotide Polymorphisms in Promoter Region of PROC Gene Are Associated with Low Protein C Activity but not Increase Risk of Thromboembolism in Pediatric Population

Speaker: Natsumon Udomkittivorakul (Thailand)

Use of Antithrombin Concentrate in Acquired Antithrombin Deficiency in Acutely Unwell Children Receiving Unfractionated Heparin -Single Centre Experience

Speaker: Deepa Jayakody Arachchillage (United Kingdom)

First Korean Case of Thrombocythemia 1 (THCYT1) with THPO Mutation (c.13+1G>A, splicing) Diagnosed by Targeted Exome Sequencing

Speaker: Do-Hoon Kim (Korea, Republic of)

Comparison of the Thromboelastographic Profile of Paired Placental and Neonatal Blood Samples

Speaker: Erica Scalabrino (Italy)

Cerebral Sinus Venous Thrombosis In One Institution

Speaker: Patcharee Komvilaisak (Thailand)

Evaluation of Venous Thromboembolism In Childhood

Speaker: Aylin Ayhan (Turkey)

Low Dose Anticoagulation in Children with Kawasaki Disease and Large Coronary Artery Aneurysms: Our Experience at Chandigarh, North India

Speaker: Surjit Singh Samlok (India)

Central Venous Line Insertion in a Child with Factor VII Deficiency and Inhibitors to FVII

Speaker: Dianne Marshall (United Kingdom)

A Retrospective Review of Antithrombotic Therapy in Paediatric Patients with Moyamoya Disease

Speaker: Nadia Poci (Australia)

Thrombotic Events in Very Low Birth Weight Infants Treated in an Intensive Care Setting

Speaker: Athis Arunachalam (United States)

Low Bone Mass/Osteoporosis in Thai Children and Adolescents Taking Long-term Warfarin

Speaker: Thanyabun Akkharawanasakul (Thailand)

The Incidence of Venous Thromboembolism in Thrombophilic Children: A Prospective Cohort Study

Speaker: Daniela Tormene (Italy)

Multidisciplinary Approach to Pediatric Thrombosis; Istanbul Pediatric Thrombosis (I-PeT) Study Group Experience

Speaker: Zeynep Karakas (Turkey)

Symptomatic and Incidental VTE in Children Differs in Epidemiology and Outcomes

Speaker: Daria Fedorova (Russian Federation)

Scientific Programme

Results of an International Survey of Practice in the Diagnosis And Management of Pediatric Pulmonary Embolism

Speaker: Madhvi Rajpurkar (United States)

Thrombolytic Therapy in Preterm Neonates: Experience of a Single Center

Speaker: Priscila Grizante-Lopes (Brazil)

Congenital Protein C Deficiency: A Family Report from Argentina

Speaker: David A. Veron (Argentina)

Inferior Vena Cava Filters (IVCF) in Children with Venous Thromboembolism (VTE): A 26-year Prospective Cohort from a Single Tertiary Center in Argentina

Speaker: Carolina Cervio (Argentina)

Aortic Valve Thrombosis in an Infant with Ischemic Stroke

Speaker: Mihir Bhatt (Canada)

Prothrombotic States as a Risk Factor for Stroke among Pediatric Patients

Speaker: Olivera Serbic (Serbia)

Clinical Characteristics and Outcome of Children with Pulmonary Embolism: A Systematic Review

Speaker: Sehar Khaliq (Pakistan)

Hemostatic Complications in Pediatric Extra Corporeal Membrane Oxygenation: The Role of Rotational Thromboelastometry

Speaker: Joppe Geert Frederik Drop (the Netherlands)

Congenital Protein C Deficiency: Unfamiliarity of this Condition Led to Unfavorable Results in a 14 Year Old Girl

Speaker: Madlen Reschke (Germany)

The Impact of the Volume of Mediastinal Lymphadenopathy on Venous Thromboembolism in Children with Lymphoma

Speaker: Daria Fedorova (Russian Federation)

Analysis of Stroke in Neonates and Children: Single Center Experience

Speaker: Hale Ören (Turkey)

Enriched Variants of Coagulation, Platelet and Related Genes Are Common in Adolescents with Idiopathic Occlusive Proximal Deep Vein Thrombosis

Speaker: Marilyn Manco-Johnson (United States)

Neonatal Inferior Vena Cava Syndrome: An Evidence-based Systematic Review of the Literature

Speaker: Paul Thuan Tieu (Canada)

Incidence and Risk Factors for Peripherally Inserted Central Catheter-related Venous Thrombosis in Critically-ill Children with Cardiac Disease: A Retrospective Single-center Case-control Study

Speaker: Jennifer Meldau (United States)

Use of Low Molecular Weight Heparins in Pediatric Thromboembolism: A Retrospective Descriptive Study

Speaker: Claudia Khayat (Lebanon)

A 10-year Case-control Study on the Risk Factors for Neonatal Portal Vein Thrombosis

Speaker: Tuan Nguyen (Viet Nam)

Scientific Programme

An Institutional Analysis of Pediatric Patients with Upper Extremity Deep Vein Thrombosis in the Context of Thoracic Outlet Syndrome

Speaker: Aamir Ameen Sholapur (Canada)

Clinical Course of Lemierre Syndrome in the Contemporary Era: Results of a Patient-level Analysis of 715 Patients

Speaker: Luca Valerio (Germany)

Monitoring of Thromboprophylaxis in Children with Fontan Procedure: Experience in an Argentinian Hospital

Speaker: Silvina Romano (Argentina)

Moving from Self-testing to Self-management: Empowering Children and Parents Managing Warfarin

Speaker: Sophie E. Jones (Australia)

International Pediatric Thrombosis Network: Advancing the Field of Pediatric Thrombosis

Speaker: C.Heleen van Ommen (the Netherlands)

Low-molecular-Weight Heparin Use in Neonates: A Systematic Review

The Effect of Hyperbilirubinemia and Phototherapy on Apoptotic, Platelet-derived, Endothelial-derived, and Tissue Factor Positive Microparticle Levels in Neonates

Speaker: Hale Ören (Turkey)

Development of an Umbilical Cord and Pediatric Plasma Bank

Speaker: Helen Atkinson (Canada)

Pediatric May-Thurner Syndrome - A Systematic Review

Speaker: Leonardo Brandão (Canada)

Pediatric Intracardiac Thrombosis: Right(venous) or Left(arterial)?

Speaker: Selin Aytaç (Turkey)

Effective and Well Tolerated Treatment with a Direct Oral Anticoagulant in a Young Patient with the Vena Cava inferior Agenesis and a Deep Vein Thrombosis

Speaker: Tomas Kuhn (Czech Republic)

Platelet Disorders - Platelet Disorders, Acquired

Anticoagulation Management and Outcomes in Thrombocytopenic Cancer Patients with Atrial Fibrillation

Speaker: Avi Leader (the Netherlands)

Safety of Using Antiplatelet Drug in Dengue Hemorrhagic Fever with Thrombocytopenia: A Retrospective Study

Speaker: Andree Kurniawan (Indonesia)

The Interactions of Protamine and Heparin with Platelets in Rodents

Speaker: Joanna Miklosz (Poland)

Optimal "Timing" of Low-dose Aspirin by Aggregation and Thromboelastometry Tests in Patients with Essential Thrombocythemia

Speaker: Emma Cacciola (Italy)

Astragalus Polysaccharide Promotes Haematopoiesis and Thrombopoiesis in Irradiation Mouse Models

Speaker: Mo Yang (China)

Scientific Programme

Major Bleeding after a Gynecological Operation in Patient with Essential Thrombocythemia - Case Report

Speaker: Marija Skoko (Croatia)

Reduced Platelet Function in Patients with Liver Cirrhosis

Speaker: Andrea Artoni (Italy)

Bleeding Complications and Platelet Dysfunction in Patients with Lymphoproliferative Disease Receiving Bruton Tyrosine Kinase Inhibitors

Speaker: Erica De Candia (Italy)

Concomitant Immune Thrombocytopenia and Positive for JAK2 V617F Mutation in a Patient: Case Report and Literature Review

Speaker: Xiaofan Liu (China)

Acquired Autoimmune Platelet Function Disorders: Description of Two Cases of Acquired Glanzmann Thrombasthenia and of One Case of Acquired Delta Storage Pool Deficiency and their Responses to Rituximab Therapy

Speaker: Erica De Candia (Italy)

Using Flow Cytometry to Improve the Risk Assessment and Management of Bleeding in Subjects with Acquired Thrombocytopenia

Speaker: David Connor (Australia)

Platelet Disorders, Acquired with Thermally Oxidized Mixed Vegetable Oils in Low and High Doses - in Animal Model

Speaker: Gul Ambreen (Pakistan)

Altered Platelet Function in Patients with Chronic Lymphocytic Leukaemia Persists Despite Treatment with Ibrutinib or Venetoclax

Speaker: Scott Russell McGregor (Australia)

Anticipation of Bleeding in Aplastic Anemia Using ISTH Bleeding Scores and Platelet Ranges: Is it Beneficial?

Speaker: Naveena Fatima (Pakistan)

Platelet Disorders - Platelet Disorders, Hereditary

Impaired Health-related Quality of Life in Patients with (suspected) Congenital Platelet Function Defects

Speaker: Rolf T. Urbanus (the Netherlands)

Bleeding Phenotype of Patients with Congenital Platelet Defects

Speaker: Rolf T. Urbanus (the Netherlands)

Whole Blood Mepacrine Flow Cytometric Determination of Platelet Dense Granules: Difficulties in Establishing a Reference Range and Interpreting Results

Speaker: Timothy A. Brighton (Australia)

Whole Mount Electron Microscopy for Determination of Platelet Dense Granules: Which Parameter to Measure to Detect Dense Granule Deficiency?

Speaker: Timothy A. Brighton (Australia)

The First Homozygous GNE Variant in the P-loop of the ManNAc Kinase Domain Causes Severe Macrothrombocytopenia and Bleeding

Speaker: Marie-Christine Morel-Kopp (Australia)

Scientific Programme

Outcome of an Enhanced Diagnostic Pipeline for Patients Suspected for Inherited Thrombocytopenia

Speaker: Eva Leinoe (Denmark)

Prospective Comparison of Whole Mount Electron Microscopy and Mepacrine Based Flow Cytometric Assay for Determination of Platelet Dense Granules and Platelet Dense Granule Deficiency

Speaker: Timothy A. Brighton (Australia)

Correlation Study between Prognostic Scores GLATIT and Prognostic Scores ISTH-BAT over the Inherited Platelet Disorders: Study in the Western of Algeria

Speaker: Reda Messaoudi (Algeria)

How Many Shades of Grey in the Gray Platelet Syndrome

Speaker: Marie-Christine Morel-Kopp (Australia)

Whole Exome Sequencing for Diagnosis of Hereditary Platelet Disorders

Speaker: Ponlapat Rojnuckarin (Thailand)

Integrin $\beta 3$ Deficiency Disrupts Triglyceride (TG) Metabolism Owing to an Impaired Lipoprotein Lipase (LPL) Secretion

Speaker: Xiaodong Xi (China)

Novel Mutations in Chinese Patients with Glanzmann Thrombasthenia

Speaker: Boyang Sun (China)

Molecular Genetic Analysis of 10 Families with Chronic Thrombocytopenia

Speaker: Yuri Uchiyama (Japan)

Glycoprotein VI Mutation is Widespread in the Chilean Population

Speaker: Amanda Dalby (United Kingdom)

The Risk Factors for Severity of the GLATIT Score during Inherited Platelets Disorders

Speaker: Reda Messaoudi (Algeria)

First Spanish Registry of Inherited Platelet Disorders [RETPLAC]

Speaker: Jose Rivera (Spain)

Identification of Compound Heterozygous Mutations in RASGRP2 Affecting Platelet Ca/DAG-GEFI Expression and Function in Patients with Epistaxis

Speaker: Guangying Sheng (China)

MYH9 Disorders in Thailand: Pediatric Case Series from Thai Macrothrombocytopenia Study Group

Speaker: Rungrote Natesirinilkul (Thailand)

MYH9 Gene Mutation Screening in Students with Macrothrombocytes/Thrombocytopenia who Are Attending in Hearing Impaired Schools in Istanbul

Speaker: Tiraje Celkan (Turkey)

Reliability and Feasibility of Self-administered ISTH-BAT (Self-BAT)

Speaker: Marieke C. Punt (the Netherlands)

Platelet Function Testing: Current Practice among Clinical Centers in the Nordic Countries

Speaker: Riitta Lassila (Finland)

Scientific Programme

The Utility of Flow Cytometric Platelet Forward Scatter as an Alternative to Mean Platelet Volume

Speaker: David Connor (Australia)

Correlation between Mutations and Clinical Features in Patients with Essential Thrombocythemia

Speaker: Mankai Ju (China)

The Added Value of Next-generation Sequencing for Diagnosis and Management of Inherited Platelet Disorders in a Specialized Hemostasis Center

Speaker: Antoine Rauch (France)

Studies on Regulation of Thromboxane Production by PCTP and RUNX1 in Megakaryocytic Cells

Speaker: A Koneti Rao (United States)

Platelet Disorders - Platelets, Pediatric Aspects

Capillary Blood Reference Intervals for Platelet Counts (PLT) and Related Parameters from Full Term Healthy Neonates in China and Influences of Gender, Gestational Age and Postnatal Age on PLT

Speaker: Qun Hu (China)

Reported Outcome and Quality of Life of Children with Chronic Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonist

Speaker: Nongnuch Sirachainan (Thailand)

Assessment of Platelet Aggregation in Umbilical Cord Blood Using Multiple Electrode Aggregometry

Speaker: Sara Joan Israels (Canada)

Targeting DNT/Treg axis, Sirolimus Is Operative in Thrombocytopenia Caused by Autoimmune Lymphoproliferative Syndrome (ALPS)/ALPS-like Syndrome: Results of a Single Centre Experience

Speaker: Hao Gu (China)

Aspirin Unresponsiveness in Pediatric Patients: Incidence and Methods of Detection

Speaker: Darintr Sosothikul (Thailand)

Platelet Volume Parameters According to Gestational Age

Speaker: Saadet Akarsu (Turkey)

Immune Thrombocytopenia in Childhood: A 15 Year Single Center Experience

Speaker: Alkistis Adramerina (Greece)

Platelets and Megakaryocytes - Megakaryocytes and Thrombopoiesis

Multi-level Defects of the Hematopoietic Niche in Essential Thrombocythemia and the Effects of Interferon α -2b on Them

Speaker: Mankai Ju (China)

Post-translational polymodification of the C-terminal Tail of TubB1 Regulates Motor Protein Activity in Platelet Production and Function

Speaker: Neil Morgan (United Kingdom)

Impact of Intracellular Calcium Imbalance in Megakaryocytic Leukaemia Cells Uncovered through the Deletion of NMDA Receptors

Speaker: James Hearn (New Zealand)

Scientific Programme

Human Bone Marrow Primary Endothelial Cells Play a Key Role in the Latest Phase of Megakaryocyte Differentiation

Speaker: Anita Eckly (France)

TLT-1 Expression during Megakaryocyte Differentiation

Speaker: Angela Doerr (Germany)

Platelets and Megakaryocytes - Platelet Antagonists & Novel Therapeutics

The Effect of a New Packing Container on Medication Adherence Department of Pharmacy

Speaker: Kana Aoki (Japan)

An Empirical Screen of the Effects of Polyphenolic Compounds on Platelet Scramblase Activity

Speaker: Sarah L. Millington-Burgess (United Kingdom)

Generation of Novel Stable Prostacyclin Analogues with Superb Ability to Inhibit Platelet Function

Speaker: Shahida Mallah (United Kingdom)

Potential of Anthocyanins to Reduce Thrombotic Risk by Alleviating platelet Activity

Speaker: Almottesembellah Gaiz (Iraq)

Remote Ischemic Preconditioning (RIPC) Reduces Platelet Mitochondrial Membrane Depolarisation, Procoagulant Platelet Formation and Infarct Size in a Rat Model of Myocardial Infarction and in Human Coronary Artery Disease

Speaker: Hai Po Helena Liang (Australia)

Platelets and Megakaryocytes - Platelet Function and Interactions

Perfusion Conditions Control the Morphology of Thrombus Growth at High Shear Rates

Speaker: Shunichi Kobayashi (Japan)

Evaluation of Platelet Membrane Potential in Assessing the Risk of Thrombosis in Patients with Chronic Myeloproliferative Neoplasms

Speaker: Viola Popov (Romania)

Does Platelet Count Impact on Measurements of Platelet Adhesion under Static Condition Using Collagen Coated 96 Well Plates?

Speaker: Mohammad Algahtani (Saudi Arabia)

The Effect of Procoagulant Platelets on Different Aspects of Hemostasis

Speaker: Sofia Ramstrom (Sweden)

Reinforcement of Integrin-actin Linkages on Platelets in Response to Force

Speaker: David Bark (United States)

Dependence of Platelet Traction Forces on Myosin Activity and GPIb Levels

Speaker: Ingmar Schoen (Ireland)

Do Donor Attributes Influence Platelet Quality Following ex vivo Storage?

Speaker: Dianne E. van der Wal (Australia)

Variation of Platelet Dependent Thrombin Generation in Phenotypes of Acute Venous Thromboembolism

Speaker: Marina Panova-Noeva (Germany)

Scientific Programme

A Synthetic Triple Helical Collagen Peptide as a New Agonist for Flow Cytometric Measurement of GPVI Specific Platelet Activation

Speaker: Dana Huskens (the Netherlands)

A Novel Rapid Method of Red Blood Cells and Platelets Permeabilization and Staining for Flow Cytometry Analysis

Speaker: Marie Christine Alessi (France)

Platelet-specific Factor XIII-A: A Novel Role in the Regulation of Platelet Function

Speaker: Joanne Mitchell (United Kingdom)

Fatal Dysfunction and Disintegration of Thrombin-activated Platelets

Speaker: John W. Weisel (United States)

Blood Clot Contraction Is Promoted by Calpain via Strengthening of the Coupling of Fibrin-bound α IIb β 3 to the Platelet Cytoskeleton

Speaker: John W. Weisel (United States)

Platelets and Megakaryocytes - Platelet Proteomics & Genomics

Platelet Storage Lesion: Proteomic Analysis of Extracellular Vesicles Derived from Platelets Treated with Mirasol

Speaker: Maria N. Barrachina (Spain)

Platelet Size Subpopulations Differ in Protein Constitution and mRNA Profile

Speaker: Aneta Wrzyszc (Poland)

Platelets and Megakaryocytes - Platelet Receptors

The Role of Platelet Membrane Fluidity in Expressions of Platelet Receptors and Platelet Derived Microparticles in Patients with Chronic Myeloproliferative Neoplasms

Speaker: Viola Popov (Romania)

Synergy in Platelet Activation and Thrombus Formation in Mice with a Combined Deletion of PECAM-1 and Ceacam1

Speaker: Fahd A. Kuriri (Australia)

Human Fc γ RIIa Receptor Contributes to E.coli-induced Thrombocytopenia in vivo

Speaker: Dermot Cox (Ireland)

Heme Induces Platelet Aggregation via Two ITAM Receptors: Implications in Rhabdomyolysis-Induced Acute Kidney Injury

Speaker: Nagaharu Tsukiji (Japan)

Metabolomics of Platelet Activation with Normoxia and Hypoxia

Speaker: Nathan Clendenen (United States)

Platelets and Megakaryocytes - Platelet Signaling

PPAR Alpha Identified as a Novel Regulator of Platelet Function in vivo with Possible Dual Regulation in Atherothrombosis

Speaker: Michael Holinstat (United States)

Pro-coagulant Platelet Formation Involves 'Supramaximal' Ca $^{2+}$ Signalling

Speaker: Nima Abbasian (United Kingdom)

Coenzyme Q10 Attenuates Platelet Function through Targeting cAMP/PKA Pathway

Speaker: Yan Yang (China)

Scientific Programme

The Differential Requirement of the Btk Kinase Domain Downstream of ITAM and HemITAM Signalling

Speaker: Sophie H Nock (United Kingdom)

Evidence for a PI3-Kinase-independent Pathway Regulating ADP-induced Rap1b Activation in Platelets

Speaker: Carol Dangelmaier (United States)

Branched-Chain Amino Acids Facilitated Thrombosis by Enhancing the Propionylation of TMOD3 in Platelets

Speaker: Yanyan Xu (China)

Effect of Recombinant Human Lactoferrin, Isolated from Transgenic Goats, on Platelet Aggregation and Ca²⁺-Response

Speaker: Irina Gorudko (Belarus)

Extracellular Vesicle Shedding from Stimulated Platelets Involves Phosphatidylserine Exposure in Addition to a Functional α IIb β 3 Integrin

Speaker: Tilman M. Hackeng (the Netherlands)

Platelet Integrin α IIb β 3-dependent Outside-in Signaling Is Regulated by Apoptosis Signal-regulating Kinase 1 through p38 MAP Kinase Signaling

Speaker: Meghna Naik (United States)

Platelets and Megakaryocytes - Platelets and Inflammation

Fibrin Modulates Shear-induced NETosis in Sterile Occlusive Thrombi Formed under Arterial Hemodynamic Flow

Speaker: Scott Diamond (United States)

Characterization of the P-selectin-TLT-1 Null Mouse

Speaker: A. Valance Washington (United States)

The VWF-GPIb Interaction Mediates Thrombo-inflammation in Experimental Stroke Via Recruitment of Monocytes, Neutrophils and T-Cells to the Brain

Speaker: Frederik Denorme (Belgium)

Effect of Ultrapure Bacterial Lipopolysaccharides on the Modulation of Platelet Activation

Speaker: Thomas Vallance (United Kingdom)

The Antimicrobial Cathelicidin CRAMP Augments Platelet Activation during Psoriasis in Mice

Speaker: Sakthivel Vaiyapuri (United Kingdom)

Platelets and Megakaryocytes - Platelets Beyond Hemostasis

Platelet Rich Plasma for Acute Achilles Tendon Rupture: A Double-Blind Multicentre Randomized Placebo-controlled Trial (PATH-2)

Speaker: Paul Harrison (United Kingdom)

Platelet-sized Polyphosphate Induces Myofibroblast Differentiation

Speaker: Patrick Suess (United States)

Activated Platelets Kill *S. Aureus* and *S. Pneumoniae* by Fc γ RIIIa-independent Mechanisms, Which Are Not Enhanced by Platelet Factor 4/Heparin-antibodies

Speaker: Martina Wolff (Germany)

Prothrombotic States - Cancer-Associated Thrombosis: Clinical

Scientific Programme

Inferior Vena Cava Filters in Cancer Patients: Indications and Outcome

Speaker: Anila Rashid (Pakistan)

A Comparison of Venous Thromboembolism (VTE) and Arterial Events between Ixazomib, Lenalidomide and Dexamethosone (ILD) and Lenalidomide and Dexamethosone (LD) Chemotherapy in Multiple Myeloma: Single Centre Experience

Speaker: Zara Sayar (United Kingdom)

Risk of Upper Limb Venous Thromboembolism from Peripherally Inserted Catheters in Cancer Patients Receiving Chemotherapy

Speaker: Hiu Lam Agnes Yuen (Australia)

A Case of Cryoglobulinemia with Microvascular Embolization as the First Manifestation and Literature Review

Speaker: Ning Tang (China)

Patients with Primary CNS Lymphoma Have High Rates of Venous Thromboembolism during R-MPV Chemotherapy

Speaker: Hiu Lam Agnes Yuen (Australia)

Laboratory Measurement of Rivaroxaban Using Anti-factor Xa Assays in Patients with Cancer-associated Thrombosis

Speaker: Eun-Ha Koh (Korea, Republic of)

Coagulation Factors and Natural Anticoagulants in Polycythemia Vera Patients, Relation with JAK2V617F Mutation Load

Speaker: Natalya Silina (Russian Federation)

Improving Care for Patients with Cancer Associated Thrombosis in the Netherlands Using Patients', Caregivers' and Health Care Professionals' Experiences

Speaker: Asiong Jie (the Netherlands)

Procoagulant Phospholipid Dependent Clotting Time, Thrombin Generation Test and D-Dimers Are New Biomarkers in the Evaluation of Treatment Failure Risk in Newly Diagnosed Patients with Symptomatic Multiple Myeloma. Results from the Prospective ROADMAP MM Study

Speaker: Patrick Van Dreden (France)

Thromboprophylaxis in the Perioperative Patient in Patients with Breast Cancer on Tamoxifen

Speaker: Beverley J. Hunt (United Kingdom)

Risk of Venous Thromboembolism in Hospitalized Medical Cancer Patients with Midline and Peripherally Inserted Central Catheters

Speaker: Scott Kaatz (United States)

Management of Superficial Venous Thrombosis in Unevaluated Situations: Cancer, Severe Chronic Renal Failure, Pregnancy and Post-partum

Speaker: Laurent Bertoletti (France)

Venous Thromboembolism in Hospitalized Medical Cancer Patients with and without Chemotherapy Infusion through Peripherally Inserted Central Catheters

Speaker: Scott Kaatz (United States)

Accuracy of the Ottawa Score in Risk Stratification of Recurrent Venous Thromboembolism in Patients with Cancer-associated Venous Thromboembolism. A Systematic Review and Meta-analysis

Speaker: Aurelien Delluc (Canada)

Scientific Programme

Clinical Risk Prediction Model for Venous Thromboembolism (VTE) in Allogeneic Blood or Marrow Transplant (BMT) Survivors

Speaker: Radhika Gangaraju (United States)

Evaluation of Outpatient Management in Patients with Cancer-associated Venous Thromboembolism

Speaker: Stephan V. Hendriks (the Netherlands)

Full Benefit of Rivaroxaban Prophylaxis in High-risk Ambulatory Cancer Patients: An Analysis of All Thromboembolic Events in CASSINI

Speaker: Alok Khorana (United States)

Efficacy and Safety of Rivaroxaban Thromboprophylaxis by Khorana Score Category: A Subgroup Analysis of CASSINI

Speaker: Alok Khorana (United States)

Global Assays (TEG and ETP) and Biomarkers in Stratifying Thromboembolic Risk in Patients with Lung and Gastrointestinal Cancer Undergoing Chemotherapy or Chemoradiotherapy - A Subsequent Analysis from the BIOTEL (Lung Cancer) and BIOTEGIC (Gastrointestinal Cancer) Studies

Speaker: Nora Lee (Australia)

Association of Complete Blood Count Parameters, d-Dimer and Soluble P-selectin with Risk of Arterial Thromboembolism in Patients with Cancer

Speaker: Ella Grilz (Austria)

Relative Risk of Arterial and Venous Thromboembolism in Persons with Cancer versus Persons without Cancer - A Nation-wide Analysis

Speaker: Ella Grilz (Austria)

Apixaban as Treatment for Cancer Related Venous Thrombosis - A Single Arm Interventional Study

Speaker: Trine-Lise Hannevik (Norway)

Superficial Vein Thrombosis and Cancer

Speaker: Jana Hirmerova (Czech Republic)

Coagulation Profile in Non Hematologic Malignancies

Speaker: Sushma Belurkar (India)

Microparticles and the Risk of Pulmonary Embolism after Surgery for Primary Brain Tumors

Speaker: Andrea Artoni (Italy)

Anticoagulant Treatment for Venous Thromboembolism in Myeloproliferative Neoplasms: A Systematic Review

Speaker: Eva Nicole Hamulyák (the Netherlands)

Thromboses in Hodgkin Lymphoma Are Caused by Acquired Risk Factors

Speaker: Nilgun Sayinalp (Turkey)

Von Willebrand Factor Levels Are Increased in Polycythemia Vera and Can Be Predicted by Erythrocyte Counts

Speaker: Monica Sacco (Italy)

The Ottawa Score Does Not Predict Recurrent Venous Thromboembolism in Cancer Patients: Results from the Hokusai-VTE Cancer Study

Speaker: Floris T.M. Bosch (the Netherlands)

Scientific Programme

Incidence, Risk Factors and Clinical Outcomes of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the BACAP Cohort

Speaker: Corinne Frere (France)

Bleeding in the Prevention of Cancer-Associated Venous Thromboembolism: Secondary Analysis of the AVERT Study

Speaker: Lana A. Castellucci (Canada)

Incidence of Venous Thromboembolism in Patients with Advanced Stage Cervico-Uterine Cancer

Speaker: Gabriela Cesarman-Maus (Mexico)

The Prognostic Value and Clinical Significance of Anti-phospholipid Antibodies in Patients with NHL

Speaker: Gaurav Prakash (India)

Venous and Arterial Thrombosis in Myeloproliferative Neoplasms

Speaker: Lugsyanti Sukrisman (Indonesia)

Portal Vein Thrombosis as a Prognostic Factor for Survival Rate in Liver Cirrhosis with Hepatocellular Carcinoma Patients

Speaker: Andree Kurniawan (Indonesia)

Incidentally Detected Venous Thromboembolism in Cancer Patients: Results from the Hokusai VTE Cancer Trial

Speaker: Frits I. Mulder (the Netherlands)

The Performance of the Ottawa Score in Predicting Recurrence in Cancer Patients with Incidental Pulmonary Embolism

Speaker: Frits I. Mulder (the Netherlands)

Incidence Of Venous Thromboembolism (VTE) In Childhood Cancers - Tertiary Care Centre Experience From Kingdom Of Saudi Arabia

Speaker: Mahasen Saleh (Saudi Arabia)

Role of microRNAs in Venous Thromboembolic Disease of Patients with Lung Cancer

Speaker: Julia Oto (Spain)

DOACs and Cancer-associated Thrombosis: Effect of Online CME on Knowledge and Confidence of Physicians

Speaker: Jelena Spyropoulos (United States)

Prospective Registry of Cancer and Events Involving Venous Thromboembolism (PERCEIVE): 12-month Outcomes

Speaker: Gloria Petralia (United Kingdom)

Risk Factors for Edoxaban-related Gastrointestinal Bleeding in Patients with Gastrointestinal Cancer: Results from the Hokusai VTE Cancer Study

Speaker: Floris T.M. Bosch (the Netherlands)

Catheter Related Thrombosis in Patients with Hematologic Malignancies: A Venous ThromboEmbolism Network US (VENUS) Multicenter Retrospective Cohort Study

Speaker: Lisa Baumann Kreuziger (United States)

Evaluation of Platelet Parameters in a Prospective Cohort of Healthy Subjects in Relation to Cancer Diagnosis

Speaker: Marina Marchetti (Italy)

Scientific Programme

Cancer Associated Thrombosis and Direct Oral Anticoagulants: A Meta-Analysis of Randomised Clinical Trials

Speaker: Marilyn Rees (United Kingdom)

Incidental Pulmonary Embolism (IPE): Clinical Implication of Contemporaneous Cancer Response Status and Swiftness of PE Reporting

Speaker: Anthony Maraveyas (United Kingdom)

Incidental Pulmonary Embolism (I-PE): How Important Are Abnormal Conventional Lab Indices in Predicting Clinical Outcomes?

Speaker: Farzana Haque (United Kingdom)

Thromboelastometry Alterations Are Related with Multiple Myeloma Disease Status. Results of the ROADMAP-MM-CAT Study

Speaker: Grigorios Gerotziafas (France)

Efficacy Outcomes and Treatment Pattern in Patients with Cancer-associated Venous Thromboembolism: A Korean Nationwide Venous Thromboembolism Study

Speaker: Hun-Gyu Hwang (Korea, Republic of)

Risk and Management of Cancer-associated Venous Thromboembolism: A 10-year Retrospective Study in a Tertiary Teaching Hospital in Hong Kong

Speaker: Carmen Ka Man Cheung (Hong Kong)

Prothrombotic States - Cancer-Associated Thrombosis: Clinical and Perioperative Management

Perioperative Management of Direct Oral Anticoagulants: A Single Centre Observational Study

Speaker: Stephanie P'ng (Australia)

Comparison of Outcomes in Patients Undergoing Periprocedural Interruption of Warfarin or Direct Oral Anticoagulants

Speaker: Brian Haymart (United States)

A Retrospective Analysis of the real-world use of Idarucizumab at Two Tertiary Care Centres in Toronto, Canada

Speaker: Jameel Abdulrehman (Canada)

Reversal of Warfarin Using Low Dose Prothromplex Total, a 4-factor Prothrombin Complex and Its Implications on Fix-dosing Regimens

Speaker: Shu Hui Yeang (Singapore)

Perioperative Management of Anticoagulant Therapies in Elderly Patients Undergoing Orthopedic Surgery: Preliminary Results from the ORTHO-START Registry

Speaker: Elvira Grandone (Italy)

Idarucizumab for Dabigatran Reversal, the First 6 Months in a Tertiary Center

Speaker: Matt Wheeler (New Zealand)

Use of Low Molecular Weight Heparin during the Postoperative Period: Perioperative Management Plan of Patients Treated with Direct Oral Anticoagulants

Speaker: Desiree Campoy (Spain)

Venous Thromboembolism - VTE Anticoagulant Bleeding

Oral Anticoagulant-associated Bleeding Requiring Hospitalization: Incidences, Risk Factors and Outcomes

Speaker: Kochawan Boonyawat (Thailand)

Scientific Programme

Risk for Major and Fatal Bleeding After Discontinuing Oral Anticoagulation for Unprovoked Venous Thromboembolism: Systematic Review and Meta-analysis

Speaker: Faizan Khan (Canada)

Excessive Bleeding on Dabigatran Therapy Possibly Due to Genetically Predisposed Low Transport Activity of ABCB1 - A Case Report

Speaker: Silva Zupančić Šalek (Croatia)

Does INR Predict Bleeding Events in Children on Warfarin? A Longitudinal Study

Speaker: Natsaruth Songthawee (Canada)

What is the Incidence and Severity of Abnormal Uterine Bleeding Associated with Rivaroxaban in the Treatment of VTE and is there an Impact on Treatment Satisfaction? Early Results from the 'Follow-up in Rivaroxaban Patients in Setting of Thromboembolism' (FIRST) Registry

Speaker: Vicky Speed (United Kingdom)

Rates, Management and Outcome of Bleeding Complications during Edoxaban Therapy in Daily Care: Results from the Dresden NOAC Registry (NCT01588119)

Speaker: Jan Beyer-Westendorf (Germany)

Analysis of Bleeding Events on Prophylactic Rivaroxaban in the CASSINI Study

Speaker: Gerald A. Soff (United States)

Risk of Bleeding According to Renal Function in Patients with Venous Thromboembolic Disease under Treatment with Enoxaparin

Speaker: Fernando Chuliber (Argentina)

Resumption of Anticoagulant Therapy After Anticoagulant-Related Bleeding: A Population-Based Cohort Study

Speaker: Deborah M. Siegal (Canada)

Prediction of Major Bleeding in Patients Receiving DOACs for Venous Thromboembolism: A Prospective Cohort Study

Speaker: Cecilia Becattini (Italy)

Management and Outcome of Bleeding Complications in Patients Treated with Direct Oral Anticoagulants - Updated Interim Analysis

Speaker: Roisin Bavalia (the Netherlands)

Effect of Polypharmacy on Bleeding of Rivaroxaban Versus Vitamin K Antagonist for Treatment of Venous Thromboembolism

Speaker: Ingrid Bistervels (the Netherlands)

Risk Factors for Gastro-intestinal Bleeding Associated with DOACs: A Case Control-study

Speaker: Cecilia Becattini (Italy)

Venous Thromboembolism - VTE Anticoagulant Reversal

Factor Xa Inhibitor Antidote, Andexanet Alfa Differentially Reverses the Effects of Apixaban, Betrixaban, Edoxaban and Rivaroxaban

Speaker: Fakiha Siddiqui (United States)

Management of Oral Anticoagulant Reversal Prior to Emergency Surgery: Are we Following Guidelines in the United States?

Speaker: Jerrold Levy (United States)

Scientific Programme

Efficacy of Idarucizumab to Reverse the Anticoagulant Effect of Dabigatran in Emergency Situations

Speaker: Laura Francisca Ávila Idrovo (Spain)

Effect of 4F-PCC Weight Capped Dosing on INR Reversal for Patients with Life-threatening Bleeding or Requiring Emergent Surgery

Speaker: Jessica Rimsans (United States)

Contribution of Coagulation Factors in Prothrombin Complex Concentrates (PCCs) to TF-initiated Thrombin Generation in Normal and FXa Inhibitor-anticoagulated Plasma: The Relationship between Inhibitor Concentration and PCC-mediated Thrombin Generation

Speaker: Genmin Lu (United States)

Coordinating Emergent Procedures after Factor Xa Inhibitor (Xai) Reversal with Andexanet Alfa

Speaker: Sarah Culbreth (United States)

Pharmacokinetics of Direct Oral Anticoagulants in Overdose in Self-Poisoned Patients Admitted to the Intensive Care Unit: A Bi-Center Observational Study

Speaker: Virginie Siguret (France)

Differential Effects of Dabigatran, Rivaroxaban, Apixaban, Edoxaban and Betrixaban on Fibrinokinetics and their Modulation by FEIBA

Speaker: Fakiha Siddiqui (United States)

Venous Thromboembolism - VTE Therapy

Response to New Oral Anticoagulants in Nigerian Patients with Venous Thromboembolism

Speaker: Wuraola A. Shokunbi (Nigeria)

The Use of Direct Oral Anticoagulants in Inherited Antithrombin Deficiency

Speaker: Andrew Doyle (United Kingdom)

Therapy Persistence, Adherence and Predictors for Non-adherence in Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants

Speaker: Myrthe M.A. Toorop (the Netherlands)

The Season Role in the Occurrence of Thromboembolic Disease

Speaker: Mohamed Habib Houman (Tunisia)

Dabigatran for Failed Warfarin Treatment in High-risk Patients with Antiphospholipid Syndrome

Speaker: Natalia V. Seredavkina (Russian Federation)

Factors that Influence Inferior Vena Cava Filter Placement and Long-term Efficacy

Speaker: Elizabeth Lun (United States)

Effect of Anticoagulant Treatment on Pain in Distal Deep Vein Thrombosis: An Ancillary Analysis from the CACTUS Trial

Speaker: Marc Righini (Switzerland)

Incidence of Superficial Venous Thrombosis in Primary Care and Risk of Subsequent Venous Thromboembolic Sequela: A Retrospective Cohort Study Performed with Routine Healthcare Data from the Netherlands

Speaker: Geert-Jan Geersing (the Netherlands)

Scientific Programme

Automated IVC Filter Retrieval Requests and Haematology Liaison Improves Documentation and Retrieval of Temporary Inferior Vena Cava Filters: A Quality Improvement Initiative

Speaker: Lara Roberts (United Kingdom)

Mesoglycan vs Placebo in Secondary Prevention of Superficial Vein Thrombosis. Rationale and Protocol

Speaker: Giuseppe Camporese (Italy)

Drug-drug Interactions of Direct Oral Anticoagulants in Clinical Settings: A Systematic Review

Speaker: Allen Li (Canada)

An Audit of the Use of the Direct Oral Anticoagulants (DOACs) in Clinical Practice: 6 Years of Data

Speaker: Sue Rhodes (United Kingdom)

Anticoagulation with Direct Factor Xa Inhibitors in Transplant Recipients: Results from the Dresden NOAC Registry (NCT01588119)

Speaker: Jan Beyer-Westendorf (Germany)

Clinical Predictors of Pulmonary Embolism for Inpatients: Are Computed Tomography Pulmonary Angiograms Being Requested Appropriately? Retrospective Analysis

Speaker: Lisa Luo Lan Ling (Australia)

Thrombosis of the Jugular Veins: What Are the Particularity?

Speaker: Mohamed Habib Houman (Tunisia)

Anticoagulant Treatment Satisfaction and Concerns among Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants

Speaker: Myrthe M.A. Toorop (the Netherlands)

Superficial Vein Thrombosis (SVT) - Treatment of SVT < 3cm from the Deep Vein with Therapeutic DOAC - Too Close to Call?

Speaker: Marilyn Rees (United Kingdom)

Recurrence Risk According to Anticoagulant Prescribed for the Secondary Prevention of Venous Thrombosis

Speaker: Neil Zakai (United States)

Efficacy and Safety of Apixaban for Treatment of Venous Thromboembolism in a Daily Practice-based Cohort

Speaker: Stephan V. Hendriks (the Netherlands)

A Single Centre Retrospective Review of Prophylactic Apixaban Safety and Efficacy in Patients after Venous

Speaker: Dominic Pepperell (Australia)

Venous Thromboembolism in Asia and Worldwide: Emerging Insights from GARFIELD-VTE

Speaker: Pantep Angchaisuksiri (Thailand)

Low Level of Antithrombin Causes Underestimation of Anti-Xa and Discrepancy of Anti-Xa Test and Activate Partial Thromboplastin Time in the Monitoring of Heparin

Speaker: Ari Ahn (Korea, Republic of)

Outcomes in the Secondary Prevention of Cerebral Venous Thrombosis in Cancer Only Population

Speaker: Cristhiam Mauricio Rojas Hernandez (United States)

Scientific Programme

Incidence and Characteristics of Venous Thromboembolism in East Asian Primary Central Nervous System Lymphoma

Speaker: Sung-Soo Yoon (Korea, Republic of)

Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Survey on Physicians' Considerations and Guideline Adherence

Speaker: Maria Adriana de Winter (the Netherlands)

MAC Project - Monitoring Anti-coagulant Therapy - Preliminary Result from 2 Years Follow-up with Rivaroxaban Users

Speaker: Giuseppe Camporese (Italy)

Anticoagulant Treatment Patterns among Venous Thrombosis Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases

Speaker: Daniel Wiederkehr (United States)

Incidence, Risk Factors and Outcomes of Venous Thromboembolism in Haploidentical Versus Matched Related Donor Hematopoietic Stem Cell Transplantation: a 13-year Retrospective Study of 5471 Recipients

Speaker: Gaochao Zhang (China)

Inferior Vena Cava Filters in Venous Thromboembolism: Indications, Complications and Extraction Predictors

Speaker: Fernando Chuliber (Argentina)

Particularities of Upper-extremity Venous Thrombosis

Speaker: Mohamed Habib Houman (Tunisia)

A Rock and a Hard Place - are We Balancing Bleeding and Thrombotic Risk in Patients with Thrombocytopenia?

Speaker: Amanda Tey (Australia)

Retrospective Study of the Management of Anticoagulant Therapy in the Pacemaker Implant. Experience in an Intensive Care Unit

Speaker: Pablo Romero Garcia (Spain)

Superficial Vein Thrombosis: To Treat beyond 3cm?

Speaker: Marilyn Rees (United Kingdom)

The Use of Apixaban or Rivaroxaban in Patients Taking Calcineurin Inhibitors (CNIs): A Review of Therapeutic Levels

Speaker: Beverley J. Hunt (United Kingdom)

First Analysis of an Observational, Prospective, Specific Registry of Cancer-Associated Thrombosis (CAT): TESEO Registry

Speaker: Andrés J. Muñoz Martín (Spain)

Direct Oral Anticoagulant (DOAC) Monitoring: A Real World Experience

Speaker: Alison Slocombe (Australia)

Therapeutic Monitoring of Rivaroxaban Plasma Levels in 31 Patients with or without Major Bleeding Events (MBE) in a Single Centre in Singapore

Speaker: Lester Jun Long Wong (Singapore)

Prescribing Practises of Dabigatran in Patients Presenting with Bleeding and Requiring Major Surgery in a Tertiary New Zealand Centre

Speaker: Matt Wheeler (New Zealand)

Scientific Programme

Non-Invasive Detection of Early Phase of Deep Vein Thrombus with Diffusion-Weighted Magnetic Resonance Imaging

Speaker: Toshihiro Gi (Japan)

Incidence and Characteristics of Double Lumen Induced Central Venous Catheter-related Thromboembolism in Hemodialytic Patients

Speaker: Andree Kurniawan (Indonesia)

Evaluation of Strategies Focused on Empowerment and Change of Behavior with a Potential Utility in Patients with Thromboembolic Disorders

Speaker: Luci Dusse (Brazil)

Therapeutic monitoring of Apixaban levels in 17 patients in a single centre in Singapore

Speaker: Christina Lai Lin Sum (Singapore)

GMP Manufactured Ovine Mucosal Enoxaparin Is Comparable to Commercially Available Porcine Mucosal Enoxaparin

Speaker: Manoj Niverthi (United States)

Ovine Mucosal Enoxaparin Exhibit Comparable Pharmacokinetic Profiles to Porcine Mucosal Enoxaparin

Speaker: Ahmed Kouta (United States)

Vitamin K Antagonist vs Direct Oral Anticoagulant As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Speaker: Pável Olivera (Spain)

Anti-factor Xa Levels Correlate with Recurrent Venous Thromboembolism and Clinically Relevant Bleeding in Patients Receiving Low-molecular-Weight Heparin

Speaker: Luca Valerio (Germany)

Scientific Programme

Tuesday, 09. July 2019

Registration
07:00 - 19:00

Main Foyer

Registration

State-of-the-Art Session
08:00 - 09:15

Plenary Hall

SOA 15, Challenges in Anticoagulant Management II

Chair: Jennifer Curnow (Australia)
Chair: Per Morten Sandset (Norway)

Immune Thrombosis From a Clinical Perspective	08:00
Speaker: Sam Schulman (Canada)	
Combining Antiplatelet and Anticoagulant Therapy	08:25
Speaker: John Eikelboom (Canada)	
Risk Stratification of Patients with Acute PE: Implications for Home Treatment and Reperfusion Strategies	08:50
Speaker: Stefano Barco (Germany)	

State-of-the-Art Session
08:00 - 09:15

Melbourne Room 1

SOA 16, Coagulation Proteins and Platelets Beyond Hemostasis

Chair: Emma Josefsson (Australia)
Chair: Shaun Jackson (Australia)

Platelet Microparticles and Inflammatory Diseases	08:00
Speaker: Eric Boilard (Canada)	
Platelets, Angiogenesis, and Malignancy	08:25
Speaker: Elisabeth M. Battinelli (United States)	
Coagulation Proteins and Liver Disease	08:50
Speaker: James Luyendyk (United States)	

State-of-the-Art Session
08:00 - 09:15

Melbourne Room 2

SOA 17, Microbiome and Cardiovascular Risk

Chair: Masako Yamazaki (Japan)
Chair: Connie Wong (Australia)

Scientific Programme

Diet and Health: Lessons From Ancient DNA	08:00
Speaker: Yassine Souilmi (Australia)	
Microbiome Interactions with Host Metabolism and Immunity	08:25
Speaker: Emad El-Omar (Australia)	
Microbiota and Cardiovascular Risk	08:50
Speaker: Christoph Reinhardt (Germany)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 203/204

SOA 18, Megakaryocyte Development and Platelet Biogenesis

Chair: Samir Taoudi (Australia)
Chair: Lining Arnold Ju (Australia)

Interplay Between HSCs and Megakaryocytes	08:00
Speaker: Susie Nilsson (Australia)	
Activation and Regulation of the Thrombopoietin Receptor	08:25
Speaker: Ian Stuart Hitchcock (United Kingdom)	
Beyond Platelet Production In Vitro	08:50
Speaker: Koji Eto (Japan)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 210/211

SOA 19, Thrombosis in Pregnancy

Chair: Barry F. Jacobson (South Africa)
Chair: Saskia Middeldorp (the Netherlands)

VKA are the Anticoagulant of Choice for Mechanical Valves in Pregnancy (Debate)	08:00
Speaker: Claire McLintock (New Zealand) Speaker: Dominica Zentner (Australia)	
Diagnosis of PE in Pregnancy	08:25
Speaker: Grégoire Le Gal (Canada)	
Obstetric Antiphospholipid Syndrome	08:50
Speaker: Karen Schreiber (United Kingdom)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 212/213

SOA 20, Novel Fibrinolytic Functions and Therapies

Chair: Robert Ariëns (United Kingdom)
Chair: Ruby Law (Australia)

Scientific Programme

Monoclonal Antibodies Against Antifibrinolytic Proteins	08:00
Speaker: Paul J. Declerck (Belgium)	
Spatiotemporal Regulation of Plasminogen Activation and its Disruption	08:25
Speaker: Tetsumei Urano (Japan)	
Fibrin/ogen Structure as a Potential Therapeutic Target	08:50
Speaker: Alisa S. Wolberg (United States)	

State-of-the-Art Session
08:00 - 09:15

Meeting Room 219/220

SOA 21, Regulation of VWF in Health and Disease

Chair: Cecile Denis (France)
Chair: Sandra Haberichter (United States)

ADAMTS13 and VWF in TTP	08:00
Speaker: José López (United States)	
VWF and Force	08:25
Speaker: Cheng Zhu (United States)	
Modifiers and Genetics of VWF	08:50
Speaker: Jill Johnsen (United States)	

Exhibition
09:30 - 17:30

Exhibition Hall

Exhibition

Plenary Session
09:30 - 10:15

Plenary Hall

PL 04, Oscar Ratnoff Plenary Lecture

Chair: Robert Medcalf (Australia)

Safe Anticoagulants: Targeting the Contact Pathway	09:30
Speaker: Thomas Renné (Germany)	

Oral Communication Session
10:45 - 12:00

Plenary Hall

OC 50, Perioperative Coagulation

Chair: James Douketis (Canada)
Chair: Simon Jonathan Stanworth (United Kingdom)

Scientific Programme

Effect of DOAC Type and DOAC Dose, and Residual DOAC Level on Risk for Perioperative Major Bleeding and Arterial Thromboembolism	10:45
Speaker: James Douketis (Canada)	
Retrospective Analysis of the Clinical Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal	11:00
Speaker: Louisa Stone (New Zealand)	
Neither a Structured Questionnaire at Pre-anesthesia Visit Nor the Prescription of Routine Hemostatic Tests Have Acceptable Performances to Detect Hemostatic Abnormalities before Surgery	11:15
Speaker: Nadine Ajzenberg (France)	
Retrospective Review of Outcomes and Anticoagulation use for Elderly Patients that Present with an Acute Hip Fracture at Three Tertiary Hospitals in Perth, Western Australia	11:30
Speaker: Katherine Creeper (Australia)	
Efficacy and Safety of Prothrombin Complex Concentrate in Patients with Intracranial Bleeding Treated with Factor Xa Inhibitors and Patients Treated with Vitamin K Antagonists	11:45
Speaker: Roisin Bavalia (the Netherlands)	

Oral Communication Session
10:45 - 12:00

Melbourne Room 1

OC 51, Prediction and Management of Inhibitors

Chair: Shannon Meeks (United States)
Chair: Stephanie P'ng (Australia)

An Engineered Protein Analogous to IL-2, Mutein 24, Decreases the Formation of Factor VIII Inhibitors in Hemophilia Mice Receiving Factor VIII Treatment	10:45
Speaker: Alex Chen (United States)	
High-Throughput Immunoprofile Mimotope Variation Analysis in Previously Untreated Patients with Severe Haemophilia A before and after FVIII Exposure	11:00
Speaker: Roberta Palla (Italy)	
Exploring Spontaneous Readthrough Over Recurrent F8 Nonsense Mutations: Potential Correlation with Inhibitor Risk?	11:15
Speaker: Silvia Lombardi (Italy)	
A Dysbiotic Gut Microbiota Diminishes Short-Chain Fatty Acid Production and Increases Factor VIII Immunogenicity in Haemophilia A Mice	11:30
Speaker: Matthew Christopher Cormier (Canada)	
Recombinant Canine and Human FXa-I16L Provide Safe and Efficacious Hemostasis during Major Bleeding Events in Hemophilia A Dogs with High-titer Inhibitory Anti-FVIII Antibodies	11:45
Speaker: Timothy Nichols (United States)	

Scientific Programme

Oral Communication Session
10:45 - 12:00

Melbourne Room 2

OC 52, Immune Thrombocytopenia

Chair: Jenny M. Despotovic (United States)
Chair: Philip Choi (Australia)

Feasibility of a New, Rapid Functional Assay for the Diagnosis of Heparin-induced Thrombocytopenia: A Standardized Flow Cytometry Assay	10:45
Speaker: Justine Brodard (Switzerland)	
FcγRIIa Polymorphisms and Allele-Specific Haplotypes in Heparin-Induced Thrombocytopenia (HIT)	11:00
Speaker: Christine Lee (Australia)	
Anti Platelet Antibodies Predict Platelet Desialylation and Apoptosis in ITP	11:15
Speaker: Shiyong Silvia Zheng (Australia)	
Clinical Association of Increased Antioxidant Enzymes Levels in Immune Thrombocytopenic Purpura	11:30
Speaker: Aisha Arshad (Pakistan)	
Immune Phenotyping Predicts Prognosis and Treatment Response in Newly Diagnosed Childhood Immune Thrombocytopenia	11:45
Speaker: David E. Schmidt (the Netherlands)	

Oral Communication Session
10:45 - 12:00

Meeting Room 203/204

OC 53, Cellular Pathways in Hemophilia

Chair: Antonia Follenzi (Italy)
Chair: Zane Kaplan (Australia)

Differential Production of Cytokines in Response to FVIII in Hemophilia Patients Undergoing ITI: A Preliminary Analysis of a Multi-center Longitudinal Study	10:45
Speaker: Davide Matino (Canada)	
Identification and Characterization of Murine FVIII-producing Cells in vivo	11:00
Speaker: Morisada Hayakawa (Japan)	
Plasma-derived FVIII/VWF Combined with Emicizumab in Hemophilia A Plasma with and without Inhibitor Has a Non-additive Effect on in vitro Thrombin Generation	11:15
Speaker: Maria Isabel Bravo (Spain)	
In vivo Enrichment of Genetically Manipulated Platelets for Murine Haemophilia B Gene Therapy	11:30
Speaker: Yingyu Chen (United States)	
The Route of FVIII Endocytosis by Antigen-presenting Cells Determines the Pattern of FVIII Peptide-specific T Cells Activation	11:45
Speaker: Birgit Maria Reipert (Austria)	

Scientific Programme

Oral Communication Session
10:45 - 12:00

Meeting Room 210/211

OC 54, Epigenetics, Genomics and Bioinformatics

Chair: Willem H. Ouwehand (United Kingdom)
Chair: Marie Lordkipanidzé (Canada)

- | | |
|--|--------------|
| The Rare MAST2 Arg89Gln Mutation Causes Venous Thrombosis in a French Family with Unexplained Thrombophilia: The Breizh MAST2 Mutation | 10:45 |
| Speaker: Pierre Emmanuel Morange (France) | |
| Development and Validation of a Plasma micro-RNAs Profile Associated with Venous Thrombosis | 11:00 |
| Speaker: José Manuel Soria (Spain) | |
| Generating Plasma Protein Signatures For Murine Venous Thrombosis and Slc44a2 Deficiency Using a Multiplex Targeted Proteomics Approach | 11:15 |
| Speaker: Julia Tilburg (the Netherlands) | |
| Proteomic Analysis Reveals Age-Specific Global Changes in Platelet, Plasma and Endothelial Haemostatic Proteins | 11:30 |
| Speaker: Conor McCafferty (Australia) | |
| Curating Disease-causing Genes for Bleeding, Thrombotic and Platelet Disorders, and Application to the ThromboGenomics Gene Panel Test | 11:45 |
| Speaker: Karyn Megy (United Kingdom) | |

Oral Communication Session
10:45 - 12:00

Meeting Room 212/213

OC 55, Fibrinolytic Factors and Inhibitors

Chair: Matthew James Flick (United States)
Chair: Yu Ping Yuan (Australia)

- | | |
|--|--------------|
| Platelet-dependent Activation of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) | 10:45 |
| Speaker: Yuko Suzuki (Japan) | |
| The Imbalanced Hepatic Production of PAI1 and tPA Contributes to Decreased Fibrinolysis in Obesity | 11:00 |
| Speaker: Ze Zheng (United States) | |
| Novel Plasmin Generation Assay Reveals a Plasminogen Activator Inhibitor-1-Independent Mechanism That Contributes to the Hemostatic Imbalance in Experimental Obesity | 11:15 |
| Speaker: Adam Miszta (United States) | |
| Targeting Thrombolytics for Thrombotic Thrombocytopenic Purpura | 11:30 |
| Speaker: Steven de Maat (the Netherlands) | |
| Activated Thrombin Activable Fibrinolysis Inhibitor (TAFIa) Regulates Plasmin Generation on Thrombin-activated Platelets | 11:45 |
| Speaker: Paul Kim (Canada) | |

Scientific Programme

Oral Communication Session
10:45 - 12:00

Meeting Room 219/220

OC 56, VWF Basic Science

Chair: Cecile Denis (France)
Chair: Cheng Zhu (United States)

Increased in vivo Angiogenesis in von Willebrand Factor (VWF)-deficient Mice	10:45
Speaker: Soundarya Selvam (Canada)	
Allele-Specific Inhibition of VWF p.Cys1190Tyr in Patient-Derived Endothelial Colony Forming Cells Corrects the Von Willebrand Disease Type 2A Phenotype	11:00
Speaker: Annika de Jong (the Netherlands)	
Investigations of the von Willebrand Factor (VWF) p.Arg273Trp Variant Using Endothelial Colony Forming Cells (ECFCs)	11:15
Speaker: Mackenzie Bowman (Canada)	
Large Gene Deletion in a VWD Patient Impairs VWF Storage in WPBs and Affects Phenotypic Features of Blood Outgrowth Endothelial Cells	11:30
Speaker: Hamideh Yadegari (Germany)	
In vitro And in vivo Amelioration of the Von Willebrand Disease Type 2B Phenotype Using an Allele-Specific siRNA	11:45
Speaker: Annika de Jong (the Netherlands)	

Oral Communication Session
10:45 - 12:00

Meeting Room 105

OC 57, Evidence-Based Antithrombotic Use in Pediatrics

Chair: Katharina Thom (Austria)
Chair: Fiona Newall (Australia)

Safety of Dabigatran Etxilate for Secondary Prevention of Venous Thromboembolism in Paediatric Patient	10:45
Speaker: Leonardo Brandão (Canada)	
Investigation of the Age-specific in vitro Effect of Bivalirudin in Children Compared to Adults	11:00
Speaker: Xavier Busuttill-Crellin (Australia)	
Efficacy and Safety of Dabigatran Etxilate for Treatment of Venous Thromboembolism in Paediatric Patients - Results of the DIVERSITY Trial	11:15
Speaker: Manuela Albisetti (Switzerland)	
Comparison of Stroke Incidence in Fontan Patients Receiving Warfarin or Aspirin	11:30
Speaker: Chantal Attard (Australia)	

Scientific Programme

Oral Communication Session
10:45 - 12:00

Meeting Room 106

OC 58, Platelet Analysis and New Approaches

Chair: Robert Campbell (United States)
Chair: Matthew Linden (Australia)

Extensive Tyrosine Phosphoproteomic Analysis of the CLEC-2 Signalling Cascade in Human Platelets: New Players on the Team	10:45
Speaker: Maria Nuñez Barrachina (Spain)	
TMT-based Temporal Quantitative Phosphoproteome of Human Platelets in Response to Collagen	11:00
Speaker: Peng Jiang (China)	
Platelet mRNA Splicing Landscape and its Effect on Platelet Activity: An ACCOuNT Consortium Study	11:15
Speaker: Kaitlin Garofano (United States)	
Hepatic Thrombopoietin Gene Silencing Induces Platelet Count Reduction within the Hemostatic Range and Reduces Breast Cancer Progression in MMTV-PyMT Mice	11:30
Speaker: Toshiaki Shirai (United States)	
Novel Single Cell Mechanobiology Approach Reveals an Intermediate State of Integrin αIIbβ3 that Mediates Platelet Aggregation under Blood Flow Disturbance	11:45
Speaker: Lining Arnold Ju (Australia)	

Oral Communication Session
10:45 - 12:00

Meeting Room 109/110

OC 59, Platelet Activation and Function

Chair: Dianne E. van der Wal (Australia)
Chair: Paul Harrison (United Kingdom)

Shear Rate Gradients Promote a Bi-phasic Thrombus Formation in a Vwf-dependent Manner	10:45
Speaker: Nicolas Receveur (France)	
Characterization of a Novel GPIIbα Knockin Mouse that Lacks the Last 24 Amino Acids of its Intracellular Domain	11:00
Speaker: Isabelle I Salles-Crawley (United Kingdom)	
Role of β-arrestin2 in Regulation of Platelet Activation and Thrombus Formation through GPCR Desensitization	11:15
Speaker: Preeti Kumari Chaudhary (Korea, Republic of)	
Decoding Gαq Signaling in Platelets	11:30
Speaker: Peisong Ma (United States)	
Sodium-calcium Exchanger Reverse Mode is Required for Generation of Procoagulant COAT Platelets	11:45
Speaker: Alessandro Aliotta (Switzerland)	

Scientific Programme

Special Session
12:15 - 13:15

Meeting Room 209

INVENT Network: Dragon's Den Competition 2019

Applicants to the competition will present proposals of their research studies to potentially be endorsed by the INVENT network and/or be awarded an International Collaboration grant. Each applicant will have 5-8 minutes to present their proposal. After each presentation, the presenter will be probed by three INVENT Dragons with pointed questions geared towards determining if the proposed study is well designed, feasible, and will be practice-changing. Simultaneously, the audience, using an interactive polling system, will rate each proposed study on its potential to change practice. After the final presentation, the audience will be asked to vote for the project that is most likely practice-changing.

Product Theater Presentations
12:15 - 13:00

Theatre A

Product Theater

Title: ADAMTS13 Diagnostics This session is supported by [Technoclone Please visit here](#)

Product Theater Presentations
12:15 - 13:00

Theatre B

Product Theater

Title: Optimizing Lab Efficiency in Coagulation This session is supported by [Roche Diagnostics Please view the program here](#)

Product Theater Presentations
12:15 - 13:00

Theatre C

Product Theater

Title: Real-World Perspectives on Adopting Jivi® Into Your Practice This session is supported by [Bayer Please view the program here](#)

Supported Symposia
13:15 - 14:30

Melbourne Room 2

Supported Symposium

Title: Considering Emergent Approaches to Overcome Challenges for People With Haemophilia A Without FVIII Inhibitors This session is supported by [Roche Please view the program here](#)

Scientific Programme

Supported Symposia
13:15 - 14:30

Meeting Room 203/204

Supported Symposium

Title: Managing Thrombotic Risk with Microvesicles: Ready for the Clinics? This session is supported by [Stago](#) Please [view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 210/211

Supported Symposium

Title: Harnessing Innovation to Transform Standards of Care in VWD and cTTP This session is supported by [Takeda](#) Please [view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 212/213

Supported Symposium

Title: Improving Outcomes in Hemophilia A This session is supported by [CSL Behring](#) Please [view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 219/220

Supported Symposium

Title: Anticoagulation in Active Cancer Patients: How NOACs Changed Clinical Practice This session is supported by [Bayer AG](#) Please [view the program here](#)

Supported Symposia
13:15 - 14:30

Meeting Room 109/110

Supported Symposium

Title: New Light Shed on VTE Prophylaxis in Medical Patients: The Current State of the art This session is supported by [Sanofi](#) Please [view the program here](#). This symposium will also be live-streamed. Please visit <http://vteandmedpatients.isth2019.live.cyim.com> for more information.

Master Class
13:15 - 14:15

Meeting Room 218

How I Treat: Hemophilia with Inhibitors

Dr. Meeks will (1) review what is known about the risk factors for inhibitor development; (2) Understand the underlying immune response that makes each inhibitor patient unique; (3) Strategies for ITI and bleeding prevention/treatment in newly diagnosed inhibitor patients; (4) Strategies for next steps when traditional ITI is not working; (5) Understand the potential changes to treatment strategies in the era of novel therapies

Scientific Programme

Hemophilia with Inhibitors

13:15

Speaker: Shannon Meeks (United States)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 1

Cancer-Associated Hemostatic Dysregulation on the Risk of Metastasis

Master Class Focus: Clinical A/Prof Kate Burbury is a consultant haematologist at the Peter McCallum Cancer Centre and Victorian Comprehensive Cancer Centre. She is the lead clinician for MPN/CML, as well as haemostasis, thrombosis and peri-procedural optimisation, including prehabilitation, for all patients with malignancy. Kate has an active research programme, with a particular interest in haemostatic/endothelial dysfunction associated with malignancy, with an extensive portfolio in clinical trials and correlative research assessing thrombogenic biomarker profiles and risk-targeted thromboprophylaxis in cancer patients. As well as the interactions between the hemostatic system and cancer, facilitating enhanced tumour cell survival, proliferation and metastatic potential.

Cancer-Associated Hemostatic Dysregulation on the Risk of Metastasis

13:15

Speaker: Kate Burbury (Australia)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 2

Refractory ITP

Master Class Focus: Clinical Dr. Gernsheimer's original work on the pathophysiology of ITP and platelet production helped us to consider ITP in a whole new way. ITP therapies that increase platelet production have allowed us to avoid immunosuppression with fewer side effects overall and much improved efficacy. These therapies have encouraged physicians to take a "watch and wait" approach to managing thrombocytopenia without more toxic or irreversible treatments or surgery. This session will focus on choosing therapeutic options that take into account platelet number, risks of both therapy and bleeding, and patient life style. Dr. Gernsheimer will discuss the approach to acute onset ITP, when and what therapies to consider during the natural course of the disease and how to recognize a patient who has entered remission while still on therapy.

Refractory ITP

13:15

Speaker: Terry B. Gernsheimer (United States)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 3

Dynamic Imaging of Megakaryocyte and Platelets

Master Class Focus: Basic Steve Thomas is a senior lecturer in Cardiovascular Sciences at the University of Birmingham in the United Kingdom. Originally trained as a plant cell biologist, he made the move to working with platelets and megakaryocytes when he joined Professor Steve Watsons' lab in 2006. Steve has a long-standing interest in the cytoskeleton, and in understanding how the actin and tubulin cytoskeletons help to regulate dynamic cellular processes. This has included understanding how actin polymerisation status can trigger programmed cell death and how dynamic actin structures known as actin nodules are important in thrombus formation and in resistance to high shear stress. A key part of this work, and a major research interest of Steve's, is the application of advanced fluorescence imaging techniques. He was one of the first groups to apply super-resolution techniques to the study of platelets and is also applying light-sheet microscopy to allow long term imaging of the cytoskeleton and other cellular components during megakaryocyte development. Steve is a committee member for The Platelet Society, serves on the Life Science committee of the Royal Microscopical Society and is the academic technical lead for the Centre of Membrane Proteins and Receptors (COMPARE) based between the Universities of Birmingham and Nottingham. His desire is to use imaging to answer key questions about platelet and megakaryocyte biology whilst producing images to inspire both scientists and non-scientists alike.

Dynamic Imaging of Megakaryocyte and Platelets

13:15

Speaker: Steven G. Thomas (United Kingdom)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 4

Cancer-Associated Thrombosis

Master Class Focus: Clinical Dr. Marc Carrier, M.D., MSc, FRCPC, is a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. Dr. Carrier holds a Tier 2 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa. He is the current Chair of the ISTH SSC on Malignancy & Haemostasis. His clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management.

Cancer-Associated Thrombosis

13:15

Speaker: Marc Carrier (Canada)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 5

Choosing the Right Product for Hemophilia Patients

Master Class Focus: Clinical The treatment of hemophilia has evolved tremendously over the past few decades with rapid growth and innovations occurring on a nearly continuous basis. The goal of therapy remains to eliminate breakthrough bleeding events and prevent inhibitor formation while decreasing the burden of care. EHL replacement products have achieved some of these goals but treatment gaps remain. Novel therapeutics are being developed with alternate modes of delivery, addressing targets that overcome the limitations of current replacement therapy, as well as improved PK profiles resulting in a lower burden of treatment. New directions of innovation show alternative strategies that do not involve protein replacement therapy. Hemostatic rebalancing therapies and emicizumab substitution therapy offer great potential for the future of care for hemophilia while addressing the remaining challenges of inhibitor formation and burden of treatment. Dr. Pipe is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory and has >25 years of experience with clinical care of hemophilia, has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy and currently serves as Chair of the Medical and Scientific Advisory Committee to the National Hemophilia Foundation.

Scientific Programme

Choosing the Right Product for Hemophilia Patients

13:15

Speaker: Steven W. Pipe (United States)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 6

The Hypercoagulable Endothelium

Master Class Focus: Clinical This Master Class will focus on the pro- and anti-coagulant properties of the vascular endothelium in health and disease. In a variety of clinical inflammatory disorders, activation of the endothelium can shift the delicate homeostatic balance towards a procoagulant and pro-adhesive phenotype that may be maladaptive and contribute to end organ dysfunction. Dr. Nigel Key's translational research focus has included in vitro and in vivo modeling of endotheliopathies occurring in sickle cell disease, sepsis and more recently, acute liver failure. His laboratory seeks to identify novel biomarkers, based on recognized pathophysiologic processes that are predictive of adverse outcomes. These biomarkers include circulating endothelial-derived microvesicles and other soluble components.

The Hypercoagulable Endothelium

13:15

Speaker: Nigel Key (United States)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 7

Atrial Fibrillation and Thromboembolism: Insights from Epidemiology and Pathophysiology, to Optimize Anticoagulation

Master Class Focus: Clinical Professor Lip, MD, is Price-Evans Chair of Cardiovascular Medicine, at the University of Liverpool, UK – and Director of the Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital. He is also Distinguished Professor at Aalborg University, Denmark; and Adjunct Professor, Yonsei University, Seoul, Korea. Half of his time is spent as a clinical cardiologist, including outpatient clinics (leading large atrial fibrillation and hypertension specialist services) and acute cardiology. Professor Lip has had a major interest into the epidemiology of atrial fibrillation (AF), as well as the pathophysiology of thromboembolism in this arrhythmia. Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification. The CHA₂DS₂-VASc and HAS BLED scores - for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into international guidelines. He was selected to the Thomson Reuters Science Watch list of 'World's Most Influential Scientific Minds 2014', a ranking of today's top 17 scholars who have published the greatest number of hot papers, ranked in the top 0.1% by citations, [issued June 2014; see website: <http://bit.ly/1sx4uyM>]. In 2014, Professor Lip was ranked by [Expertscape](http://bit.ly/2apB1Dt) as one of the world's leading experts in the understanding and treatment of AF [<http://bit.ly/2apB1Dt>]. Professor Lip was on the writing committee for various international guidelines, including the American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as various guidelines and/or position statements from the European Society of Cardiology (ESC) or EHRA. Specifically, he was also on the writing committees of the 2010 ESC Guidelines on Atrial Fibrillation, the 2012 ESC Focused Update Guidelines on Atrial Fibrillation, the 2012 ESC Guidelines on Heart Failure, and the 2014 NICE guidelines on AF. He was Deputy Editor ("content expert") for the 9th ACCP guidelines on antithrombotic therapy for AF (2012), and Chair of the new 2018 ACCP Guidelines on antithrombotic therapy for AF. Professor Lip has acted as senior/section editor for major international textbooks and at senior editorial level for major international journals, including Thrombosis & Haemostasis (Editor-in-Chief, Clinical Studies); Europace (Associate Editor); and Circulation (Guest Editor).

Atrial Fibrillation and Thromboembolism: Insights from Epidemiology and Pathophysiology, to Optimize Anticoagulation

13:15

Speaker: Gregory YH Lip (United Kingdom)

Scientific Programme

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 8

Imaging Modalities for Inflammation Research

Master Class Focus: Basic In vivo imaging affords an unparalleled understanding of inflammation. These analyses are performed in vivo, maintaining physiological conditions. In vivo imaging technologies are undergoing continual improvement. A wide range of cell types can be investigated, including platelets. I have experience in imaging skin, kidneys, muscles, the colon, and the brain.

Imaging Modalities for Inflammation Research

13:15

Speaker: Michael Hickey (Australia)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 9

Anticoagulant Pathways in Thrombotic and Bleeding Disorders

Master Class Focus: Basic Our research group focuses on the regulation of coagulation by natural anticoagulants, particularly the protein C pathway and the tissue factor pathway inhibitor (TFPI) system, which share the key cofactors protein S (PS) and factor V (FV). Specifically, we combine genetic analyses, biochemical assays and global coagulation tests (especially thrombin generation) to unravel functional alterations of these anticoagulant pathways in patients with thrombotic or bleeding disorders.

Anticoagulant Pathways in Thrombotic and Bleeding Disorders

13:15

Speaker: Elisabetta Castoldi (the Netherlands)

Master Class
13:15 - 14:15

Exhibition Hall Meeting Room 10

Thromboprophylaxis in Pregnancy

Master Class Focus: Clinical Dr. Bates has published extensively and given a number of international presentations on the management of thrombosis, thrombophilia and anticoagulant therapy in pregnancy. She was the lead author for the chapter examining the use of antithrombotic agents during pregnancy in the 7th, 8th and 9th editions of the American College of Chest Physicians (ACCP) Evidence-Based Clinical-Practice Guidelines for Antithrombotic and Thrombolytic Therapy and also led the development of guidelines on the prevention and treatment of obstetric-related venous thromboembolism for the Anticoagulation Forum. She participated in the development of a consensus statement on the anesthetic management of pregnant and postpartum women receiving anticoagulant therapy for the Society of Obstetric Anesthesia and Perinatology published in 2018. Dr. Bates is the Chair of the American Society of Hematology Guideline Panel on venous thromboembolism in the context of pregnancy. In 2014, she was named the Eli Lilly Canada/May Cohen Chair in Women's Health at McMaster University.

Thromboprophylaxis in Pregnancy

13:15

Speaker: Shannon M. Bates (Canada)

Scientific Programme

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 11

Managing Authorship and Collaborative Research

Professor Morrissey has published more than 200 scientific papers, reviews and book chapters. As of January 2019, he and Dr. David Lillicrap will take over as the new Editors-in-Chief of the Journal of Thrombosis and Haemostasis. For much of his research career, he has participated in and managed collaborations, both large and small. He is delighted to share his experiences and insights in collaborative research and scientific publishing.

Managing Authorship and Collaborative Research

13:15

Speaker: James H. Morrissey (United States)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 12

Abstract Writing Workshop

I am a PhD prepared nurse working in the area of pediatric thrombosis and anticoagulation management. I have over 20 publications and have had more than 25 conference abstracts accepted. This workshop will guide nurses in the communication of outputs from clinical practice to conference audiences via clear abstract writing.

Abstract Writing Workshop

13:15

Speaker: Sophie E. Jones (Australia)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 13

Cohort and Case-Control Studies: Role, Design, and Interpretation

Dr. Eikelboom is a Clinician Scientist with an interest in antithrombotic therapy for arterial and cardiac indications. He has conducted small and large randomized trials, most of which were aimed at determining the efficacy and safety of therapeutic interventions. On many occasions, the design of these trials was informed by first performing a case-control or cohort study.

Cohort and Case-Control Studies: Role, Design, and Interpretation

13:15

Speaker: John Eikelboom (Canada)

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 14

Using Visual Abstracts to Increase Your Scientific Impact

Social media can be a powerful tool to spread the word about your scientific contributions. In this workshop, we will discuss the use of Visual Abstracts to increase the reach and impact of your scientific work. We will also discuss how these principles may be applicable to more traditional scientific engagement, such as poster and podium presentations at scientific meetings. Dr. Barnes currently serves as the social media editor for the journal Vascular Medicine.

Using Visual Abstracts to Increase Your Scientific Impact

13:15

Speaker: Geoffrey Barnes (United States)

Scientific Programme

Career Development Sessions
13:15 - 14:15

Exhibition Hall Meeting Room 15

Planning a Career in Coagulation

The following aspects are relevant for a successful clinical scientific career in Coagulation: 1) solid clinical training; 2) introduction in clinical/translational research in an experienced institute, preferably with the possibility of completing a PhD; 3) dedication to the topic; 4) identification of one aspect of coagulation in which you can excel on national/international level; and last but not least finding a mentor that can help you focus and introduces you to coagulation society

Planning a Career in Coagulation **13:15**
Speaker: Frederikus Klok (the Netherlands)

Oral Communication Session
14:45 - 16:00

Plenary Hall

OC 60, Hemophilia Novel Therapies 2

Chair: Michael Makris (United Kingdom)
Chair: Liane Khoo (Australia)

Surgical Experience from Four Phase III Studies (HAVEN 1-4) of Emicizumab in Persons with Haemophilia A (PwHA) With or Without FVIII Inhibitors **14:45**

Speaker: Elena Santagostino (Italy)

Emicizumab Treatment is Efficacious and Well Tolerated Long Term in Persons with Haemophilia A (PwHA) with or without FVIII Inhibitors: Pooled Data from Four HAVEN Studies **15:00**

Speaker: Michael Callaghan (United States)

A Single-arm, Multicentre, Open-Label, Phase III Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Persons with Haemophilia A (PwHA) with FVIII Inhibitors (STASEY): Interim Analysis Results **15:15**

Speaker: Victor Jiménez-Yuste (Spain)

Correcting Bleeding Disorders Using Blood Clotting Factors Produced in vivo by Shielded Engineered Allogeneic Cells **15:30**

Speaker: David Peritt (United States)

Development of a Formulation for Oral Delivery of FVIII via a Robotic Pill **15:45**

Speaker: Gerald Schrenk (Austria)

Oral Communication Session
14:45 - 16:00

Melbourne Room 1

OC 61, ADAMTS13 and Microangiopathies

Chair: Masanori Matsumoto (Japan)
Chair: Flora Peyvandi (Italy)

Efficacy of Recombinant ADAMTS13 (TAK-755/SHP655) in a Humanized Mouse Model for Sickle Cell Disease **14:45**

Speaker: Werner Hoellriegl (Austria)

Scientific Programme

Pregnancy Outcomes in Patients with Atypical Haemolytic Uraemic Syndrome	15:00
Speaker: Marie Scully (United Kingdom)	
Age at First Disease Manifestation in Relation to Residual ADAMTS13 Activity in Patients with Congenital Thrombotic Thrombocytopenic Purpura	15:15
Speaker: Erika Tarasco (Switzerland)	
Successful Treatment of Pregnant Patients with Congenital Thrombotic Thrombocytopenic Purpura Using Prophylactic Fresh Frozen Plasma Infusion	15:30
Speaker: Kazuya Sakai (Japan)	
Genetic Landscape in Korean Adult Patients with Atypical Hemolytic Uremic Syndrome	15:45
Speaker: Jae Won Yun (Korea, Republic of)	

Oral Communication Session
14:45 - 16:00

Melbourne Room 2

OC 62, Rare Bleeding Disorders

Chair: Michiel Coppens (the Netherlands)
Chair: Alfonso Iorio (Canada)

A Test of the GPIIb/IIIa β-switch Hypothesis for Platelet-type von Willebrand Disease	14:45
Speaker: Matthew Auton (United States)	
Evaluation of Different Therapeutic Strategies to Manage the Rare Coagulation Defect Induced by Thrombomodulin c.1611C>Ap.Cys537Stop Mutation	15:00
Speaker: Gael Beverley Morrow (United Kingdom)	
Acquired Haemophilia A: 25 Years of Experience in The Netherlands	15:15
Speaker: Sarah Schep (the Netherlands)	
Rare Bleeding Disorders in the Netherlands - Update	15:30
Speaker: Joline L. Saes (the Netherlands)	
Emicizumab for the Treatment of Acquired Hemophilia A	15:45
Speaker: Paul Knoebl (Austria)	

Oral Communication Session
14:45 - 16:00

Meeting Room 203/204

OC 63, VTE: Risk Stratification

Chair: Paul A. Ockelford (New Zealand)
Chair: Raymond S. Wong (Hong Kong)

Scientific Programme

Diagnosis of Pulmonary Embolism Using D-Dimer Thresholds Selected According to Clinical Pre-Test Probability	14:45
Speaker: Kerstin de Wit (Canada)	
Predicting venous Thromboembolism Risk after Immobilization of the Lower-limb for Trauma: Update and Validation of a Clinical Risk Assessment Model, the TRiP(Cast) Score	15:00
Speaker: Delphine Douillet (France)	
Machine-learning Algorithms Can Improve upon Current Methods of Risk-stratification of Patients Presenting with Suspected Deep Vein Thrombosis	15:15
Speaker: John Willan (United Kingdom)	
External Validation of Radiological Signs of Chronic Thromboembolic Pulmonary Hypertension on Computed Tomography Pulmonary Angiography at the Time of Suspected Pulmonary Embolism	15:30
Speaker: Duliëtte Boon (the Netherlands)	
Acute Submassive Pulmonary Embolism is Not Associated with an Increased Rate of Chronic Thromboembolic Pulmonary Hypertension	15:45
Speaker: Hannah Stevens (Australia)	

Oral Communication Session
14:45 - 16:00

Meeting Room 210/211

OC 64, Laboratory Diagnostics Platelets

Chair: Ian Jennings (United Kingdom)
Chair: David Connor (Australia)

CLOTSref: A Mobile Application for Standardized Reference Ranges in Developmental Haemostasis	14:45
Speaker: Paul Thuan Tieu (Canada)	
Mepacrine Uptake Can Be Used in the Diagnosis of Platelet Dense Granule Deficiency	15:00
Speaker: Rolf T. Urbanus (the Netherlands)	
Fibrinolysis in Patients with Chemotherapy Induced Thrombocytopenia and the Effect of Platelet Transfusion	15:15
Speaker: Floor Heubel-Moenen (the Netherlands)	
High-throughput Sorting of Platelet Aggregates by Intelligent Image-activated Cell Sorting	15:30
Speaker: Atsushi Yasumoto (Japan)	
The Prevalence of Giant Platelets in Children without Platelet Disorders on Screening Blood Counts	15:45
Speaker: Michele Lambert (United States)	

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 212/213

OC 65, Insights From Cellular and Animal Models

Chair: Yujiro Asada (Japan)
Chair: Yu Ping Yuan (Australia)

- | | |
|---|--------------|
| Development of a Novel Peptide Tracer for Detection of Cardiac Fibrosis and Atrial Fibrillation Using Mouse Models of Cardiomyopathies | 14:45 |
| Speaker: Be'eri Niego (Australia) | |
| Possible Indicators for High Shear Thrombosis: An Enlarged Cell-free Layer and High Shear Rate | 15:00 |
| Speaker: Britt Johanna Maria van Rooij (the Netherlands) | |
| Investigation of Recanalization and Cerebral Perfusion with Adjunctive Thrombolytic Therapies in the iCAT Mouse Model of Ischemic Stroke | 15:15 |
| Speaker: Jessica Maclean (Australia) | |
| Slc44a2 Deficient Mice Exhibit Less Severity of Thrombosis in a Stenosis Model of DVT | 15:30 |
| Speaker: Chrissta Maracle (the Netherlands) | |
| Prophylactic Inhibition of Factor XI Contact Activation Enhances Deep Vein Thrombosis Resolution in an in vivo Model of Inferior Vena Caval Constriction | 15:45 |
| Speaker: Khanh Nguyen (United States) | |

Oral Communication Session
14:45 - 16:00

Meeting Room 219/220

OC 66, Mechanism of Thrombosis

Chair: Jonas Emsley (United Kingdom)
Chair: Mike Wu (Australia)

- | | |
|---|--------------|
| Identification of Amino Acids that are Crucial for FXIII-A Subunit Interactions and Stability | 14:45 |
| Speaker: Bojun Li (Switzerland) | |
| Potential Multifactorial Mechanisms for Hormone-induced Venous Thromboembolism | 15:00 |
| Speaker: Jordan Shavit (United States) | |
| DNase-dependent but NETs-independent Pathway of Thrombus Formation in vivo | 15:15 |
| Speaker: Estelle Carminita (France) | |
| Identification of a Possible Allosteric Disulfide in the αIIbβ3 Integrin | 15:30 |
| Speaker: Aster E. Pijning (Australia) | |
| Platelet but Not Plasma Protein S Limits Thrombus Growth in Large Veins but Not in Large Arteries by Controlling Coagulation in situ | 15:45 |
| Speaker: Sara Calzavarini (Switzerland) | |

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 105

OC 67, VWF Biology

Chair: José López (United States)
Chair: Caterina Casari (France)

Knockout of von Willebrand Factor in Zebrafish by CRISPR/Cas9 Mutagenesis	14:45
Speaker: Pudur Jagadeeswaran (United States)	
The Crystal Structure of Monomeric D'D3 Reveals Principles of VWF Concatemer Formation and its Interaction with FVIII	15:00
Speaker: Nina C. Leksa (United States)	
von Willebrand Factor Induces Human Vascular Smooth Muscle Cells Proliferatio through Low Density Lipoprotein-related Receptor Protein 4 and $\alpha\beta$3 Integrin	15:15
Speaker: Cecile Denis (France)	
Mapping the Interaction with Vwf and Fxii and Its Potential as a New Anti-coagulant Target	15:30
Speaker: Patricia Henne (United Kingdom)	
VWFA1 Interacts with Scavenger Receptor LRP1 via Lysine 1408	15:45
Speaker: Alain Chion (Ireland)	

Oral Communication Session
14:45 - 16:00

Meeting Room 106

OC 68, Protease Activated Receptors

Chair: Justin Hamilton (Australia)
Chair: Samantha J. Montague (Australia)

FXa Inhibitors Target Tumor-associated Macrophage FXa-PAR2 Signaling	14:45
Speaker: Claudine Graf (Germany)	
Protease Activated Receptor 4 Activation Requires a Coordinated Rearrangement of Extracellular Loop 3 and Thr153 in the Ligand Binding Site Formed by TM3 and TM7	15:00
Speaker: Xu Han (United States)	
Protease-activated Receptor 4 Protects Mice against H1N1 Influenza A Virus Infection	15:15
Speaker: Silvio Antoniak (United States)	
A Thrombin-PAR1/2 Positive Feedback Loop Amplifies TLR3-mediated Endothelial Procoagulant and Proinflammatory Responses	15:30
Speaker: Saravanan Subramaniam (United States)	
Suppression of Human Macrophage NLRP3 Inflammasome Activity by Activated Protein C or by PAR1-derived and PAR3-derived Peptides	15:45
Speaker: Laura Healy (United States)	

Scientific Programme

Oral Communication Session
14:45 - 16:00

Meeting Room 109/110

OC 69, Platelet Structure and Function

Chair: Dermot Kenny (Ireland)
Chair: Michael Berndt (Australia)

Platelet Deficiency of ERp5 is Compensated for by Increased Levels of ERp57 and PDI	14:45
Speaker: Angelina Lay (Australia)	
Impact of miR-204 on Human Platelet-like Structures	15:00
Speaker: Alix Garcia (Switzerland)	
Platelet Lamellipodia Formation Is Not Required for Thrombus Formation and Stability	15:15
Speaker: Yvonne Schurr (Germany)	
Platelet Actomyosin Response to Flow or Substrate Stiffness-Induced Biomechanical Forces	15:30
Speaker: David Bark (United States)	
Using a Mathematical Model of Platelet Aggregation in an Extravascular Injury to Investigate Modifiers of Primary Hemostasis	15:45
Speaker: Keith Neeves (United States)	

SSC Session
16:30 - 18:30

Melbourne Room 1

Disseminated Intravascular Coagulation

Disseminated Intravascular Coagulation in Non-Human Primate Models of Sepsis	16:30
Speaker: Florea Lupu (United States)	
What Vitamin C Is Purported to Do?	16:50
Speaker: Donald Brophy (United States)	
Clot Wave Form Analysis for Disseminated Intravascular Coagulation	17:10
Speaker: Hideo Wada (Japan)	
Recombinant Thrombomodulin for Sepsis-Induced Coagulopathy	17:25
Speaker: Kazuma Yamakawa (Japan)	
Dessiminated Intravascular Coagulation in Your Emergency Room	17:40
Speaker: Bernd Jilma (Austria)	
Constructing the Japanese Guidelines for Sepsis Management 2020	18:00
Speaker: Yutaka Umemura (Japan)	
Assessment of Fibrinolysis in Sepsis	18:15
Speaker: Ecaterina Scarlatescu (Romania)	

Scientific Programme

SSC Session
16:30 - 18:30

Melbourne Room 2

Predictive and Diagnostic Variables in Thrombotic Disease

Updates on On-Going Projects Moderators: Kerstin de Wit
<i>Canada</i>, John-Bjarne Hansen <i>Norway</i>

Welcome 16:30

Speaker: John-Bjarne Hansen (Norway)

Standardized Definition for the Diagnosis of Death from Venous Thromboembolism in Clinical Studies 16:40

Speaker: Tobias Tritschler (Canada)

Definition of Diagnostic Criteria and Classification of Subsegmental Pulmonary Embolism 17:00

Speaker: Frederikus Klok (the Netherlands)

Q&A session 17:20

New Project Initiatives Moderators: Marc Righini <i>Switzerland</i>, Cecilia Becattini <i>Italy</i>

Standardization of Diagnostic Assessment for Venous Thrombolism in Cancer 17:25

Speaker: Kerstin de Wit (Canada)

Standardized Assessment of Bleeding Risk in Venous Thromboembolism Patients Initiating Anticoagulant Treatment 17:40

Speaker: Geert-Jan Geersing (the Netherlands)

Biomarkers for and Prediction of Venous Thromboembolism After Stroke 17:55

Speaker: Vania Morelli (Norway)

Prediction of Death in Acute Pulmonary Embolism 18:10

Speaker: Cecilia Becattini (Italy)

Q&A session 18:25

SSC Session
16:30 - 18:30

Meeting Room 203/204

Plasma Coagulation Inhibitors

Moderators: Zsuzsanna Bereczky <i>Hungary</i>, Vera Ignjatovic
<i>Australia</i>

New Classification of Protein S Deficiency - Role as a Co-factor of Tissue Factor Pathway Inhibitor 16:30

Speaker: Herm Jan Brinkman (the Netherlands)

Natural Changes in Natural Anticoagulants 16:50

Speaker: Vera Ignjatovic (Australia)

Laboratory Diagnosis and Phenotypic Characterization of Antithrombin Deficiency and Antithrombin Deficiency Registry 17:10

Speaker: Zsuzsanna Bereczky (Hungary)

Scientific Programme

Moderators: Cecilia Guillermo <i>Uruguay</i>, Jun Teruya <i>United States</i>

Interference with Classical Methods 17:40

Speaker: Cecilia Guillermo (Uruguay)

New Method to Test Protein S 17:55

Speaker: Eriko Morishita (Japan)

Use of Protein C Concentrates 18:05

Speaker: Leonardo Brandão (Canada)

Discussion for Future Projects 18:25

Speaker: Jun Teruya (United States)

SSC Session
16:30 - 18:30

Meeting Room 210/211

Genomics in Thrombosis and Hemostasis

Introduction 16:30

Speaker: Kathleen Freson (Belgium)

Genetics for Rare Bleeding and Platelet Disorders

Tier1 Genes and Gold Variants for Bleeding, Thrombotic and Platelet Disorders 16:32

Speaker: Karyn Megy (United Kingdom)

The ClinGen Working Group for Thrombosis and Hemostasis 16:47

Speaker: Jorge A. Di Paola (United States)

Diagnostics of Inherited Thrombocytopenia: A Clinical Perspective 17:02

Speaker: Patrizia Noris (Italy)

Ethical Considerations When Applying Gene Panel Tests for Platelet Disorders 17:17

Speaker: Andreas Greinacher (Germany)

Genetics for Complex Bleeding and Platelet Disorders

French Genomics Initiatives for Rare and Common Venous Thrombosis 17:32

Speaker: Pierre Emmanuel Morange (France)

Whole Genome Sequencing Study for Platelet Function 17:47

Speaker: Andrew Johnson (United States)

Complex Genetics for Platelet Traits 18:02

Speaker: Willem H. Ouwehand (United Kingdom)

Genetic Control of Platelet Gene Expression 18:16

Speaker: Leonard Edelstein (United States)

Scientific Programme

SSC Session
16:30 - 18:30

Meeting Room 212/213

Fibrinolysis

Update and Proposal of Standardization Projects	16:30
Speaker: Matthew Locke (United Kingdom)	
SSC Project Update: Validation of the t-AUCi Parameter Using ROTEM to Assess Fibrinolytic Resistance in Septic Patients	16:45
Speaker: Ecaterina Scarlatescu (Romania)	
Trauma Induced Coagulopathy: The Need for Nomenclature Standardization	17:00
Speaker: Satoshi Gando (Japan)	
Finding Consensus in Defining Trauma Induced Coagulopathy: Part 1	17:15
Speaker: Hunter Moore (United States)	
Finding Consensus in Defining Trauma Induced Coagulopathy: Part 2	17:30
Speaker: Beverley J. Hunt (United Kingdom)	
Bridging the Gap to Find Consensus on Trauma Induced Coagulopathy Nomenclature: Updates from the Tranexamic Acid/Trauma Symposia	17:45
Speaker: Dominik Drexler (Switzerland)	
Open Discussion: SSC Consensus Statement on Trauma Induced Coagulopathy	18:00
Speaker: Paul Kim (Canada)	

SSC Session
16:30 - 18:30

Meeting Room 219/220

Women's Health Issues in Thrombosis and Hemostasis

Women and Bleeding Moderators: Emmanuel Favaloro <i>Australia</i>, Maha Othman <i>Canada</i>	
Welcome: Outline of the Women's SSC and Overview of Activities	16:30
Speaker: Maha Othman (Canada)	
Challenges in the Management of Von Willebrand Disease in Pregnancy: Results from an International Survey	16:40
Speaker: Michelle Lavin (Ireland)	
Hemophilia Carrier Nomenclature: Proposed Terminology to Improve Communication	16:55
Speaker: Robert Sidonio (United States)	
Setting Standards for Appropriate and Necessary Care for Young Women with Heavy Menstrual Bleeding and Bleeding Disorders: An International Panel Survey	17:10
Speaker: Ayesha Zia (United States)	
Women and Thrombosis and Complex Pathologies Moderators: Predrag Miljic <i>Serbia</i>, Robert Francis Sidonio Jr. <i>United States</i>	

Scientific Programme

The MAPP Registry: Thrombolysis and Invasive Treatments for Massive Pregnancy-Related Pulmonary	17:25
Speaker: Marc Blondon (Switzerland)	
The Role of Tissue Plasminogen Activator in Reproductive and Depressive Disorders: The Hibernation Model	17:40
Speaker: Silvia Hoirisch-Clapauch (Brazil)	
A New Algorithm Based on Thrombin Generation to Assess Hormone-Related Prothrombotic Changes	17:55
Speaker: Jonathan Douxfils (Belgium)	
International Registry on Disseminated Intravascular Coagulation in Pregnancy	18:10
Speaker: Offer Erez (Israel)	
Concluding Remarks	18:25
Speaker: Maha Othman (Canada)	

Nurses Forum
16:30 - 18:30

Meeting Room 111/112

Nurses Forum Day 3: Global Needs Assessment Workshop

We encourage you to review [these materials](#) prior to the session.

Chair: Kate Khair (United Kingdom)
Chair: Fiona Newall (Australia)

Global Needs Assessment: Study Results and Future Directions	16:30
Speaker: Fiona Newall (Australia) Speaker: Kate Khair (United Kingdom)	
Breakout Discussion Groups	17:00
Speaker: Regina Butler (United States) Speaker: Maura Malone (United States) Speaker: James E. Munn (United States)	

Posters
18:30 - 19:30

Exhibition Hall

Poster Networking Session

Arterial Thromboembolism - Atrial Fibrillation

Design of the FRAIL-AF Trial: Safety of Switching from VKA to DOAC in Frail Elderly with Atrial Fibrillation

Speaker: Linda Joosten (the Netherlands)

PCSK9 as a Predictor of Cardiovascular Events in Atrial Fibrillation: Role of Platelet Activation

Speaker: Pasquale Pignatelli (Italy)

Scientific Programme

Intracardiac Blood Sampling Reveals a Better Inhibition of Hemostasis Activation by Dabigatran as Compared to Vitamin K Antagonists during Cryoballoon Catheter Ablation in Atrial Fibrillation

Speaker: Zsuzsa Bagoly (Hungary)

The Differences of Clinical Effect on Bone Density between Non-vitamin K Oral Antagonist (NOAC) and Vitamin K Antagonist (VKA)

Speaker: Kengo Ayabe (Japan)

The Effect of Fasting Ramadan on the Efficacy and Safety of Oral Anticoagulants

Speaker: Fakhr Alayoubi (Saudi Arabia)

Arterial Thromboembolism - Cardiovascular Risk Factors

Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Events: Translating Basic Science into Clinical Benefit

Speaker: Calin Pater (Switzerland)

The Mortality Outcomes and Survival Patterns of Myeloproliferative Neoplasm Registry in Malaysia

Speaker: Yee Yee Yap (Malaysia)

Acetaldehyde Reduces Blood Fluidity by Activating Leukocyte Adhesion and Platelet Aggregation

Speaker: Haruchi Namba (Japan)

A Diabetic Microvascular Whole Blood Flow Model as a New Tool to Study Diabetes-associated Thrombotic Complications

Speaker: Verena Schroeder (Switzerland)

Frequency of Arterial Thromboembolism in Patients with Cancer: A Systematic Review

Speaker: Allen Li (Canada)

Combination of High Levels of Fibrinogen and High Sensitivity C-reactive Protein Enhances Risk of Acute Coronary Syndrome

Speaker: Chananikan Makmool (Thailand)

Demographic, Clinical and Hematological Predictors of Carotid Atherosclerotic Plaque Histology

Speaker: Gian Luca Salvagno (Italy)

Endocan and Homocysteine Levels in Brazilian Renal Transplant Recipients

Speaker: Luci Dusse (Brazil)

An Intracardiac Thrombus Associated with Antithrombin Deficiency with a Novel Mutation c.1063T>G in SERPINC1

Speaker: Yacine Larfi (Algeria)

Cardiovascular Diseases and Use of Antithrombotic Agents in Patients with End-stage Renal Disease on Hemodialysis: Cross-sectional Results of the Vienna InVestigation of Atrial Fibrillation and Thromboembolism in HemoDialysis Patients (VIVALDI)

Speaker: Oliver Königsbrügge (Austria)

Platelet Indices and Cardiovascular Events: Prospective Findings from the CAMELIA Study

Speaker: Marco Cattaneo (Italy)

Arterial Thromboembolism - Peripheral Vascular Disease

Scientific Programme

Regulation of Smooth Muscle Cell Phenotype and Neointima Formation by Endothelial Cell-secreted MicroRNA-21

Speaker: Mao Luo (China)

Elevated Circulating Levels of ANGPTL8 Are Associated with Thoracic Aortic Dissection and hs-CRP

Speaker: Yanwen Qin (China)

Thrombin Generation and Cardiovascular Events in Patients with Peripheral Arterial Disease and Patients with Abdominal Aortic Aneurysm

Speaker: Daniela Calderaro (Brazil)

Arterial Thromboembolism - Stroke

Experiences in Carotid Artery Dissection in Children

Speaker: Patcharee Komvilaisak (Thailand)

Audit of the Use of the GEKO Device on an Acute Stroke Unit (ASU)

Speaker: Sue Rhodes (United Kingdom)

Immunohistologic Analysis of von Willebrand Factor in Thrombi Retrieved from Patients with Acute Ischemic Stroke

Speaker: Hisao Shimizu (Japan)

Rheological and Hemostatic Aspects of Venous Thromboembolism in Patients with Severe Stroke

Speaker: Kostiantyn Stepanchenko (Ukraine)

Augmented and Synergistic Effect of Factor V Leiden (FVL) and MTHFR Genes Polymorphisms and Platelet Activity and Reactivity as Risk Factors for Ischemic Cerebrovascular Stroke (IS)

Speaker: Alaa Eldin Abdelhamid (Egypt)

Performance of Point-Of Care INR as Part of Pre-Thrombolysis Laboratory Panel

Speaker: Tuukka Helin (Finland)

Isolated A2 Domain of von Willebrand Factor Binds to Stimulated Endothelial Cells via Vimentin, Promoting Cell Signals

Speaker: Marina Martinez-Vargas (United States)

Using Machine Learning for Predicting Length of Hospital Stay after Stroke Diagnosis, Survival, Stroke Type and Post-stroke Depression

Speaker: Mohamed Osman (Egypt)

Patients with High Post-endovascular Treatment Plasma Levels of Neutrophil Activation Markers Are at Higher Risk of Poor Functional Outcome, HT and Mortality

Speaker: Martine Jandrot-Perrus (France)

Coagulation and Anticoagulation - Cellular Mechanisms of Hemophilia

The Role of HLA-class-II (HLAII) Molecules in Determining the Immunogenicity Potential of Therapeutic Factor VIII Proteins (tFVIIIs) in Hemophilia A (HA): The Gate Keeper Hypothesis

Speaker: Vincent P. Diego (United States)

Modulation of the FVIII-specific Immune Response by CD4+CD25+Foxp3+ Regulatory T Cells

Speaker: Mirjam Meissner (Germany)

Coagulation and Anticoagulation - FVIII and FIX Basic and Laboratory

Scientific Programme

Assessment of Single-factor Deficiency Sensitivity of Three APTT Reagents

Speaker: Claire Martin (France)

Toll-like Receptor 9 Activation Robustly Enhances Germinal Center and Inhibitor Formation in Response to Factor VIII

Speaker: Radoslaw Kaczmarek (United States)

The Calibrated Automated Thrombinography for Hemophilia Treatment Monitoring

Speaker: Natalya Silina (Russian Federation)

Comparison of Factor VIII Half-life as Determined Using Two Web-accessible Population-based Pharmacokinetic Applications

Speaker: Jerome Teitel (Canada)

Functional Characterization of a Novel vWF-independent Long-acting FVIII (MG1121)

Speaker: Changsun Yu (Korea, Republic of)

Laboratory Measurement of Emicizumab Requires a Product Specific Calibrator

Speaker: Helen Wilmot (United Kingdom)

Thrombin-mediated Activation of Factor VIII is Insufficient to Produce All Necessary Cofactor Activity in vivo

Speaker: Ivan Peyron (France)

The Traceability of Commercial Plasma Calibrators to the Plasma International Standard for Factor IX

Speaker: Helen Wilmot (United Kingdom)

Heterogeneity in Levels of FVIII and VWF Expression in Subpopulations of Human Endothelial Cells

Speaker: David Lillicrap (Canada)

Mapping of Coagulation Factor IX Binding Site on Collagen Toolkits II, III and XIII

Speaker: Samir Hamaia (United Kingdom)

Recombinant FVIII-neutralising Antibodies: Characteristics and Application in Product Testing and ex-vivo Models of Haemophilia A

Speaker: Carmen Coxon (United Kingdom)

Paediatric Factor VIII and IX Reference Intervals using STA®-ImmunoDef VIII and STA®-ImmunoDef IX

Speaker: Natasha Letunica (Australia)

Additive Effect on the Global Clotting Function in Moderate/Mild Hemophilia A by Addition of Emicizumab, Evaluated by Clot Waveform Analysis

Speaker: Yuto Nakajima (Japan)

PBMCs from Healthy Individuals Respond Stronger and Differently towards FVIII than towards Myelin-oligodendrocyte Glycoprotein

Speaker: Christoph Königs (Germany)

Coagulation and Anticoagulation - Hemostasis and Organ Dysfunction

Relationship of Markers of Inflammation, Infection, and Endothelial Function to Mortality and Severity of Coagulopathy in Patients with Sepsis-associated DIC

Speaker: Matthew Rondina (United States)

Scientific Programme

Thrombin Time Test of Patients with Liver Disease Attending Medicine Outpatient Department UCTH, Calabar, Nigeria

Speaker: Dorothy Chioma Okpokam (Nigeria)

Increased Platelet Contribution to Clot Strength in Cirrhotic Patients with Non-malignant Recent Portal Vein Thrombosis

Speaker: Ecaterina Scarlatescu (Romania)

ERK Activation was Associated with Transfusion-related Acute Lung Injury in C-reactive Protein-enhanced Antibody-mediated Murine Model of Transfusion-related Acute Lung Injury

Speaker: Chih-Chun Chang (Taiwan, Republic of China)

Haemostatic Profiles and Hepatic Dysfunction in Fontan Patients

Speaker: Vera Ignjatovic (Australia)

Effects of Acute Liver Failure of Yellow Fever Infection on Haemostasis Assessed by Thromboelastometry

Speaker: Letícia Lemos Jardim (Brazil)

Clinical and Laboratory Profile of the Bleeding Diathesis in Yellow Fever Infection

Speaker: Letícia Lemos Jardim (Brazil)

Intraperitoneal Activation of the Coagulation System via Tissue Factor-exposing Extracellular Vesicles and Enhanced Fibrinolysis in Patients with Advanced Chronic Liver Disease and Ascites

Speaker: Johannes Thaler (Austria)

Evaluation of Endothelial Dysfunction and Hypercoagulability Markers in Sickle Cell Anemia Patients with and without Hydroxyurea Therapy

Speaker: Erich Vinicius de Paula (Brazil)

Coagulation imbalance in patients with Acute-on-Chronic Liver Failure (ACLF) measured by global and classical coagulation tests

Speaker: Elena Campello (Italy)

ADAMTS-13 and Von Willebrand Factor Involved in Portal Vein Thrombosis Development in Cirrhotic Patients

Speaker: Monica Sacco (Italy)

Coagulation Status of Critically Ill Patients with Liver Disease Assessed Using a Novel Thrombin Generation Analyser

Speaker: Gael Beverley Morrow (United Kingdom)

Increased Parameters of Thrombin Generation in Patients with Chronic Urticaria that Associate Angioedema

Speaker: Julia Oto (Spain)

A Novel Plasma Panel for the Assessment of Chronic Liver Disease Severity

Speaker: Vladimir Bogdanov (United States)

Coagulation and Anticoagulation - Protein C/S Pathway

Efficiency of Anticoagulant Protein C System in Patients with Primary Myelofibrosis

Speaker: Olesia Matvienko (Russian Federation)

Scientific Programme

Assessment of Second and Third Generation Oral Contraceptives APC Resistance by a Newly Validated ETP-Based APC Resistance Assay: A Pilot Study

Speaker: Laure Morimont (Belgium)

Assessment of Thrombomodulin Resistance in Women Using Second Generation, Third Generation and Progestin-Only Contraceptives

Speaker: Laure Morimont (Belgium)

Validation of an Original ETP-based APC Resistance Assay for the Evaluation of Prothrombotic States

Speaker: Laure Morimont (Belgium)

Data Interpretation of the ETP-based APC Resistance Assay and the Concept of nAPCsr10, an Improved nAPCsr

Speaker: Laure Morimont (Belgium)

Detection of Direct Intramembrane Interaction between the Endothelial Protein C Receptor and Thrombomodulin

Speaker: Ingmar Schoen (Ireland)

Endothelial Protein C Receptor (EPCR) Levels and EPCR Gene A3 Haplotype in Patients with Sickle Cell Anemia

Speaker: Anil Tombak (Turkey)

Understanding the Mechanisms of Acquired Protein S Deficiency in Sickle Cell Disease

Speaker: Morayma Reyes Gil (United States)

Assessment of the APC Resistance Measured by Thrombin Generation and Clot Waveform Analysis: A Pilot Study

Speaker: Jonathan Evrard (Belgium)

Clinical Presentation and Management of Homozygous Protein C Deficiency: Case Study

Speaker: Hatice Ilgen Sasmaz (Turkey)

New, Highly Sensitive and Specific Multiplatform Latex Automated Turbidimetric Assay for Measurement of Free Protein S in Plasma

Speaker: Claire Dunois (France)

Polymorphisms in Non-coding Regions of the Protein C Gene Regulate Plasmatic Protein C Levels

Speaker: Julia Oto (Spain)

Coagulation and Anticoagulation - Regulation of Coagulation

Competitive Binding, and Accounting for Procoagulant Platelets, Significantly Change Thrombin Profiles in *in vitro* Coagulation

Speaker: Mohan Anand (India)

New Functional Test for the TFPI α Cofactor Activity of Protein S Working in Synergy with FV-Short

Speaker: Björn Dahlbäck (Sweden)

The Regulation of Blood Coagulation with Lysine Peptides in Oral and Intranasal Administration

Speaker: Ludmila Lyapina (Russian Federation)

Scientific Programme

Determining the Contribution of FXa Activation of FV to Thrombin Generation Using TIX-5: Variation in Healthy Controls and Association of High TIX-5 Sensitivity with Complications in Patients on Vitamin K Antagonists (VKAs)

Speaker: Anja Maag (the Netherlands)

Thrombosis Initiation Examined through a Flexible 3D non-Newtonian Computational Framework

Speaker: Sabrina R. Lynch (United States)

Myeloperoxidase (MPO) Neutralizes the Procoagulant Activity of Extracellular DNA Derived from Polymorphonuclear Leukocytes (PMNs)

Speaker: Lennart Beckmann (Germany)

A Proximity-based in silico Approach to Identify Redox-labile Disulfide Bonds: The Example of FVIII

Speaker: Carmen Coxon (United Kingdom)

Identification and Molecular Characterization of Alternatively Spliced Novel Isoforms of Human Antithrombin Gene

Speaker: Sayeed Ur Rehman Abul Kalam (India)

Effect of Catechins on Blood Coagulation and on Various Proteins Related to the Regulation of Blood Coagulation Which Are Produced in HepG2 Cells

Speaker: Tatsuya Hayashi (Japan)

Defective Zn²⁺ Homeostasis in Mouse and Human Platelets with α - and δ -storage Pool Disorders

Speaker: Elmina Mammadova-Bach (Germany)

Heme Induces Expression and Activation of Hematopoietic Tissue Factor via TLR4 and PDIA3-dependent Signaling Pathways

Speaker: Erich Vinicius de Paula (Brazil)

Crosslinking of Poly(vinyl) Alcohol Hydrogels Determines Material Thrombogenicity

Speaker: Novella Bates (United States)

Coagulation and Anticoagulation - Thrombosis Beyond Hemostasis

The Procoagulant Activity on Diabetic Nephropathy Induced by Streptozotocin in Rats

Speaker: Meixia He (China)

Diagnostics and OMICs - Biomarkers of Thrombosis and Haemostasis

Longitudinal Evaluation of Plasma Circulating Microparticles and Serum Biomarker Levels in Women Destined to Develop Preeclampsia

Speaker: Shrimati Shetty (India)

Investigation of Pharmacodynamic Biomarkers and Neutralizers for ONO-7684 (ONO-5450598), an Oral FXIa Inhibitor

Speaker: Sho Kouyama (Japan)

Abstract 1: Assessment of Validated Risk Assessment Models and a Biomarker Ubiquitous in Routine Clinical Care to Identify Hospitalized Medical Patients at Risk for 90-day Post-discharge Venous Thromboembolism

Speaker: Scott Woller (United States)

Laboratory Marker of Hypercoagulability: A Ratio Combining Thrombin-generation with Fibrin-clot-Formation

Speaker: Debora Bertaggia Calderara (Switzerland)

Scientific Programme

Antiphospholipid Antibodies and Thrombosis in BCR-ABL Negative Myeloproliferative Neoplasms

Speaker: Rolandas Gerbutavičius (Lithuania)

Soluble P-selectin Level in Diagnosis of Deep Vein Thrombosis in Adult Myanmar Population

Speaker: May Thandar Oo (Myanmar)

Variation of rs3754689 at Lactase Gene and Inhibitors in Admixed Brazilian Patients with Hemophilia A

Speaker: Daniel G. Chaves (Brazil)

Effect of Standard and Intensive Insulin Therapy on Membrane-Bound Tissue Factor and Plasma Coagulation Biomarkers in Patients with Hyperglycemia and Acute Stroke: Differential Effects of rtPA Administration

Speaker: A Koneti Rao (United States)

Global Coagulation Assays in Transgender Individuals

Speaker: Hui Yin Lim (Australia)

Compared with P-selectin and Lysosomal Associated Membrane Protein 3, TREM-like Transcript 1 is a More Sensitive Marker of Platelet Activation in Patients with Acute Coronary Syndromes

Speaker: Shundong Ji (China)

Absence of Measurable Contact System Activation of Coagulation during Hemodialysis: A Randomized Crossover Study

Speaker: Christelle Orlando (Belgium)

Potential Role of High-sensitive Troponin T in Identification of Patients with Pulmonary Embolism (PE) Who May Be Treated Safely at Home?

Speaker: Stephan V. Hendriks (the Netherlands)

Coagulation Activation in Sickle Cell Disease and the Effect of Hydroxyurea

Speaker: Munira Borhany (Pakistan)

Immuno-magnetic Separation Allows Antigen-specific Extraction of Microvesicle subsets for Measurement of TF-Dependent Procoagulant Activity. A Proof of Concept Using Pleural Fluids Containing Tumor-derived Vesicles

Speaker: Romaric Lacroix (France)

Global Coagulation Assays in Patients with Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance

Speaker: Rowena Brook (Australia)

A New and Rapid Assay for Intact Fibrinogen Adaptable to Existing Portable Point-of-Care Devices

Speaker: San Pun (Switzerland)

Mutational Analysis and BAT Scoring Assessment in Patients with Glanzmann's Thrombasthenia

Speaker: Kousar Perveen (Pakistan)

Abstract 2: Comparative Benefit of Adding a Biomarker Ubiquitously Available in Clinical Care to Validated Risk Assessment Models for the Identification of Hospitalized Medical Patients at Risk for 90-day Hospital-associated Venous Thromboembolism

Speaker: Scott Stevens (United States)

Scientific Programme

Age-adjusted D-dimer Cutoff for the Diagnosis of Pulmonary Embolism: A Cost-effectiveness Analysis

Speaker: Marc Blondon (Switzerland)

Relationship of type 1 Plasminogen Activator Inhibitor with Glycosilated Hemoglobin levels in type 2 Diabetic Patients - Guillermo Almenara National Hospital - ESSALUD - Lima, 2016

Speaker: Haydee Iparraguirre (Peru)

Evaluation of Hemostasis in Patients with Alzheimer'S Disease and Frontotemporal Dementia by Thrombin Generation Test

Speaker: Luci Dusse (Brazil)

Thrombin Generation test in Brazilian Renal Transplant Recipients

Speaker: Luci Dusse (Brazil)

Patterns of JAK2-V617F Testing and Predictive Value of Erythropoietin in Adult Erythrocytosis: Experience at a Comprehensive Cancer Center

Speaker: Cristhiam Mauricio Rojas Hernandez (United States)

To Describe D-Dimer Levels in Patients Receiving Direct Oral Anticoagulants with and without Suspected Recurrence of Venous Thromboembolism

Speaker: Patrick Leung (Australia)

A Newly Developed Kit for High-Sensitivity Measurement of TF-Dependent Procoagulant Activity on Microvesicles Purified by High-Speed Centrifugation

Speaker: Romaric Lacroix (France)

Biomarkers for Prediction of Thromboembolic Disease

Speaker: Mikkel Lundbeck (Denmark)

Plasma Fibrin Clot Proteomics in Healthy Subjects: Relation to Clot Permeability and Lysis Time

Speaker: Anetta Undas (Poland)

No Change in Coagulation Factor Levels after Knee Arthroscopy

Speaker: Carolina Eveline Touw (the Netherlands)

Integrated GWAS and Gene Expression Data Identifies ORM1 as Potential Regulator of Plasma Cell-free DNA Levels in Families of the GAIT2 Project

Speaker: José Manuel Soria (Spain)

Effects of Veno-venous Extracorporeal Membrane Oxygenation on Coagulation Factors - a Prospective Observational Study

Speaker: Deepa Jayakody Arachchillage (United Kingdom)

Thrombin Generation in Patients with Lower-leg Trauma or Knee Arthroscopy

Speaker: Carolina Eveline Touw (the Netherlands)

Definitions, Adjudication, and Reporting of Pulmonary Embolism-related Death in Clinical Studies: A Systematic Review

Speaker: Noémie Kraaijpoel (the Netherlands)

Diagnostic Accuracy of Four Different D-dimer Assays Additional Analyses of the YEARS Study

Speaker: Roisin Bavalia (the Netherlands)

Evaluation of Thrombin Generation in Patients with Dermatomyositis and Polymyositis

Speaker: Jerzy Dropiński (Poland)

Scientific Programme

Factors Associated with a Negative D-dimer Test in Patients Diagnosed with Acute Symptomatic Pulmonary Embolism

Speaker: Stefano Barco (Germany)

The FDP/D-dimer Ratio and LDH/Hb Ratio Are Useful to Distinguish between TTP and DIC

Speaker: Nobushiro Nishimura (Japan)

Auto- or Allo-antibodies to Hemostasis Proteins and their Patho-physiological Effects

Speaker: Jean Amiral (France)

Validation of a Profile of 4 Plasmatic Metabolites Associated with Venous Thromboembolism

Speaker: Julia Oto (Spain)

Specific Protein Plasma Profile Associated to Venous Thromboembolism

Speaker: Julia Oto (Spain)

Deep Vein Thrombosis Metabolomic Profiling by 1H NMR

Speaker: Melissa Quintero (Brazil)

Thrombin Generation in Patients Undergoing Pharmacokinetics Analysis

Speaker: Nikoleta Daskoulidou (United Kingdom)

The Predictive Value of Right Ventricle Strain Assessed by CTPA Compared to the Simplified Pulmonary Embolism Severity Index for 30 Day Mortality in Outpatients Presenting with Symptomatic Pulmonary Embolism

Speaker: Indu Raman (Australia)

Serum Lipoprotein (a) Is Not Increased in Patients with Previous Spontaneous Venous Thrombosis or Correlated with Global Fibrinolysis

Speaker: Andreza Lamônica (Brazil)

TEG-based Evaluation of Gender-associated Hypercoagulability

Speaker: Kristen Carter (United States)

Thrombin Generation and Endothelial Dysfunction in Patients with Systemic Sclerosis

Speaker: Jerzy Dropiński (Poland)

Diagnostics and OMICs - Laboratory Diagnostics: Bleeding

Assessment of Factor IX Padua Activity with a One-stage Clotting Method and with FXIa- and Tissue Factor/FVIIa-based Chromogenic Methods

Speaker: Steffen Rosén (Sweden)

Recombinant Factor IX Fused with Albumin (rFIX-HSA) is Underassigned by One-stage Methods with Silica as Contact Activator

Speaker: Steffen Rosén (Sweden)

Factor VIII, IX and XI Measurement by One Stage Clotting Assay with Silica Clotting Time Confirm reagent: A Clinical Laboratory Helpful Tool in the Presence of Lupus Anticoagulant

Speaker: Marina Sol Lopez (Argentina)

Analytical Performance of a Modified One-stage Clotting Assay for Measuring Emicizumab on Cobas t 511/711 Analyzers

Speaker: Nina Richter (Germany)

Performance Evaluation of a New Fully Automated Thrombin Generation Instrument for the Measurement of TGA in Haemophilia Samples

Speaker: Nikolaus B. Binder (Austria)

Scientific Programme

Use of Chromogenic Factor VIII Activity Determination in Haemophilia A Plasma of Patients under Emicizumab Treatment

Speaker: Nikolaus B. Binder (Austria)

Development of a Point-of-Care Diagnostic Test to Identify and Differentiate between Factor-deficient and Autoantibody-induced Hemophilia A, B and C

Speaker: Galit Frydman (United States)

Variation in one-stage coagulation reagents in FIX Extended Half-life product measurements in External Quality Control Assessment programs

Speaker: Moniek P.M. de Maat (the Netherlands)

Novel Measurement of Factor VIII by Template Matching Method Using Weighted Center on APTT Clot Waveform

Speaker: Naruto Shimonishi (Japan)

Next Generation Sequencing as a New Tool to Improve Molecular Diagnosis of VWD

Speaker: Christophe Zawadzki (France)

Evaluation of Emicizumab Calibrator and Controls with a Modified One-stage FVIII Assay on an Automated Coagulation Analyzer

Speaker: Sho Shinohara (Japan)

Discordant Collagen Binding Assay Results in a von Willebrand Disease Patient: A Novel 2M?

Speaker: Diane Zebeljan (Australia)

Discrepancy between Clotting Versus Chromogenic FVIII Procoagulant Assay Is Determined by a Combination of APTT Reagent and FVIII-Deficient Plasma

Speaker: Atsuo Suzuki (Japan)

Performance Evaluation of a Homogeneous Research Prototype Immunoassay for the Detection of Emicizumab in Human Plasma on an Automated Coagulation Analyzer

Speaker: Silke Echternacht (Germany)

Comparison of One Stage APTT FVIII Assay and Chromogenic Factor (F) VIII Assays in Patients with Severe Haemophilia A, Receiving FVIII Treatment Products

Speaker: Anne Riddell (United Kingdom)

Quantitative and Qualitative Differences Exist between APTT reagents in Clot Waveform Analysis in Haemophilic Plasma Spiked with Normal Plasma and rFVIII Products

Speaker: Geoff Kershaw (Australia)

Assays Performed on Samples Containing Emicizumab - Data from a Multicentre Study of UK NEQAS Blood Coagulation (BC) Laboratories

Speaker: Ian Jennings (United Kingdom)

Self-Administered Bleeding Assessment Tool as a Screening Test for Laboratory Testing of Bleeding Diathesis

Speaker: Deepti Warad (United States)

Fully Automated Quantitation of (Non-factor VIII) Inhibitory Antibodies

Speaker: Thomas Siegemund (Germany)

Lab Diagnosis of Inherited Bleeding Disorders in Pakistan: From Water Bath to DNA Sequencer

Speaker: Arshi Naz (Pakistan)

Diagnostics and OMICs - Laboratory Diagnostics: Platelets

Scientific Programme

Correlation of Bleeding Scores with Flowcytometry Platelet Aggregation Test in Patients with a Suspected Bleeding Disorder

Speaker: Jasmina Ahluwalia (India)

Exome Sequence Findings and Bleeding Manifestations for Uncharacterized Platelet Function Disorders with Impaired Aggregation Responses and/or Non-syndromic Dense Granule Deficiency: Results from the Hamilton Platelet Disorder Study

Speaker: Catherine Hayward (Canada)

Microscopic Platelet Adhesion Assessment - An Approach towards Standardization

Speaker: Johanna Charlotte Clauser (Germany)

Effects of Clopidogrel Versus Ticagrelor on Platelet Function in Patients Undergoing Percutaneous Coronary Intervention: Assessed by Light Transmission Aggregometry, Vasodilator-Stimulated Phosphoprotein Assay and Mean Platelet Volume

Speaker: Yang Zhang (China)

Platelet Function Testing Using Born's Optical Aggregometry on Automated Coagulation Analyzer Systems Compared to a Manual Aggregometer (Atellica COAG 360 - CS 2500i - Chronolog 700)

Speaker: Florian Prüller (Austria)

Non-EDTA Dependent Pseudotrombocytopenia

Speaker: Gian Luca Salvagno (Italy)

Standardization of Light Transmission Aggregometry for the Diagnosis of Inherited Platelet Function Disorders: First Inter-Laboratory External Quality Assessment in Germany and Austria

Speaker: Karina Althaus (Germany)

In Vitro Comparison of Three Whole Blood Platelet Function Analyzers: VerifyNow, Multiplate and PlateletMapping

Speaker: Joao. D Dias (Switzerland)

Sensitive Method for Diagnosing a Platelet Population Behavior after Stimulation

Speaker: Alena Litvinenko (Russian Federation)

Mean Platelet Volume and Blood Loss in Total Hip Replacement Surgery

Speaker: Irina P. Antropova (Russian Federation)

Phenotypic Variability in Antiplatelet and Anticoagulant Therapy in African Americans: An ACCOuNT Consortium Study

Speaker: Minoli Perera (United States)

Comparison between Plateletworks Method and Aggregation with Platelet-rich Plasma for the Evaluation of Platelet Function in Patients with Acute Coronary Syndrome

Speaker: Mirta Arias (Argentina)

The Total Thrombus Formation (T-TAS) Platelet Assay, a Novel Point-of-Care Test that Uses Arterial Shear Stress Evaluating Antiplatelet Therapy

Speaker: K.L. Zheng (the Netherlands)

The Effect of Rivaroxaban on the Platelet Functional Activity

Speaker: Olesia Matvienko (Russian Federation)

First Evidence: Reduced Thrombin-dependent Platelet Aggregation by Selected Xabans

Speaker: Lubica Vadelova (Slovakia)

Scientific Programme

Fibrinolysis and Proteolysis - Fibrinolytic Factors and Inhibitors

Plasminogen Activator Inhibitor-1 Deficiency Prevents the Neonatal Chronic Lung Disease in Mice

Speaker: Kohei Tatsumi (Japan)

Inhibition of the Procarboxypeptidase U (proCPU, TAFI, proCPB2) System due to Hemolysis

Speaker: Joachim Mertens (Belgium)

Features of the Action of a New Synthetic Peptide of the Melanocortin Family on Fibrinolysis

Speaker: Tatyana Shubina (Russian Federation)

Towards the Structure-function Analysis of Factor VII Activating Protease (FSAP)

Speaker: Dipankar Manna (Norway)

Fibrinolysis Patterns of Different Plasminogen Mutant Proteins in Patients with Inherited Plasminogen Deficiency: Impact on the Development of Ligneous Conjunctivitis

Speaker: Nadine Ajzenberg (France)

Dipicolinic Acid Release t-PA from HUVEC

Speaker: Hiroyuki Sumi (Japan)

Fibrin Clots Containing NETs Show Slower Fibrinolysis and Are Stiffer in Patients with Diabetes

Speaker: Judith Juliana de Vries (the Netherlands)

Fibrin Clot Lysis Analysis: Tissue Factor versus Thrombin as Activator

Speaker: Mai Stenulm Veirup (Denmark)

Exploratory Study of Fibrinolytic Parameters in Patients with JAK2V617F Positive Essential Thrombocythemia

Speaker: Sithakom Phusanti (Thailand)

Fibrinogenolytic Effects of Night Adder Snake Venoms

Speaker: Francisco Cyrne Pacheco Coimbra (Australia)

Levels of Factor XII and Plasmin-antiplasmin Complex Serum in Acute Coronary Syndrome Patients

Speaker: Irza Wahid (Indonesia)

A Multimodal Approach Using Tranexamic Acid Plus Fibrinogen Compensates Low Levels of Thrombin Generation Following PCC Therapy in a Polytrauma Model

Speaker: Oliver Grottke (Germany)

Streptokinase and Staphylokinase: Mechanisms Underlying the Differences in their Thrombolytic and Fibrinogenolytic Effects

Speaker: Roza Aisina (Russian Federation)

Interaction of Cationic and Anionic of Polyamidoamine Dendrimers with Plasminogen: Influence on the Structure and Activation of Zymogen by Streptokinase

Speaker: Liliya Mukhametova (Russian Federation)

Further Studies on Hereditary Angioedema due to a Plasminogen Mutation

Speaker: Georg Dewald (Germany)

Gender-specific Alteration in α 2-antiplasmin Incorporation in Type 2 Diabetes Mellitus

Speaker: Agata Hanna Bryk (Poland)

Scientific Programme

Highest Nattokinase Activity in Japanese Fermented Food-Natto

Speaker: Hiroyuki Sumi (Japan)

Determinants of Plasma Fibrin Clot Lysis Using Three Different Assays in Patients with Aortic Stenosis

Speaker: Jakub Siudut (Poland)

Fibrinolysis and Proteolysis - Thrombolytic Therapy

Elucidation of the Molecular Mechanisms of Nanobodies that Affect Plasminogen Activator Inhibitor 1 (PAI-1) Activity Highlights their Versatility in Modulating Various Stages in the PAI-1/Plasminogen Activator (PA) Interaction

Speaker: Paul J. Declerck (Belgium)

Single Institution Experience of Thrombolysis for Acute Pulmonary Embolism in a Retrospective Cohort of Australian Patients

Speaker: Ming Sheng Lim (Australia)

A New Treatment for Thrombosis Prevention?

Speaker: Pia Larsson (Sweden)

Ultrasonic Monitoring of Blood Coagulation and Drug-induced Fibrinolysis

Speaker: Konstantin Guria (Russian Federation)

Indications and Outcomes of Thrombolytic Therapy 2010-2016: A Retrospective Single Center Study

Speaker: Peter Verhamme (Belgium)

Hemophilia and Bleeding - Acquired Hemorrhagic Coagulation Disorders

Immunoabsorption for the Treatment of Acquired Haemophilia: New Observational Data, Systematic Review and Meta-analysis

Speaker: Michael Nagler (Switzerland)

Characterization of the Coagulopathy in Patients Treated with Extracorporeal Membrane Oxygenation: Conventional Coagulation Assays versus "Point of Care" Analyses

Speaker: Andreas Straub (Germany)

Single Center Analysis of Clinical Characteristics and Outcomes of Patients with Acquired Hemophilia A

Speaker: Yoshiyuki Ogawa (Japan)

Outcome of CARE: A 6-year National Registry of Acquired Hemophilia A in China

Speaker: Boyang Sun (China)

Peptides Derived from Basement Membrane Hydrolysis by Snake Venom Metalloproteinases Contribute to the Vascular Effects of Viper Venoms

Speaker: Ana M. Moura-da-Silva (Brazil)

Differences in the Hemostatic Disturbances in Snakebite Patients and Eventual Role of Individual Snake Venom Composition

Speaker: Ana M. Moura-da-Silva (Brazil)

Acquired FXIII Inhibitor: Patient Characteristics and Treatment Outcome, a Case Series

Speaker: Sheng-Chieh Chou (Taiwan, Republic of China)

Venous Thromboembolism Trends and Impact in Patients with Cirrhosis: Analysis of The National Inpatient Sample Database 2003-2014

Speaker: Ian Greenberg (United States)

Scientific Programme

Implication of Deranged Coagulation Parameters on Clinical Management of Patients with Dengue Fever

Speaker: Madiha Abid (Pakistan)

Influence of Antiaggregation Therapy in Bone Marrow Biopsy Haemorrhagic Complication

Speaker: Rogerio Bassitt (Brazil)

Acquired Hemophilia A (AHA): A Single Centre Malaysian Outlook

Speaker: Christopher, Chin Keong Liam (Malaysia)

Validation of Hemostatic Impairment Induced by Hydroxyethyl Starch (HES) Due to Influence on Vascular Endothelium

Speaker: Ryu Azumaguchi (Japan)

New Elements Involved in the Skin Haemorrhage Induced by Snake Venom Metalloproteinases: Proteoglycans and Platelet-derived Growth Factor Receptor

Speaker: Solange M T Serrano (Brazil)

Peptidomics of Metalloproteinase-induced Haemorrhage: Insights from the Analysis of the Degradation of Components of the Mouse Skin and Human Plasma by the Snake Venom Metalloproteinase HF3

Speaker: Solange M T Serrano (Brazil)

Acquired von Willebrand Syndrome: A Case Series in a University Hospital in Argentina

Speaker: Fernando Chuliber (Argentina)

Acquired VKOR Inhibitor: A New Entity?

Speaker: Veena Selvaratnam (Malaysia)

The Paradox: Bleeding Presentation in Antiphospholipid Syndrome

Speaker: Veena Selvaratnam (Malaysia)

Use of a thrombin generation assay and thromboelastometry in the assessment of the Efficacy of Treatment with Activated Prothrombin Complex Concentrate (APCC) or Recombinant Factor VIIa (rFVIIa) Concentrate in Patients with Acquired Haemophilia and in Patients with Haemophilia A with Inhibitor - A Multicenter Study

Speaker: Krystyna Zawilska (Poland)

Acquired Hemophilia A Presenting in a 13 Year-old Boy - A Clinical Case

Speaker: Rute Preto (Portugal)

Bleeding Complications after Percutaneous Renal Biopsy: Analysis of Probable Risk Factors

Speaker: Veronica Privitera (Argentina)

Combination of Cyclophosphamide and Corticosteroids Therapy Facilitate Remission in Acquired Hemophilia A Patients with High Titers of Inhibitors: A Single Center Experience in China

Speaker: Naifang Ye (China)

Three Successful Cases of AHA Patients Presenting Severe Cardiovascular Diseases Treated with Susoctocog-alfa (rpFVIII): A Single Centre Experience

Speaker: Ezio Zanon (Italy)

Acquired Hemophilia A with an Exorbitant Inhibitor and Venous Thrombosis: Successful Treatment with Recombinant Porcine FVIII Plus Recombinant FVIIa and Immediate Anti-CD20 Therapy

Speaker: Wolfgang Korte (Switzerland)

Scientific Programme

Acquired Hemophilia A Presenting in an Elderly Man after a Thrombotic Event - A Clinical Case

Speaker: Rute Preto (Portugal)

Acquired Hemophilia A and B Associated with Thyroid Cancer Successfully Treated by Activated Factor VII (rFVIIa). Case Report

Speaker: Alejandro Jaramillo Yepes (Colombia)

Hemophilia and Bleeding - Complement & Hemostatic System

Properdin, a Positive Regulator of the Alternative Pathway of Complement, Inhibits Factor XI Autoactivation by Dextran Sulphate

Speaker: Samantha Heal (United Kingdom)

The Evaluation of Paroxysmal Nocturnal Hemoglobinuria Patients who Underwent Eculizumab Therapy

Speaker: Fahri Şahin (Turkey)

Reported Presentation, Treatment, Mutation Analysis and Outcome of Two Children with Atypical Hemolytic Uremic Syndrome

Speaker: Pongpak Pongphitcha (Thailand)

Hemophilia and Bleeding - Disseminated Intravascular Coagulation

Effect of Complement Activation in Septic Disseminated Intravascular Coagulation

Speaker: Tomohiro Abe (Japan)

A Validation Study of Plasminogen Activator Inhibitor-1 as a Predictive Marker of Mortality in Sepsis

Speaker: Kota Hoshino (Japan)

Evaluation of Fulfilment Sequences of Two Different Criteria for Assessing Coagulopathy in Sepsis: A Nationwide Japanese Registry Study

Speaker: Katsunori Mochizuki (Japan)

Predictive Value of Soluble Fibrin and New Diagnostic Criteria by the Japanese Society on Thrombosis and Hemostasis (JSTH) for the Prognosis of Patients with Sepsis-associated Disseminated Intravascular Coagulation

Speaker: Seiji Madoiwa (Japan)

A Study of the Prognostic Value of Smartphone Application on Disseminated Intravascular Coagulation (DIC) Score in Prediction of 28-day Mortality

Speaker: Tanapun Thamgrang (Thailand)

Hemophilia and Bleeding - Hemophilia: Clinical

Evaluation of Intracranial Haemorrhage in Patients with Congenital Factor Deficiencies: A Single-Center Experience from Turkey

Speaker: Murat Soker (Turkey)

Use of rFIX-FP in a Child with Mild Hemophilia B during a Surgical Procedure

Speaker: John Puetz (United States)

Psychosocial Issues in Mothers of Children with Hemophilia

Speaker: Aya Nakao (Japan)

Long-term Safety of N8-GP (turoctocog alfa pegol) Prophylaxis in Patients with Severe Haemophilia A

Speaker: Nicola J Curry (United Kingdom)

Scientific Programme

Non-adherence to Treatment May Have a Direct Relationship to Lower Bleeding Rate in Hemophilia A (APT Project)

Speaker: Ricardo Camelo (Brazil)

Treatment Patterns and Outcomes in Persons with Hemophilia A (PwHA): Analysis from the CHOICE Survey in the United States

Speaker: Anisha M. Patel (United States)

Successful Management with a Major Trauma Caused by Vehicle Accident in a Severe Hemophilia A Patient with Inhibitor under Emicizumab Treatment

Speaker: Sheng-Chieh Chou (Taiwan, Republic of China)

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A (MOTIVATE) - An International Observational Study

Speaker: Carmen Escuriola-Ettingshausen (Germany)

Menorrhagia in Congenital Factor Deficiencies

Speaker: Zafer Salcioglu (Turkey)

Anti-FVIII IgG1 Antibodies in Patients with Hemophilia A during Factor VIII Replacement: Results from the HEMFIL Study

Speaker: Letícia Lemos Jardim (Brazil)

Evaluation of the Analytical Performances of a New Emicizumab Assay on STA-R & STA Compact Max

Speaker: Matthieu Bourdin (France)

Long-term Outcomes after Switch from On-demand Treatment to Prophylaxis with rFVIII-Fc: Longitudinal Subgroup Analysis of the A-LONG and ASPIRE Study Population

Speaker: María Teresa Álvarez Román (Spain)

Clinical Characteristics and Incidence of Inhibitors in Patients with Haemophilia: Results of the HEMIL Cohort Study

Speaker: Letícia Lemos Jardim (Brazil)

Validation of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study Questionnaire

Speaker: Mark Skinner (United States)

Evaluation of Active Genetic Counseling Service for Female Family Members of Hemophilia Patients in Korea

Speaker: Hyon Kim (Korea, Republic of)

Identification of New Deep Intronic Variants Causing Hemophilia A by Whole F8 Gene Sequencing, mRNA Analysis and Functional Confirmation, in "Variant-Negative" French and Canadian Patients

Speaker: Fanny Lassalle (France)

Measuring Health Related Quality of Life (HRQoL) in Boys with Hemophilia Using Extended Half-life Clotting Factor Concentrates (CFCs)

Speaker: Victoria Price (Canada)

Changes in Bleeding Symptoms and Daily Life with Emicizumab Prophylaxis: A Questionnaire in Patients with Hemophilia A (PwHA) without FVIII Inhibitors in a Long-term Phase 1/2 Study

Speaker: Midori Shima (Japan)

Scientific Programme

The Outcome of Intermediate-dose Prophylaxis and On-demand Episodic Treatment for Severe Hemophilia A Patients in Taiwan - A Longitudinal Study

Speaker: Shyh-Shin Chiou (Taiwan, Republic of China)

Haemostatic Therapy for Insertion of Central Venous Access Devices in Severe Haemophilia A and B - Melbourne Paediatric Protocol

Speaker: Sally Campbell (Australia)

Predictors of Bleeding in Severe Haemophilia A

Speaker: Samuel Sarmiento (Colombia)

Incidence and Prevalence of Diagnosed and Undiagnosed Hemophilia A and Hemophilia B in Select Countries

Speaker: Emily S. Brouwer (United States)

The Role of Prophylaxis in Paediatric Patients with Moderate Haemophilia

Speaker: Alice Wilkinson (United Kingdom)

Simoctocog-alfa (rhFVIII): An Interesting Option for the Immune Tolerance Induction Rescue (ITI-R) in the Hemophilia A Patients with High-titer Inhibitors

Speaker: Ezio Zanon (Italy)

Results from the Immune Tolerance Induction (ITI) with Moroctocog-alpha in a Population of Haemophilia A Patients and High-titre Inhibitors: The REF.IT Registry

Speaker: Ezio Zanon (Italy)

Comparison of Pharmacokinetic Outputs from a Non-compartmental Analysis and myPKFit™ in Taiwanese Hemophilia Patients

Speaker: Shin-Nan Cheng (Taiwan, Republic of China)

Survey of Haemophilia Care in Nigeria: Physicians Response from 35 Centres in 20 States of the Federation

Speaker: Wuraola A. Shokunbi (Nigeria)

HLA-DR Processing and Presentation of Two Peptide Antigen Clusters in PEG-BDD-FVIII (BAY94-9027) by Dendritic Cells is Impaired Resulting in Defective T-helper Response In Vitro

Speaker: Pedro Paz (United States)

Effectiveness and Safety of Real-world Treatment with BAY 94-9027 in Previously Treated Patients with Haemophilia A: Rationale and Design of the HEM-POWR Study

Speaker: Martin Sanabria (Switzerland)

Clinical Use of Recombinant Factor VIII Fc (rFVIII-Fc) in Patients with Haemophilia A in a Single Centre

Speaker: Segolene Claeysens (France)

The Estimated Impact of New Therapies on Factor VIII (FVIII) Use and Product Cost by 2023

Speaker: Jonathan Ducore (United States)

AHEAD International and German Studies: Subgroup Analysis of Patients with Moderate or Severe Hemophilia A Receiving Antihemophilic Factor (Recombinant) as Immune Tolerance Induction (ITI) Therapy

Speaker: Margareth Ozelo (Brazil)

Various Complications after Vascular Procedure in Patients with Hemophilia

Speaker: Eun Jin Choi (Korea, Republic of)

Scientific Programme

Cardiovascular Clinical and Laboratory Profiles of Hemophilia Patients from the Brazilian Hemophilia Treatment Center of Pernambuco (HEMOPE)

Speaker: Ricardo Camelo (Brazil)

Low-Dose Immune Tolerance Induction Strategy Eradicates High-Titer Inhibitor with Poor Risk(S) in Hemophilia A Children: A Pilot Study in China

Speaker: Zekun Li (China)

Comparing Qualitative and Quantitative Data on BAY 94-9027, a New Extended Half-life Recombinant Factor VIII (EHL-rFVIII) for the Treatment of Haemophilia A: A Mixed-method Research Approach

Speaker: Emilio Musi (Switzerland)

Review of a Port-A-Cath Training Programme for Caregivers in a Paediatric Haemophilia Treatment Centre

Speaker: Chiew Ying Lim (Singapore)

Clinical, Pharmacokinetic and Economic Analysis of the First Switch to an Extended Half-life Factor IX (albutrepenonacog alfa) in Spain

Speaker: Santiago Bonanad (Spain)

Management and Outcomes of Hemophilia Carriers during Pregnancy and Peripartum Period: A Hemophilia Treatment Center Experience

Speaker: Hana Iris Lim (United States)

Successful Transfemoral cerebral angiography(TFCA) and Therapeutic Coil Embolization of Unruptured Dissecting Aneurysm in Vertebral Artery of Hemophilia Patient

Speaker: Ji Kyoung Park (Korea, Republic of)

Successful Transition to Extended Half-Life (EHL) Therapies (Eloctate, Adynovate and Alprolix) as Part of the National Blood Authority (NBA) Limited Interim Agreement in Australia - a Single Centre Real World Experience

Speaker: Kristen Piper (Australia)

Major Impact of the World Federation of Hemophilia Humanitarian Aid Program on Initiation of Primary Prophylaxis with Extended Half-life Factor VIII and IX in Côte d'Ivoire

Speaker: Cedric Hermans (Belgium)

Transition from Standard Half-life to Extended Half-life Products in Patients with Haemophilia A and B: A Single Center Experience

Speaker: Marissa Johanna Maria Traets (the Netherlands)

The Experience of Major Orthopedic Surgeries in Patients with Severe Hemophilia

Speaker: Alphan Kupesiz (Turkey)

Seroprevalence and Clinical Characteristics of Viral Hepatitis in Hemophilia Patients

Speaker: Fahri Şahin (Turkey)

Outcomes with an Extended Prophylactic Treatment Schedule of Rurioctocog Alfa Pegol in a Phase 3b, Open-label, Multicenter, CONTINUATION Study in Previously Treated Patients with Severe Hemophilia A

Speaker: Srilatha Tangada (United States)

A Fixed "Single Vial" Dose of 15 Micrograms of Subcutaneous Desmopressin (SC-DDAVP) Produces Adequate Biologic Responses for Persons with Mild Haemophilia A

Speaker: Jane Mason (Australia)

Scientific Programme

Current Status of Hemophilia in China

Speaker: Xuewen Song (China)

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment with Nuwiq®, Octanate® or Wilate® - the Protect-NOW Study

Speaker: Johannes Oldenburg (Germany)

Immune Tolerance Induction for the Hemophilia A Inhibitor Patients with Poor Prognostic Factors

Speaker: Soonki Kim (Korea, Republic of)

Target Joint Resolution in Patients with Hemophilia A Receiving Long-Term Prophylaxis with BAY 94-9027

Speaker: Mark Reding (United States)

Prediction of Anti-FVIII Inhibitor Persistence by Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia a in the SIPPET Cohort Study

Speaker: Roberta Palla (Italy)

Bone Health In Hemophilic Arthropathy - A Systematic Study from Eastern India

Speaker: PRAKAS Mandal (India)

Long-Term Efficacy and Safety of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B: Results from a Phase 3b Extension Study

Speaker: Maria Elisa Mancuso (Italy)

Pharmacokinetic Properties of BAY 81-8973: Real-World Data from the TAURUS Non-Interventional Study

Speaker: Phu Quoc Le (Belgium)

Treatment Success of rVIII-SingleChain in Obese Previously Treated Patients with Severe Hemophilia A in Study CSL627_1001

Speaker: Johnny Mahlangu (South Africa)

Analysis of Recombinant FVIII Consumption and Treatment Outcomes and Comparison with Other FVIII Products Based on US Hemophilia A Prophylaxis Patient Charts

Speaker: Songkai Yan (United States)

Results from a Prospective, Multicenter, Dose Escalating, Prophylaxis Study in Young Boys with Severe Haemophilia A in China: The China Haemophilia Individualized Prophylaxis Study (CHIPS) (NCT02999308)

Speaker: Runhui Wu (China)

Social Participation of Patients with Haemophilia: Preliminary Results from the Nationwide 'Haemophilia in the Netherlands 6 study'

Speaker: Erna van Balen (the Netherlands)

Immune Tolerance Induction with Simoctocog Alfa in Nine Patients with Severe Haemophilia A and FVIII Inhibitors

Speaker: Ri Liesner (United Kingdom)

Comparative Pharmacokinetic Study between Alphanate and Octanate Using WAPPS-Hemo

Speaker: Santiago Bonanad (Spain)

Clinical Assessment with Focus on Health-related Quality of Life in Adult Patients with Severe Hemophilia B

Speaker: Anna Buczma (Poland)

Scientific Programme

Acquired Haemophilia Still Remains a Complex Clinical Challenge

Speaker: Cristina Claudia Tărniceriu (Romania)

6 Consecutive Patients and 100% of Inhibitors: Is Inhibitor Development Inevitable?

Speaker: Cristina Catarino (Portugal)

Utility of an Educational Material for Primary Caregivers of Pediatric Patients with Hemophilia

Speaker: Aida Mashenka Moreno González (Mexico)

A Case Series of Continuous Infusion with Kovaltry® (Octocog Alfa) in Patients with Hemophilia A

Speaker: Jerome Teitel (Canada)

Haemophilia B Minor - Lab Error or Possible Misdiagnosis

Speaker: Florije Raka (Macedonia, the Former Yugoslav Republic of)

Hemophilia and Bleeding - Infection and Hemostatic Factors

Comorbidity and Transfusion Transmitted Infections in Patients with Severe Haemophilia: Report from Taiwan Society of Thrombosis and Hemostasis registry

Speaker: Jiaan-Der Wang (Taiwan, Republic of China)

Structure, Mechanical and Lytic Stability of Fibrin and Plasma Coagulum Generated by Staphylocoagulase from Staphylococcus aureus

Speaker: Craig Thelwell (United Kingdom)

Hemophilia and Bleeding - Management of Bleeding and Trauma

Systemic Antifibrinolytic Agents for Hemoptysis Management in Adults with Cystic Fibrosis

Speaker: Jean M. Connors (United States)

Heparin-binding Copolymer as a Universal Antidote for Low-molecular-Weight Heparins in Rats

Speaker: Bartłomiej Kalaska (Poland)

Cerebral Hemorrhage Developed in a Hemophilia A Patient without Inhibitor during Prophylactic Treatment with Emicizumab

Speaker: Azusa Nagao (Japan)

Barriers and Challenges for the Fast Treatment of Bleeds in the Non-haemophilia Treatment Centre Hospital Setting

Speaker: Robert Klamroth (Germany)

Reversal of Anticoagulation in Patients on Rivaroxaban or Apixaban (DOAC) with Major Bleeding Episodes (MBE) with 4 Factor Prothrombin Complex Concentrates (PCC): A Multicentre Retrospective Study

Speaker: Christian Aledia Gallardo (Singapore)

Injectable Biotinylated Platelets for Transfusion in Clinical Trials

Speaker: Arnaud Dupuis (France)

Thromboelastometry in Patients with Positive Lupus Anticoagulant. Is there any Potential Impact on Haemostasis Monitoring during Cardiovascular Surgery?

Speaker: Marina Sol Lopez (Argentina)

Dynamic Coagulability during Cardiovascular Surgery and its Correlations with Bleeding Volume

Speaker: Satoshi Fujii (Japan)

Scientific Programme

Real-world Use of 4-factor Prothrombin Complex Concentrates (4F-PCC) in Warfarin-associated Intracranial Haemorrhage Patients in Hong Kong: A Descriptive Patient Management Protocol

Speaker: Wing Chi Fong (Hong Kong)

Management of Antithrombotic Therapy After Gastrointestinal Bleeding: A Qualitative Study of Healthcare Providers

Speaker: Deborah M. Siegal (Canada)

Perioperative Management of Antiplatelets and Anticoagulants in Elective Surgery

Speaker: James Sindone (Australia)

Adherence to Prophylaxis in Hemophilia and von Willebrand Disease: Systematic Assessment from an Electronic Diary

Speaker: Andreas Tiede (Germany)

Seek and Ye Shall Find - Elearning as a Method to Improve Knowledge of Bleeding Management

Speaker: Louise English (Australia)

Clinically Guided 4 Factor Prothrombin Complex Concentrate Therapy in Cardiac Surgery Is Not Associated with a Sustained Procoagulant State

Speaker: Oliver Grottke (Germany)

Efficacy of Three Factor Prothrombin Complex in Achieving Haemostasis in Patients with Major Bleeding on Anti-coagulation - Retrospective Single Centre Study

Speaker: Usha Chandra Sekaran (Australia)

GPVI Shedding Contributes to Platelet Dysfunction in Trauma-induced Coagulopathy

Speaker: Samantha J. Montague (Australia)

Efficacy and Safety of a 4-factor Prothrombin Complex Concentrate for Management of Direct Xa Inhibitor-induced Major Bleeding

Speaker: Paul Dobesh (United States)

Measurement of Factor VIII Replacement Therapy for Patients with Haemophilia A on Emicizumab Prophylaxis

Speaker: Claire Haran (Ireland)

A Comparison of Management Strategies for Patients with Warfarin-induced Bleeding

Speaker: Paul Dobesh (United States)

Warfarin Reversal with a 4-factor Prothrombin Complex Concentrate Prior to Urgent surgery

Speaker: Paul Dobesh (United States)

Direct Xa-inhibitor Reversal with a 4-factor Prothrombin Complex Concentrate Prior to Urgent Surgery

Speaker: Paul Dobesh (United States)

Comparative Studies on the Anticoagulant Activities of Orally Active Anti-Xa and Anti-IIa Agents in Whole Blood and Retrieved Plasma and their Neutralization by FEIBA

Speaker: Rithik Raina (United States)

Idarucizumab for Dabigatran Reversal in Clinical Practice: A French Retrospective Study of 41 Cases

Speaker: Nicolas Gendron (France)

Immunothrombosis and Vascular Biology - Blood Cells and Vessel Wall

Scientific Programme

von Willebrand Factor in Experimental Malaria-associated Acute Respiratory Distress Syndrome

Speaker: Sirima Kraisin (Belgium)

Involvement of Glycoprotein VI in Platelet Mediated Amyloid- β Fibril Formation

Speaker: Lili Donner (Germany)

Regulation of NET Formation by von Willebrand Factor

Speaker: Kim Martinod (Belgium)

Impairment of Erythrocyte Deformability Observed in Type 2 Diabetic Patients with Clustering Diabetic Complications

Speaker: Toru Maruyama (Japan)

Immunothrombosis and Vascular Biology - Endothelial Cell Signaling

Plasmodium Falciparum Histidine Rich Protein HRP2 Inhibits the Anti-inflammatory Function of Antithrombin

Speaker: Alireza Rezaie (United States)

Regulation of Vascular Inflammation and Liver Defense System by a Lipid Substrate of N-terminal Phosphatase of Soluble Epoxide Hydrolase

Speaker: Eriko Suzuki (Japan)

Partially Methylated Domains of Fetal and Adult Liver Sinusoidal Endothelial Cells Revealed Cell-type as Well as Differentiation-stage Specificity

Speaker: Muhammad Ahmer Jamil (Germany)

Endothelial Dysfunction, Oxidative Stress and Activation of Rho A/Rho Kinase Pathway in Major Depressive Disorder

Speaker: Claudia Saez (Chile)

Molecules Derived from Procoagulant Lipocalin (Lopap) as Potential Hits on Blood Coagulation, Cytoprotection and Tissue Remodeling

Speaker: Ana Marisa Chudzinski-Tavassi (Brazil)

Immunothrombosis and Vascular Biology - Inflammation and Sepsis

Decreased Thrombin Generation Potential is Associated with Increased Thrombin Generation Markers in Sepsis Associated Coagulopathy

Speaker: Fakiha Siddiqui (United States)

Plasma Activated Protein C Activity in the Presence of Recombinant Thrombomodulin in vivo and in vitro

Speaker: Takashi Ito (Japan)

Platelet Aggregation in Patients with Septic Shock

Speaker: Mathies Appel Laursen (Denmark)

Investigating the Role of Tissue Factor in Abdominal Sepsis

Speaker: Agostina Carestia (Canada)

High Plasmatic Levels of Cell Free DNA Are Associated with Poor Prognosis in Septic Patients

Speaker: Mauro Hernán Moiana (Argentina)

Venous Thromboembolism Trends and Impact in Patients with Rheumatoid Arthritis: Analysis of The National Inpatient Sample Database 2003-2014

Speaker: Juan Pablo Salazar Adum (United States)

Scientific Programme

Activation-specific Small Binding Proteins Targeted Towards the Integrin Mac-1 - Measuring Inflammation by Means of Monocyte Activation in STEMI- and ECMO-patients

Speaker: Patrick Malcolm Siegel (Germany)

Platelets and Coagulation Mediate Bacterial Adhesion to Damaged and Inflamed Heart Valves in Staphylococcus Aureus Endocarditis

Speaker: Severien Meyers (Belgium)

Coagulation and Fibrinolysis Waveform Analysis May Identify the Patients Susceptible for Multiple Organ Failure and Thrombocytopenia in Septic DIC

Speaker: Noritaka Yada (Japan)

Pro-inflammatory Macrophage Polarization Enhances Neutrophil Extracellular Trap Degradation

Speaker: Patrick Haider (Austria)

Investigating the Role of Neutrophils and NETs in Staphylococcus aureus Endocarditis

Speaker: Severien Meyers (Belgium)

Immunothrombosis and Vascular Biology - Innate and Adaptive Immunity

Remote Ischemic Preconditioning Does Not Influence Lectin Pathway Protein Levels in Cancer Patients Undergoing Surgery: A Randomized Controlled Trial

Speaker: Kristine Frederiksen (Denmark)

Modulation of the Liver Immune Microenvironment by an Adeno-associated Virus Serotype 8 (AAV8) Gene Therapy Vector

Speaker: Agostina Carestia (Canada)

Immunothrombosis and Vascular Biology - Non-Coding RNAs

MiR-146a Participates in Thrombo-inflammation Regulating Neutrophil Extracellular Trap Formation

Speaker: Ana Belen Arroyo Rodriguez (Spain)

Non-coding RNA miR-365a-3p Suppresses Tissue Factor Levels and Decreases Thrombin Generation

Speaker: Jiayin Tian (Australia)

Immunothrombosis and Vascular Biology - Stem Cells and Vascular Cell Growth

Developing a Novel Stem Cell and Gene Therapy System Based on Resveratrol-induced HSP70 Promoter-regulated VEGFA Expression

Speaker: Kowit-Yu Chong (Taiwan, Republic of China)

Prolonged Therapeutic Effects of Adipose-derived Stem Cells via the Photoactivation after Ischemic Injury

Speaker: Jianbo Wu (China)

A Latent Procoagulant State Transcriptionally Primes Hematopoietic Stem Cells: Hematopoiesis in Mice with Altered Protein C Signaling and Anticoagulant Activity

Speaker: Hartmut Weiler (United States)

Platelets and Megakaryocytes - Platelet Antagonists and Novel Therapeutics

Symptomatic Profiles of Chinese Patients with Essential Thrombocythemia Assessed by MPN 10 Score

Speaker: Yuchen Gao (China)

Scientific Programme

miR-125a-5p Regulates Human and Mouse Thrombopoiesis through Leukocyte Cytosolic Protein 1 (LCP1)

Speaker: Paul F. Bray (United States)

The Role of Serotonin on Haematopoiesis and Proplatelet Formation

Speaker: Mo Yang (China)

Buffy Coat, a Potential Source of Hematopoietic Stem Cells for in vitro Platelet Production

Speaker: Irene Marini (Germany)

Aerobic Glycolysis and the Consequent Flux through Pentose Phosphate Pathway Fuel Platelet Activation: Small-molecule Modulators of Platelet Metabolism as Anti-thrombotic Agents

Speaker: Paresh Kulkarni (India)

The Highly Efficacious Antithrombotics Act as Selective Inhibitors of α IIb β 3 Outside-in Signaling with a High Safety Profile

Speaker: Tur-Fu Huang (Taiwan, Republic of China)

A Proposed "ABN Score" for Prediction of Aspirin Resistance in Thai Patients with Polycythemia Vera and Essential Thrombocythemia

Speaker: Yingyong Chinthammitr (Thailand)

Do Paracetamol and Nonsteroidal Anti-Inflammatory Drugs Affect the Quality of Platelets for Transfusion?

Speaker: Dianne E. van der Wal (Australia)

APAC, a Dual Antiplatelet and Anticoagulant - Towards a Local, Vascular Targeting Antithrombotic

Speaker: Riitta Lassila (Finland)

Platelets and Megakaryocytes - Platelet Function and Interactions

Outside-in Integrin Signaling Induces Disabled-2 (Dab2) Ser24 Phosphorylation Causing Dab2 Dissociation from Phosphatidic Acid in Human Platelets

Speaker: Ching-Ping Tseng (Taiwan, Republic of China)

Plasma Inhibitors of Platelet Sheddase Activity - Rocks to the Scissors on the Paper

Speaker: Christine Lee (Australia)

Peptide Correction of Prothrombotic Effects of Erythrocytes on Aggregation of Platelets

Speaker: Maria Golubeva (Russian Federation)

All-trans Retinoic acid (ATRA) Impairs Platelet Function and Thrombus Formation and Inhibits Protein Kinase C β I and δ Phosphorylation

Speaker: Jianlin Qiao (China)

The Mammalian Target of Rapamycin Controls Platelet Integrin Activation, Aggregation, and Ischemic Stroke

Speaker: Robert Campbell (United States)

Lenalidomide and Dexamethasone Enhanced Platelet Activation and in vitro Thrombus Formation under Arterial Flow

Speaker: Fehaid Alanazi (Australia)

The Role of the Formin Proteins mDia1 and Fhod1 on Megakaryocyte and Platelet Function

Speaker: Steven G. Thomas (United Kingdom)

Scientific Programme

Platelet Function Testing by Flow Cytometry in Venous and Arterial Blood: A Comparative Study

Speaker: Sofia Ramstrom (Sweden)

Computer Simulation with Virtual Platelet Accumulation for Assessing Pathophysiology about Coronary Stent Thrombosis Occurring at the Site of Mal-apposed Stent Strut

Speaker: Yota Kawamura (Japan)

Moderate Decreased Platelet Counts but High Platelet Activation Defects Alter Hemostasis and Arterial Thrombosis after Partial Hepatectomy in Mice

Speaker: Lili Donner (Germany)

Simultaneous Secretion of Spatially-Separated Dense Granules in Single Platelets Upon their Activation with ADP and Thrombin

Speaker: Taisiya O. Shepelyuk (Russian Federation)

Continuous Flow Cytometry Assay of Platelet Signalling and Function: A Tool for Characterization of Inherited and Acquired Platelet Disorders

Speaker: Alexey Martyanov (Russian Federation)

The Rate of Platelet Activation Varies Within the Normal Population and Does Not Correlate With Maximal Levels of Platelet Activation

Speaker: Joanne Mitchell (United Kingdom)

Assessment of Platelet Function after Shear Stress Simulation Using ex vivo Closed-loop ECC Model (Modified Chandler-loop)

Speaker: Jan Zlamal (Germany)

Deciphering the Molecular Interactions of Streptococcus gordonii with Human Platelets and Endothelial Cells in the Context of Infective Endocarditis

Speaker: Sylviane Yoba (United Kingdom)

Platelets and Megakaryocytes - Platelet Proteomics and Genomics

The Integrin α IIb β 3 Signalling Pathway is Hyperactivated in Platelets from Obese Patients: A Phosphoproteomic Study

Speaker: Maria N. Barrachina (Spain)

Age-wise Variation in Expression Level of Plasminogen Activator Inhibitor-1 (PAI-1) within Platelets Sets Incidences of Thrombotic Disorders

Speaker: Ram Lala Mallick (Nepal)

Comparison of Anucleated and Nucleated Platelet Transcriptomes

Speaker: Farzana Ferdous (United States)

Platelets and Megakaryocytes - Platelet Receptors

Gradient Dependent Inhibition of Platelet Stimulatory G-Protein Coupled Receptors is Mediated through cAMP Dependent Pathway

Speaker: Ankit S Macwan (Sweden)

Potential for Ice Recrystallisation Inhibitors to Improve Cryopreserved Platelet Recovery and Quality

Speaker: Lauren Waters (Australia)

The Role of NMDA Receptors in Platelet Specific Hemostasis

Speaker: Lili Donner (Germany)

Scientific Programme

Elevated Soluble GPVI Levels in Patients with Symptomatic Aortic Stenosis and Left Ventricular Remodelling

Speaker: Cecile Oury (Belgium)

Platelets and Megakaryocytes - Platelet Signaling

Panax Notoginseng Flower Extratives and Its Saponins Attenuate Human Platelet Hyperactivity via P2Y₁₂ Signaling Pathways in vitro

Speaker: Yan Yang (China)

Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets

Speaker: Meike Klier (Germany)

Src-family Kinase Inhibition by Dasatinib Blocks Both Initial and Subsequent Platelet Deposition on Collagen under Flow, but Lacks Any Effect when Thrombin is Generated

Speaker: Scott Diamond (United States)

ABT-737 Triggers Caspase-dependent inhibition of Platelet Procoagulant Extracellular Vesicle Release during Apoptosis and Secondary Necrosis in vitro

Speaker: Matthew Harper (United Kingdom)

Platelets Express a Truncated Form of TrkB Involved in BDNF Signaling

Speaker: Imane Boukhatem (Canada)

Study on the Mechanism of SCUBE1 in Regulating Platelet Function

Speaker: Zhou Xianghui (China)

Redox Based Regulation of GPVI-mediated Platelet Function: Role for S-Glutathionylation

Speaker: Amandeep Kaur (Australia)

Phosphate-induced ORAI1 Expression and Store Operated Ca²⁺ Entry in Megakaryocytes

Speaker: Tamam Bakchoul (Germany)

Simultaneous Quantification of Oxygen Radicals and Platelet Aggregation Highlights the Importance of NADPH Oxidases in the Regulation of Thrombus Formation in Health and Disease

Speaker: Giordano Pula (United Kingdom)

Study of Calcium Signaling Dynamics in Single Platelets

Speaker: Daria Spiriyova (Russian Federation)

Platelets and Megakaryocytes - Platelets and Inflammation

Inflammatory Responses in Mice Deficient for Platelet α -granules during Intestinal Ischemia Reperfusion Injury

Speaker: Katrina J Ashworth (United States)

PDI Regulation of Neutrophil Mac-1 Function by Allosteric Disulphides in the β 2 Subunit

Speaker: Joyce Chiu (Australia)

Combining a Novel GPVI Inhibitor ACT017 with Conventional Antiplatelet Therapy Provides Greater Inhibition of Platelet-leukocyte Aggregate Formation

Speaker: Mark Thomas (United Kingdom)

Ceruloplasmin Reduces the Ability of Thrombin to Cause Platelet Aggregation

Speaker: Irina Gorudko (Belarus)

Scientific Programme

Effect of Monomeric Myeloperoxidase on Platelet Function

Speaker: Irina Gorudko (Belarus)

Platelets and Megakaryocytes - Platelets Beyond Hemostasis

Platelets Are Associated with Reduced Survival in Lung Adenocarcinoma Patients and Promote Metastatic Dissemination in Murine Models

Speaker: Stephanie R. Hyslop (Australia)

Interaction Between Large and Small Platelets with Bacteria

Speaker: Patrick Telle (Germany)

Multiplex Profiling of Platelet Rich Plasma vs Platelet Concentrate Bioproducts: A Comparative Analysis

Speaker: Laura Gutierrez (Spain)

Prothrombotic States - ADAMTS13 and Microangiopathies

"TWO-FACED TTP" - The Many Causes of Thrombotic Microangiopathy in Cancer Patients

Speaker: Rebecca Barrett (Australia)

Adult Onset Hereditary Thrombotic Thrombocytopenic Purpura (TTP) with a Novel ADAMTS13 Mutation

Speaker: Julian Matias Freue (Argentina)

Cost of Illness (COI) of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) in the United States

Speaker: Abiola Oladapo (United States)

Design of the First Clinical Study of Recombinant ADAMTS13 for the Acute Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Speaker: Christopher Hibbard (United States)

Clinical Safety Of Therapeutic Plasma Exchange with Fresh Frozen Plasma Inactivated with Mirasol PRT System in Patients with Acquired TTP

Speaker: Magdalena Łętowska (Poland)

Analytical Performance Validation of a New Screening Assay for the Deficiency of ADAMTS-13 Activity

Speaker: Nikolaus B. Binder (Austria)

Feasibility of a New Fully Automated ADAMTS-13 Activity Assay

Speaker: Marcos Llusà (Austria)

Feasibility Study for Subcutaneous Route of Administration of Recombinant ADAMTS13 (TAK-755/SHP655)

Speaker: Werner Hoellriegl (Austria)

Extension of Non-clinical Safety Margins for Recombinant ADAMTS13 (TAK-755/SHP655)

Speaker: Werner Hoellriegl (Austria)

Characterization of von Willebrand Factor and ADAMTS13 in the Tim Townes Mouse Model of Sickle Cell Disease

Speaker: Werner Hoellriegl (Austria)

Evaluation of A Rapid, Fully-automated ADAMTS13 Activity Assay

Speaker: Josep Serra (Spain)

Scientific Programme

Efficacy and PK/PD Relationship of Recombinant ADAMTS13 (TAK-755) in a Humanized Mouse Model of Sickle Cell Disease

Speaker: Michael Dockal (Austria)

Recombinant ADAMTS13 (TAK-755/SHP655) Can Override the Inhibitory Effect of Free Hemoglobin on von Willebrand Factor (VWF) Multimer Cleavage in vitro

Speaker: Werner Hoellriegl (Austria)

Dose-dependent Effects of Recombinant ADAMTS13 (TAK-755/SHP655) on Recovery in a Humanized Mouse Model of Sickle Cell Disease

Speaker: Werner Hoellriegl (Austria)

The Presence of Anti-ADAMTS13 Autoantibodies in Immune-mediated Thrombotic Thrombocytopenic Purpura Patients Does Not Hamper Correct Determination of ADAMTS13 Antigen Levels

Speaker: Charlotte Dekimpe (Belgium)

A Novel Mutation Description in Late-onset Phenotype Case of Congenital Thrombotic Thrombocytopenic Purpura (TTP)

Speaker: Juvenal Paiva (Argentina)

ADAMTS13 Antigen together to Collagen Binding to von Willebrand Factor (VWF:CB) and VWF Antigen (VWF:Ag) Were Potential Markers of Acute Disease Severity in Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Speaker: Juvenal Paiva (Argentina)

Severe Hemolytic Jaundice with Thrombocytopenia at Birth in Congenital TTP Is Caused by Physiological Constriction of Ductus Arteriosus

Speaker: Kazuya Sakai (Japan)

Non-severe Congenital Deficiency of ADAMTS13 Presenting as Thrombotic Microangiopathy during Pregnancy

Speaker: Miguel Escobar (United States)

Complement Abnormalities in a Cohort of Argentinean Patients with Atypical Hemolytic Uremic Syndrome

Speaker: Célia Dos Santos (Argentina)

Abnormal ADAMTS13 and Chemotherapy-associated Thrombosis in Women with Ovarian Cancer

Speaker: Alexander Vorobev (Russian Federation)

Successful International Standardisation of ADAMTS13 Assays Highlights Challenges in the Result Interpretation for the Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP) - results of the Asia-Pacific Microangiopathic (APMAT) Network

Speaker: Jim Y Tiao (Australia)

Time from Suspected Thrombotic Thrombocytopenic Purpura to Initiation of Plasma Exchange in Alberta, Canada and Impact on Survival: 10-Year Provincial Retrospective Cohort Study

Speaker: Haowei Sun (Canada)

The Incidence of Low ADAMTS13 Activity in Systemic Lupus Erythematosus Patients with Thrombocytopenia

Speaker: Theera Ruchutrakool (Thailand)

Rituximab Prophylaxis in Acquired Thrombotic Thrombocytopenic Purpura Improves Thrombus Formation by Shear Flow-Based Assay

Speaker: Marie Scully (United Kingdom)

Scientific Programme

A Survey on the Use of Rituximab in Korean Patients with Acquired Thrombotic Thrombocytopenic Purpura

Speaker: Sung-Hyun Kim (Korea, Republic of)

A Case of Hereditary Thrombotic Thrombocytopenic Purpura

Speaker: Li Zhou (China)

Red Blood Cells Transfusion Can Improve Hemostatic Dysfunction of Heyde Syndrome

Speaker: Ayaka Kakiwaki (Japan)

Acquired Thrombotic Thrombocytopenic Purpura Occurring in Advanced Age: Impact of a Delayed Onset on Disease Expression

Speaker: Andrea Artoni (Italy)

Long-term Neuropsychological Sequelae, Emotional Wellbeing and Quality of Life in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Speaker: Ilaria Mancini (Italy)

ADAMTS-13 Inhibitor Testing Is often Negative on Initial Testing

Speaker: Gloria Lim (Canada)

ADAMTS13 Levels in Sickle Cell Anaemia: Is there a Change between Steady State and Vaso-occlusive State

Speaker: Kingsley Akaba (Nigeria)

Severe ADAMTS13 Deficiency during Follow Up in Remission iTTP

Speaker: Ingrid Hrachovinová (Czech Republic)

Venous Thromboembolism - VTE Heparins & Heparinoids

Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery

Speaker: Ahmed Kouta (United States)

Enoxaparins Derived from Ovine (Sheep) Tissues Are Biosimilar to Branded Enoxaparin of Porcine (Pig) Origin

Speaker: Tishya Indran (United States)

Heparins Derived from Ovine (Sheep) Mucosa Are Interchangeable to their Porcine (Pig) Counterparts

Speaker: Tishya Indran (United States)

Bovine and Porcine Mucosal Heparins Exhibit Comparable Pharmacodynamic Behaviors at USP Potency Adjusted Doses

Speaker: Ahmed Kouta (United States)

Venous Thromboembolism - VTE Post-Thrombotic Syndrome

Efficacy and Safety of Bronchial Artery Embolization on Hemoptysis in Chronic Thromboembolic Pulmonary Hypertension: A Pilot Prospective Cohort Study

Speaker: Suqiao Yang (China)

The Independent Effect of Being a Strict Stockings Complier on the Outcome of the SOX Trial

Speaker: Susan R. Kahn (Canada)

Scientific Programme

External Validation of the SOX-PTS Score (Clinical Prediction Model for the Post-thrombotic Syndrome) in a Prospective Multicenter Study of Patients with Proximal Deep Vein Thrombosis

Speaker: Susan R. Kahn (Canada)

Quality of Initial Anticoagulant Treatment is Not a Risk Factor for Developing Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism

Speaker: Duliëtte Boon (the Netherlands)

Contrast Enhanced Computed Tomography Has a High Sensitivity for Diagnosing Chronic Thromboembolic Pulmonary Hypertension

Speaker: Eli Westerlund (Sweden)

Can a 9-item Modified Villalta Score Adequately Predict Post Thrombotic Syndrome? A Subgroup Analysis from the 'Follow-up in Rivaroxaban Patients in Setting of Thromboembolism' (FIRST) Registry

Speaker: Vicky Speed (United Kingdom)

Initial Thrombus Above or Below Popliteal Fossa Is More Predictive than Residual Thrombosis for Postthrombotic Syndrome after Episode of Deep Venous Thrombosis - RIETE Experience with 1183 Patients

Speaker: Marijan Bosevski (Macedonia, the Former Yugoslav Republic of)

Sex-specific Differences in the Clinical Presentation, Surgical Complications, and Course of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Insights from the European CTEPH Registry

Speaker: Stefano Barco (Germany)

Post-thrombotic Syndrome, Some Unexpected Results

Speaker: Mohamed Habib Homan (Tunisia)

Substantial Increase in Quality Adjusted Life Years by Earlier Diagnosis of Chronic Thromboembolic Pulmonary Hypertension

Speaker: Duliëtte Boon (the Netherlands)

Robotic Assisted Thrombotripsy Allows High Accurate Venous Recanalization in a Porcine Model of Femoral Venous Thrombosis

Speaker: Lina Khider (France)

The Low Prevalence of Post-thrombotic Syndrome and Residual Vein Thrombosis after the Treatment of Proximal Lower Limb Deep Vein Thrombosis with Rivaroxaban

Speaker: Stephany Cares Huber (Brazil)

Decreased Plasma Fibrinolytic Potential in Venous Thrombosis Patients using CloFAL Assay and the Association with Post-Thrombotic Syndrome and Residual Thrombus

Speaker: Melissa Quintero (Brazil)

Venous Thromboembolism - VTE Therapy

Virchow's Triad: Is it Applicable to Thrombosis of Mesenteric Vessels?

Speaker: Bushra Moiz (Pakistan)

Utility of the DASH Score after Unprovoked Venous Thromboembolism: Single Centre Study and Long-term Patient Outcomes

Speaker: Will Thomas (United Kingdom)

An Exploration of the Psychological Impact of Pulmonary Embolism

Speaker: Anna Tran (Canada)

Scientific Programme

Diagnostic Performance of Current Imaging Modalities for Diagnosing Cerebral Vein Thrombosis

Speaker: Lisette F. van Dam (the Netherlands)

Decline in Periprocedural Anticoagulant Use in Warfarin-treated VTE Patients Following the BRIDGE Trial Publication

Speaker: Geoffrey Barnes (United States)

Cost Savings Associated with Extended INR Testing Intervals

Speaker: Scott Kaatz (United States)

MAC Project - Monitoring Anticoagulant Therapy Observational Study - Rationale and Protocol

Speaker: Giuseppe Camporese (Italy)

Absence of Interaction between Rivaroxaban, Tacrolimus and Everolimus in Renal Transplant Recipients Anticoagulated for Proximal Deep Vein Thrombosis or Atrial Fibrillation

Speaker: Giuseppe Camporese (Italy)

Time in Therapeutic Range (TTR) of Ghanaian VTE Patients on Warfarin

Speaker: Edeghonghon Olayemi (Ghana)

Trends in Referrals to an Ambulatory Deep Vein Thrombosis Service over Ten Years at Cambridge University NHS Foundation Trust

Speaker: Will Thomas (United Kingdom)

Features of Thrombosis of the Vena Cava on a Series of 1045 Vein Thrombosis

Speaker: Mohamed Habib Houman (Tunisia)

MRDTI Can Distinguish Between Old and New Thrombosis in the Abdominal Aorta: A Case Report

Speaker: Lisette F. van Dam (the Netherlands)

Rationale for Clinicians to Hospitalize Patients with Acute Pulmonary Embolism: A Post-hoc Analysis of the Hestia and Vesta Studies

Speaker: Stephan V. Hendriks (the Netherlands)

Thrombogenic Potential in Patients Undergoing Hemodialysis Using Central Venous Catheter

Speaker: Luci Dusse (Brazil)

Single Centre Retrospective Review of Non-catheter Associated upper Extremity Deep Venous Thrombosis

Speaker: Stephanie P'ng (Australia)

Birth of a Coagulation Clinic and its Burden at the Department of Clinical Hematology, Yangon General Hospital, Myanmar

Speaker: Sein Win (Myanmar)

Outcomes of NOAC-treated Patients with Depression - Results from the Dresden NOAC Registry (NCT01588119)

Speaker: Jan Beyer-Westendorf (Germany)

The Role of Anxiety and Depression in the Pathogenesis of Thromboembolic Events Currently Classified as Unprovoked

Speaker: Silvia Hoirisch-Clapauch (Brazil)

Scientific Programme

Analysis of Central Venous Catheter Preservation on Prophylactic Rivaroxaban in the CASSINI Study

Speaker: Gerald A. Soff (United States)

Incidences of Thrombosis, Major Bleeding and 30-day Mortality in Patients Receiving Venovenous Extracorporeal Membrane Oxygenation and Value of Laboratory Parameters at Presentation in Predicting Outcomes

Speaker: Deepa Jayakody Arachchillage (United Kingdom)

The PECAN study: Diagnosing Pulmonary Embolism in the context of Common Alternative diagnoses in Primary Care

Speaker: Rosanne van Maanen (the Netherlands)

Treatment of PICC-related Upper Limb Deep-vein or Superficial Vein Thrombosis with Edoxaban. Rationale and Protocol

Speaker: Cristiano Bortoluzzi (Italy)

Identifying Patient Values and Expectations for Pulmonary Embolism CT Scanning in the Emergency Department

Speaker: Vidushi Swarup (Canada)

Complication Rates after Upper Extremity Venous Thrombosis: a Systematic Review and Meta-analysis

Speaker: Rick Ikesaka (Canada)

Thrombin Generation during Bleeding in Orally Anticoagulated Patients: Reversal Can Lead to Hypercoagulability

Speaker: Aurelien Lebreton (France)

Cerebral Venous Thrombosis Risk Factors

Speaker: Milan Kostal (Czech Republic)

Cerebral Venous Thrombosis: A Study about 1045 Cases

Speaker: Mohamed Habib Houman (Tunisia)

Recurrences after Splanchnic Vein Thrombosis: Risk Factors and Efficacy of Vitamin K-Antagonists in a Retrospective Monocenter Cohort of 207 Patients

Speaker: Valerio De Stefano (Italy)

Extended INR Recall Interval in Patients with Stable INR - Real World Experience

Speaker: Petr Kessler (Czech Republic)

An Easy-To-Use Tool to Flag Patients at Risk of Poor INR Control: A Streak of Subtherapeutic INRs

Speaker: Jasper H.A. van Miert (the Netherlands)

Risk factors of Recurrences after Stopping Anticoagulant of First Non-Cancer Related Venous Thromboembolism in Thai Patients: A Prospective Cohort Study

Speaker: Pitiphong Kijrattanakul (Thailand)

Dual Antiplatelet Therapy on Veno-Arterial ECMO: to Bleed or Not to Bleed?

Speaker: Christophe Vandenbrielle (United Kingdom)

Non Hepatic Causes of Adult Splanchnic Vein Thrombosis. A Monocentric Report of 24 Cases

Speaker: Zoubida Tazi Mezalek (Morocco)

Scientific Programme

Interim Analysis - Safety and Efficacy of Rivaroxaban in a Patient Population with Short Bowel Syndrome; A Prospective Observational Cohort Study

Speaker: Roisin Bavalia (the Netherlands)

Incidence of Venous Thromboembolism in Post-bariatric Surgery Patients

Speaker: Feras Almarshad (Saudi Arabia)

Influence of Polymorphisms in the CYP2C9, VKORC1, MDR1 and APOE Genes and Other Patient Variables on Warfarin Dose in Patients Treated at Anticoagulation Clinics in Brazil

Speaker: Luci Dusse (Brazil)

Diagnostic Accuracy of Limited Versus Whole-leg Ultrasonography for Suspected Deep Vein Thrombosis: A Systematic Review and Meta-analysis

Speaker: Noémie Kraaijpoel (the Netherlands)

Brazilian Version of the Oral Anticoagulation Knowledge Test: An Item Response Theory Approach

Speaker: Luci Dusse (Brazil)

Dabigatran Etxilate: Efficacy and Safety in the Treatment of Localized Intravascular Coagulopathy Associated with Venous Malformations

Speaker: Cedric Hermans (Belgium)

Management of Anticoagulant Therapy around Delivery: Results from the Ongoing Highlow Study

Speaker: Ingrid Bistervels (the Netherlands)

A Quality Improvement Program to Reduce the Use of Inferior Vena Cava Filters for Unnecessary Indications in a Tertiary Care Center

Speaker: Tzu-Fei Wang (United States)

Safety and Efficacy of Full Dose Dabigatran in the Treatment of Deep Vein Thrombosis in a Very Young Adolescent

Speaker: Franco Piovella (Italy)

Direct Oral Anticoagulant Laboratory Assay Assessment at a Large Academic Medical Center

Speaker: Sharonlin Bhardwaj (United States)

The CTPA Epidemic?

Speaker: Sarah Kelliher (Ireland)

Innovation in Interprofessional Education and Curriculum Development: A Simulation-based Anticoagulation Management Workshop for Hematology Trainees

Speaker: Prakash Vishnu (United States)

ISTH Guidelines and Apixaban Plasma Levels in Obese Patients

Speaker: Marilyn Rees (United Kingdom)

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

Speaker: Antoine Lurkin (France)

Predicting Recurrence after Unprovoked Venous Thromboembolism: Comparison of DASH, HERDOO2, and Vienna Score in the Same Cohort of Patients

Speaker: Stephany Huber (Brazil)

Women's Health - Pregnancy and Pregnancy Complications

Scientific Programme

Antithrombin and D-dimer in Predicting Pregnancy Complications in the 3rd Trimester of Pregnancy

Speaker: Ning Tang (China)

Assessment of the Knowledge about Venous Thromboembolism (VTE) on Pregnant Women Attending Kigali Referral Hospitals

Speaker: Christine Ashimwe (Rwanda)

Effects of Low-dose Combined Oral Contraceptives and Protein S K196E Mutation on Anticoagulation Factors: A Prospective Observational Study

Speaker: Toshiyuki Miyata (Japan)

Activated Partial Thromboplastin Time-based Unfractionated Heparin Dosing Protocol for Pregnant Patients

Speaker: Reiko Neki (Japan)

Profiling of Hypercoagulability Biomarkers and Development of a New Risk Assessment Model for the Identification of Outcome of in vitro Fertilization. The ROADMAP-IVF Study

Speaker: Patrick Van Dreden (France)

Current ISTH Registries on Women's Health Issues in Thrombosis and Haemostasis: Powerful Tools for Improved Data Collection and Outcome Measurement

Speaker: Maha Othman (Canada)

High Titer of False Positive Venereal Disease Research Laboratory (f+VDRL) Test among Patients with Obstetric Antiphospholipid Antibodies Syndrome (OAPS) Having Triple Positivity Profile of Antiphospholipid Antibodies (aPL)

Speaker: Silvia Perés (Argentina)

Glycoprotein VI (GP6) Single Nucleotide Polymorphisms Affect Recurrent Pregnancy Loss (RPL)

Speaker: Jeong Yong Lee (Korea, Republic of)

Study of Utilisation of Combined Hormonal Contraceptives in Europe

Speaker: Deeksha Khialani (the Netherlands)

Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in GDM Patients

Speaker: Xiaowei Qi (China)

Changes in the Thrombocytic Link of the Hemostasis System in Pregnant Women with Preeclampsia

Speaker: Bakhodir Kurbanov (Uzbekistan)

Transfusions during Pregnancy or Postpartum in 3 Italian Tertiary Level Obstetrics Departments: A Retrospective Analysis

Speaker: Elvira Grandone (Italy)

Pulmonary Embolism in Women Transfused after Postpartum Hemorrhage: A Single Centre Audit

Speaker: Elvira Grandone (Italy)

The Thromboelastography G Parameter as a Potential Marker for Coagulation Status Evaluation in Elderly Puerperant

Speaker: Qiuya Lu (China)

Is Platelets Count Useful for Preeclampsia Diagnosis?

Speaker: Luci Dusse (Brazil)

Scientific Programme

Systemic Soluble Mediators in HELLP Syndrome Case Report

Speaker: Luci Dusse (Brazil)

The Challenges of Managing Severe Haemophilia A and Pregnancy in Same Sex Couples

Speaker: Bella Madan (United Kingdom)

Pregnancy, Childbirth and Neonatal Outcomes in Women with Inherited Bleeding Disorders

Speaker: Lisa Clarke (Australia)

A Model for the Dual Actions of Plasminogen Activator Inhibitor Type-2 (PAI-2) during Oxidative Stress

Speaker: Jordan Cater (Australia)

Risk of Pregnancy- Related Thromboembolism and Obstetrical Complications in Women with Type I Antithrombin Deficiency

Speaker: Marco Capecchi (Italy)

Is the Resolution of Inflammation Altered in Preeclampsia?

Speaker: Luci Dusse (Brazil)

An Obstetric Thrombophilia Patient with Heterozygous Factor V Leiden (A1691G) and Homozygous C677T MTHFR Mutations in Family History; Case Report and Literature Review

Speaker: Justyna Teliga-Czajkowska (Poland)

Outcome of Pregnancies Inadvertently Conceived during Rivaroxaban Anticoagulation Therapy - Case Series

Speaker: Justyna Teliga-Czajkowska (Poland)

The Changes in Platelet Function during the Three Trimesters of Uncomplicated Pregnancy and Puerperium Compared to Non-pregnant Controls

Speaker: Anne Riddell (United Kingdom)

The Impact of Glycemic Control in Pregnant Women with Gestational and Pregestational Diabetes on Coagulation Status and Lipid Metabolism

Speaker: Justyna Teliga-Czajkowska (Poland)

Inherited Thrombophilia in Infertility Patients in Macedonia

Speaker: Elena Petkovikj (Macedonia, the Former Yugoslav Republic of)

Scientific Programme

Wednesday, 10. July 2019

Special Session
06:00 - 06:45

Windows near Meeting Room 106

Yoga

Registration
07:30 - 14:00

Main Foyer

Registration

State-of-the-Art Session
08:30 - 09:45

Plenary Hall

SOA 22, Managing Bleeding on Antithrombotic Therapy

Chair: James McFadyen (Australia)
Chair: Deborah M. Siegal (Canada)

Is There an Ethnic Difference in the Risk of Bleeding Complications with the Use of Antithrombotic Agents? **08:30**

Speaker: Shinya Goto (Japan)

Anticoagulant-Associated Bleeding in AF Patients **08:55**

Speaker: Elaine M. Hylek (United States)

Triple Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome or PCI/Stenting **09:20**

Speaker: Gregory YH Lip (United Kingdom)

State-of-the-Art Session
08:30 - 09:45

Melbourne Room 1

SOA 23, Contact Pathway Mechanisms and Drug Development

Chair: Stephanie A. Smith (United States)
Chair: Joost C.M. Meijers (the Netherlands)

Contact Pathway Activation: An Unfolding Story **08:30**

Speaker: Coen Maas (the Netherlands)

Structure and Function of FXI/FXII **08:55**

Speaker: Jonas Emsley (United Kingdom)

Clinical Trials with FXI Inhibitors **09:20**

Speaker: Jeffrey I. Weitz (Canada)

Scientific Programme

State-of-the-Art Session
08:30 - 09:45

Melbourne Room 2

SOA 24, ITP

Chair: Takaaki Hato (Japan)
Chair: Christopher M. Ward (Australia)

Mechanisms of Fc-Independent Thrombocytopenia	08:30
Speaker: Heyu Ni (Canada)	
Thrombopoietin Receptor Agonists	08:55
Speaker: David J. Kuter (United States)	
Thrombocytopenia in Pregnancy	09:20
Speaker: Terry B. Gernsheimer (United States)	

State-of-the-Art Session
08:30 - 09:45

Meeting Room 203/204

SOA 25, Genomics, Proteomics and Big Data

Chair: David Rabbolini (Australia)
Chair: Kathleen Freson (Belgium)

Thrombogenomics	08:30
Speaker: Keith Gomez (United Kingdom)	
Epigenetics in Hemostasis	08:55
Speaker: Elisa Danese (Italy)	
Platelet Proteome	09:20
Speaker: Andrew Webb (Australia)	

State-of-the-Art Session
08:30 - 09:45

Meeting Room 210/211

SOA 26, Managing Trauma Coagulopathy

Chair: Beverley J. Hunt (United Kingdom)
Chair: Dominik Draxler (Australia)

Cryopreserved Platelets in Trauma	08:30
Speaker: Michael C. Reade (Australia)	
Tranexamic Acid: An Effective Treatment for Acute Severe Bleeding	08:55
Speaker: Ian Roberts (United Kingdom)	
Massive Transfusion: Algorithm-Based or Empiric Therapy?	09:20
Speaker: Simon Jonathan Stanworth (United Kingdom)	

Scientific Programme

State-of-the-Art Session
08:30 - 09:45

Meeting Room 212/213

SOA 27, Vascular Cell Function in Inflammation, Sepsis and Beyond

Chair: Beng Chong (Australia)
Chair: Katsue Suzuki-Inoue (Japan)

Molecular Links Between Coagulation and Innate Immunity	08:30
Speaker: Edward M. Conway (Canada)	
Endothelial Cell Contribution to the Pathology in HIT	08:55
Speaker: Lubica Rauova (United States)	
VWF and Angiogenesis	09:20
Speaker: Anna Randi (United Kingdom)	

State-of-the-Art Session
08:30 - 09:45

Meeting Room 219/220

SOA 28, Acquired Coagulopathy in Children

Chair: Paul Monagle (Australia)
Chair: Nongnuch Sirachainan (Thailand)

Management Strategies for Hematological Derangement in Dengue Hemorrhagic Fever	08:30
Speaker: Ampaiwan Chuansumrit (Thailand)	
Hemostasis in Liver Disease	08:55
Speaker: Maria Magnusson (Sweden)	
DIC and Vascular Endothelium	09:20
Speaker: Toshiaki Iba (Japan)	

Oral Communication Session
10:15 - 11:30

Plenary Hall

OC 70, Hemophilia Clinical 2

Chair: Paul A. Ockelford (New Zealand)
Chair: Barbara A. Konkle (United States)

Joint Bleeds in Paediatric Patients with Haemophilia A: A CHES Study Analysis	10:15
Speaker: Kate Khair (United Kingdom)	
Efficacy and Safety of BAY 94-9027 is Sustained for 5 Years: Outcomes in 36 Patients in the PROTECT VIII Extension Study	10:30
Speaker: Mark Reding (United States)	
Intracranial Hemorrhage in Hemophilia - A Systematic Review	10:45
Speaker: AnneFleur Zwagemaker (the Netherlands)	

Scientific Programme

- Spontaneous Bleeding and Poor Bleeding Response with Extended Half-life Factor IX Products: A Survey of Select US Hemophilia Treatment Centers** 11:00
Speaker: Robert Sidonio (United States)
- Diagnostic and Score Value of Ultrasound and Magnetic Resonance Imaging in Hemophilia Arthropathy** 11:15
Speaker: Fei Ma (China)

Oral Communication Session
10:15 - 11:30

Melbourne Room 1

OC 71, Contact Pathway

Chair: Evi X. Stavrou (United States)
Chair: Sabine Kossmann (Australia)

- Isolation of Silica-free DNA and Studies of its Effects on Organ Damage in Mice** 10:15
Speaker: Sarah K Medeiros (Canada)
- Coagulation Activation Induced By Platelet-Derived Microvesicles Is Mediated by Kallikrein-Dependent Activation of Factor IX** 10:30
Speaker: Nigel Key (United States)
- Endothelial Plasminogen Activator Inhibitor-1 Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of Activated Factor XI** 10:45
Speaker: Cristina Puy (United States)
- Factor XII-W268R, a Human Mutation Causing Autoinflammation, Accelerates Activation through Exposure of the Activation Loop** 11:00
Speaker: C C Clark (the Netherlands)
- High-molecular-Weight Kininogen Is a Critical Component of Host Defense against Gram-negative Bacteria: Evidence from a Humanized HK Mouse Model** 11:15
Speaker: Aizhen Yang (China)

Oral Communication Session
10:15 - 11:30

Melbourne Room 2

OC 72, Hereditary Platelet Disorders 2

Chair: Heyu Ni (Canada)
Chair: Elizabeth Gardiner (Australia)

- A RNA Interference-based Approach to Autosomal Dominant Glanzmann Thrombasthenia: A Step towards Personalized Treatment** 10:15
Speaker: Loredana Bury (Italy)
- Impaired Hemostatic Activity of Healthy Transfused Platelets in Select Inherited Platelet Disorders: Mechanisms and Implications** 10:30
Speaker: Robert Lee (United States)

Scientific Programme

New Constitutional GATA1 Variants Study Reveals the Contribution of GATA1 in MYH10 Silencing During Megakaryopoiesis	10:45
Speaker: Paul Saultier (France)	
Confirmation of ACTN1 Variants as the Cause of Macrothrombocytopenia Using an in Vitrocellular Model	11:00
Speaker: Yuki Takagi (Australia)	
The Thrombocytopathy in the Netherlands Study: A Horizontal Diagnostic Approach for Suspected Congenital Platelet Defects	11:15
Speaker: Rolf T. Urbanus (the Netherlands)	

Oral Communication Session
10:15 - 11:30

Meeting Room 203/204

OC 73, VTE: Anticoagulant Challenges

Chair: Pantep Angchaisuksiri (Thailand)
Chair: Hannah Cohen (United Kingdom)

DOAC Plasma Concentrations in High Weight Patients: An Observational Study	10:15
Speaker: Anne Celine Martin (France)	
Association of Body Weight with Efficacy and Safety of Apixaban and Rivaroxaban in Relation to Low Molecular Heparin and Vitamin K Antagonists in Acute Venous Thromboembolism	10:30
Speaker: Waldemar Wysokinski (United States)	
Use of Direct Oral Anticoagulants in Patients with Different Types of Hereditary Thrombophilia: A Retrospective Cohort Study	10:45
Speaker: Elena Campello (Italy)	
Thrombus Resolution in Splanchnic Vein Thrombosis	11:00
Speaker: Ana I Casanegra (United States)	
Australian and New Zealand Registry of Anticoagulation in the Obese	11:15
Speaker: Georgia McCaughan (Australia)	

Oral Communication Session
10:15 - 11:30

Meeting Room 210/211

OC 74, Models and Methods for Studying Fibrinogen/FXIII

Chair: Tetsumei Urano (Japan)
Chair: Alisa S. Wolberg (United States)

Novel Murine Venous Thromboembolism Model to Evaluate Role of Factor XIII in Pulmonary Embolism Risk	10:15
Speaker: Sravya Kattula (United States)	
Understanding the Chromatin Regulatory Landscape Controlling Fibrinogen Gene Expression	10:30
Speaker: Richard Fish (Switzerland)	

Scientific Programme

The Fibrin αC Region is Critical for Mechanical Strength, Resistance to Fibrinolysis and the Formation of a Stable Whole Blood Clot	10:45
Speaker: Helen McPherson (United Kingdom)	
Venous Thrombosis and Thrombocyte Activity in Zebrafish Models of Quantitative and Qualitative Human Fibrinogen Disorders	11:00
Speaker: Cristina Freire Sanz (Switzerland)	
Detection and Analysis of Gene Mutations in Patients with Fibrinogen Deficiency by Next Generation Sequencing	11:15
Speaker: Boyang Sun (China)	

Oral Communication Session
10:15 - 11:30

Meeting Room 212/213

OC 75, Hemophilia Basic 1

Chair: David Lillicrap (Canada)
Chair: Simon A. Brown (Australia)

Extended Stability of Activated TAFI Normalizes Vascular Dysfunction in Hemophilic Joint Disease in Mice	10:15
Speaker: Tine Wyseure (United States)	
Targeting Protein S Protects Mice with Hemophilia A from Acute and Chronic Hemarthrosis	10:30
Speaker: Raja Prince (Switzerland)	
Targeting Protease Nexin-1, a Natural Anticoagulant, to Control Bleeding in Hemophilia A	10:45
Speaker: Karen Aymonnier (France)	
Hemarthrosis in FVIII-deficient Mice Causes Altered Expression of Local and Systemic Iron Regulators and Defective Iron Clearance from the Joint	11:00
Speaker: Annette von Drygalski (United States)	
Recombinant Factor VIII Fc Fusion Protein Inhibits Inflammatory Osteoclast Formation in vitro	11:15
Speaker: Robert Peters (United States)	

Oral Communication Session
10:15 - 11:30

Meeting Room 219/220

OC 76, FVIII and FIX

Chair: Qizhen Shi (United States)
Chair: Kenichi Ogiwara (Japan)

Unexpected Enhancement of FVIII Immunogenicity by Endothelial Expression in Lentivirus-transduced and Transgenic Mice	10:15
Speaker: Qizhen Shi (United States)	

Scientific Programme

Suppression of FVIII-specific Memory B Cells by Regulatory T Cells Expressing BARs	10:30
Speaker: Ai-Hong Zhang (United States)	
Characterization of Factor VIII Binding Sites on the Low-density Lipoprotein Receptor-related Protein 1 (LRP) Suggests a Dynamic Bivalent Mode of this Interaction	10:45
Speaker: Andrey Sarafanov (United States)	
Variants from Patients with Hemophilia Impair Proper Carboxylation of Factor IX	11:00
Speaker: Nicholas Popp (United States)	
Factor VIII (FVIII)-Haplotype Mismatch Increases Risk of Inhibitor Development in the Treatment of Hemophilia A (HA)	11:15
Speaker: Tom E. Howard (United States)	

Oral Communication Session
10:15 - 11:30

Meeting Room 105

OC 77, Blood Cells and the Vessel Wall

Chair: Anna Randi (United Kingdom)
Chair: Claudine Bonder (Australia)

Blood Endothelial Progenitor Cell-on-a-Chip: A Disease and Patient-specific Cell Source for in vitro Vascular Tissue Engineered Platforms	10:15
Speaker: Tanmay Mathur (United States)	
Ceramide 1 Phosphate Is a Potent Chemoattractant Factor of Endothelial Colony Forming Cells and Improve Post Ischemia Tissue Regeneration	10:30
Speaker: Hebe Agustina Mena (Argentina)	
Neutrophils Prothrombotic Characteristics during Myeloproliferative Neoplasms	10:45
Speaker: Chloé James (France)	
Characterization of Blood Outgrowth Endothelial Cells (BOECs) from Hermansky-Pudlak Syndrome (HPS) Type 1	11:00
Speaker: Giulio Purgatorio (Italy)	

Oral Communication Session
10:15 - 11:30

Meeting Room 106

OC 78, Platelet Inhibitors and New Targets

Chair: Sonia Severin (France)
Chair: Jianlin Qiao (China)

Novel NADPH Oxidase 1-selective Inhibitors Impair Collagen-dependent Platelet Activation and Thrombus Formation in vitro and Ferric Chloride-induced Carotid Occlusion in vivo with Negligible Effects on Thrombin Responses and Bleeding Time	10:15
Speaker: Giordano Pula (United Kingdom)	

Scientific Programme

Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of ACT017, an Anti-platelet Glycoprotein VI Fab: First in Human Healthy Volunteer Trial	10:30
Speaker: Martine Jandrot-Perrus (France)	
First Generation PI3KC2α Inhibitors are Potently Anti-Thrombotic and Improve on the Safety Profile of Current Anti-Platelet Therapies	10:45
Speaker: Mitchell Moon (Australia)	
Two Birds, One Stone: Anti-β3 Integrin PSI Domain Antibodies Inhibit Both Platelet Aggregation and Blood Coagulation	11:00
Speaker: Miguel Neves (Canada)	
Olfactory Receptors and Dysregulated Platelet Activity in Abdominal Aortic Aneurysms	11:15
Speaker: Scott Cameron (United States)	

Oral Communication Session
10:15 - 11:30

Meeting Room 109

OC 79, Platelet Activity: Inflammation and Cancer

Chair: Belinda Guo (Australia)
Chair: Michael Hickey (Australia)

Neutrophils Are Responsible for Colitis-induced Anemia and Thrombosis in P2X1-deficient Mice	10:15
Speaker: Cecile Oury (Belgium)	
Platelet C-type Lectin-like Receptor 2 (CLEC-2) is Required for Optimal Regulation of Erythropoiesis	10:30
Speaker: Shimon Otake (Japan)	
Inhibition of Platelet GPVI Induces Intratumor Hemorrhage and Increases Efficacy of Chemotherapy in Mice	10:45
Speaker: Julia Volz (Germany)	
Transforming Growth Factor β Released by Platelets Primes Macrophage Activation and Extracellular Trap Formation, Thereby Influencing Breast Cancer Growth in Mice	11:00
Speaker: Elmina Mammadova-Bach (Germany)	
Targeting Activated Platelets in the Tumor Microenvironment for Localized Delivery of Antibody-drug Conjugates to Tumors and Metastases	11:15
Speaker: James McFadyen (Australia)	

Scientific Programme

Plenary Session
11:45 - 13:00

Plenary Hall

Highlights of ISTH 2019

Chair: Philip J. Hogg (Australia)
Chair: Christopher M. Ward (Australia)
Chair: Jennifer Curnow (Australia)

Surgical Experience from Four Phase III Studies (HAVEN 1-4) of Efficacy of Emicizumab in Persons with Haemophilia A (PwHA) With or Without FVIII Inhibitors	11:45
Speaker: Elena Santagostino (Italy)	
Apoptosis Inhibition: A Promising Approach for Cold Storage of Apheresis Platelet Concentrates	11:49
Speaker: Irene Marini (Germany)	
Platelet Transcription and Translation Is Altered in Sepsis and Associated with Mortality	11:53
Speaker: Elizabeth Middleton (United States)	
Inhibition of Platelet GPVI Induces Intratumor Hemorrhage and Increases Efficacy of Chemotherapy in Mice	11:57
Speaker: Julia Volz (Germany)	
FXa Inhibitors Target Tumor-associated Macrophage FXa-PAR2 Signaling	12:01
Speaker: Claudine Graf (Germany)	
Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Hemophilia: Interim Analysis from the Open-label Extension Study	12:05
Speaker: K. John Pasi (United Kingdom)	
An Engineered Activated Factor V (SuperFVa) for Prevention and Treatment of Acute Traumatic Coagulopathy and Bleeding	12:09
Speaker: Bilgimol Chumappumkal Jospeh (United States)	
VTE-BLEED Score Predicts Major Bleeding in Patients with Atrial Fibrillation	12:13
Speaker: Gordon Chu (the Netherlands)	
Efficacy of Recombinant ADAMTS13 (TAK-755/SHP655) in a Humanized Mouse Model for Sickle Cell Disease	12:17
Speaker: Werner Hoellriegl (Austria)	
Premature Platelet Clearance via Clustering of the Hyposialylated GPIIb/IIIa Receptor in GNE-related Thrombocytopenia	12:21
Speaker: Rolf T. Urbanus (the Netherlands)	